{"meta":{"query_hash":"83756d19b7bf","filters":{"venue":"ESMO Open"},"cohort_total":245,"direct_labels_cover":1,"predictions_cover":245,"exported":245,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/83756d19b7bf","api":"https://metacan.xera.ac/api/v1/cohort?venue=ESMO+Open"},"results":[{"id":"W2334461454","doi":"10.1136/esmoopen-2016-000040","title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Amgen","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Radiation therapy; Cancer; Hormone therapy; Orchiectomy; Gynecology; Breast cancer","score_opus":0.07717180705185608,"score_gpt":0.41484243752290983,"score_spread":0.3376706304710537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334461454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143004,0.00028509094,0.0001301164,0.004413772,0.00012402803,0.0023410628,0.000574619,0.000006168091,0.00069512834],"genre_scores_gemma":[0.9917525,0.003491826,0.0002269942,0.0001270222,0.00002309088,0.00052386837,0.00016886009,0.000013980888,0.0036718578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993037,0.000036419708,0.00018873093,0.00015956972,0.00016763266,0.00014395955],"domain_scores_gemma":[0.999369,0.00017035623,0.00007277716,0.00012284276,0.00022192857,0.0000430465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005405128,0.00007276728,0.00018900596,0.00008607044,0.000025540241,0.000022257609,0.0001604282,0.000019108893,0.00041378225],"category_scores_gemma":[0.00010410377,0.000041935826,0.000022344897,0.00011895382,0.00005973141,0.0001730156,0.00005323672,0.000030696665,0.000007469228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040465477,0.000120142024,0.94397897,0.00003992681,0.00016701336,0.0000071981945,0.00038856023,0.0000021925111,0.0011320071,0.000042053132,0.0021049096,0.047970463],"study_design_scores_gemma":[0.012679254,0.00030789498,0.9279616,0.00022912126,0.000010882351,0.0000021535106,0.000035913934,0.0000693441,0.03829805,0.0002517597,0.020073602,0.00008040977],"about_ca_topic_score_codex":0.0062475023,"about_ca_topic_score_gemma":0.0016942485,"teacher_disagreement_score":0.047890052,"about_ca_system_score_codex":0.0001422522,"about_ca_system_score_gemma":0.00045386617,"threshold_uncertainty_score":0.94443965},"labels":[],"label_agreement":null},{"id":"W2410706806","doi":"10.1136/esmoopen-2016-000057","title":"Does clinical trial participation improve outcomes in patients with ovarian cancer?","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Wellbeing of Women","keywords":"Medicine; Clinical trial; Internal medicine; Randomized controlled trial; Cancer; Progression-free survival; Ovarian cancer; Cohort; Retrospective cohort study; Oncology; Overall survival","score_opus":0.4646980747278531,"score_gpt":0.6343433884378196,"score_spread":0.16964531370996644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410706806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746509,0.000001067319,0.00003151164,0.020408623,0.00077712984,0.002132297,0.000021764537,0.000015640138,0.0019610662],"genre_scores_gemma":[0.9891462,0.00003475026,0.0004729347,0.0008827004,0.00022517923,0.00030056768,0.0000063906336,0.000020307438,0.008911017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976624,0.00024121988,0.00071473664,0.0004288568,0.0006499432,0.00030281578],"domain_scores_gemma":[0.99396104,0.004827601,0.00015115483,0.0005650709,0.00028279057,0.00021231906],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004135519,0.000106046275,0.0004553083,0.000047408226,0.000041468626,0.000044245997,0.0003709082,0.0002598238,0.00069053966],"category_scores_gemma":[0.01576934,0.000041092262,0.00006220948,0.00010995823,0.00019592592,0.00018657841,0.00031252403,0.00065799546,0.00008236663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034279197,0.0008044137,0.9341308,0.000012969948,0.00006214216,0.00000637739,0.000044296445,8.300605e-8,0.0000035807352,0.00095093326,0.000085572894,0.029619668],"study_design_scores_gemma":[0.09749972,0.0022274703,0.89606214,0.00020329487,0.00002900638,2.1639218e-8,0.000008080397,0.0000040005607,0.00009980617,0.0030402148,0.0007401183,0.00008610382],"about_ca_topic_score_codex":0.0016190467,"about_ca_topic_score_gemma":0.0084231375,"teacher_disagreement_score":0.06322052,"about_ca_system_score_codex":0.00011510695,"about_ca_system_score_gemma":0.0006107839,"threshold_uncertainty_score":0.9925212},"labels":[],"label_agreement":null},{"id":"W2485154160","doi":"10.1136/esmoopen-2016-000097","title":"ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Curriculum; Medicine; Medical education; Oncology; Clinical Oncology; Internal medicine; Medical physics; Cancer; Psychology","score_opus":0.09685524511029993,"score_gpt":0.4029989969889585,"score_spread":0.3061437518786586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485154160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012659019,0.8446154,0.0021559447,0.005575435,0.0039324663,0.002110203,0.0028557417,0.000023986899,0.13872956],"genre_scores_gemma":[0.000010907414,0.9926831,0.0007196202,0.0007623716,0.0012235495,0.0013496092,0.0005245503,0.000049534985,0.0026767545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968417,0.00006208035,0.0017200762,0.00077508745,0.000039904433,0.0005611478],"domain_scores_gemma":[0.9978205,0.00025070106,0.00120181,0.000448704,0.000044829223,0.00023346746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001698102,0.00037318224,0.002394667,0.00022932004,0.00011444492,0.00014355923,0.0013172524,0.0008950274,0.004535994],"category_scores_gemma":[0.00072216865,0.00034330247,0.00042388242,0.00025156146,0.000097197655,0.0006623998,0.00039896742,0.0003393708,0.002454758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006509008,0.00010905968,0.00010357577,0.00031197016,0.000062573454,0.0000039903016,0.000011302598,5.7555376e-8,1.1225659e-10,0.1488987,0.15158342,0.69890887],"study_design_scores_gemma":[0.0010055404,0.000116559626,0.000093333474,0.004031923,0.00002870624,0.000016159072,0.0000069073426,0.000010623924,1.5914283e-8,0.041258138,0.9529976,0.00043447272],"about_ca_topic_score_codex":0.0023456302,"about_ca_topic_score_gemma":0.0020350614,"teacher_disagreement_score":0.8014142,"about_ca_system_score_codex":0.0017481603,"about_ca_system_score_gemma":0.0012061094,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W2528890271","doi":"10.1136/esmoopen-2016-000077","title":"Interventions to improve care coordination between primary healthcare and oncology care providers: a systematic review","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto; McMaster University; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Psychological intervention; CINAHL; Systematic review; MEDLINE; Health care; Cochrane Library; Randomized controlled trial; Family medicine; Meta-analysis; Oncology; Intensive care medicine; Nursing; Internal medicine","score_opus":0.1949507299562116,"score_gpt":0.49353616242909787,"score_spread":0.29858543247288627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528890271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.649428e-7,0.9743441,0.00003851571,0.0027322369,0.00013837773,0.019880928,0.0003137023,0.000036607293,0.002514565],"genre_scores_gemma":[0.000067981564,0.9922487,0.00041362035,0.0018553754,0.00017696476,0.0033959681,0.0007322269,0.00005103358,0.0010581329],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969685,0.00049298204,0.0012473757,0.00065163267,0.00031493022,0.00032457671],"domain_scores_gemma":[0.9975709,0.00016401701,0.00072218996,0.000683782,0.0005316277,0.0003275028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006481073,0.0003922761,0.004191629,0.0001604337,0.00013271451,0.00009567719,0.00055380666,0.00031043636,0.000049528364],"category_scores_gemma":[0.00051142595,0.00026030303,0.0004694821,0.00028417932,0.000039860257,0.000233176,0.0006624998,0.00029824034,0.000122016325],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005101059,0.000004969388,0.000012997331,0.6436969,0.00009345925,0.000021089523,0.0002461231,7.305565e-10,1.0573257e-8,0.000025442034,0.0015052587,0.35438862],"study_design_scores_gemma":[0.00029204055,0.00067737995,0.000018313072,0.68104833,0.00567005,0.00006385435,0.00067224225,5.1062368e-9,1.2647482e-7,0.00000480661,0.3113622,0.00019066573],"about_ca_topic_score_codex":0.00088893436,"about_ca_topic_score_gemma":0.0004940047,"teacher_disagreement_score":0.35419795,"about_ca_system_score_codex":0.002213725,"about_ca_system_score_gemma":0.001488285,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W2571465553","doi":"10.1136/esmoopen-2016-000127","title":"The European Cancer Patient’s Bill of Rights, update and implementation 2016","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Leeds; National Institute for Health and Care Research; Francis Crick Institute","keywords":"Bill of rights; Political science; Law; Human rights","score_opus":0.05318769051880295,"score_gpt":0.32791698128121416,"score_spread":0.2747292907624112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571465553","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001726174,0.9509533,0.000019624033,0.00028928384,0.0006239195,0.000862768,0.001551502,0.0000068953104,0.045675457],"genre_scores_gemma":[0.00022980208,0.9978982,0.00004182837,0.000089463145,0.00019068255,0.00011272347,0.000042999025,0.000046793193,0.0013475134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808884,0.0000671123,0.0011245494,0.00041294596,0.000023337394,0.0002832101],"domain_scores_gemma":[0.99780333,0.00007891134,0.0015644849,0.0004444317,0.000031049374,0.00007778642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000832267,0.0002537679,0.0010599411,0.00009993854,0.00019775257,0.00019044957,0.0007165099,0.000088693436,0.00080430286],"category_scores_gemma":[0.000023401408,0.00014325297,0.00016369141,0.00008534339,0.000115549614,0.0003963412,0.00041803182,0.00011839347,0.0006001157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000036640968,0.0000070245314,0.00007818523,0.00015509204,0.00011266655,7.375023e-7,0.00003997258,3.615394e-8,4.6582365e-9,0.038118877,0.020045018,0.94143873],"study_design_scores_gemma":[0.0002645538,0.000034883386,0.00029316678,0.0011163884,0.000034168723,0.0000013924684,0.000006292803,2.3828427e-7,8.946735e-7,0.017596776,0.9804014,0.00024982693],"about_ca_topic_score_codex":0.009365267,"about_ca_topic_score_gemma":0.0010820042,"teacher_disagreement_score":0.9603564,"about_ca_system_score_codex":0.00013609983,"about_ca_system_score_gemma":0.00011154699,"threshold_uncertainty_score":0.9972315},"labels":[],"label_agreement":null},{"id":"W2576796004","doi":"10.1136/esmoopen-2016-000118","title":"Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Samsung; Genentech; Eisai; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Helsinn; Clovis Oncology; Sanofi; Helsinn Therapeutics; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Atezolizumab; Medicine; Ramucirumab; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Immunotherapy; Nintedanib; Cancer; Lung","score_opus":0.015096098638421188,"score_gpt":0.3330041230318293,"score_spread":0.3179080243934081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576796004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900569,0.000009931013,0.00057332206,0.0021585005,0.000049028735,0.0029790523,0.00014076581,0.000024174995,0.0040083323],"genre_scores_gemma":[0.9912311,0.000011153227,0.0027448544,0.00057651417,0.000025712314,0.00082323555,0.00011727617,0.000039706174,0.0044304808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907774,0.000012780598,0.00017039041,0.00031938168,0.00020344707,0.0002162731],"domain_scores_gemma":[0.9993609,0.00002717112,0.00009498088,0.00026382506,0.00015227175,0.000100835765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003181135,0.00016946015,0.00025130555,0.00007565716,0.000067176734,0.000029453888,0.00011547144,0.00004824859,0.0004577495],"category_scores_gemma":[0.00001806855,0.00009817385,0.00003236573,0.0001340331,0.00006965934,0.00039922888,0.000044507153,0.000063740765,0.00002674562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030348287,0.0012579247,0.949778,0.000012248985,0.00022635334,0.000015144035,0.0016899866,0.000010611852,0.000020021873,0.000013558949,0.00020869827,0.043732625],"study_design_scores_gemma":[0.027799701,0.00058554846,0.9658656,0.00054568273,0.00009456699,0.0000014048161,0.000058460293,0.000017601704,0.00063168694,0.000028062786,0.004222942,0.0001487437],"about_ca_topic_score_codex":0.00022554457,"about_ca_topic_score_gemma":0.0012774522,"teacher_disagreement_score":0.04358388,"about_ca_system_score_codex":0.00025323709,"about_ca_system_score_gemma":0.00012978482,"threshold_uncertainty_score":0.5012036},"labels":[],"label_agreement":null},{"id":"W2587762331","doi":"10.1136/esmoopen-2016-000123","title":"Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?","year":2017,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Medical Research Council; Medical Research Council; Canadian Urological Oncology Group","keywords":"Cystectomy; Medicine; Radiation therapy; Bladder cancer; Adjuvant; Oncology; Occult; Internal medicine; Cancer; Pathology","score_opus":0.04459885941320157,"score_gpt":0.33904296998624284,"score_spread":0.29444411057304126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587762331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94427234,0.008358369,0.0024605398,0.0150923375,0.001211699,0.017856067,0.0009818025,0.00012759534,0.00963927],"genre_scores_gemma":[0.9857351,0.000249894,0.0063879048,0.00083145563,0.00037549072,0.0021472224,0.00003785584,0.00007624973,0.0041587935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859935,0.000034051463,0.00024876682,0.0005776606,0.00014360034,0.00039654612],"domain_scores_gemma":[0.9987016,0.00017244508,0.00015058751,0.00073460024,0.00004911329,0.00019166844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001617624,0.00030895055,0.00072141294,0.000047041554,0.00064757373,0.000196104,0.00039129824,0.00014708216,0.0001259281],"category_scores_gemma":[0.00010508463,0.00022098297,0.00030703546,0.000022921944,0.00011503461,0.0001874133,0.000097748336,0.00006821596,0.0000054440957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027239073,0.0036221342,0.205843,0.001017743,0.010754397,0.0020594175,0.028831927,0.000003522953,0.012458749,0.0028178208,0.021508174,0.68384403],"study_design_scores_gemma":[0.11789747,0.015190723,0.2077231,0.00055711734,0.0026674843,0.0002826474,0.0012608547,0.0006915928,0.019858684,0.0028587813,0.6299852,0.0010263317],"about_ca_topic_score_codex":0.004366981,"about_ca_topic_score_gemma":0.00044789372,"teacher_disagreement_score":0.6828177,"about_ca_system_score_codex":0.00032214628,"about_ca_system_score_gemma":0.00046965198,"threshold_uncertainty_score":0.9011424},"labels":[],"label_agreement":null},{"id":"W2591339550","doi":"10.1136/esmoopen-2016-000124","title":"Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Alberta; Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Flexibility (engineering); Summative assessment; Context (archaeology); Risk analysis (engineering); Value (mathematics); Management science; Medicine; Computer science; Business; Process management; Psychology; Formative assessment; Engineering; Economics","score_opus":0.11356981760722823,"score_gpt":0.33099553725649755,"score_spread":0.21742571964926932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591339550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032460698,0.98533505,0.00028279543,0.0031101177,0.0015650465,0.0015201478,0.003453132,0.000011072809,0.00439804],"genre_scores_gemma":[0.0022286985,0.9923278,0.00012645357,0.0007483912,0.0010179409,0.0004594856,0.00013995559,0.00008765547,0.0028636027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975894,0.00005300259,0.0010008359,0.0007957645,0.000050456234,0.00051055854],"domain_scores_gemma":[0.9971179,0.0008366793,0.0011997559,0.0006168558,0.000042881657,0.0001859401],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.00052830507,0.0004705566,0.0025191074,0.000058288337,0.00031304962,0.0012215044,0.0015570961,0.00038074137,0.00052168407],"category_scores_gemma":[0.000089103145,0.00034080664,0.00017707652,0.000120490586,0.00010215405,0.0005255109,0.0006162877,0.00075230334,0.00004205712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043853615,0.00000761475,0.018186543,0.00038154548,0.00038356992,9.782254e-7,0.00015980977,7.077048e-7,6.9864026e-10,0.008029364,0.008956073,0.9638894],"study_design_scores_gemma":[0.00031451002,0.000019654935,0.013594796,0.005569148,0.000108676984,3.546938e-7,0.00004946611,0.000013052515,4.3586482e-8,0.004854124,0.97495794,0.00051824236],"about_ca_topic_score_codex":0.7302746,"about_ca_topic_score_gemma":0.59807175,"teacher_disagreement_score":0.96600187,"about_ca_system_score_codex":0.0007107593,"about_ca_system_score_gemma":0.0011786381,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W2596828328","doi":"10.1136/esmoopen-2017-000169","title":"Male breast cancer: finding the way in this uncommon path","year":2017,"lang":"en","type":"article","venue":"ESMO Open","topic":"Male Breast Health Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Breast cancer; Path (computing); Cancer; Medicine; Oncology; Internal medicine; Computer science; Programming language","score_opus":0.06279836858799495,"score_gpt":0.38662129945098,"score_spread":0.3238229308629851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596828328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5404489,0.0003265197,0.0000014072039,0.104961015,0.0004814838,0.0013303534,0.000047973954,0.00002182797,0.35238054],"genre_scores_gemma":[0.97855294,0.00025620326,0.000094166964,0.0012818542,0.00024003725,0.00015538982,0.0000039247925,0.000015835203,0.019399626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990717,0.000047018024,0.00019421233,0.0002151298,0.00017338431,0.0002985537],"domain_scores_gemma":[0.9989341,0.00006249267,0.00014410584,0.00073598704,0.00004288994,0.00008043927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060921046,0.00011514222,0.00029527946,0.00003232828,0.0005932407,0.000097418415,0.00066037907,0.000050838993,0.0022617148],"category_scores_gemma":[0.000089289,0.00007197991,0.0000330163,0.00005882279,0.00009768908,0.00015370807,0.0006787528,0.0002631739,0.00013296939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013818392,0.000044375127,0.9461381,0.000068092406,0.000020343841,0.00007071184,0.00080413837,8.872622e-7,0.000006275828,0.00031418455,0.024099564,0.02829518],"study_design_scores_gemma":[0.0010346193,0.000029571665,0.9563241,0.00040000607,0.0000201872,0.000164724,0.00018776656,0.000060731534,0.00002001977,0.00005236796,0.04162651,0.000079393736],"about_ca_topic_score_codex":0.07294662,"about_ca_topic_score_gemma":0.016905297,"teacher_disagreement_score":0.43810406,"about_ca_system_score_codex":0.00013370923,"about_ca_system_score_gemma":0.00014827546,"threshold_uncertainty_score":0.9986504},"labels":[],"label_agreement":null},{"id":"W2683897270","doi":"10.1136/esmoopen-2017-000201","title":"Where do they come from? A call for complete transparency regarding the origin of human tissues in research","year":2017,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Medical History and Research","field":"Arts and Humanities","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transparency (behavior); Context (archaeology); Subject (documents); Medical research; Publishing; Human research; Research ethics; Object (grammar); Political science; Law; Public relations; Library science; Sociology; Psychology; Medicine; History; Engineering ethics; Computer science; Pathology; Engineering; Cognitive science","score_opus":0.3651091709438655,"score_gpt":0.46548726773837934,"score_spread":0.10037809679451382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2683897270","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010268579,0.0031128926,0.0000029623525,0.0015721585,0.46666276,0.0042660767,0.0036911427,0.000027754746,0.5196374],"genre_scores_gemma":[0.031269845,0.0007787162,0.000038751237,0.000014262666,0.73088914,0.0008210266,0.0009865231,0.00010617229,0.23509556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964749,0.000680749,0.0005357989,0.00049639173,0.0012990028,0.0005131474],"domain_scores_gemma":[0.99558127,0.0026496234,0.00021568705,0.00096837326,0.00047705084,0.00010797657],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046725003,0.000225468,0.0007759119,0.00016688283,0.0017947657,0.00067005696,0.0040025595,0.00036709764,0.003657673],"category_scores_gemma":[0.00073296175,0.00014343922,0.00014360034,0.000026519061,0.0013700639,0.00020018588,0.0004231461,0.0018507681,0.00006405952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018668422,0.00007642663,0.000020994428,0.0003781672,0.000072407696,0.00002007834,0.027242452,2.4345024e-7,0.000006419912,0.02494429,0.9465035,0.00054829795],"study_design_scores_gemma":[0.0010698342,0.0002694117,0.000016733236,0.0016031505,0.000023524146,7.868737e-8,0.0010312164,0.0000040118043,0.000004500214,0.011778574,0.9840106,0.00018841188],"about_ca_topic_score_codex":0.0969142,"about_ca_topic_score_gemma":0.28048617,"teacher_disagreement_score":0.28454185,"about_ca_system_score_codex":0.00012708985,"about_ca_system_score_gemma":0.00046991426,"threshold_uncertainty_score":0.99950475},"labels":[],"label_agreement":null},{"id":"W2748599797","doi":"10.1136/esmoopen-2017-000219","title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; Lung cancer; Tolerability; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; ALK inhibitor; Oncology; Adverse effect; Population; Clinical trial; Phases of clinical research","score_opus":0.016457186674279232,"score_gpt":0.34050324695636136,"score_spread":0.3240460602820821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748599797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867952,0.000047452566,0.00001468599,0.00030684072,0.00006675284,0.005646082,0.0007844584,0.0000034042725,0.0063351295],"genre_scores_gemma":[0.99545383,0.000026440272,0.0017454281,0.000031394942,0.00001725955,0.00028251662,0.00022112663,0.000014818696,0.0022071896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899554,0.000056822635,0.00034308492,0.00024933746,0.00019496716,0.00016023705],"domain_scores_gemma":[0.9988567,0.00010205406,0.0004463456,0.0003239846,0.00021878874,0.00005209096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016617104,0.00012896671,0.0003312218,0.00004000974,0.00016908027,0.000022140037,0.00019456337,0.00003208886,0.000045691933],"category_scores_gemma":[0.000112609865,0.00007848868,0.000036851645,0.00008593842,0.00009218676,0.00015680809,0.00012681447,0.00009209178,6.441049e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12523136,0.005287411,0.8436404,0.0003507055,0.0005701707,0.000014059176,0.0091736,0.00025222523,0.00011285646,0.000036729703,0.0006200942,0.014710402],"study_design_scores_gemma":[0.17418775,0.0009157588,0.82150817,0.0007864808,0.00033761555,6.313075e-7,0.000092724455,0.00026038225,0.0016977171,0.0000030375336,0.00013446753,0.000075289405],"about_ca_topic_score_codex":0.002087255,"about_ca_topic_score_gemma":0.0016826664,"teacher_disagreement_score":0.04895639,"about_ca_system_score_codex":0.000090462505,"about_ca_system_score_gemma":0.0003439458,"threshold_uncertainty_score":0.32006752},"labels":[],"label_agreement":null},{"id":"W2757470630","doi":"10.1136/esmoopen-2017-000225","title":"Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Hospital for Sick Children; Public Health Ontario; University of Toronto; SickKids Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Subgroup analysis; Systemic therapy; Clinical trial; Randomized controlled trial; Clinical endpoint; Cancer; Oncology; Systematic review; MEDLINE; Breast cancer","score_opus":0.25827546618447417,"score_gpt":0.4876232192284989,"score_spread":0.22934775304402472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757470630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018940808,0.98309964,0.0000049835407,0.00027582096,0.00009854727,0.0147795975,0.001343935,0.000013670718,0.00019437261],"genre_scores_gemma":[0.00067354925,0.9863908,0.00020916846,0.0005620159,0.000050236118,0.007032379,0.00061114045,0.00006614958,0.0044045374],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99669397,0.00029967443,0.0014666589,0.0007861924,0.00044880278,0.00030471024],"domain_scores_gemma":[0.9949191,0.0004132071,0.002223575,0.0019284489,0.00031109195,0.0002045774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006504327,0.0006051597,0.009197087,0.00008654795,0.00032808838,0.0002752534,0.00071142573,0.00016201609,0.00076068944],"category_scores_gemma":[0.00011481412,0.00022332858,0.0011004546,0.00029512492,0.00011133267,0.00017044791,0.00024467317,0.0003399098,0.000027964912],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007526022,0.00025599622,0.0006141809,0.40289137,0.5708858,0.000009073033,0.00049614446,9.4477593e-7,2.540372e-9,0.0000070587644,0.00023000741,0.024534186],"study_design_scores_gemma":[0.0010108912,0.00018593147,0.0009226559,0.121171646,0.8233215,0.000012162211,0.000052773037,0.000001897484,1.7411166e-8,7.2955163e-7,0.053063918,0.00025587925],"about_ca_topic_score_codex":0.00366582,"about_ca_topic_score_gemma":0.0007836034,"teacher_disagreement_score":0.2817197,"about_ca_system_score_codex":0.00030284928,"about_ca_system_score_gemma":0.0009169775,"threshold_uncertainty_score":0.91070753},"labels":[],"label_agreement":null},{"id":"W2782158179","doi":"10.1136/esmoopen-2017-000258","title":"Differential research impact in cancer practice guidelines’ evidence base: lessons from ESMO, NICE and SIGN","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Research Councils UK; Economic and Social Research Council; National Institute for Health and Care Research; King's College London; King's College Hospital NHS Foundation Trust","keywords":"Nice; Excellence; Sign (mathematics); Medicine; Evidence-based practice; Health care; Evidence-based medicine; Systematic review; Family medicine; MEDLINE; Alternative medicine; Computer science; Pathology; Political science","score_opus":0.803943401852388,"score_gpt":0.7237889410570072,"score_spread":0.0801544607953808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782158179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7776102,0.0005017796,0.00078067713,0.21701354,0.00044418284,0.0019025048,0.00007700738,0.000031969743,0.0016381296],"genre_scores_gemma":[0.98092175,0.0013140695,0.009375304,0.0060618515,0.0013728578,0.00013681267,0.00007495328,0.000042593256,0.00069979526],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99582946,0.00095662323,0.0011532033,0.00073327095,0.0008401356,0.00048731006],"domain_scores_gemma":[0.9881877,0.008187847,0.0003291697,0.0007416226,0.0022520702,0.00030163262],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006174725,0.00020452851,0.000443991,0.00016739935,0.00020094456,0.0002679488,0.00047897085,0.00015222248,0.007181479],"category_scores_gemma":[0.070859395,0.00016859578,0.000055591372,0.00057299365,0.00023196504,0.001642224,0.0008740686,0.00078393304,0.00020905903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013148999,0.00121614,0.16003612,0.00008274214,0.0005055256,0.0003286619,0.0023415184,0.000020153895,0.014516304,0.0002882277,0.5352302,0.2722854],"study_design_scores_gemma":[0.008774865,0.002177017,0.8746071,0.0020201735,0.00057787437,0.00007784459,0.0037562272,0.0062591154,0.0036201554,0.0013011167,0.09627197,0.00055655965],"about_ca_topic_score_codex":0.31107113,"about_ca_topic_score_gemma":0.03416115,"teacher_disagreement_score":0.71457094,"about_ca_system_score_codex":0.0003410152,"about_ca_system_score_gemma":0.0012114992,"threshold_uncertainty_score":0.9937261},"labels":[],"label_agreement":null},{"id":"W2785347004","doi":"10.1136/esmoopen-2017-000302","title":"Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"Cancer Institute NSW; American Society of Clinical Oncology","keywords":"Colorectal cancer; Cognition; Internal medicine; Medicine; Oncology; Cancer-related fatigue; Cancer; Psychiatry","score_opus":0.018494252764772828,"score_gpt":0.2949056941593668,"score_spread":0.27641144139459395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785347004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994508,0.000040905557,0.00009374579,0.000093162875,0.00015440413,0.0037290708,0.000088437635,0.000011736977,0.0012805053],"genre_scores_gemma":[0.99910164,0.000011102846,0.000044752982,0.000095699565,0.000060493217,0.0005376009,0.00007175728,0.000018280887,0.00005869588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991818,0.000044842196,0.00019587648,0.00023049072,0.00017475638,0.00017222311],"domain_scores_gemma":[0.99912494,0.00019623307,0.00014635174,0.000049944152,0.00042999943,0.000052521467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018872725,0.00012673088,0.00028465866,0.0000956099,0.00006954571,0.000014577262,0.0000496807,0.000057365418,0.00009341564],"category_scores_gemma":[0.00020846473,0.00010110859,0.00001727221,0.00017369987,0.00030876248,0.0001620471,0.00008537834,0.00008551191,0.0000017158314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016840337,0.00016814258,0.9769525,0.00011156479,0.0003660209,0.0000013331764,0.00053559715,5.0260877e-7,0.000010687649,0.000009496555,0.00022129017,0.004782561],"study_design_scores_gemma":[0.013008054,0.004154441,0.9800495,0.0010266862,0.00033152985,4.0071052e-7,0.0006928028,0.000036497724,0.0004677806,0.000024922763,0.000088199675,0.00011919628],"about_ca_topic_score_codex":0.0007536985,"about_ca_topic_score_gemma":0.003494551,"teacher_disagreement_score":0.004663365,"about_ca_system_score_codex":0.00006565659,"about_ca_system_score_gemma":0.0001518708,"threshold_uncertainty_score":0.41230884},"labels":[],"label_agreement":null},{"id":"W2787423031","doi":"10.1136/esmoopen-2017-000319","title":"Extrapolation concept at work with biosimilar: a decade of experience in oncology","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Extrapolation; Work (physics); Medical physics; Computer science; Oncology; Data science; Medicine; Medical education; Internal medicine; Mathematics; Statistics; Engineering","score_opus":0.06550678048535025,"score_gpt":0.3813891271215389,"score_spread":0.31588234663618864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787423031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95949495,0.00055680366,0.0007552706,0.0023469732,0.000436722,0.0007044179,0.000017624106,0.0000239238,0.035663337],"genre_scores_gemma":[0.9921384,0.000015773754,0.0048739635,0.000670202,0.00001973039,0.000022872691,0.000008708044,0.000007544027,0.0022428227],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895096,0.00024380279,0.00026184917,0.00027206232,0.000027166852,0.0002441819],"domain_scores_gemma":[0.99940604,0.00016397709,0.000117273354,0.00023130569,0.000058449477,0.00002297916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031388787,0.00011031598,0.00029959015,0.000060088663,0.000065228305,0.00000910289,0.00039744296,0.00026736662,0.0024938744],"category_scores_gemma":[0.00006775365,0.000078336474,0.00002908999,0.0003247078,0.0008971427,0.00008735267,0.00025226048,0.0001498261,0.000048076174],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009819904,0.0013299388,0.49332154,0.000026991534,0.0004365492,0.00005653526,0.020314367,0.000004426084,0.29221565,0.00765146,0.03735359,0.13746907],"study_design_scores_gemma":[0.0025838153,0.0015601971,0.14706747,0.00011001493,0.000034519388,0.00003904675,0.0006028953,0.000007695936,0.59784937,0.00023206178,0.24964266,0.00027027773],"about_ca_topic_score_codex":0.0002621156,"about_ca_topic_score_gemma":0.00080408686,"teacher_disagreement_score":0.34625405,"about_ca_system_score_codex":0.00005578972,"about_ca_system_score_gemma":0.00005672172,"threshold_uncertainty_score":0.998418},"labels":[],"label_agreement":null},{"id":"W2808864948","doi":"10.1136/esmoopen-2018-000361","title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Genentech; GlaxoSmithKline; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Metastatic breast cancer; Meta-analysis; Breast cancer; Adverse effect; Neutropenia; PARP inhibitor; Population; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase","score_opus":0.15249025861087392,"score_gpt":0.4081192647699527,"score_spread":0.2556290061590788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808864948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000068553272,0.966957,0.000058752332,0.00049356435,0.00005482446,0.028776227,0.0035914157,0.000015799304,0.000045609107],"genre_scores_gemma":[0.00006587735,0.9792897,0.00050542835,0.00040980437,0.000040253057,0.01831573,0.0004773763,0.000090271635,0.00080554705],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961606,0.0007028493,0.001632533,0.00070178905,0.00050793577,0.00029429526],"domain_scores_gemma":[0.994891,0.0008855207,0.0023225392,0.0010708477,0.0006703654,0.00015976104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006861151,0.0007479239,0.01086509,0.00020602868,0.00014108716,0.00007904647,0.00037916878,0.000092514696,0.0008206913],"category_scores_gemma":[0.000067106484,0.0003220121,0.0019207855,0.0011228494,0.00024866863,0.00010841632,0.00006527189,0.00011150456,0.000010566105],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001378472,0.00075512455,0.000015732812,0.49232268,0.5001175,0.000004711516,0.0003317463,0.0000011909334,9.933778e-9,0.0000049941673,0.0009051742,0.005403313],"study_design_scores_gemma":[0.0016119211,0.0010825018,0.000016418056,0.06054107,0.87165874,0.000020053165,0.000035644785,0.000002675477,0.000005864021,0.000006758883,0.064725965,0.0002923729],"about_ca_topic_score_codex":0.0012159733,"about_ca_topic_score_gemma":0.00048106545,"teacher_disagreement_score":0.4317816,"about_ca_system_score_codex":0.0006298673,"about_ca_system_score_gemma":0.00039790416,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W2809727906","doi":"10.1136/esmoopen-2018-eacr25.104","title":"PO-060 ErbB2/Her2-dependent downregulation of a transcription factor IRF6 in breast cancer cells is required for their three-dimensional growth","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Downregulation and upregulation; Transcription factor; Cancer research; Breast cancer; Cancer; Oncology; Medicine; Internal medicine; Biology; Gene; Genetics","score_opus":0.07786127573367449,"score_gpt":0.37090880091018413,"score_spread":0.29304752517650967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809727906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839678,0.00013493001,0.0005885042,0.009021531,0.00038489542,0.003553419,0.0010095236,0.00003056863,0.0013088406],"genre_scores_gemma":[0.99720126,0.000044774646,0.0005933716,0.0004936661,0.00029881723,0.0002852512,0.00005764663,0.00004615675,0.0009790428],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813557,0.000076160664,0.0004302477,0.0004444202,0.00053168944,0.00038193667],"domain_scores_gemma":[0.9988492,0.000072529074,0.00011918606,0.0003764803,0.00044235672,0.0001402252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058084156,0.00018791902,0.00041021145,0.00016162352,0.000075818476,0.00003874506,0.0003389624,0.00016079676,0.00372124],"category_scores_gemma":[0.000022675571,0.00015237983,0.0001017368,0.00025857234,0.00015123622,0.00027077334,0.00010363742,0.00017512136,0.00004153597],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010633833,0.0010710905,0.052700154,0.0008702147,0.0003674171,0.00001956635,0.0053914404,0.00004437016,0.8301825,0.00040014196,0.026556704,0.07176259],"study_design_scores_gemma":[0.0056280256,0.00066989346,0.53969836,0.0008173535,0.000047856796,0.0000189568,0.00010332553,0.0018461811,0.44655824,0.0012825953,0.0030621304,0.00026709063],"about_ca_topic_score_codex":0.017884275,"about_ca_topic_score_gemma":0.008065229,"teacher_disagreement_score":0.4869982,"about_ca_system_score_codex":0.00035391905,"about_ca_system_score_gemma":0.00049405236,"threshold_uncertainty_score":0.9971895},"labels":[],"label_agreement":null},{"id":"W2809754085","doi":"10.1136/esmoopen-2018-eacr25.913","title":"PO-401 Tumour stem cell characteristics are negatively associated with anti-cancer immunity in diverse solid cancers","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunity; Cancer research; Cancer; Solid tumor; Stem cell; Medicine; Biology; Oncology; Immunology; Internal medicine; Immune system; Genetics","score_opus":0.038939276018340845,"score_gpt":0.3102179298636768,"score_spread":0.27127865384533595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809754085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943752,0.000071165385,0.000009356822,0.00048205085,0.00025657692,0.0007644297,0.00018537854,0.000033200853,0.0038226373],"genre_scores_gemma":[0.9944254,0.0002343802,0.000031834512,0.0011341521,0.000120212324,0.00005634406,0.000055690638,0.000035591253,0.00390636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986889,0.00011654489,0.0002947233,0.00029884183,0.00023538363,0.00036561085],"domain_scores_gemma":[0.99900085,0.00004589758,0.00034416624,0.000295069,0.00021465536,0.000099346],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003619615,0.00021994526,0.00051247014,0.00008852275,0.00018557157,0.000078201345,0.00036488817,0.00010777756,0.0009344017],"category_scores_gemma":[0.000022819813,0.00017756273,0.00005598495,0.0004238759,0.00024276215,0.00021918843,0.00015864761,0.00029206896,0.00003452254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011371565,0.000882847,0.9226052,0.00013278234,0.00091918954,0.00027556054,0.007249048,0.000005167909,0.03163799,0.0000069594735,0.00915971,0.01575394],"study_design_scores_gemma":[0.005713973,0.00054786913,0.9411125,0.0007600364,0.000076779565,0.000004378636,0.00198799,0.000038549704,0.046510592,0.0000033564702,0.0029700643,0.00027391707],"about_ca_topic_score_codex":0.018510878,"about_ca_topic_score_gemma":0.010607917,"teacher_disagreement_score":0.018507253,"about_ca_system_score_codex":0.0007415362,"about_ca_system_score_gemma":0.00054276834,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2809970955","doi":"10.1136/esmoopen-2018-eacr25.551","title":"PO-016 Inhibition of cell proliferation by anti-epidermal growth factor receptor (EGFR) aptamer conjugated chitosan/siRNA nanoparticles","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Epidermal growth factor receptor; Aptamer; Chitosan; Epidermal growth factor; Chemistry; Conjugated system; Cell biology; Cell growth; Cancer research; Biophysics; Receptor; Molecular biology; Biology; Biochemistry","score_opus":0.013682860184561723,"score_gpt":0.2535070439744746,"score_spread":0.23982418378991288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809970955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700135,0.00005381451,0.00020284331,0.00024593793,0.00016566298,0.00036036002,0.000111137815,0.000010031335,0.0018488417],"genre_scores_gemma":[0.997993,0.00008534641,0.00022623515,0.00047184757,0.00020234742,0.000024911686,0.0004490754,0.000019007934,0.00052824646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989716,0.00009055632,0.00029166293,0.00032456918,0.00011236318,0.00020929484],"domain_scores_gemma":[0.99936247,0.0000067352307,0.00015173612,0.00023160514,0.00017787855,0.000069600974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010064077,0.00015096733,0.00017914192,0.000030473622,0.00009084062,0.0000698764,0.00024411989,0.00013989286,0.00026806875],"category_scores_gemma":[0.000048958136,0.0001355731,0.000054254666,0.00008270534,0.00012286413,0.000032597865,0.00017433411,0.000060879524,0.00009515894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014906505,0.00011770871,0.004197261,0.000011529394,0.000029765559,5.7925354e-7,0.00012521615,5.8395375e-7,0.97768015,0.0000114103905,0.017246917,0.0004298151],"study_design_scores_gemma":[0.00062794314,0.0007185684,0.0030497445,0.00002565594,0.000011555933,0.0000022951147,0.00006750835,0.000018416526,0.9930914,0.000019865001,0.0021880195,0.00017903744],"about_ca_topic_score_codex":0.00027733544,"about_ca_topic_score_gemma":0.000051343748,"teacher_disagreement_score":0.015411241,"about_ca_system_score_codex":0.0000070398073,"about_ca_system_score_gemma":0.000066332665,"threshold_uncertainty_score":0.552851},"labels":[],"label_agreement":null},{"id":"W2810191124","doi":"10.1136/esmoopen-2018-eacr25.158","title":"PO-117 Role of NFE2L3 in colon cancer by regulating cancer cells proliferation","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Circular RNAs in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Colorectal cancer; Cancer research; Cancer; Cancer cell; Oncology; Internal medicine; Medicine","score_opus":0.009736661331849205,"score_gpt":0.30709212001904873,"score_spread":0.29735545868719954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810191124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961381,0.0008517406,0.000021315504,0.00011396167,0.000105979714,0.00039939352,0.000066963774,0.00000354911,0.0022990291],"genre_scores_gemma":[0.99849594,0.00008555584,0.00011727559,0.00019726942,0.00018042461,0.00013600479,0.000074196156,0.000016499158,0.00069683173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930537,0.000048922364,0.00016707405,0.0002454872,0.0000875506,0.00014560645],"domain_scores_gemma":[0.9995343,0.000004381533,0.00009877071,0.0002411009,0.00008275239,0.00003865943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011414713,0.00008612366,0.000121174984,0.000018422708,0.000044633507,0.000028337696,0.00027043684,0.00008483405,0.00025337408],"category_scores_gemma":[0.000037431288,0.00008901183,0.00002782093,0.00007397856,0.0000656714,0.0000082888955,0.00018878457,0.0000378921,0.0000041037474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001003679,0.00006202593,0.05013958,0.000012771798,0.000026871629,3.8778595e-7,0.0000963712,0.00009914937,0.93754804,0.000018350402,0.0072930385,0.0046030222],"study_design_scores_gemma":[0.0005035249,0.00007505148,0.012017474,0.00004378523,0.0000111356885,4.4360226e-7,0.000040758583,0.00013180384,0.9704099,0.000061828534,0.016592799,0.00011148794],"about_ca_topic_score_codex":0.0038787988,"about_ca_topic_score_gemma":0.0059486297,"teacher_disagreement_score":0.038122106,"about_ca_system_score_codex":0.000032900218,"about_ca_system_score_gemma":0.00014994071,"threshold_uncertainty_score":0.58636093},"labels":[],"label_agreement":null},{"id":"W2810273617","doi":"10.1136/esmoopen-2018-eacr25.400","title":"PO-372 Investigating the epigenetic changes underlying combination treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Retinoic acid; Epigenetics; Arsenic; Cancer research; Tretinoin; Medicine; Chemistry; Biochemistry; Organic chemistry; Gene","score_opus":0.0391299488620396,"score_gpt":0.30444627371135596,"score_spread":0.2653163248493164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810273617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961972,0.0006613536,0.0005340731,0.000702715,0.000041900843,0.0007196425,0.000006331657,0.000009117915,0.001127647],"genre_scores_gemma":[0.99711925,0.0006703941,0.0012084056,0.00016755743,0.00006844906,0.000105096704,0.0000702682,0.000026604619,0.0005639582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900734,0.00009984926,0.00018826245,0.0003535409,0.00012902867,0.00022194756],"domain_scores_gemma":[0.9993059,0.00002229289,0.00016216046,0.0003515166,0.00009478192,0.00006333812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020121367,0.0001891365,0.00020102167,0.000027196687,0.00018147695,0.000071922645,0.00032378317,0.00010886829,0.000012119103],"category_scores_gemma":[0.000027163149,0.00012435041,0.000032334472,0.000113840135,0.0003958999,0.000009735324,0.000106846215,0.000060285816,0.0000019633037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002736495,0.00009347334,0.0056281895,0.00008928376,0.0005090979,0.000008241947,0.002137542,0.000007745782,0.9742098,0.00015080228,0.000107058935,0.016785119],"study_design_scores_gemma":[0.0013563359,0.00266246,0.005000541,0.00006981997,0.00019639226,0.000050868992,0.00030596886,0.00006787465,0.9876229,0.00031024418,0.0021718852,0.00018466786],"about_ca_topic_score_codex":0.00014367072,"about_ca_topic_score_gemma":0.00037738567,"teacher_disagreement_score":0.01660045,"about_ca_system_score_codex":0.000038812388,"about_ca_system_score_gemma":0.00019336282,"threshold_uncertainty_score":0.5070862},"labels":[],"label_agreement":null},{"id":"W2810371779","doi":"10.1136/esmoopen-2018-eacr25.720","title":"PO-202 PI3K activation in neural stem cells drives tumourigenesis which can be ameliorated by targeting the cAMP response element binding (CREB) protein","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"CREB; Neural stem cell; Element (criminal law); Neuroscience; Cell biology; Cancer research; Chemistry; Stem cell; Medicine; Biology; Biochemistry; Transcription factor; Political science; Gene; Law","score_opus":0.0251261983150871,"score_gpt":0.2936227902761393,"score_spread":0.2684965919610522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810371779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893119,0.00002885597,0.0001192901,0.008008589,0.00015363084,0.002133502,0.000021923568,0.00003082204,0.0001915329],"genre_scores_gemma":[0.9958992,0.000010771408,0.00025453235,0.0008479023,0.00015039665,0.00022338946,0.000038107744,0.00004023246,0.002535484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983858,0.00033855872,0.000318601,0.00034507975,0.00027622376,0.0003357783],"domain_scores_gemma":[0.99922144,0.000067636865,0.00018031782,0.00030239104,0.00014187163,0.00008635538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011835922,0.0001787838,0.00025981525,0.000111688794,0.0002505235,0.00012949423,0.00029326012,0.000068112415,0.0005026734],"category_scores_gemma":[0.000045360553,0.00012908406,0.000033371896,0.0006301602,0.000038671104,0.00015398039,0.00012986407,0.00020010468,0.000017446366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002186927,0.0000773018,0.0006809275,0.00001195938,0.000036884303,0.0000060087973,0.0027915647,0.000008126245,0.9884174,0.000043827957,0.002770244,0.002968865],"study_design_scores_gemma":[0.0015721475,0.00065929466,0.0020811155,0.00015752108,0.00001531988,0.000001712491,0.002751932,0.00033896838,0.9832132,0.000029265002,0.009010711,0.0001688157],"about_ca_topic_score_codex":0.0065064137,"about_ca_topic_score_gemma":0.0024485386,"teacher_disagreement_score":0.0071606864,"about_ca_system_score_codex":0.00024838318,"about_ca_system_score_gemma":0.00024049464,"threshold_uncertainty_score":0.98357946},"labels":[],"label_agreement":null},{"id":"W2811271813","doi":"10.1136/esmoopen-2018-eacr25.42","title":"SPOT-009 Identification of novel hippo pathway regulators using a genome wide CRISPR screen","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hippo pathway signaling and YAP/TAZ","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CRISPR; Hippo signaling pathway; Identification (biology); Computational biology; Biology; Genome; Genetics; Gene; Botany","score_opus":0.035548303887257375,"score_gpt":0.29993585736345574,"score_spread":0.26438755347619836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811271813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839404,0.000078584126,0.0139103215,0.00006155481,0.00014548037,0.00031077946,0.00007958269,0.0000112487305,0.0014620086],"genre_scores_gemma":[0.9949298,0.000007147792,0.003226949,0.00015945658,0.00027558432,0.000009286535,0.00017316533,0.000032287688,0.001186354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987594,0.00007063027,0.0003726405,0.0004125082,0.00015345078,0.00023140252],"domain_scores_gemma":[0.99884874,0.000009903971,0.00022928997,0.0006197271,0.00020552077,0.00008680429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070613215,0.00015235417,0.00019443232,0.000057412493,0.00014217758,0.00006521298,0.0005830873,0.00015664856,0.00006478946],"category_scores_gemma":[0.00011423365,0.00015201971,0.00007887144,0.00014672859,0.0001501466,0.000013272377,0.00029137207,0.0000649129,0.000029304723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005488402,0.00007683599,0.0011404548,0.000009964206,0.00004510702,0.0000012336475,0.00012763317,0.00005643648,0.99757206,0.00011393979,0.0000790578,0.0007224081],"study_design_scores_gemma":[0.0005305401,0.00018124082,0.010562347,0.000031091084,0.000024067509,0.0000099858635,0.00007469052,0.00032374158,0.97505194,0.000096234195,0.0128973555,0.00021675877],"about_ca_topic_score_codex":0.0005852227,"about_ca_topic_score_gemma":0.000092007824,"teacher_disagreement_score":0.022520099,"about_ca_system_score_codex":0.000018762248,"about_ca_system_score_gemma":0.00015596773,"threshold_uncertainty_score":0.6199184},"labels":[],"label_agreement":null},{"id":"W2851615044","doi":"10.1136/esmoopen-2018-000364","title":"Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Crizotinib; Lung cancer; Tolerability; Internal medicine; Quality of life (healthcare); ALK inhibitor; Performance status; Clinical endpoint; Oncology; Cancer; Adverse effect; Clinical trial","score_opus":0.013236844071678787,"score_gpt":0.34607403689540206,"score_spread":0.33283719282372326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2851615044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206936,0.000009144578,0.0000039880574,0.000079467056,0.000081147205,0.00407896,0.00008172254,0.000011566473,0.0035846673],"genre_scores_gemma":[0.99846154,0.000002786895,0.00029764464,0.00019643137,0.000014827807,0.00042744764,0.00009034442,0.000031954096,0.00047700643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848574,0.000055329892,0.00051180046,0.00040868967,0.00025992343,0.00027850442],"domain_scores_gemma":[0.99887395,0.00003869171,0.00037837823,0.00035411303,0.00025000755,0.00010488711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006687829,0.00021086627,0.00059088017,0.00019807032,0.00009577119,0.000019962456,0.00014313492,0.000023532779,0.00008336623],"category_scores_gemma":[0.000024026886,0.00015496455,0.00003333172,0.00070689246,0.00008308491,0.00013037489,0.00012223562,0.00012277691,0.0000015368558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023156514,0.012345509,0.96853393,0.000019323508,0.0003716646,0.00007056115,0.012808482,0.0000107077785,0.000014420793,3.5972306e-7,0.00015921048,0.0033501734],"study_design_scores_gemma":[0.028784798,0.013253344,0.95533586,0.00014027536,0.0003567815,4.7536176e-7,0.0014920299,0.000022406648,0.00035941316,3.832943e-7,0.000091569455,0.00016264398],"about_ca_topic_score_codex":0.07551273,"about_ca_topic_score_gemma":0.1560146,"teacher_disagreement_score":0.08050188,"about_ca_system_score_codex":0.00022693358,"about_ca_system_score_gemma":0.0003409649,"threshold_uncertainty_score":0.9306435},"labels":[],"label_agreement":null},{"id":"W2954342804","doi":"10.1136/esmoopen-2019-000552","title":"Introducing a new ESMO Open article series: how I treat side effects of immunotherapy","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Internal medicine; Cancer immunotherapy; Clinical trial; Cancer; Melanoma; Pembrolizumab; Cancer research","score_opus":0.011755799005690694,"score_gpt":0.28289966512091025,"score_spread":0.27114386611521957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954342804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631701,0.0009302401,0.000093437775,0.010488245,0.0005024519,0.0036796501,0.0000050407816,0.000044853496,0.021085994],"genre_scores_gemma":[0.9205202,0.00052212854,0.0034785436,0.0022345125,0.00021464228,0.00008486619,0.000024756477,0.00007370315,0.07284666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998705,0.00008553516,0.00028473834,0.00040795392,0.00020889708,0.00030785633],"domain_scores_gemma":[0.9986487,0.000116236326,0.00016151938,0.00090569246,0.000058139824,0.00010969642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039719918,0.00021204236,0.0006071904,0.00007113506,0.0000681545,0.00021638369,0.0007127823,0.00009595243,0.0014537434],"category_scores_gemma":[0.000066902234,0.0001696242,0.00012775317,0.00032468184,0.00006781903,0.0006451064,0.00029571712,0.00014608128,0.00010115089],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0200226,0.00048338313,0.023061657,0.00037879462,0.0010906456,0.00006233046,0.0044440576,0.000012519067,0.6385413,0.00036234251,0.031612,0.27992842],"study_design_scores_gemma":[0.024327671,0.0029938961,0.11076254,0.0011206435,0.00012377552,0.000094809955,0.00068771304,0.000042816955,0.7117042,0.00030648216,0.14740314,0.00043234538],"about_ca_topic_score_codex":0.015422682,"about_ca_topic_score_gemma":0.0005046518,"teacher_disagreement_score":0.27949604,"about_ca_system_score_codex":0.00011452869,"about_ca_system_score_gemma":0.0003148305,"threshold_uncertainty_score":0.9994591},"labels":[],"label_agreement":null},{"id":"W2963723783","doi":"10.1136/esmoopen-2019-000532","title":"A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Paclitaxel; Lung cancer; Medicine; Oncology; Internal medicine; Cancer research; Chemotherapy; Cisplatin","score_opus":0.02520585020919555,"score_gpt":0.3661034264544797,"score_spread":0.34089757624528416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963723783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887448,0.00013892625,0.0000049117175,0.000103568666,0.000031689357,0.010461624,0.000023501976,0.000009020796,0.00048196278],"genre_scores_gemma":[0.9973544,0.00003642522,0.0007208894,0.000034124027,0.0000072732682,0.0009787974,0.000053580356,0.000050762614,0.00076374057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981337,0.00012854996,0.00044196646,0.0004845985,0.0004622181,0.00034893738],"domain_scores_gemma":[0.9990029,0.00016348745,0.00020149621,0.00034912888,0.00016363154,0.00011938448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003761239,0.0002455963,0.0006786212,0.00020607049,0.000059749917,0.000027936174,0.0001662228,0.0000428989,0.00019558534],"category_scores_gemma":[0.00006283243,0.0001627426,0.000016952108,0.000503008,0.000039708404,0.00018120088,0.00013866478,0.00021840414,0.0000025837355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011286919,0.011540663,0.9503987,0.0005228255,0.00011259037,0.00013741803,0.015931834,0.0009764199,0.000074958494,0.0000012355567,0.000013288032,0.009003192],"study_design_scores_gemma":[0.28896052,0.12786871,0.5633522,0.0017572386,0.0002827538,0.0000044096887,0.0075832275,0.0074757463,0.0020905593,0.000008098212,0.000127054,0.00048947165],"about_ca_topic_score_codex":0.03534264,"about_ca_topic_score_gemma":0.03906905,"teacher_disagreement_score":0.38704646,"about_ca_system_score_codex":0.0006849712,"about_ca_system_score_gemma":0.0005490684,"threshold_uncertainty_score":0.97846544},"labels":[],"label_agreement":null},{"id":"W2993287528","doi":"10.1136/esmoopen-2019-000596","title":"Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Krebsliga Schweiz","keywords":"Reimbursement; Medicine; Health care; Evidence-based medicine; Family medicine; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.4198998315788263,"score_gpt":0.5052905245244069,"score_spread":0.0853906929455806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993287528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98350996,0.0019311301,0.000055367298,0.005987943,0.00009510759,0.007816754,0.000068367386,0.0000028979669,0.0005324971],"genre_scores_gemma":[0.9958421,0.0007190429,0.0016116916,0.000431609,0.00001755503,0.00033828962,0.0000032898888,0.0000058292817,0.0010306191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929017,0.0001048209,0.00019935051,0.00015669942,0.00013962892,0.00010935511],"domain_scores_gemma":[0.9987739,0.0008405462,0.000119459095,0.00013153783,0.00010471314,0.000029883891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044780338,0.00006614231,0.00022046259,0.000014139149,0.000044288114,0.000014930231,0.00010184822,0.000016729491,0.000026770875],"category_scores_gemma":[0.0005227812,0.00004176902,0.000017993643,0.00009534291,0.000026546482,0.00017601384,0.00012711038,0.000050817907,5.7221723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005724644,0.00055226113,0.9097912,0.00073543406,0.00053765037,0.0000039637675,0.012608055,0.00020026618,0.009722513,0.00022642512,0.007404728,0.052492883],"study_design_scores_gemma":[0.009839157,0.0010808966,0.9149017,0.0023962876,0.00061009167,0.0000031172144,0.0022742306,0.0015286293,0.03351345,0.00007579417,0.033573546,0.00020313937],"about_ca_topic_score_codex":0.013231525,"about_ca_topic_score_gemma":0.0014154735,"teacher_disagreement_score":0.052289747,"about_ca_system_score_codex":0.00008107324,"about_ca_system_score_gemma":0.00014636763,"threshold_uncertainty_score":0.9933395},"labels":[],"label_agreement":null},{"id":"W3004867668","doi":"10.1136/esmoopen-2019-000573","title":"New pathways in immune stimulation: targeting OX40","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune system; Immune checkpoint; Cytotoxic T cell; Immunotherapy; Immunology; Medicine; Antigen; Cancer research; Biology; In vitro","score_opus":0.050628910180302446,"score_gpt":0.30500878946658505,"score_spread":0.2543798792862826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004867668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.826125,0.003942144,0.001769919,0.06728149,0.0007001054,0.0031077096,0.000012437605,0.0001930348,0.096868105],"genre_scores_gemma":[0.99283016,0.000045520857,0.003028411,0.0029875685,0.00020299922,0.000008509221,0.000038616494,0.000014886982,0.0008433266],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99936265,0.00002183587,0.00022210904,0.00016293685,0.00010372549,0.00012672678],"domain_scores_gemma":[0.9997125,0.000021670694,0.00004619066,0.0001234114,0.000015700016,0.00008047964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001704851,0.00007642704,0.0001854214,0.000023231234,0.000034585217,0.000038555954,0.00016223713,0.000042904627,0.0024824694],"category_scores_gemma":[0.000049066162,0.00006766604,0.00004516254,0.00023055219,0.000011737663,0.00011888008,0.0000914724,0.00011102159,0.00007685359],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017387375,0.0002994525,0.1631276,0.00021228241,0.00038715685,0.0004902046,0.015815133,0.00033412492,0.17890428,0.0010443846,0.14185224,0.48014575],"study_design_scores_gemma":[0.013384996,0.00062787486,0.5781092,0.00026047355,0.000033936638,0.000013079246,0.00067352474,0.0016631477,0.019946264,0.00020210343,0.38475358,0.00033181268],"about_ca_topic_score_codex":0.0022596894,"about_ca_topic_score_gemma":0.0000503785,"teacher_disagreement_score":0.47981393,"about_ca_system_score_codex":0.00004328685,"about_ca_system_score_gemma":0.00015222075,"threshold_uncertainty_score":0.9984294},"labels":[],"label_agreement":null},{"id":"W3012979990","doi":"10.1136/esmoopen-2020-000679","title":"Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Medicine; Oncology; Immunohistochemistry; Internal medicine; Proportional hazards model; Lung cancer; Chemotherapy; Biomarker; Cancer; Predictive marker; Adjuvant chemotherapy; Adjuvant; Cohort; Pathology; Breast cancer; Biology","score_opus":0.03734788628738827,"score_gpt":0.31927344246471207,"score_spread":0.2819255561773238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012979990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996966,0.00048293133,0.00025827857,0.0001914154,0.000042968655,0.0015314269,0.0002625634,0.000008611575,0.0002557857],"genre_scores_gemma":[0.9988098,0.00019562677,0.0003819206,0.00009031596,0.000030488767,0.00010495358,0.00027466784,0.000026468191,0.000085715736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984625,0.000054511573,0.0006468415,0.0003806598,0.0003127729,0.00014271263],"domain_scores_gemma":[0.9988107,0.00006129279,0.00040473393,0.00041758805,0.0002276967,0.0000779712],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020322102,0.00016516303,0.0009785179,0.00020069929,0.000017663931,0.000007532382,0.00033608268,0.000100931866,0.0017206167],"category_scores_gemma":[0.000020531086,0.00015143759,0.00013815548,0.0011620695,0.00003429786,0.00006254664,0.000120094046,0.00012356152,6.121916e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008991566,0.0013746732,0.06974785,0.00007324341,0.0035560206,0.0000073061883,0.010672526,0.00037356734,0.9026488,0.0000031367526,0.00016178588,0.0023895116],"study_design_scores_gemma":[0.008501053,0.0009709077,0.37273115,0.00011267456,0.0012307204,1.3815396e-7,0.00096043426,0.008301188,0.607037,0.000016595108,0.000022252683,0.00011586886],"about_ca_topic_score_codex":0.038828522,"about_ca_topic_score_gemma":0.0011607364,"teacher_disagreement_score":0.30298328,"about_ca_system_score_codex":0.000119067125,"about_ca_system_score_gemma":0.00015444112,"threshold_uncertainty_score":0.99919194},"labels":[],"label_agreement":null},{"id":"W3019428658","doi":"10.1136/esmoopen-2020-000696","title":"Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel","year":2020,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Pharmaceutical Quality and Counterfeiting","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Family medicine; Counterfeit; Alternative medicine; The Internet; Traditional medicine; Political science; World Wide Web; Pathology","score_opus":0.12221413058825949,"score_gpt":0.4184181893886838,"score_spread":0.29620405880042433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019428658","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20088825,0.00055308774,0.00011152444,0.05299947,0.70290697,0.006607938,0.010490604,0.000058946556,0.025383208],"genre_scores_gemma":[0.46381852,0.0002871391,0.0009217425,0.013165777,0.5137257,0.00028043336,0.007540497,0.00007128891,0.00018892724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805194,0.00016018633,0.0005880191,0.00039477955,0.000629231,0.0001758646],"domain_scores_gemma":[0.9974934,0.0017142717,0.00023488364,0.00025594005,0.0001895696,0.000111962865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007555277,0.00019809189,0.00058160553,0.000036679317,0.000042595664,0.000049840004,0.0005007541,0.00025074344,0.00011240682],"category_scores_gemma":[0.001438821,0.00013709588,0.00005854297,0.00007345141,0.00015203362,0.00007652922,0.000205721,0.00083755504,0.0000029962453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019000742,0.00020718426,0.0004841182,0.00017953166,0.00024189847,0.000067398716,0.004881526,2.868024e-7,0.000104540115,0.0004012896,0.9809984,0.010533739],"study_design_scores_gemma":[0.0041334582,0.0016618667,0.0026467226,0.00051752385,0.00019550558,0.0000048272864,0.002831432,0.00010708483,0.00009136727,0.00061157974,0.98704547,0.00015317254],"about_ca_topic_score_codex":0.0012077445,"about_ca_topic_score_gemma":0.00019494432,"teacher_disagreement_score":0.26293027,"about_ca_system_score_codex":0.000038656457,"about_ca_system_score_gemma":0.00030467246,"threshold_uncertainty_score":0.55906075},"labels":[],"label_agreement":null},{"id":"W3032768522","doi":"10.1136/esmoopen-2020-000825","title":"Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration","year":2020,"lang":"en","type":"letter","venue":"ESMO Open","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; National Institute for Health and Care Research; Wellcome Trust","keywords":"Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Cancer; 2019-20 coronavirus outbreak; Geography; Virology; Medicine; Biology; Genetics; Outbreak","score_opus":0.21814493844703653,"score_gpt":0.4651365985681501,"score_spread":0.24699166012111357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032768522","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008026901,0.0005523525,0.00007075241,0.9901641,0.00038113515,0.0043223137,0.0032466233,0.000039596387,0.0004204244],"genre_scores_gemma":[0.0017450772,0.00074025587,0.0003690213,0.9859318,0.0033325998,0.00051914284,0.0065618237,0.0000549695,0.0007452785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847263,0.00012398831,0.00035383776,0.00046309864,0.00027424155,0.00031223023],"domain_scores_gemma":[0.99829173,0.00075707166,0.00025661793,0.0004736067,0.00014405446,0.00007691271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060163264,0.00023375452,0.00062495936,0.000057285382,0.0002414948,0.00053669466,0.0004303013,0.00033126317,0.00003090536],"category_scores_gemma":[0.0014941677,0.00015242911,0.000050044648,0.00018706577,0.000103146245,0.00033132377,0.00036202878,0.000934393,0.000007160932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005488763,0.0000055817222,0.0009719355,0.0008152696,0.00009091186,0.00007740351,0.00073809107,4.0296064e-7,0.00003280938,0.00007889856,0.99440336,0.0022364391],"study_design_scores_gemma":[0.0030200342,0.00008938512,0.0008049367,0.0004296279,0.00024898382,0.000021162105,0.000064776876,0.00015604155,0.00013643198,0.0002231412,0.994633,0.00017245687],"about_ca_topic_score_codex":0.018467644,"about_ca_topic_score_gemma":0.011886585,"teacher_disagreement_score":0.0065810606,"about_ca_system_score_codex":0.0002379473,"about_ca_system_score_gemma":0.0020702407,"threshold_uncertainty_score":0.98806846},"labels":[],"label_agreement":null},{"id":"W3037012925","doi":"10.1136/esmoopen-2020-000820","title":"ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merck Sharp and Dohme; Daiichi-Sankyo; Cancer Research UK; Clovis Oncology; Merck KGaA; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Novartis; Pfizer; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pandemic; Flexibility (engineering); Health care; Coronavirus disease 2019 (COVID-19); Economic shortage; Medicine; Cancer; Scale (ratio); Business; Lung cancer; Intensive care medicine; Risk analysis (engineering); Medical emergency; Political science; Economics; Disease; Law; Oncology; Pathology; Geography","score_opus":0.1989447492378444,"score_gpt":0.47514961731031413,"score_spread":0.27620486807246974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037012925","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029366437,0.0004273639,0.0001384462,0.9580196,0.000081957594,0.0028330632,0.000040434945,0.000034968838,0.0090577],"genre_scores_gemma":[0.8215616,0.0021869824,0.00051087857,0.17389248,0.000114085495,0.00040956974,0.00007936475,0.000014555401,0.001230495],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915254,0.00009759807,0.00018667421,0.00024597542,0.00012421569,0.0001930214],"domain_scores_gemma":[0.999284,0.00014066849,0.000045048084,0.00021328364,0.00001658627,0.0003003893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002343151,0.00011350722,0.00021148399,0.000055280656,0.00014574715,0.00005941278,0.00015688545,0.000037670856,0.00077332114],"category_scores_gemma":[0.000089518566,0.00007563353,0.000026303705,0.0002547543,0.000021415952,0.000086201486,0.00011370056,0.00012937184,0.000013213288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013439625,0.0005564572,0.3024375,0.00074934756,0.0004983886,0.00074244506,0.039862633,0.000095831536,0.000010459051,0.005376939,0.45411748,0.19420855],"study_design_scores_gemma":[0.0032022516,0.00027654503,0.22155233,0.00006674346,0.000107922395,0.000009204502,0.001077708,0.0004451557,0.000008736778,0.000060170034,0.773106,0.000087253924],"about_ca_topic_score_codex":0.031813435,"about_ca_topic_score_gemma":0.016103715,"teacher_disagreement_score":0.79219514,"about_ca_system_score_codex":0.00043427123,"about_ca_system_score_gemma":0.00040460986,"threshold_uncertainty_score":0.9746338},"labels":[],"label_agreement":null},{"id":"W3041579002","doi":"10.1136/esmoopen-2020-000673","title":"Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma","keywords":"Temozolomide; Concomitant; Medicine; Glioblastoma; Radiation therapy; Oncology; Internal medicine; Open label; Clinical trial; Cancer research","score_opus":0.03380584647365548,"score_gpt":0.31067671535739255,"score_spread":0.2768708688837371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041579002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975784,0.000050897732,0.0000028438951,0.0010048383,0.000013795366,0.009050156,0.00001908977,0.00001442739,0.000086104286],"genre_scores_gemma":[0.9984086,0.000048454156,0.0005790008,0.00039573814,0.000007915025,0.00044677526,0.00006509049,0.00003844443,0.000009946051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983645,0.0001557214,0.00042443033,0.00049645046,0.00032938516,0.0002295294],"domain_scores_gemma":[0.99893296,0.00020247287,0.0002895666,0.0002746533,0.00013052904,0.00016982185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017188939,0.00026936576,0.0007113144,0.0001431126,0.000057226276,0.00010688514,0.00024193148,0.00005594214,0.00003967541],"category_scores_gemma":[0.00007409008,0.00015778762,0.000009033483,0.00061539066,0.000058535843,0.00047657572,0.00011863113,0.00014131608,0.0000025565998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04750469,0.028239874,0.9060903,0.000025592313,0.0002238335,0.0005623538,0.0044613257,0.000056106015,0.000036742247,0.000013080752,0.00011136551,0.012674741],"study_design_scores_gemma":[0.30518994,0.05053639,0.64043075,0.00023606994,0.000083777966,0.000003949058,0.0018107574,0.00044252846,0.0010439577,0.000001538606,0.0000615856,0.00015872928],"about_ca_topic_score_codex":0.0038326418,"about_ca_topic_score_gemma":0.010066634,"teacher_disagreement_score":0.26565954,"about_ca_system_score_codex":0.00012000334,"about_ca_system_score_gemma":0.0001515357,"threshold_uncertainty_score":0.64343923},"labels":[],"label_agreement":null},{"id":"W3043725666","doi":"10.1136/esmoopen-2020-000672","title":"Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Novartis Pharmaceuticals Corporation","keywords":"Carboplatin; Medicine; Open label; Lomustine; Internal medicine; Oncology; Glioblastoma; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Cisplatin; Vincristine","score_opus":0.05163462450066753,"score_gpt":0.3471709034432321,"score_spread":0.29553627894256457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043725666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826888,0.000057094985,0.0000024495473,0.0013432174,0.0001050677,0.014996489,0.000054421245,0.000038223916,0.0007142342],"genre_scores_gemma":[0.99726725,0.000010169623,0.00064494676,0.00058664475,0.00005458988,0.0010776257,0.00013290244,0.00005300373,0.00017287098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976257,0.00015739795,0.00060140184,0.0007337225,0.0004689755,0.0004127941],"domain_scores_gemma":[0.99856687,0.00014226529,0.00022652443,0.00047029054,0.00015349218,0.00044054494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024556465,0.0003821034,0.0010261136,0.000106638654,0.0001467438,0.00017903188,0.00054600305,0.000062959174,0.00070914463],"category_scores_gemma":[0.00035227847,0.00022281583,0.000038801598,0.00065529346,0.00003610368,0.00028510366,0.00084992306,0.00023838885,0.00006420688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5419088,0.09043612,0.319052,0.00011287272,0.0011191985,0.0037159668,0.01032219,0.000077788216,0.000039300772,0.000008752011,0.009696696,0.02351032],"study_design_scores_gemma":[0.855256,0.03352359,0.1050379,0.00040424938,0.00059361185,0.000006067473,0.00086522964,0.0016168533,0.0004243146,0.0000011006977,0.0018887605,0.0003822821],"about_ca_topic_score_codex":0.0014424955,"about_ca_topic_score_gemma":0.0025489738,"teacher_disagreement_score":0.31334725,"about_ca_system_score_codex":0.00021127175,"about_ca_system_score_gemma":0.00025946737,"threshold_uncertainty_score":0.90861654},"labels":[],"label_agreement":null},{"id":"W3080424252","doi":"10.1136/esmoopen-2020-000714","title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Exelixis","keywords":"Sorafenib; Cabozantinib; Medicine; Placebo; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Subgroup analysis; Population; Oncology; Gastroenterology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Pathology","score_opus":0.12315819482426821,"score_gpt":0.33145405545630824,"score_spread":0.20829586063204003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080424252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990566,0.00033360044,0.00022994976,0.0016853411,0.00016825703,0.006662827,0.00055995956,0.00003067593,0.00042375084],"genre_scores_gemma":[0.99545836,0.000015882359,0.0008134579,0.0004639267,0.00027399362,0.0013763201,0.0006433483,0.00004837589,0.00090635574],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980029,0.00012640603,0.00063264207,0.0005970626,0.000275388,0.0003655924],"domain_scores_gemma":[0.9985774,0.00012253608,0.00026031877,0.0006258692,0.00013750062,0.00027638653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020635247,0.00035486705,0.0011750205,0.00009998066,0.000121773664,0.000051728166,0.00035922942,0.00013412442,0.0013256681],"category_scores_gemma":[0.00008158619,0.00023364775,0.0010150997,0.00086777745,0.00008414564,0.00012674696,0.0001596702,0.00011660435,0.000014299991],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16476278,0.0030705198,0.8110527,0.0001732776,0.00494348,0.00036794457,0.002466581,0.000009241274,0.0056226877,0.00010584775,0.00042562885,0.0069993306],"study_design_scores_gemma":[0.4860751,0.020443235,0.040072136,0.00008860758,0.029906198,0.000013422281,0.00029836956,0.04840893,0.3074965,0.000037685902,0.06627652,0.00088331243],"about_ca_topic_score_codex":0.00046490054,"about_ca_topic_score_gemma":0.00033625652,"teacher_disagreement_score":0.77098054,"about_ca_system_score_codex":0.00008490078,"about_ca_system_score_gemma":0.00030311555,"threshold_uncertainty_score":0.99958724},"labels":[],"label_agreement":null},{"id":"W3080816877","doi":"10.1136/esmoopen-2020-000842","title":"Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis","year":2020,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"Seagen; Servier; G1 Therapeutics; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Meta-analysis; Breast cancer; Hormone receptor; Oncology; Medicine; Internal medicine; Cancer; HER2 negative; Hormone therapy; Endocrine system; Hormone; Metastatic breast cancer","score_opus":0.08004028103045263,"score_gpt":0.3948734691561016,"score_spread":0.314833188125649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080816877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.003087e-7,0.97989976,0.000042381187,0.0020006832,0.00004563028,0.016607977,0.0011423236,0.000058596434,0.00020204388],"genre_scores_gemma":[0.0000230424,0.9816136,0.0021633664,0.00214371,0.00009817896,0.01232779,0.0006517644,0.00017325363,0.0008053048],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99441695,0.0013454071,0.0017578927,0.0013640758,0.00049226696,0.0006233921],"domain_scores_gemma":[0.99615574,0.0005835799,0.0015758731,0.0011316678,0.00021080027,0.0003423674],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000558722,0.0012808921,0.01923513,0.0002778654,0.000120039535,0.00009009587,0.00072220026,0.00017898106,0.001264788],"category_scores_gemma":[0.000084441206,0.0008268571,0.002124327,0.0028599408,0.00013734306,0.00028248265,0.00025645416,0.000620795,0.00004976612],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053653866,0.0002815667,0.000023373676,0.3502613,0.39496216,0.00021525034,0.000115771,0.00003836142,2.9839578e-7,0.000019609437,0.00020635751,0.25333938],"study_design_scores_gemma":[0.0028995061,0.00032905003,0.00012621691,0.16166197,0.70894283,0.00012426988,0.000024577483,0.0000064449555,0.0000024011724,0.000019941506,0.12504053,0.00082223373],"about_ca_topic_score_codex":0.0015089113,"about_ca_topic_score_gemma":0.0002956774,"teacher_disagreement_score":0.3139807,"about_ca_system_score_codex":0.00084554916,"about_ca_system_score_gemma":0.00057788903,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W3095269312","doi":"10.1136/esmoopen-2020-000937","title":"MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Associazione Italiana per la Ricerca sul Cancro; Cancer Research UK","keywords":"Breast cancer; FOXA1; Medicine; Oncology; Internal medicine; Endocrine system; Biomarker; Cancer; Hormone; Biology","score_opus":0.009638807202045895,"score_gpt":0.2538399882930614,"score_spread":0.24420118109101552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095269312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99836844,0.00009409349,0.0000045138163,0.0007421389,0.000011927077,0.0005028263,0.00020517338,0.0000018745427,0.00006899579],"genre_scores_gemma":[0.9993897,0.000018402594,0.00014026648,0.00020122548,0.00003137566,0.00006959424,0.00007502135,0.000011186677,0.00006322122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945676,0.00003636297,0.00011044718,0.00022293413,0.00007592711,0.00009754702],"domain_scores_gemma":[0.999696,0.00000286299,0.000051175433,0.00010349224,0.00008523612,0.00006121881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036294005,0.00007647107,0.00011118768,0.000015842197,0.000018581193,0.000017271079,0.0001425412,0.000031343334,0.00010618543],"category_scores_gemma":[0.000011118207,0.000065780165,0.000012583994,0.00007273754,0.000040940802,0.000009394468,0.00018166131,0.000027392178,8.7292074e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019052352,0.00009327765,0.9739314,0.00006674204,0.000048018053,0.0000025052564,0.00012710955,0.000019191819,0.022386719,0.000002877474,0.0010000825,0.00041686482],"study_design_scores_gemma":[0.0014559986,0.00022854368,0.89030284,0.000059541235,0.000015900838,0.000001478132,0.000015524167,0.00002451386,0.10530188,0.0000012578358,0.0025116664,0.00008083279],"about_ca_topic_score_codex":0.00027387537,"about_ca_topic_score_gemma":0.00007424442,"teacher_disagreement_score":0.08362851,"about_ca_system_score_codex":0.000009435191,"about_ca_system_score_gemma":0.00009304944,"threshold_uncertainty_score":0.26824373},"labels":[],"label_agreement":null},{"id":"W3106792472","doi":"10.1136/esmoopen-2020-000948","title":"Prevention of venous thromboembolism in ambulatory patients with cancer","year":2020,"lang":"en","type":"review","venue":"ESMO Open","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"Bayer","keywords":"Medicine; Apixaban; Ambulatory; Rivaroxaban; Cancer; Low molecular weight heparin; Warfarin; Anticoagulant; Regimen; Intensive care medicine; Thrombosis; Complication; Venous thromboembolism; Clinical trial; Venous thrombosis; Internal medicine; Atrial fibrillation","score_opus":0.05210794562375279,"score_gpt":0.3764223271871719,"score_spread":0.3243143815634191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106792472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068993284,0.9865455,0.0000039162333,0.00007485452,0.00024401164,0.0066846143,0.00005713991,0.000023009286,0.0056769885],"genre_scores_gemma":[0.0005721469,0.99755985,0.00024130159,0.00017776429,0.000098502125,0.0006958838,0.00029703326,0.00008749774,0.00027003328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815804,0.000090014626,0.0006444317,0.0004990013,0.00034954643,0.00025895739],"domain_scores_gemma":[0.9988104,0.000027184527,0.00050448254,0.0004715041,0.00007386069,0.00011255915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017644269,0.00035389705,0.0035923854,0.00014479477,0.000033440807,0.000030500481,0.00044287374,0.00017593792,0.0004922552],"category_scores_gemma":[0.00001706806,0.0002623323,0.0002697054,0.00041992238,0.000050318846,0.00012343223,0.0004049799,0.00031218547,0.000043810887],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003131916,0.0020085252,0.00068107585,0.01675816,0.0010046229,0.000031597683,0.00027626715,0.0000020487496,2.0848079e-8,0.00022566211,0.004325667,0.97465503],"study_design_scores_gemma":[0.0012977198,0.0006800129,0.040293235,0.03309024,0.002387421,0.0000015635446,0.000017754313,0.0000010474096,7.9664875e-7,0.000024568879,0.9219476,0.0002580228],"about_ca_topic_score_codex":0.0020480356,"about_ca_topic_score_gemma":0.00043924048,"teacher_disagreement_score":0.974397,"about_ca_system_score_codex":0.00023504795,"about_ca_system_score_gemma":0.0006288836,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W3107453141","doi":"10.1136/esmoopen-2020-001079","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Sunitinib; Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Gastroenterology; Oncology; Cancer; Immunotherapy","score_opus":0.086461553476601,"score_gpt":0.333877590462352,"score_spread":0.247416036985751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107453141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98544955,0.00023837814,0.0000418072,0.0009828021,0.0005797258,0.007018694,0.00027812962,0.00002754325,0.005383386],"genre_scores_gemma":[0.995093,0.000050626375,0.0009154804,0.000058567497,0.00027111568,0.00050031027,0.00029513965,0.00006444618,0.0027513492],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977703,0.00009710244,0.00078212365,0.00053900963,0.0004200525,0.00039140787],"domain_scores_gemma":[0.99799395,0.00023561646,0.00048826882,0.00081099436,0.00021504352,0.00025610707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016840322,0.00037847657,0.0011420716,0.000061450126,0.00014250774,0.000021775086,0.00048619753,0.00011942033,0.0003127932],"category_scores_gemma":[0.00013934293,0.0002598503,0.0005741235,0.00028186984,0.00012744244,0.000111439316,0.00021826585,0.00011730668,0.000013303985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9711877,0.0034426558,0.00016479501,0.00035999742,0.00063922664,0.00010585244,0.0036184513,0.00015096259,0.009708098,0.00018215063,0.0011601696,0.009279929],"study_design_scores_gemma":[0.6368122,0.031323258,0.00075485173,0.00006657904,0.001038785,0.00000555148,0.0006242759,0.00038318877,0.32340682,0.000024920822,0.005358638,0.00020092967],"about_ca_topic_score_codex":0.0007365238,"about_ca_topic_score_gemma":0.00024928953,"teacher_disagreement_score":0.3343755,"about_ca_system_score_codex":0.00039333536,"about_ca_system_score_gemma":0.0005699875,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W3108175435","doi":"10.1136/esmoopen-2020-001081","title":"Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Symphogen; Pfizer; Incyte; BeiGene; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Huntsman Cancer Institute; Sierra Oncology; King Abdullah International Medical Research Center; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen","keywords":"Dosing; Medicine; Phase (matter); Internal medicine; Oncology; Chemistry","score_opus":0.04774679406852019,"score_gpt":0.39006136350714915,"score_spread":0.342314569438629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108175435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952938,0.000021945654,0.00007958686,0.0004314666,0.000015566462,0.0040086918,0.000056470166,0.0000025221357,0.00008996475],"genre_scores_gemma":[0.99677396,0.000006542446,0.0027844254,0.00022259747,0.000009265637,0.00007456095,0.00004914546,0.000027356202,0.00005212454],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846476,0.00028255186,0.00027372706,0.00044323746,0.00026033877,0.0002753641],"domain_scores_gemma":[0.99929106,0.000043052616,0.00007542301,0.00031949684,0.000121322046,0.00014964731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041726287,0.00016714608,0.000283386,0.000029257546,0.00008895831,0.000110077934,0.00081495417,0.00002230812,0.0000482109],"category_scores_gemma":[0.0002759514,0.00010507623,0.000012105823,0.00023410883,0.00006464101,0.000029178387,0.0015461768,0.00011753992,0.000005234317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2846147,0.028726455,0.2891255,0.00041607997,0.0019875478,0.00018397445,0.027258862,0.007866865,0.31277883,0.00003578142,0.0017766377,0.045228764],"study_design_scores_gemma":[0.25268003,0.09981943,0.33826762,0.0005321242,0.000381093,0.000008248256,0.014072985,0.004459829,0.2854757,0.00000912592,0.0026743948,0.0016193993],"about_ca_topic_score_codex":0.00020890546,"about_ca_topic_score_gemma":0.00043618263,"teacher_disagreement_score":0.07109298,"about_ca_system_score_codex":0.00001843963,"about_ca_system_score_gemma":0.00014249246,"threshold_uncertainty_score":0.42848843},"labels":[],"label_agreement":null},{"id":"W3112236294","doi":"10.1136/esmoopen-2020-000878","title":"Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"World Health Organization","keywords":"Cervical cancer; Medicine; Psychological intervention; Developing country; Palliative care; Family medicine; Health care; Cancer; Economic growth; Nursing; Economics","score_opus":0.12631647061515996,"score_gpt":0.4343093586953991,"score_spread":0.30799288808023917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112236294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5915721,0.001786213,0.00158579,0.08967144,0.00034330203,0.006717463,0.00052560813,0.0001604679,0.3076376],"genre_scores_gemma":[0.99289215,0.00009156836,0.00027211945,0.004644271,0.00037931508,0.00012815613,0.000098607554,0.000021274825,0.0014725688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985912,0.000031197123,0.00037945394,0.00035409554,0.00039501514,0.00024907987],"domain_scores_gemma":[0.9989014,0.00014510386,0.00011339634,0.0003036981,0.00024496167,0.00029141418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036156902,0.00010307856,0.0006353936,0.00016870825,0.00006157505,0.000042900036,0.00021281927,0.00007223341,0.006757671],"category_scores_gemma":[0.00048356302,0.00008547074,0.00010294159,0.0015696558,0.000053076466,0.00008185441,0.00026834186,0.00015630468,0.000003945019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036268085,0.00019298664,0.84252036,0.0010046621,0.0027235697,0.0001898105,0.0015315576,0.00029377494,0.0010736235,0.0011281875,0.034189258,0.11152538],"study_design_scores_gemma":[0.001069546,0.00034528068,0.9284167,0.000044832002,0.00088536716,0.0000030599485,0.000104626684,0.003189562,0.0013004829,0.00007089544,0.06445494,0.00011464905],"about_ca_topic_score_codex":0.011421706,"about_ca_topic_score_gemma":0.0021042286,"teacher_disagreement_score":0.40132,"about_ca_system_score_codex":0.00011318549,"about_ca_system_score_gemma":0.0005220945,"threshold_uncertainty_score":0.9951613},"labels":[],"label_agreement":null},{"id":"W3119548493","doi":"10.1016/j.esmoop.2020.100001","title":"Sex as decisive variable in lymphoid neoplasms—an update","year":2021,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Variable (mathematics); Mathematics; Biology; Mathematical analysis","score_opus":0.012617745334106664,"score_gpt":0.3292280976095206,"score_spread":0.31661035227541395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119548493","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005556328,0.00089396694,0.000009874255,0.0007400473,0.88518244,0.0024429185,0.00045384504,0.000073600975,0.10464696],"genre_scores_gemma":[0.0023264007,0.003017846,0.006532139,0.0020588108,0.9202947,0.0014103322,0.018309979,0.00026808845,0.045781687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690336,0.00016341692,0.0005511488,0.0010509057,0.00082150573,0.0005096709],"domain_scores_gemma":[0.997341,0.000682325,0.00020194684,0.001163158,0.0002624234,0.00034914672],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004989495,0.00049778825,0.0013310291,0.00016180713,0.000099069046,0.00040254343,0.0007024451,0.0009014961,0.003111688],"category_scores_gemma":[0.0008312756,0.00043228522,0.00014054119,0.00034655098,0.000038180875,0.0002736455,0.0006994687,0.00041244566,0.0009432075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031345253,0.0012122971,0.002330833,0.00005091363,0.00031698265,0.003596268,0.00018910618,0.0000072930925,0.0000036719646,0.00034479506,0.9867634,0.0048709614],"study_design_scores_gemma":[0.009033753,0.00046921417,0.0005260752,0.00074891315,0.0003545092,0.00009580405,0.00013290205,0.000015667914,0.000894054,0.00058446714,0.98673415,0.00041049198],"about_ca_topic_score_codex":0.025348654,"about_ca_topic_score_gemma":0.0023694446,"teacher_disagreement_score":0.05886527,"about_ca_system_score_codex":0.0010833933,"about_ca_system_score_gemma":0.0045530004,"threshold_uncertainty_score":0.99983466},"labels":[],"label_agreement":null},{"id":"W3120723698","doi":"10.1016/j.esmoop.2020.100019","title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; European Society for Medical Oncology; Eisai; Eli Lilly and Company; Takeda Pharmaceutical Company; Roche; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Eribulin; Gemcitabine; Medicine; Internal medicine; Metastatic breast cancer; Triple-negative breast cancer; Oncology; Neutropenia; Regimen; Clinical endpoint; Phases of clinical research; Febrile neutropenia; Breast cancer; Adverse effect; Clinical trial; Cancer; Toxicity","score_opus":0.08808522107393496,"score_gpt":0.45142079871338525,"score_spread":0.3633355776394503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120723698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863081,0.00010676991,0.000004918503,0.0013216515,0.0002026817,0.011167912,0.0008158285,0.0000035735068,0.000068556656],"genre_scores_gemma":[0.9972127,0.00045372828,0.000212451,0.00013865191,0.000027838858,0.0013805976,0.00008318239,0.000018159673,0.00047265305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792004,0.00041593387,0.0008749276,0.0003772757,0.0002504284,0.00016140746],"domain_scores_gemma":[0.9973403,0.0012358621,0.00068565167,0.00031162918,0.00036168334,0.000064835345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003993402,0.00020291007,0.0008976417,0.000045111276,0.00008999659,0.0000074216805,0.0001705376,0.000043797052,0.00013646629],"category_scores_gemma":[0.00012006929,0.00009120864,0.000083513325,0.00037867285,0.00024030899,0.00006455778,0.00007576434,0.000102227394,1.5163168e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7705467,0.09939826,0.059580687,0.000059026865,0.0017760885,0.00002601462,0.0026521883,0.00015424578,0.00006676431,0.0000061802116,0.00016069924,0.06557314],"study_design_scores_gemma":[0.5228265,0.17426719,0.29685214,0.00012713239,0.001977581,0.0000021182473,0.00076241506,0.000103833365,0.002530336,0.000008571688,0.00045276023,0.000089394096],"about_ca_topic_score_codex":0.0008366315,"about_ca_topic_score_gemma":0.0056859045,"teacher_disagreement_score":0.24772018,"about_ca_system_score_codex":0.00011544024,"about_ca_system_score_gemma":0.00060006743,"threshold_uncertainty_score":0.37193802},"labels":[],"label_agreement":null},{"id":"W3130302511","doi":"10.1016/j.esmoop.2020.100043","title":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Medical Research Council; Canadian Cancer Society Research Institute; Cancer Research UK; Cancer Australia; Canadian Cancer Society; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Chemotherapy; Placebo; Ovarian cancer; Maintenance therapy; Progression-free survival; Oncology; Randomized controlled trial; Confidence interval; Surgery; Cancer; Pathology","score_opus":0.033239662900949984,"score_gpt":0.33713862508399317,"score_spread":0.3038989621830432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130302511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421575,0.000021349113,0.00019470668,0.007243156,0.000361827,0.008305881,0.0011185306,0.00001784013,0.0085209925],"genre_scores_gemma":[0.99181783,0.000056890753,0.0014362335,0.0011519225,0.0003078395,0.002846313,0.0004454161,0.00003889225,0.0018986675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984203,0.00009977456,0.0004986991,0.00046813407,0.00023417732,0.00027890445],"domain_scores_gemma":[0.9987777,0.00034014805,0.00019966798,0.00032053722,0.00020928509,0.00015269987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005451408,0.00019009692,0.0008188608,0.000075857286,0.000045830475,0.000039393755,0.000089612964,0.0000864,0.00072783005],"category_scores_gemma":[0.00015275837,0.00015295463,0.00007955563,0.0002467759,0.000027380791,0.000105264924,0.00003413338,0.00010115981,0.0000023293526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9750944,0.0018156767,0.000098503864,0.00003725372,0.0006987495,0.00015910092,0.0041755727,0.00004271283,0.0009156217,0.0002047052,0.004621334,0.012136382],"study_design_scores_gemma":[0.9560712,0.004163835,0.0063760313,0.000496418,0.00012636613,0.0000055911414,0.00045581165,0.00007513902,0.022716977,0.00009352302,0.009231762,0.00018733049],"about_ca_topic_score_codex":0.002563731,"about_ca_topic_score_gemma":0.0023241777,"teacher_disagreement_score":0.021801354,"about_ca_system_score_codex":0.00038571496,"about_ca_system_score_gemma":0.0006795952,"threshold_uncertainty_score":0.7969228},"labels":[],"label_agreement":null},{"id":"W3132264975","doi":"10.1016/j.esmoop.2021.100057","title":"Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Ipsen; Medizinische Universität Wien; Universität Wien; Roche; AbbVie; GlaxoSmithKline; Merck; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; CMC Microsystems; Amgen; Pfizer; Exelixis","keywords":"Renal cell carcinoma; Tumor-infiltrating lymphocytes; Medicine; Brain metastasis; FOXP3; CD8; Pathology; Tumor microenvironment; Immunohistochemistry; Lung; Oncology; Metastasis; Immune system; Internal medicine; Cancer; Immunology","score_opus":0.019465888356380186,"score_gpt":0.2860749971873176,"score_spread":0.2666091088309374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132264975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892393,0.0018811793,0.00000936126,0.006462818,0.000023227667,0.0003801354,0.00006789032,0.0000070716487,0.001929044],"genre_scores_gemma":[0.9918344,0.000023019998,0.005946537,0.0005612621,0.000042772797,0.000042047086,0.0003063161,0.000013950468,0.0012296749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991256,0.00010841097,0.0002161653,0.0002713499,0.00012025479,0.00015821274],"domain_scores_gemma":[0.9994575,0.00018311902,0.00005063436,0.00016636515,0.000042166015,0.00010020897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002889417,0.0001279694,0.00032274995,0.00005430312,0.000053878957,0.00008983107,0.000057347876,0.00002622063,0.0006069445],"category_scores_gemma":[0.000079827165,0.00010672152,0.000031491873,0.00013100613,0.000056198118,0.00011578605,0.00016369073,0.000098008786,0.000010177866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036848192,0.0034602683,0.67761505,0.0017916049,0.001965,0.061138947,0.013882538,0.00021392619,0.10891393,0.017582757,0.015289,0.09446215],"study_design_scores_gemma":[0.008401485,0.00038617515,0.90832406,0.00011474592,0.00019647693,0.0014214838,0.0021743074,0.00013552819,0.071836926,0.0013308857,0.0054532923,0.00022461839],"about_ca_topic_score_codex":0.0026247364,"about_ca_topic_score_gemma":0.00028753004,"teacher_disagreement_score":0.23070902,"about_ca_system_score_codex":0.000023518878,"about_ca_system_score_gemma":0.00016012948,"threshold_uncertainty_score":0.6645616},"labels":[],"label_agreement":null},{"id":"W3134169755","doi":"10.1016/j.esmoop.2021.100063","title":"Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer","year":2021,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metastatic breast cancer; Oncology; Medicine; Breast cancer; Cancer; Internal medicine","score_opus":0.024948662635954227,"score_gpt":0.3808935649606516,"score_spread":0.35594490232469733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134169755","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043400182,0.005889658,0.005139788,0.011065959,0.8668877,0.019312339,0.08777659,0.00016173352,0.003332261],"genre_scores_gemma":[0.0007873709,0.0033936778,0.08249243,0.0015774023,0.65158415,0.022931283,0.0887828,0.0005965682,0.14785428],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970967,0.00016686623,0.0005767136,0.0009864824,0.00064087904,0.0005323384],"domain_scores_gemma":[0.9969927,0.0009343569,0.00034024214,0.0006764775,0.000726537,0.00032970656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043021975,0.00058212224,0.0013942738,0.00007685228,0.0002354535,0.00022155746,0.00044384133,0.00031743717,0.0021411362],"category_scores_gemma":[0.00038726447,0.00043012828,0.00033834146,0.00026474165,0.0001013065,0.00018319566,0.00027133778,0.00052721443,0.000028510618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024315736,0.0011583245,0.000007299476,0.00040289955,0.0020880788,0.00018571988,0.00020329947,0.000010032093,0.000013588956,0.00006899322,0.96766084,0.025769357],"study_design_scores_gemma":[0.011044888,0.0014229225,0.0000920238,0.001532926,0.002623724,0.00007883344,0.0006997907,0.00003297544,0.00026846136,0.00005550079,0.98162377,0.00052418374],"about_ca_topic_score_codex":0.0028121688,"about_ca_topic_score_gemma":0.0013197646,"teacher_disagreement_score":0.2153035,"about_ca_system_score_codex":0.00043578102,"about_ca_system_score_gemma":0.0030885588,"threshold_uncertainty_score":0.99981505},"labels":[],"label_agreement":null},{"id":"W3138851413","doi":"10.1016/j.esmoop.2021.100089","title":"An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Johnson and Johnson; Genentech; Astellas Pharma; Roche; National Institute for Health and Care Research; Novartis; Sanofi; GlaxoSmithKline; Merck; Bayer; AstraZeneca; Amgen; Pfizer","keywords":"Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.14885466249602713,"score_gpt":0.4834998996692597,"score_spread":0.3346452371732326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138851413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937745,0.0032204913,0.00000211372,0.0014415932,0.000008305975,0.0013815573,0.00012253349,0.0000024722813,0.00004643257],"genre_scores_gemma":[0.9989636,0.00033884638,0.00019102103,0.00007301079,0.0000016942196,0.00013017465,0.00024303657,0.0000073151077,0.000051330677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797475,0.00053161144,0.00070252747,0.00025300644,0.00035742694,0.00018069735],"domain_scores_gemma":[0.9989384,0.00014045199,0.00032062441,0.0002522958,0.00028500753,0.0000632373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013160808,0.00010733724,0.0008097568,0.00016551327,0.0000770711,0.00003921522,0.000091137554,0.000017141698,0.000027178758],"category_scores_gemma":[0.00012888748,0.00006226633,0.00003068809,0.0012345593,0.00013513188,0.00022246843,0.000043737196,0.00011872274,5.988328e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028107888,0.0019252003,0.9702292,0.00044759343,0.0019652857,0.000042962107,0.01869791,0.00015968754,0.00019453077,0.000046480753,0.000018013781,0.0034623523],"study_design_scores_gemma":[0.013331538,0.0006457739,0.97054106,0.00030497691,0.00037223985,3.2651553e-7,0.014267038,0.00022265324,0.0002161618,0.000026008353,0.0000053131807,0.000066902],"about_ca_topic_score_codex":0.024390895,"about_ca_topic_score_gemma":0.041904446,"teacher_disagreement_score":0.01751355,"about_ca_system_score_codex":0.00013359627,"about_ca_system_score_gemma":0.0008841809,"threshold_uncertainty_score":0.9821058},"labels":[],"label_agreement":null},{"id":"W3154880036","doi":"10.1016/j.esmoop.2021.100117","title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Novartis Farmacéutica; European Society for Medical Oncology; Shire; Eisai; Seagen; G1 Therapeutics; Genentech; Veracyte; SkylineDx; Roche; Nordic Nanovector; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Celldex Therapeutics; Ipsen; Array BioPharma; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Boehringer Ingelheim; Radius Health; Daiichi Sankyo Europe; Servier; Bayer; Gilead Sciences; NeraCare; Cancer Research UK; World Health Organization; Sanofi; Novartis; Ariad Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Scale (ratio); Food and drug administration; Agency (philosophy); Clinical study design; Medical physics; Research design; Risk analysis (engineering); Pathology; Statistics","score_opus":0.5438960934358554,"score_gpt":0.5372332370321362,"score_spread":0.0066628564037192195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154880036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.095173106,0.8981757,0.0002577992,0.00008507785,0.00067631726,0.0024324437,0.0022385714,0.000007954501,0.0009529911],"genre_scores_gemma":[0.05499976,0.9429012,0.0010451699,0.000054092026,0.00020220534,0.00011815035,0.00048515212,0.00005143188,0.00014282168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930859,0.00023594756,0.004787419,0.0014244723,0.00009607363,0.0003701458],"domain_scores_gemma":[0.9922962,0.002461151,0.0032703583,0.0017189623,0.000083386854,0.00016990751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0096547045,0.0004237222,0.005537518,0.00037174358,0.000121076264,0.00023021059,0.0017813456,0.00031355539,0.00031181253],"category_scores_gemma":[0.0010237813,0.00037547067,0.0004876948,0.00064684683,0.00029745634,0.00070096593,0.0021197996,0.00050654483,0.00000817981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031464268,0.00031122853,0.72776455,0.00028090389,0.0014072785,0.0000048239767,0.0001451655,0.000021044525,1.005577e-9,0.0010995523,0.00025328377,0.26868072],"study_design_scores_gemma":[0.00154913,0.0002734257,0.8054482,0.0008715961,0.0018968041,0.0000034459724,0.00064170413,0.000112136266,3.28913e-7,0.00031330856,0.1883831,0.0005068765],"about_ca_topic_score_codex":0.012990631,"about_ca_topic_score_gemma":0.023564404,"teacher_disagreement_score":0.26817384,"about_ca_system_score_codex":0.000056220313,"about_ca_system_score_gemma":0.00033400065,"threshold_uncertainty_score":0.9998697},"labels":[],"label_agreement":null},{"id":"W3157783125","doi":"10.1016/j.esmoop.2021.100092","title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":505,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; McMaster University; University of Toronto","funders":"European Society for Medical Oncology; Kyowa Hakko Kirin; Celgene; Novartis; Helsinn; Amgen","keywords":"Cachexia; Guideline; Expert opinion; Medicine; Multidisciplinary approach; Clinical Practice; Cancer cachexia; Intensive care medicine; Cancer; Physical therapy; Internal medicine; Pathology","score_opus":0.2250451284064284,"score_gpt":0.5728219565235178,"score_spread":0.3477768281170893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157783125","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28461683,0.0009911871,0.00008974537,0.5389344,0.003225531,0.0021585727,0.000042908847,0.00008998361,0.16985083],"genre_scores_gemma":[0.22819243,0.0068597947,0.11272757,0.63466924,0.0020015638,0.00039233186,0.00041595695,0.00009229282,0.014648817],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982013,0.00017016953,0.0008188688,0.00032920073,0.0002459855,0.00023445103],"domain_scores_gemma":[0.99755275,0.00017617595,0.00014575722,0.00031289487,0.0016166136,0.00019581609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008754051,0.000097425254,0.00034198884,0.000044496606,0.0000611426,0.000041565014,0.00014804337,0.00011307773,0.0014102987],"category_scores_gemma":[0.005712629,0.000090537316,0.000051478266,0.0002636509,0.000027755772,0.00023201821,0.00017637113,0.0004308903,0.00015737039],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004907907,0.0012802564,0.60115725,0.00013831066,0.000048287235,0.00035479708,0.0002544592,0.00000258317,0.0000045325837,0.0012035387,0.34319738,0.051867805],"study_design_scores_gemma":[0.0054544816,0.00008096294,0.28371555,0.0005551568,0.000039316972,0.000020037418,0.00036826415,0.00010974025,0.00007008665,0.00009179015,0.70939416,0.00010048907],"about_ca_topic_score_codex":0.005844255,"about_ca_topic_score_gemma":0.002555076,"teacher_disagreement_score":0.36619678,"about_ca_system_score_codex":0.00012679218,"about_ca_system_score_gemma":0.00068164873,"threshold_uncertainty_score":0.99950254},"labels":[],"label_agreement":null},{"id":"W3159801410","doi":"10.1016/j.esmoop.2021.100113","title":"Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; National Cancer Institute; Bayer Yakuhin; Ignyta; Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; AstraZeneca; Genentech; Pfizer Japan; Bavarian Nordic; Ipsen; Exelixis; European Medicines Agency; PharmaMar; Celgene; Yakult Honsha; Bayer; Astellas Pharma; Eisai; Daiichi-Sankyo; AstraZeneca España; Ludwig Center at Harvard; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Roche España; Nippon Kayaku; BeiGene; Les Laboratories Pierre Fabre; Helsinn; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Lung Cancer Research Foundation; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Ono Pharmaceutical; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; G1 Therapeutics; Roche; Merck Sharp and Dohme; Novartis; Kissei; Merck; Kyowa Hakko Kirin; Sanofi; Foundation Medicine; GlaxoSmithKline; Servier; Incyte; Pfizer; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Canadian Asian Studies Association; Boehringer Ingelheim España; Eli Lilly and Company; Society for Academic Continuing Medical Education","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Cancer; Lung cancer; Phases of clinical research; ROS1; Adenocarcinoma","score_opus":0.018021475982970155,"score_gpt":0.36851374264837883,"score_spread":0.35049226666540867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159801410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888981,0.00034143272,0.000103499195,0.0009651577,0.00043124892,0.004870715,0.0025726806,0.000022423515,0.001794717],"genre_scores_gemma":[0.99579114,0.000054409327,0.0010644108,0.0005280038,0.00006488819,0.00062639243,0.0008843417,0.000031974258,0.0009544213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981608,0.0000756959,0.0005284661,0.00063539913,0.0002901413,0.0003094998],"domain_scores_gemma":[0.9983426,0.00020187136,0.00034566387,0.0003632604,0.0005181068,0.00022850439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009848941,0.0002938656,0.0007196508,0.000051123574,0.0003664659,0.000071360846,0.00011303741,0.0000769947,0.00046461736],"category_scores_gemma":[0.00008061124,0.00024056988,0.000119762524,0.00024091541,0.000040584015,0.00015635678,0.00039121605,0.00011190389,0.000001616864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033272489,0.015847137,0.9100898,0.000087099834,0.0045141866,0.0009025818,0.042029634,0.00003700926,0.0026311127,0.000020558382,0.004217078,0.01629654],"study_design_scores_gemma":[0.057750467,0.0055581448,0.87702817,0.0006808668,0.005996913,0.000031280142,0.025926847,0.00044527455,0.02558393,0.00007227799,0.00042523924,0.0005005869],"about_ca_topic_score_codex":0.020373086,"about_ca_topic_score_gemma":0.0051303776,"teacher_disagreement_score":0.054423217,"about_ca_system_score_codex":0.00028495002,"about_ca_system_score_gemma":0.00077313656,"threshold_uncertainty_score":0.9861503},"labels":[],"label_agreement":null},{"id":"W3168750154","doi":"10.1016/j.esmoop.2021.100168","title":"Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Roche; AstraZeneca; Bristol-Myers Squibb; AbbVie; Merck; GlaxoSmithKline; Daiichi-Sankyo; CMC Microsystems; Amgen","keywords":"Medicine; Colorectal cancer; Internal medicine; Hazard ratio; Descending colon; Confidence interval; Oncology; Rectum; Gastroenterology; Primary tumor; Cancer; Cecum; Multivariate analysis; Ascending colon; Metastasis","score_opus":0.016417043705608137,"score_gpt":0.2760134320180843,"score_spread":0.25959638831247617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168750154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938371,0.00014809203,0.000004532352,0.0018385549,0.00002803487,0.0011897206,0.00065740506,0.000017781002,0.0022787375],"genre_scores_gemma":[0.9922954,0.000008952789,0.0032607545,0.00240728,0.000012115046,0.00025903236,0.0008845497,0.000035522582,0.000836404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987339,0.000113791655,0.00021692483,0.00032758847,0.0003819197,0.0002258761],"domain_scores_gemma":[0.99902636,0.00014186808,0.00019031578,0.00019800392,0.00032736795,0.00011608958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016652085,0.00018058108,0.0005523518,0.000037434293,0.000063362204,0.000035777157,0.00010892143,0.00003007545,0.00086260354],"category_scores_gemma":[0.0001087852,0.00011442138,0.00006412304,0.0003472835,0.00007760772,0.000120438934,0.00012260638,0.00009614297,0.0000052593937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001401867,0.003195546,0.9783692,0.000091822374,0.0029058694,0.0006269819,0.0003158543,0.000006332028,0.00015397517,0.00004032113,0.008915383,0.003976891],"study_design_scores_gemma":[0.00836136,0.002092722,0.9511767,0.0005228396,0.0009466347,0.000021940541,0.00011487254,0.0000056811696,0.034121092,0.000010260099,0.0024519789,0.00017391148],"about_ca_topic_score_codex":0.0014740947,"about_ca_topic_score_gemma":0.0014984743,"teacher_disagreement_score":0.033967115,"about_ca_system_score_codex":0.00012972293,"about_ca_system_score_gemma":0.0005778785,"threshold_uncertainty_score":0.9444904},"labels":[],"label_agreement":null},{"id":"W3170831652","doi":"10.1016/j.esmoop.2021.100170","title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Merck Sharp and Dohme; Johnson and Johnson; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Cancer Research UK; MedImmune; Sanofi; Canadian Aeronautics and Space Institute; Merck; Sarcoma UK; Desmoid Tumor Research Foundation; Roche; Novartis; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Aimmune Therapeutics; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Bayer","keywords":"Epithelioid hemangioendothelioma; Medicine; Cancer; Pathology; Internal medicine","score_opus":0.1298996345763592,"score_gpt":0.4058236368459077,"score_spread":0.2759240022695485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170831652","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009572125,0.99268633,0.0000010843094,0.00062081753,0.0001859582,0.0019193792,0.00080495595,0.000028842791,0.002795408],"genre_scores_gemma":[0.0007227651,0.99504405,0.00024068683,0.0009891125,0.00033864332,0.00035614113,0.0011994754,0.00011341982,0.0009957054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996667,0.0015345974,0.000714485,0.00041601845,0.0003507996,0.0003170939],"domain_scores_gemma":[0.9963461,0.00065231964,0.0003987771,0.0022613117,0.00015041379,0.00019106986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059381046,0.00048196697,0.002741193,0.00006879997,0.00027705103,0.00009390793,0.0013257958,0.00022969344,0.002190195],"category_scores_gemma":[0.00018487399,0.00028263184,0.0010426424,0.00036690762,0.0002024666,0.00007126388,0.00034845807,0.00072145776,0.0000274747],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050268856,0.0008257792,0.0003425112,0.0046376004,0.0025981693,0.0007989601,0.002663642,3.2913533e-7,0.00006978804,0.00024769412,0.022189206,0.96557605],"study_design_scores_gemma":[0.0007648753,0.000104918356,0.00015568477,0.026516609,0.0016753662,0.00036175514,0.0013835273,5.157599e-7,0.00019560507,0.00003786661,0.96848637,0.00031691277],"about_ca_topic_score_codex":0.046614144,"about_ca_topic_score_gemma":0.0029909548,"teacher_disagreement_score":0.96525913,"about_ca_system_score_codex":0.000076081385,"about_ca_system_score_gemma":0.00083429925,"threshold_uncertainty_score":0.99996257},"labels":[],"label_agreement":null},{"id":"W3179670484","doi":"10.1016/j.esmoop.2021.100211","title":"Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Seventh Framework Programme; Genentech; National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Servier; Regione del Veneto; Astellas Pharma; European Commission; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; EMD Serono; Novartis; Royal Marsden NHS Foundation Trust; NIHR Imperial Biomedical Research Centre; Amgen; Pfizer; Imperial College London; Institute of Cancer Research; Bayer; Roche; Astellas Pharma US","keywords":"KRAS; Microsatellite instability; Colorectal cancer; Neuroblastoma RAS viral oncogene homolog; Tumour heterogeneity; Genetic heterogeneity; Biology; Phenotype; Transcriptome; Cancer research; Adenocarcinoma; Grading (engineering); Pathology; Gene expression profiling; Immunohistochemistry; Medicine; Gene; Cancer; Gene expression; Genetics; Microsatellite; Allele","score_opus":0.04380060235115114,"score_gpt":0.32740663437978035,"score_spread":0.2836060320286292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179670484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922257,0.0019994702,0.000004101004,0.0016383147,0.00010469227,0.00069952523,0.00002690754,0.000022769213,0.0032785295],"genre_scores_gemma":[0.9979161,0.00015809006,0.00047320029,0.0006839691,0.000016118809,0.00013959644,0.00005813868,0.000015662574,0.00053913356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989166,0.00009500112,0.00023280598,0.00039490688,0.0001095309,0.00025114478],"domain_scores_gemma":[0.99961466,0.000045066558,0.000038468217,0.00015155629,0.000049536324,0.00010074055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001337062,0.00017455441,0.0005097158,0.000055801964,0.00007872315,0.000060282593,0.00009379548,0.00004018272,0.0003019349],"category_scores_gemma":[0.00004861335,0.0001396061,0.000056381294,0.0002568282,0.000093648865,0.00010392714,0.00014631441,0.00015453083,0.000014223295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007428665,0.0033001937,0.8828239,0.0003825281,0.002574601,0.026460247,0.008391553,0.00003696562,0.032368906,0.00080387003,0.0045500547,0.030878542],"study_design_scores_gemma":[0.0055029537,0.00074280496,0.9694469,0.00006688709,0.00022735014,0.0008989016,0.0006082121,0.00015275134,0.02130558,0.00032691818,0.0005236229,0.00019710089],"about_ca_topic_score_codex":0.0008683898,"about_ca_topic_score_gemma":0.0056511993,"teacher_disagreement_score":0.08662304,"about_ca_system_score_codex":0.00012091101,"about_ca_system_score_gemma":0.000159243,"threshold_uncertainty_score":0.5692972},"labels":[],"label_agreement":null},{"id":"W3211466869","doi":"10.1016/j.esmoop.2021.100292","title":"Distribution of the workforce involved in cancer care: a systematic review of the literature","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"; European Society for Medical Oncology; Daiichi-Sankyo; Università degli Studi di Milano-Bicocca; World Health Organization","keywords":"Workforce; Systematic review; Cancer; Distribution (mathematics); Medicine; MEDLINE; Political science; Economics; Mathematics; Internal medicine; Economic growth","score_opus":0.03988454844191102,"score_gpt":0.44281526066433424,"score_spread":0.4029307122224232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211466869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023942355,0.99295807,0.0000039582274,0.00035442467,0.00051948463,0.0056410013,0.0001213867,0.0000023220146,0.0003969649],"genre_scores_gemma":[0.000018127286,0.9972136,0.000030514451,0.0005807126,0.00007771272,0.0006400412,0.00016047148,0.00001663394,0.0012621793],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979571,0.00076163636,0.0007821216,0.00019912602,0.0001869923,0.00011300944],"domain_scores_gemma":[0.99787194,0.00020760557,0.00085314346,0.0008961672,0.00015026076,0.000020907873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047115423,0.00019677116,0.0027175827,0.000018046603,0.000041606072,0.000007947434,0.0007749676,0.00026094177,0.000055380086],"category_scores_gemma":[0.0005150091,0.000081142745,0.00047609897,0.00093409873,0.00012070737,0.000040324558,0.00021277687,0.0005487851,5.627609e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050606404,0.00003458666,0.00008893093,0.97683394,0.0001576869,0.0000057859215,0.00019257986,3.3644048e-7,3.201886e-8,0.00037559148,0.0011558485,0.021149646],"study_design_scores_gemma":[0.00013276392,0.000013141204,0.00002258064,0.61836463,0.00090203487,0.000020623394,0.000022700173,1.0303024e-7,0.0000014922606,0.000006166545,0.38046673,0.00004700045],"about_ca_topic_score_codex":0.000049935697,"about_ca_topic_score_gemma":0.00010605667,"teacher_disagreement_score":0.37931088,"about_ca_system_score_codex":0.0003767237,"about_ca_system_score_gemma":0.0009152042,"threshold_uncertainty_score":0.33089054},"labels":[],"label_agreement":null},{"id":"W4210298192","doi":"10.1016/j.esmoop.2022.100403","title":"Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Janssen Pharmaceuticals; Chugai Pharmaceutical; AstraZeneca; Genentech; MorphoSys; PharmaMar; Daiichi Sankyo Europe; European Society for Medical Oncology; Deutsche Krebshilfe; Pfizer; José Carreras Leukämie-Stiftung; Shionogi; British Society for Haematology; National Institute for Health and Care Research; Bayer; Astellas Pharma; Celltrion; SkylineDx; Sanofi-Aventis Deutschland; BeiGene; Sanofi; TG Therapeutics; Medac; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Meso Scale Diagnostics; Helsinn; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; AOP Orphan; Bundesministerium für Bildung und Forschung; EUSA Pharma; Merck KGaA; Incyte; Servier; Gilead Sciences; Celgene; Novartis; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Roche; Sierra Oncology; Galecto; Astellas Pharma US; Boehringer Ingelheim; Amgen","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Medicine; Consensus conference; MEDLINE; Family medicine; 2019-20 coronavirus outbreak; Intensive care medicine; Political science; Internal medicine; Pathology; Disease; Law","score_opus":0.15542100492980257,"score_gpt":0.4771415186154561,"score_spread":0.3217205136856536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210298192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92891896,0.0002246009,0.000011995602,0.06756864,0.0004114483,0.0013366299,0.000043843156,0.00011183256,0.0013720324],"genre_scores_gemma":[0.9645471,0.000066626715,0.00005087146,0.033765137,0.00013012766,0.00040233386,0.000056099096,0.000030108911,0.0009515836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800146,0.0003147658,0.00036100578,0.00047120705,0.00039219696,0.00045935728],"domain_scores_gemma":[0.99851495,0.0002637984,0.00013736195,0.0005267389,0.000052759973,0.0005044042],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006152854,0.00019473537,0.00039208573,0.00009335663,0.0012888012,0.00006674205,0.0005852773,0.000067474575,0.0022983202],"category_scores_gemma":[0.00023021037,0.00013486636,0.00007988198,0.00022187718,0.00012097213,0.000096730044,0.0024692572,0.0005615101,0.000015896798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021299028,0.0004830706,0.9539415,0.00023444789,0.00009402388,0.00070796424,0.014464904,0.00013890106,0.00008057916,0.00016455443,0.021627637,0.005932463],"study_design_scores_gemma":[0.007355665,0.0012875552,0.8097555,0.00016281055,0.00008614488,0.0011427281,0.012307314,0.00053966313,0.000107150234,0.001483157,0.16521163,0.00056069647],"about_ca_topic_score_codex":0.011004271,"about_ca_topic_score_gemma":0.0023243625,"teacher_disagreement_score":0.14418608,"about_ca_system_score_codex":0.001046073,"about_ca_system_score_gemma":0.00062486547,"threshold_uncertainty_score":0.9986137},"labels":[],"label_agreement":null},{"id":"W4210758222","doi":"10.1016/j.esmoop.2021.100379","title":"Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process","year":2022,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Israel Science Foundation; Takeda Pharmaceutical Company; Israel Cancer Association; Roche; AstraZeneca; Meso Scale Diagnostics; Novartis; Pfizer","keywords":"Scopus; Reimbursement; Medicine; Family medicine; MEDLINE; Library science; Oncology; Health care; Internal medicine; Political science; Law; Computer science","score_opus":0.0750572833316422,"score_gpt":0.383854516719842,"score_spread":0.3087972333881998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210758222","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12064846,0.0011290906,0.000027006177,0.0021467265,0.7276824,0.0036067048,0.028375192,0.000024024795,0.116360374],"genre_scores_gemma":[0.34423128,0.0057018613,0.0006195532,0.0021269582,0.6140326,0.0018319166,0.0071386746,0.00031911695,0.023998016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961126,0.00007778088,0.0024303093,0.0007354205,0.00033867778,0.00030519924],"domain_scores_gemma":[0.9945492,0.0008888395,0.0034177764,0.00078605284,0.00029076575,0.00006734878],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034841152,0.00028397367,0.0011073757,0.000118365584,0.00028387015,0.00012832231,0.0026019942,0.00026646306,0.009639692],"category_scores_gemma":[0.0004571204,0.00024350018,0.00034859072,0.00034958604,0.0001945112,0.00036665914,0.0010704891,0.00083441276,0.000032298394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014338108,0.00012633987,0.10317623,0.000026320833,0.0002610644,2.8059364e-7,0.0005027251,0.00007757513,1.9424591e-7,0.014751754,0.8787228,0.0022113293],"study_design_scores_gemma":[0.0013873697,0.00009360797,0.20825127,0.00003963374,0.00004627435,7.3466694e-8,0.00036015044,0.000014849881,0.000027489226,0.018827695,0.77071273,0.00023883236],"about_ca_topic_score_codex":0.1939066,"about_ca_topic_score_gemma":0.07370789,"teacher_disagreement_score":0.2235828,"about_ca_system_score_codex":0.0003525898,"about_ca_system_score_gemma":0.0010593146,"threshold_uncertainty_score":0.9929649},"labels":[],"label_agreement":null},{"id":"W4214857206","doi":"10.1016/j.esmoop.2022.100407","title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Subgroup analysis; Cochrane Library; Hazard ratio; Confidence interval; Oncology; Combination therapy","score_opus":0.2095376817135196,"score_gpt":0.40761220168294227,"score_spread":0.19807451996942266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214857206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024487172,0.9877361,2.3043258e-7,0.00025311342,0.000024242301,0.009842779,0.0002452317,0.000007060271,0.0018888119],"genre_scores_gemma":[0.0000063506814,0.9890064,0.000061647224,0.00077781896,0.000011839383,0.007842938,0.0006686024,0.00004304341,0.0015813422],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969951,0.00053275446,0.0012966787,0.0006131819,0.0003755655,0.00018672351],"domain_scores_gemma":[0.9975658,0.00038109763,0.0008499519,0.0010647548,0.000043296208,0.00009506547],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010045922,0.0004403611,0.013391371,0.00032794007,0.00004166263,0.000041453364,0.0003349273,0.000085745975,0.008143022],"category_scores_gemma":[0.000028618791,0.00026441386,0.0020811097,0.0013679335,0.000037914542,0.0000486744,0.00025695702,0.0002535174,0.000017310345],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014514845,0.00023861032,0.00003082519,0.8186517,0.15486786,0.00009474962,0.000118436576,8.9069516e-7,8.826735e-9,0.000032886455,0.0024426708,0.023506876],"study_design_scores_gemma":[0.00027389274,0.00009763006,0.00001984095,0.026890889,0.43588063,0.000013455922,0.000004492775,1.0403248e-7,6.9983926e-8,8.823087e-7,0.536689,0.00012914963],"about_ca_topic_score_codex":0.0042721652,"about_ca_topic_score_gemma":0.0014386908,"teacher_disagreement_score":0.7917608,"about_ca_system_score_codex":0.00090991915,"about_ca_system_score_gemma":0.00047079579,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W4214935792","doi":"10.1016/j.esmoop.2022.100410","title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Janssen Research and Development; EMD Serono; Genentech; Ipsen; PharmaMar; Astellas Pharma; National Institute for Health and Care Research; Seagen; G1 Therapeutics; AstraZeneca España; Daiichi-Sankyo; ViewRay; BeiGene; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; TG Therapeutics; Amgen; Boehringer Ingelheim; Elekta; Taiho Pharmaceutical; Mirati Therapeutics; Varian Medical Systems; Takeda Pharmaceutical Company; AbbVie; Sanofi; Celgene; Novartis; Manchester Biomedical Research Centre; Merck; GlaxoSmithKline; Daiichi Sankyo Europe; Servier; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Incyte; Pfizer; Roche; Astellas Pharma US","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Hazard ratio; Clinical endpoint; Internal medicine; Post-hoc analysis; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Clinical trial; Confidence interval; Pembrolizumab; Immunotherapy","score_opus":0.02197590166635086,"score_gpt":0.31315415271906755,"score_spread":0.29117825105271666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214935792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285555,0.00084540667,0.000011849383,0.0027183702,0.00020375376,0.0024659105,0.00023117008,0.000020996671,0.0006469862],"genre_scores_gemma":[0.99011123,0.00028645052,0.00018032007,0.0015664529,0.00013842096,0.005881331,0.00017884091,0.000045705976,0.0016112699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983032,0.00021498957,0.0002917146,0.000540054,0.00038240265,0.0002676682],"domain_scores_gemma":[0.99874485,0.000104318475,0.00013917804,0.0008645331,0.000031973817,0.000115165036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040871138,0.00023856829,0.00072545826,0.00010871185,0.00017242532,0.00011311022,0.00041431896,0.00004045161,0.004540338],"category_scores_gemma":[0.0000036241531,0.00014597987,0.00015621197,0.00061650027,0.00003862772,0.00015888675,0.00016264396,0.00024745596,0.000004361324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013087879,0.0010192612,0.97569674,0.000012966827,0.0016813398,0.00020300887,0.0062781544,0.00032719786,0.000005891403,0.0000033899983,0.0011002799,0.00058389327],"study_design_scores_gemma":[0.0860191,0.0010996682,0.8970167,0.00004846389,0.0020091166,9.227807e-7,0.0048799617,0.0005408014,0.000317537,0.0000054410057,0.0077411025,0.00032116694],"about_ca_topic_score_codex":0.024933826,"about_ca_topic_score_gemma":0.027185043,"teacher_disagreement_score":0.078680016,"about_ca_system_score_codex":0.0007786185,"about_ca_system_score_gemma":0.00042611914,"threshold_uncertainty_score":0.99636966},"labels":[],"label_agreement":null},{"id":"W4220770313","doi":"10.1016/j.esmoop.2022.100413","title":"“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores","year":2022,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; Ipsen; Servier; Nordic Nanovector; Radius Health; Merck KGaA; FibroGen; Gilead Sciences; Amgen; Ariad Pharmaceuticals; Chugai Pharmaceutical; Roche; Meso Scale Diagnostics; Sanofi; Merck; Pfizer; G1 Therapeutics; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pazopanib; Medicine; Sunitinib; Axitinib; Cabozantinib; Renal cell carcinoma; Pembrolizumab; Internal medicine; Oncology; Nivolumab; Context (archaeology); Tyrosine-kinase inhibitor; Cancer; Immunotherapy","score_opus":0.05402991100113508,"score_gpt":0.2882864576658172,"score_spread":0.2342565466646821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220770313","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005984203,0.005250731,0.000050517425,0.028829046,0.92316014,0.0053070844,0.0002587248,0.00011801171,0.031041536],"genre_scores_gemma":[0.27852634,0.0025576735,0.00035303703,0.0015143676,0.55174327,0.0015911342,0.0016388355,0.0006480542,0.16142732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961982,0.00019667308,0.0008557375,0.0007334955,0.00147934,0.0005365781],"domain_scores_gemma":[0.9952425,0.002371467,0.0007336396,0.001311817,0.0001842088,0.0001563813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012183642,0.00051812385,0.0010989081,0.000114606424,0.00089747243,0.000186369,0.0013949357,0.00038164057,0.000848664],"category_scores_gemma":[0.0005426657,0.00030383506,0.00033731098,0.00021041697,0.0002693493,0.00019113785,0.001073768,0.0012770421,0.000021810161],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090102234,0.000095630756,0.01522864,0.0001354934,0.0005209949,0.00029186436,0.001391006,0.000002833044,0.00000391616,0.0005423632,0.9807992,0.00008701037],"study_design_scores_gemma":[0.0016631866,0.0006335401,0.0012857915,0.00039244967,0.00054244685,0.000027777156,0.0008403245,0.0000064646365,0.00008374057,0.00073521957,0.99348617,0.00030288676],"about_ca_topic_score_codex":0.003105898,"about_ca_topic_score_gemma":0.0087528825,"teacher_disagreement_score":0.3714169,"about_ca_system_score_codex":0.005510108,"about_ca_system_score_gemma":0.0006632327,"threshold_uncertainty_score":0.99994135},"labels":[],"label_agreement":null},{"id":"W4220876994","doi":"10.1016/j.esmoop.2022.100448","title":"Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Instituto De Saúde Pública, Universidade do Porto; European Social Fund; European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Instituto Português de Oncologia do Porto","keywords":"Montreal Cognitive Assessment; Medicine; Androgen deprivation therapy; Prostate cancer; Cognitive decline; Pandemic; Enzalutamide; Cognition; Cohort; Cohort study; Internal medicine; Pediatrics; Gerontology; Cancer; Coronavirus disease 2019 (COVID-19); Disease; Psychiatry; Cognitive impairment; Dementia","score_opus":0.06738769527049374,"score_gpt":0.37046081070128056,"score_spread":0.30307311543078685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220876994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834104,0.00048283034,0.000013034835,0.0076171528,0.000056848727,0.0072468207,0.000025122075,0.000031778683,0.0011160105],"genre_scores_gemma":[0.98974293,0.00023901321,0.000003933595,0.007272314,0.000065273656,0.0023082993,0.000015894431,0.000018252007,0.00033406867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984269,0.00043740138,0.00022672377,0.00035140215,0.00036005073,0.0001974805],"domain_scores_gemma":[0.9990577,0.0005153773,0.0001094285,0.00019814276,0.00007141564,0.000047935493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013534641,0.00015250279,0.00024113369,0.00007785076,0.0008459222,0.00006228555,0.0002568062,0.000023629362,0.00024559136],"category_scores_gemma":[0.00039431913,0.00009184519,0.000032990993,0.00047725005,0.00012642353,0.00010624708,0.00067198736,0.0004563573,0.000004594333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002282987,0.0004927118,0.9666341,0.000006737066,0.00025332574,0.00006788304,0.02723719,0.0000094606585,0.000025791767,0.000027266185,0.00019940228,0.0027631724],"study_design_scores_gemma":[0.011720671,0.0011630583,0.93500274,0.000020196641,0.000095054755,0.00018099109,0.048985474,0.000018999765,0.00004642485,0.00039041383,0.002263565,0.00011238287],"about_ca_topic_score_codex":0.0019589341,"about_ca_topic_score_gemma":0.0018837659,"teacher_disagreement_score":0.031631306,"about_ca_system_score_codex":0.0002815636,"about_ca_system_score_gemma":0.00014469816,"threshold_uncertainty_score":0.6506235},"labels":[],"label_agreement":null},{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","score_opus":0.09255978133815697,"score_gpt":0.4642404448781073,"score_spread":0.37168066353995033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221092886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246633,0.00012891779,0.0000060954867,0.0004543081,0.00018078192,0.004504402,0.000042625292,0.000024252495,0.0021922833],"genre_scores_gemma":[0.9957134,0.000069771275,0.00034069002,0.00026518747,0.00003678665,0.0018220902,0.000025597683,0.000052453626,0.0016739878],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997814,0.00020442647,0.0004623233,0.00045717775,0.0006620917,0.0003999702],"domain_scores_gemma":[0.9989221,0.00008431572,0.00011097208,0.00066508894,0.00008050343,0.00013703774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068317266,0.00016029604,0.0005500162,0.00020901617,0.00022412204,0.00001661394,0.0006710341,0.000034876026,0.002237116],"category_scores_gemma":[0.00011125757,0.00015969895,0.000051759525,0.0005669905,0.00006156642,0.00012013267,0.00075788697,0.00047007858,0.000008962208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042043272,0.04586055,0.35490444,0.00021885932,0.0008407053,0.0014273631,0.06591828,0.02081599,0.027686188,0.000041176525,0.008383836,0.4318593],"study_design_scores_gemma":[0.4072911,0.09151485,0.14377347,0.0004207419,0.00016023515,0.00007509437,0.05664677,0.035336837,0.048847195,0.00011661231,0.21443143,0.0013856542],"about_ca_topic_score_codex":0.04076487,"about_ca_topic_score_gemma":0.00866337,"teacher_disagreement_score":0.4304737,"about_ca_system_score_codex":0.0010427617,"about_ca_system_score_gemma":0.0007204586,"threshold_uncertainty_score":0.998675},"labels":[],"label_agreement":null},{"id":"W4280609905","doi":"10.1016/j.esmoop.2022.100483","title":"Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Genentech; Ipsen; Servier; European Organisation for Research and Treatment of Cancer; Eisai; Daiichi-Sankyo; Astellas Pharma; Mylan; Genomic Health; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Medicine; Cancer; Internal medicine; Oncology","score_opus":0.015109955563295373,"score_gpt":0.31884134745765325,"score_spread":0.3037313918943579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280609905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95720977,0.00035745834,0.0001718396,0.018144244,0.00046518355,0.00391487,0.014127687,0.000016564944,0.0055924044],"genre_scores_gemma":[0.9966934,0.000018491446,0.0006809124,0.0005688018,0.000028142766,0.0006997347,0.00027416265,0.000021690164,0.0010146752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978629,0.00030565847,0.00038510136,0.00034293,0.0009202867,0.00018315903],"domain_scores_gemma":[0.9988633,0.00007605795,0.00029663576,0.0006436167,0.00006362293,0.000056784775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006865369,0.00017771084,0.0003770543,0.000033547767,0.00021073225,0.00004788353,0.0010433408,0.000015042709,0.0023045922],"category_scores_gemma":[0.0000029910066,0.000105703635,0.0001617233,0.00026454142,0.00006693565,0.00007377998,0.0018181776,0.00014955508,0.0000011235256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009767625,0.007927901,0.8325408,0.00010234139,0.021997552,0.00031165688,0.0021784136,0.00046225233,0.0005337219,0.0076561505,0.048970293,0.07634211],"study_design_scores_gemma":[0.004703045,0.00032359894,0.97964126,0.0000782024,0.0012725354,0.00017909531,0.006280146,0.0002015304,0.00006134664,0.00014271661,0.0070008184,0.00011568608],"about_ca_topic_score_codex":0.03565193,"about_ca_topic_score_gemma":0.0007812037,"teacher_disagreement_score":0.14710045,"about_ca_system_score_codex":0.00032673735,"about_ca_system_score_gemma":0.00009363748,"threshold_uncertainty_score":0.99860746},"labels":[],"label_agreement":null},{"id":"W4282916823","doi":"10.1016/j.esmoop.2022.100510","title":"Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi Genzyme; Genentech; Takeda Pharmaceutical Company; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; Merck; Bayer; Astellas Pharma Global Development; AstraZeneca; Amgen; Pfizer; Astellas Pharma; Daiichi Sankyo Company; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Prostate cancer; Hazard ratio; Medicine; Placebo; Cabazitaxel; Oncology; Internal medicine; Antiandrogen; Confidence interval; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.270638878063148,"score_gpt":0.47585124211778135,"score_spread":0.20521236405463333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282916823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012064715,0.96516126,0.0000019952215,0.00018683485,0.00047873147,0.019269088,0.0024613154,0.000011793683,0.00036424483],"genre_scores_gemma":[0.008565735,0.9820628,0.00016078558,0.0000050480357,0.000059679725,0.005454466,0.00065797404,0.00008038909,0.0029530865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969651,0.0003805583,0.0011964499,0.00047017334,0.0006094266,0.00037830844],"domain_scores_gemma":[0.99519,0.0023575274,0.0012907488,0.00096030656,0.00011088885,0.00009050772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036578183,0.0005188705,0.0027809176,0.00015869956,0.0002694324,0.000031576874,0.00064754393,0.00009033902,0.00035049056],"category_scores_gemma":[0.00006320373,0.00023784822,0.00093077595,0.00059649104,0.000266326,0.0000499238,0.00016388283,0.00019191798,0.0000020771172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006556291,0.0028803037,0.00031227566,0.007679029,0.0077855457,0.000015699798,0.0056553944,0.0001904721,0.000023055161,0.00006182689,0.00016445378,0.9686757],"study_design_scores_gemma":[0.018968942,0.010244438,0.0015655897,0.0059317388,0.01761987,0.00000936757,0.001855805,0.00004727893,0.0028103672,0.000021020409,0.9405804,0.00034513848],"about_ca_topic_score_codex":0.010124185,"about_ca_topic_score_gemma":0.0033060082,"teacher_disagreement_score":0.9683305,"about_ca_system_score_codex":0.0014587797,"about_ca_system_score_gemma":0.0024837109,"threshold_uncertainty_score":0.9964675},"labels":[],"label_agreement":null},{"id":"W4283392628","doi":"10.1016/j.esmoop.2022.100519","title":"Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Medicine, Georgetown University; Servier; Medizinische Universität Wien; Daiichi-Sankyo; CMC Microsystems; Novartis; Meso Scale Diagnostics; AbbVie; Merck; Bayer; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Roche; Astellas Pharma US","keywords":"Medicine; Stage (stratigraphy); Underweight; Internal medicine; Body mass index; Confidence interval; Cancer; Adenocarcinoma; Framingham Risk Score; Stenosis; Surgery; Disease; Overweight","score_opus":0.05488120348029787,"score_gpt":0.337989065606764,"score_spread":0.28310786212646616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283392628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209005,0.0010908752,0.001413364,0.00017321963,0.00014237117,0.004249793,0.00043111612,0.000058278776,0.000350962],"genre_scores_gemma":[0.98380125,0.000012288393,0.012509347,0.00015266553,0.00006866346,0.0020145967,0.001056443,0.000040582276,0.00034419456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797946,0.00014896586,0.0004145104,0.00045422034,0.0006290289,0.0003738196],"domain_scores_gemma":[0.99887025,0.00007379689,0.00018196116,0.00044548087,0.00013387928,0.0002946449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007747087,0.00018596268,0.00038900782,0.0002071321,0.0004429589,0.000034987213,0.00039699234,0.000046528923,0.000823057],"category_scores_gemma":[0.000066761255,0.00016430598,0.000104536215,0.0003683497,0.000055884124,0.00013281549,0.00027455649,0.00023618224,0.000010425083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010268483,0.0024261305,0.916435,0.00031448127,0.0005996028,0.00025510768,0.0010305454,0.00066002575,0.00015876212,0.00015649876,0.0018470613,0.0658483],"study_design_scores_gemma":[0.023240296,0.007642749,0.92918575,0.00012728175,0.0003209679,0.000046647478,0.0004101497,0.0044014,0.028393503,0.00017064926,0.0058388677,0.00022174163],"about_ca_topic_score_codex":0.00076666713,"about_ca_topic_score_gemma":0.00013157933,"teacher_disagreement_score":0.065626554,"about_ca_system_score_codex":0.00057855126,"about_ca_system_score_gemma":0.0014328647,"threshold_uncertainty_score":0.90118974},"labels":[],"label_agreement":null},{"id":"W4283400007","doi":"10.1016/j.esmoop.2022.100520","title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; National Cancer Institute; Johnson and Johnson; Deciphera Pharmaceuticals; Roche; Bundesministerium für Gesundheit; Exelixis; Meso Scale Diagnostics; Merck; GlaxoSmithKline; Novartis; Pfizer; U.S. Food and Drug Administration; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Melanoma; Gastroenterology; Tyrosine-kinase inhibitor; Metastatic melanoma; Progression-free survival; Oncology; Phases of clinical research; Cancer; Chemotherapy; Cancer research","score_opus":0.023874243337882205,"score_gpt":0.3035334139704138,"score_spread":0.2796591706325316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283400007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957944,0.000017868348,0.0000039298957,0.0003064858,0.000009265569,0.0013171739,0.000035288504,0.000004351222,0.0025112014],"genre_scores_gemma":[0.9974484,0.0000015829858,0.0020793588,0.000041406154,0.0000031071183,0.00007191207,0.00008707831,0.000010103528,0.00025708895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991531,0.000098879755,0.00016049229,0.0001656751,0.0002590822,0.00016280866],"domain_scores_gemma":[0.99956775,0.00007427492,0.00005469619,0.00017118789,0.00003295321,0.00009916167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000211429,0.000076616794,0.00023509418,0.00006854772,0.000050786697,0.000010343159,0.00011430106,0.0000036491924,0.000530714],"category_scores_gemma":[0.00008070527,0.000055209664,0.000014466911,0.00014465906,0.00004390513,0.000043223703,0.0002713003,0.00012755931,0.0000044032345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008515038,0.0011042864,0.98657745,0.00003737225,0.0000839484,0.00018874469,0.00021805211,0.000011742099,0.000010436891,0.00010809097,0.00012815642,0.0030166695],"study_design_scores_gemma":[0.014620527,0.0054300157,0.9790274,0.000078116216,0.00003517527,0.000043830525,0.00011848772,0.000018461202,0.00008130164,0.0000338766,0.00046815988,0.000044646],"about_ca_topic_score_codex":0.000718119,"about_ca_topic_score_gemma":0.00005695634,"teacher_disagreement_score":0.00755006,"about_ca_system_score_codex":0.00005822232,"about_ca_system_score_gemma":0.000078331905,"threshold_uncertainty_score":0.5810946},"labels":[],"label_agreement":null},{"id":"W4288987527","doi":"10.1016/j.esmoop.2022.100530","title":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Relay Therapeutics; Tessa Therapeutics; Aptose Biosciences; Banco Bilbao Vizcaya Argentaria; BeiGene; Jounce Therapeutics; Lilly Oncology; Bayer Fund; Mirati Therapeutics; Halozyme; Regeneron Pharmaceuticals; Boston Scientific Corporation; Fundación BBVA; F. Hoffmann-La Roche; AbbVie; Novartis; Celgene; Medtronic; Fundación Cellex; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Mersana Therapeutics; Merck; GlaxoSmithKline; Eli Lilly and Company; “la Caixa” Foundation; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Amgen; Boehringer Ingelheim; Pfizer; National Cancer Institute; Servier; Gilead Sciences; Taiho Pharmaceutical; Conquer Cancer Foundation","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Adverse effect; Immunogenicity; Oncology; Internal medicine; Cancer; Antibody; Response Evaluation Criteria in Solid Tumors; Pharmacology; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","score_opus":0.052148434982048526,"score_gpt":0.40883257729806105,"score_spread":0.35668414231601253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288987527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953094,0.00002683995,0.00003806256,0.00011008813,0.00032410468,0.0030580366,0.00019955129,0.000038684047,0.0008952142],"genre_scores_gemma":[0.9980725,0.0000029735995,0.00022212783,0.00010419313,0.00012438236,0.00047126526,0.0002627345,0.000051133586,0.0006886661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816334,0.00007442494,0.0006850803,0.00045350567,0.00032281285,0.00030080567],"domain_scores_gemma":[0.9989611,0.00011006746,0.00028886733,0.0004197149,0.000118827455,0.00010143392],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000308485,0.00021673666,0.0007174183,0.00026847297,0.00045679012,0.000038632807,0.00039360972,0.00003658789,0.0017834023],"category_scores_gemma":[0.00008623273,0.00021521795,0.00015605259,0.00025874234,0.000041385676,0.00021954681,0.0004160216,0.00037830014,0.0000050543977],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046145855,0.019306716,0.028163861,0.0002353111,0.0004220566,0.00039108223,0.0106417285,0.0014523561,0.9279683,0.00030682288,0.004965814,0.0015313585],"study_design_scores_gemma":[0.20881322,0.05731695,0.13633111,0.0012016416,0.00059402635,0.00024462322,0.02960068,0.006828301,0.49433658,0.00034678794,0.06248858,0.0018975013],"about_ca_topic_score_codex":0.001699494,"about_ca_topic_score_gemma":0.00050961424,"teacher_disagreement_score":0.43363175,"about_ca_system_score_codex":0.00032340852,"about_ca_system_score_gemma":0.0002664243,"threshold_uncertainty_score":0.9991291},"labels":[],"label_agreement":null},{"id":"W4290993146","doi":"10.1016/j.esmoop.2022.100553","title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Lilly Deutschland; Merck Sharp and Dohme; Eisai; Clovis Oncology; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Novartis; Merck; Sanofi-Aventis Deutschland; Pfizer; Queen Mary University of London; Bristol-Myers Squibb; AstraZeneca; Gilead Sciences","keywords":"Medicine; Breast cancer; Trastuzumab; Internal medicine; Pneumonitis; Nausea; Context (archaeology); Neutropenia; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Lung","score_opus":0.33804201657331107,"score_gpt":0.5932876732972931,"score_spread":0.2552456567239821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290993146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001432475,0.9530732,0.0000052670234,0.00046226094,0.0002583239,0.0053669736,0.00023378567,0.000010095363,0.040575765],"genre_scores_gemma":[0.00003649796,0.99092776,0.004930607,0.000055777717,0.000100055935,0.0019212011,0.000091671456,0.000082972765,0.0018534778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569625,0.0008122235,0.0017021935,0.00065524917,0.0007540502,0.0003800311],"domain_scores_gemma":[0.9973365,0.0006869261,0.0007745457,0.00094719586,0.00008995891,0.00016485517],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002458106,0.0003377872,0.0028128757,0.00026266262,0.00004135132,0.000023923863,0.00087528053,0.00017692294,0.0046294043],"category_scores_gemma":[0.000109041284,0.0002690715,0.00045592966,0.0007494318,0.0001146076,0.00010280728,0.0009208563,0.0007353676,0.000015771198],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031154425,0.001241117,0.0001032527,0.015185115,0.0014601959,0.00054117816,0.00016586021,0.000008033049,1.9976424e-8,0.00006925586,0.0006479766,0.98026645],"study_design_scores_gemma":[0.0018850697,0.00074399885,0.00043868064,0.019760313,0.0019893495,0.000134647,0.00042949742,0.0000049396663,0.0000010493527,0.0000030174501,0.9744275,0.00018194229],"about_ca_topic_score_codex":0.011864519,"about_ca_topic_score_gemma":0.00039882807,"teacher_disagreement_score":0.98008454,"about_ca_system_score_codex":0.002138154,"about_ca_system_score_gemma":0.00245074,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W4292411599","doi":"10.1016/j.esmoop.2022.100562","title":"Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; PharmaMar; Servier; Astellas Pharma; Eisai; Incyte; Seagen; Gilead Sciences; Ipsen; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Adverse effect; Tolerability; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.049488667941219096,"score_gpt":0.38240333920553315,"score_spread":0.33291467126431407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292411599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858233,0.000024781999,0.0000016438554,0.00041584938,0.00008967653,0.009768686,0.0010946033,0.000032156488,0.0027493392],"genre_scores_gemma":[0.9928691,0.0000038950884,0.0011995119,0.000301548,0.000025781661,0.0014663573,0.0022676103,0.000059450773,0.001806793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967564,0.00030698304,0.00056743925,0.0008980584,0.0008562973,0.00061482465],"domain_scores_gemma":[0.9983233,0.00010583836,0.00019603547,0.0009360426,0.00012434705,0.0003144237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038250306,0.0003092305,0.0007382605,0.00017116246,0.00045795873,0.00015969426,0.00106901,0.00003390767,0.00095532526],"category_scores_gemma":[0.0002179458,0.0002425758,0.000029312449,0.00042521392,0.000050484356,0.00052732386,0.0032570846,0.00047905606,0.00007372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42935508,0.14919533,0.3347297,0.000027044644,0.0012021692,0.0054607242,0.01286879,0.00012132314,0.00008097537,0.0000062004046,0.003895324,0.06305736],"study_design_scores_gemma":[0.574192,0.028301252,0.38989156,0.00017771781,0.00008293458,0.000003788053,0.0021624654,0.0011297942,0.00019807281,0.0000125034485,0.003517066,0.00033086012],"about_ca_topic_score_codex":0.017718546,"about_ca_topic_score_gemma":0.0023712679,"teacher_disagreement_score":0.14483692,"about_ca_system_score_codex":0.00071395806,"about_ca_system_score_gemma":0.00039482405,"threshold_uncertainty_score":0.9999579},"labels":[],"label_agreement":null},{"id":"W4295592704","doi":"10.1016/j.esmoop.2022.100572","title":"The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Eli Lilly Japan; Medtronic Japan; Chugai Pharmaceutical; Genentech; Taiho Pharmaceutical; Sanofi; GlaxoSmithKline; Teijin Pharma; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ono Pharmaceutical","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Adjuvant; Hazard ratio; Stage (stratigraphy); Lung cancer; Clinical endpoint; Adjuvant therapy; Disease; Erlotinib; Cancer; Confidence interval; Clinical trial; Epidermal growth factor receptor","score_opus":0.024786912971332804,"score_gpt":0.33895353061155414,"score_spread":0.31416661764022136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295592704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831052,0.001126752,0.0000018145522,0.008298396,0.00071868213,0.0011434989,0.00014580305,0.000008716198,0.0054511335],"genre_scores_gemma":[0.9974947,0.00045760666,0.000099248864,0.00029184582,0.00009276744,0.0005700117,0.00007756035,0.000020267498,0.00089600205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987461,0.00009150684,0.00034233593,0.00032095768,0.00033118366,0.0001679277],"domain_scores_gemma":[0.9989558,0.00014563234,0.00017006008,0.0005309543,0.00006817115,0.00012938559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055891677,0.00011762659,0.00024916333,0.00004352452,0.00013890721,0.000036594323,0.0003778988,0.000019435505,0.00023034631],"category_scores_gemma":[0.000066191824,0.000086052314,0.000048975144,0.00009885733,0.00006114633,0.000049364746,0.00059971854,0.00013332322,7.127713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010367121,0.00054918963,0.99011695,0.000039385843,0.00021137141,0.00073133997,0.00052859675,0.00020074142,0.000031251016,0.0004047674,0.004543324,0.0016063615],"study_design_scores_gemma":[0.005732029,0.00024828428,0.98147154,0.00015800232,0.00024935868,0.00004241454,0.0006899842,0.0017388152,0.00042304766,0.00012298305,0.008986719,0.00013684],"about_ca_topic_score_codex":0.01242204,"about_ca_topic_score_gemma":0.0030070492,"teacher_disagreement_score":0.014389486,"about_ca_system_score_codex":0.00024817282,"about_ca_system_score_gemma":0.00051404565,"threshold_uncertainty_score":0.99415433},"labels":[],"label_agreement":null},{"id":"W4302029121","doi":"10.1016/j.esmoop.2022.100597","title":"The current role of precision surgery in oligometastatic prostate cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Current (fluid); Oncology; Prostate; Cancer; Medical physics; Internal medicine; Geology; Oceanography","score_opus":0.14927890532467877,"score_gpt":0.46674198326922145,"score_spread":0.31746307794454265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302029121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008131778,0.99347967,5.9628455e-8,0.00013383287,0.00033418406,0.0043409117,0.00014489346,0.0000066013804,0.0014785202],"genre_scores_gemma":[0.000027935297,0.9928096,0.000008386951,0.000006849553,0.0000425354,0.0035473066,0.00035343567,0.00004430019,0.0031596548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771506,0.00038031687,0.00069064525,0.00035456335,0.0005016255,0.00035781955],"domain_scores_gemma":[0.9980212,0.0010176336,0.0003245995,0.00049995864,0.00004521518,0.00009140656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013709773,0.00024269885,0.0015148325,0.00026007197,0.000119064236,0.000057764257,0.0005049792,0.00003860805,0.00074807357],"category_scores_gemma":[0.00016576072,0.00012780349,0.00028867248,0.0007879068,0.00008105195,0.00007457378,0.00065547373,0.0006255811,0.000022882532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015088798,0.00014312853,0.00044787073,0.0055627236,0.00016686754,0.000034750585,0.000127452,4.1112685e-7,4.658288e-8,0.000011718596,0.0023103885,0.99104375],"study_design_scores_gemma":[0.0004061442,0.0000742795,0.00025340464,0.012528511,0.00027632716,0.000007938533,0.000048537786,0.0000027890524,0.0000046266096,0.00010971166,0.9861691,0.00011861622],"about_ca_topic_score_codex":0.0011734288,"about_ca_topic_score_gemma":0.00024543228,"teacher_disagreement_score":0.99092513,"about_ca_system_score_codex":0.00046950165,"about_ca_system_score_gemma":0.0026729063,"threshold_uncertainty_score":0.8190881},"labels":[],"label_agreement":null},{"id":"W4308422411","doi":"10.1016/j.esmoop.2022.100605","title":"Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario; University Health Network; University of Toronto; Centre for Addiction and Mental Health; Northeast Cancer Centre; Canadian Agency for Drugs and Technologies in Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Cancer; Head and neck cancer; Adverse effect; Tobacco smoke; Tobacco use; Quality of life (healthcare); Disease; Internal medicine; Environmental health; Population","score_opus":0.5908685605313396,"score_gpt":0.5960784053624977,"score_spread":0.00520984483115805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308422411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934627,0.005835687,0.000005981048,0.00028058692,0.00015640106,0.0042373063,0.000007979014,0.000013250504,0.00011651817],"genre_scores_gemma":[0.99654895,0.002100432,0.0000664457,0.00043693796,0.000017172828,0.00064586813,0.00004127675,0.000013241876,0.00012968402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936655,0.0018110396,0.0038466107,0.00028652712,0.00027682565,0.00011350118],"domain_scores_gemma":[0.9960826,0.00077027356,0.0026883236,0.00028908256,0.00011758,0.00005211601],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0144379,0.00010721847,0.0019166011,0.00008656504,0.00008557338,0.00004812317,0.000120665405,0.00005127196,0.0005947003],"category_scores_gemma":[0.0134621365,0.000081620434,0.00011589144,0.00047515094,0.000033121567,0.000215825,0.00021196122,0.00027381675,4.408152e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010022166,0.00016744163,0.9877963,0.0100252675,0.00017437614,0.000071919356,0.00039750198,0.000029879593,0.000096443284,0.000034384673,0.00017899172,0.0009272883],"study_design_scores_gemma":[0.0029487864,0.0003552222,0.76658016,0.22522552,0.0029420606,0.00007824576,0.0013857107,0.000085014726,0.00017176018,0.000008467044,0.000013160595,0.00020589709],"about_ca_topic_score_codex":0.004252416,"about_ca_topic_score_gemma":0.00049739116,"teacher_disagreement_score":0.22121614,"about_ca_system_score_codex":0.00010183055,"about_ca_system_score_gemma":0.00023585517,"threshold_uncertainty_score":0.9948479},"labels":[],"label_agreement":null},{"id":"W4310798566","doi":"10.1016/j.esmoop.2022.100634","title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute; Amgen; Prostate Cancer Foundation","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Overall survival; Oncology; Progression-free survival; Expanded access; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Progressive disease; Disease; Immunotherapy","score_opus":0.0410528661734179,"score_gpt":0.2901908751238391,"score_spread":0.2491380089504212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310798566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400187,0.00005564894,0.0000012416716,0.0005528655,0.000038914157,0.0039978805,0.000014809889,0.000007083571,0.0013296859],"genre_scores_gemma":[0.99880946,0.0000029308824,0.00020921387,0.00009301448,0.000008729562,0.0006239466,0.00009491869,0.000022182126,0.0001355994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827296,0.00035297245,0.0003391736,0.00030988792,0.00051480316,0.0002101893],"domain_scores_gemma":[0.999123,0.00009943495,0.00020280987,0.00047657714,0.00005465012,0.000043557713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005269823,0.00016380787,0.0003088483,0.00011066306,0.00015223125,0.00007793682,0.0005217305,0.000021220401,0.00007954203],"category_scores_gemma":[0.000040430717,0.000092123344,0.00004148114,0.000584678,0.000065230095,0.0002084513,0.00050071144,0.00021093615,5.7195956e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085749105,0.0011134533,0.99244523,0.00009769688,0.000028092762,0.000046289635,0.0026209708,0.00022863151,0.000025471614,0.0000074552127,0.00012893109,0.0024002765],"study_design_scores_gemma":[0.007891296,0.0018133218,0.9845666,0.00011599641,0.00011913985,0.000015220502,0.00066676695,0.00011281812,0.0044471454,0.00006145696,0.0000852159,0.000105016145],"about_ca_topic_score_codex":0.0027713599,"about_ca_topic_score_gemma":0.0018734378,"teacher_disagreement_score":0.007878634,"about_ca_system_score_codex":0.00019932092,"about_ca_system_score_gemma":0.00012571734,"threshold_uncertainty_score":0.41894856},"labels":[],"label_agreement":null},{"id":"W4319301760","doi":"10.1016/j.esmoop.2022.100744","title":"Cancer burden in adolescents and young adults in Europe","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"European Society for Medical Oncology","keywords":"Medicine; Overdiagnosis; European union; Incidence (geometry); Cancer; Population; Public health; Thyroid cancer; Young adult; Epidemiology; Demography; Environmental health; Gerontology; Internal medicine; Pathology","score_opus":0.03520839912292764,"score_gpt":0.3470547380021982,"score_spread":0.3118463388792706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319301760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734146,0.00022997071,4.572171e-7,0.0071819103,0.00028164327,0.0007509365,0.000009916626,0.00004263293,0.004161051],"genre_scores_gemma":[0.9961799,0.00047649947,0.000029450617,0.0012106306,0.00017471639,0.000060081726,0.000017886308,0.000028871793,0.0018220119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998782,0.00009562163,0.0002864387,0.00034203194,0.00022591783,0.0002680365],"domain_scores_gemma":[0.99952483,0.000021362128,0.000050033625,0.00025319852,0.000041959498,0.000108609405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005485585,0.00011777481,0.00030847685,0.0001519571,0.000026102847,0.00004026526,0.00022658012,0.00005487418,0.000091989095],"category_scores_gemma":[0.00020510292,0.000116486815,0.000016272605,0.00078031287,0.000034562116,0.0001399033,0.00036803482,0.0002300842,0.00013037177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034562167,0.00006690516,0.98014295,0.00020572035,0.000013344298,0.00018555835,0.007365094,0.0000094260295,0.000027871449,0.00002403197,0.0037758315,0.007837657],"study_design_scores_gemma":[0.003652682,0.000053833028,0.986326,0.0026377111,0.000007807478,0.000007276321,0.0008030326,0.00016387156,0.000052326868,0.000029281882,0.0061355177,0.0001306757],"about_ca_topic_score_codex":0.1156119,"about_ca_topic_score_gemma":0.09202,"teacher_disagreement_score":0.0235919,"about_ca_system_score_codex":0.00007071638,"about_ca_system_score_gemma":0.00013866992,"threshold_uncertainty_score":0.92454827},"labels":[],"label_agreement":null},{"id":"W4321507085","doi":"10.1016/j.esmoop.2023.100881","title":"A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Engineering and Physical Sciences Research Council; Medical Research Council; Howat Foundation; Ministero della Salute; Cancer Research UK; Wellcome Trust; Pancreatic Cancer UK","keywords":"Medicine; Ethnic group; Meta-analysis; Internal medicine; Demography; Pancreatic cancer; Cancer","score_opus":0.12442951287304822,"score_gpt":0.43876554196935214,"score_spread":0.3143360290963039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321507085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024748968,0.99286854,0.000009936342,0.000059082813,0.000034528664,0.0036246716,0.0008943731,0.0000035303337,0.000030461251],"genre_scores_gemma":[0.0017119758,0.9928253,0.00030318782,0.00016818095,0.000013277271,0.0043788115,0.00039789337,0.000029620081,0.00017173347],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99759364,0.00034427523,0.0011800166,0.0005417571,0.00015653194,0.00018375652],"domain_scores_gemma":[0.9987399,0.00013964719,0.00052863336,0.00038904542,0.00014842508,0.000054323802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046287378,0.00028706645,0.0032223142,0.00025210905,0.00004357906,0.0001510329,0.00053883187,0.00012544171,0.000023498793],"category_scores_gemma":[0.0009508198,0.00023738247,0.00025322378,0.0016976693,0.00006298734,0.000016084456,0.0007812575,0.00007999889,0.0000016235845],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008197645,0.00010881562,0.008498799,0.91855246,0.06662206,0.000010149692,0.00017330995,0.00040215862,0.0000010727746,0.000012435364,0.0003063294,0.0053042034],"study_design_scores_gemma":[0.00040669442,0.00008642463,0.03165228,0.069896445,0.89531463,0.000007919619,0.000043965287,0.000047354177,0.0000052434116,0.00010067411,0.0015551104,0.00088326767],"about_ca_topic_score_codex":0.0040943655,"about_ca_topic_score_gemma":0.025966583,"teacher_disagreement_score":0.848656,"about_ca_system_score_codex":0.00010943207,"about_ca_system_score_gemma":0.0002852367,"threshold_uncertainty_score":0.991807},"labels":[],"label_agreement":null},{"id":"W4321769995","doi":"10.1016/j.esmoop.2023.100787","title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Hazard ratio; Randomized controlled trial; Confidence interval; Meta-analysis; Placebo; Odds ratio; Oncology; Pathology","score_opus":0.09677872305832615,"score_gpt":0.40661535831806084,"score_spread":0.3098366352597347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321769995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046847148,0.98308784,6.1685e-7,0.00020481917,0.0001528508,0.01626732,0.000109937915,0.000028692984,0.000101057354],"genre_scores_gemma":[0.00028612808,0.9938407,0.000035118494,0.000037917955,0.00000961248,0.0013647927,0.00033344782,0.00007473068,0.0040175724],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98988014,0.0020318462,0.0066591096,0.0005749048,0.00059124664,0.0002627709],"domain_scores_gemma":[0.9918637,0.0012006972,0.0053219143,0.0011593404,0.00037477355,0.00007956159],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.009674848,0.0007094877,0.036217123,0.0006862566,0.000071916234,0.00001411922,0.0006034514,0.000274778,0.0006655329],"category_scores_gemma":[0.00213537,0.0004039958,0.013651152,0.0021731805,0.0003510334,0.000093907634,0.0005917647,0.00031369875,0.000035933423],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018172127,0.00009485661,1.4824363e-7,0.46418482,0.53340834,0.000013162824,0.00015674335,3.9652565e-7,0.0000027703034,0.000006260276,0.000020862277,0.0002943972],"study_design_scores_gemma":[0.020148009,0.000091906055,0.0000058385467,0.19859676,0.7801633,0.00003286905,0.000116943615,0.0000018386296,0.000018877656,0.000009792481,0.00056191004,0.00025199953],"about_ca_topic_score_codex":0.0016260529,"about_ca_topic_score_gemma":0.00003187991,"teacher_disagreement_score":0.26558807,"about_ca_system_score_codex":0.0001124447,"about_ca_system_score_gemma":0.0002958527,"threshold_uncertainty_score":0.9998412},"labels":[],"label_agreement":null},{"id":"W4321770001","doi":"10.1016/j.esmoop.2023.100781","title":"Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Takeda Pharmaceuticals International; Bristol-Myers Squibb; Samsung; F. Hoffmann-La Roche; Grifols; European Society for Medical Oncology; Eisai; AstraZeneca; Institute for Oil Sands Innovation, University of Alberta; Ipsen; Mirati Therapeutics; Sun Pharma; Regeneron Pharmaceuticals; Mersana Therapeutics; International Association for the Study of Lung Cancer; Merck KGaA; Daiichi Sankyo Europe; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company","keywords":"Salary; Harassment; Ethnic group; Career development; Medicine; Workforce; Promotion (chess); Sexual orientation; Respondent; Equity (law); Psychology; Medical education; Political science; Nursing; Social psychology","score_opus":0.4922037669356153,"score_gpt":0.43787201853964547,"score_spread":0.054331748395969826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321770001","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1542603,0.0007450143,0.000008465303,0.43347383,0.0029925646,0.0025774373,0.00018408507,0.000061382496,0.4056969],"genre_scores_gemma":[0.9896001,0.0023637805,0.00004294926,0.0015181341,0.0002674484,0.0000560176,0.000019192083,0.000010823649,0.0061215074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725664,0.0014197294,0.00024640473,0.00024735596,0.00041000827,0.00041987564],"domain_scores_gemma":[0.99718183,0.0020663007,0.00019548084,0.00034403862,0.00012404294,0.0000882986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010542093,0.000090965725,0.0003248252,0.00006062804,0.0004491437,0.000045385965,0.002159065,0.0001924696,0.00006868319],"category_scores_gemma":[0.0013097109,0.00006054521,0.000053942753,0.0005076535,0.00043163376,0.00010745255,0.00077754084,0.00024748416,0.000016584772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051940524,0.000118854216,0.022924805,0.0000335989,0.000093845156,0.000020476518,0.39762938,0.000068754496,0.0000029993116,0.008498559,0.47276747,0.09732186],"study_design_scores_gemma":[0.0012456704,0.00013484716,0.1522287,0.000035883615,0.0000122574975,4.6280852e-7,0.22506112,0.000005848561,0.000009198456,0.0044000526,0.6167992,0.00006680213],"about_ca_topic_score_codex":0.03315509,"about_ca_topic_score_gemma":0.39688095,"teacher_disagreement_score":0.83533984,"about_ca_system_score_codex":0.00034557324,"about_ca_system_score_gemma":0.0007710297,"threshold_uncertainty_score":0.97328323},"labels":[],"label_agreement":null},{"id":"W4322012021","doi":"10.1016/j.esmoop.2023.100830","title":"50P Can we learn from failures? A systematic review and metanalysis of phase III trials in platinum resistant ovarian cancer","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Ovarian cancer; Internal medicine; Oncology; Population; Biomarker; Chemotherapy; Clinical trial; Meta-analysis; Progression-free survival; Cancer","score_opus":0.18683416395359573,"score_gpt":0.45734650762827594,"score_spread":0.27051234367468024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322012021","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000032250493,0.9823906,0.0000019173992,0.0029664955,0.00009428487,0.01258039,0.0016678497,0.00001854213,0.0002766923],"genre_scores_gemma":[0.000044978926,0.9911455,0.00021759972,0.0001742174,0.00009392695,0.005836802,0.0005957592,0.00009099921,0.0018002501],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9929269,0.0018306907,0.0036585208,0.00083719165,0.00044150752,0.00030521685],"domain_scores_gemma":[0.99430937,0.001691057,0.0025636265,0.0011314165,0.000094728035,0.00020983117],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042129275,0.00060459954,0.017417,0.00039106872,0.000055511755,0.00010475571,0.0004673226,0.00024539186,0.0013993509],"category_scores_gemma":[0.0013975417,0.0003808998,0.00084903673,0.0011539472,0.0000471369,0.000073390634,0.00026662785,0.00034601137,0.00002770076],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011405478,0.00029918557,0.000010101714,0.92040044,0.01576568,0.00032781917,0.00019697442,2.1492758e-7,2.2145335e-7,0.00014609763,0.0023495904,0.060389604],"study_design_scores_gemma":[0.0045013446,0.00014873895,0.000011184342,0.71865433,0.113357306,0.0000070149713,0.000057431997,0.000001889594,0.0000012337053,0.000048607224,0.16294287,0.00026804395],"about_ca_topic_score_codex":0.06417259,"about_ca_topic_score_gemma":0.025036426,"teacher_disagreement_score":0.20174612,"about_ca_system_score_codex":0.00050598825,"about_ca_system_score_gemma":0.0011252541,"threshold_uncertainty_score":0.9998643},"labels":[],"label_agreement":null},{"id":"W4322012040","doi":"10.1016/j.esmoop.2023.100869","title":"14P Clinical outcomes of women who attend the Cameroon Baptist Convention Health Services (CBCHS) with cervical cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Cervical cancer; Cancer; Proportional hazards model; Stage (stratigraphy); Disease; Survival analysis; Gynecology; Radiation therapy; Internal medicine; Obstetrics","score_opus":0.08878968171285871,"score_gpt":0.47338876491152465,"score_spread":0.3845990831986659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322012040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9489711,0.00018727974,0.000009144874,0.03682461,0.0002240774,0.0015870786,0.00006852581,0.000058530095,0.012069682],"genre_scores_gemma":[0.98785067,0.00069423905,0.000033357228,0.0048860977,0.0001925413,0.00024509133,0.00006507982,0.000032220898,0.0060007144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997806,0.00020199457,0.000499883,0.00035875072,0.0005966686,0.0005366648],"domain_scores_gemma":[0.99856454,0.00024819138,0.00015525697,0.00049865176,0.00018032466,0.0003530491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017304217,0.00014512082,0.000716616,0.000066018176,0.0001531204,0.00006335449,0.00051957986,0.00007964635,0.0062469286],"category_scores_gemma":[0.000034829976,0.00008152173,0.00010790036,0.0005245567,0.00021771668,0.000108017695,0.00042683136,0.0003833442,0.00014836279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011287787,0.00016065831,0.94836944,0.0005768828,0.0003057328,0.000017163029,0.0012501564,0.000005452794,0.0000017621139,0.00048501586,0.004813468,0.042885464],"study_design_scores_gemma":[0.0025530544,0.00073566206,0.9620479,0.00012112881,0.00003669669,0.0000038098892,0.0016722948,0.00016430176,0.000018326034,0.000111335656,0.032446116,0.00008942677],"about_ca_topic_score_codex":0.036007296,"about_ca_topic_score_gemma":0.027501442,"teacher_disagreement_score":0.042796038,"about_ca_system_score_codex":0.00022100593,"about_ca_system_score_gemma":0.0005143269,"threshold_uncertainty_score":0.9946615},"labels":[],"label_agreement":null},{"id":"W4322012051","doi":"10.1016/j.esmoop.2023.100876","title":"21TiP Molecular alterations predictive of outcome in early staged cervical cancer: A translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cervical cancer; Medicine; Stage (stratigraphy); Oncology; Sentinel node; Biopsy; Cancer; Internal medicine; Biology; Breast cancer","score_opus":0.06910291452903516,"score_gpt":0.37139732552923016,"score_spread":0.302294411000195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322012051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316317,0.000019994552,0.00003730518,0.0041768653,0.00013628542,0.0020576557,0.00012103296,0.000012898322,0.0002747982],"genre_scores_gemma":[0.9984082,0.000015661033,0.0000788259,0.00023732781,0.000055583976,0.00091723225,0.00021376016,0.000015997552,0.000057396872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761236,0.0002747517,0.00083534274,0.0003371764,0.000743252,0.00019713097],"domain_scores_gemma":[0.9991952,0.00020017523,0.00018685631,0.00020662489,0.00014833524,0.000062775085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006243833,0.00015565244,0.00042103123,0.0005050558,0.000035560595,0.000043105734,0.00033952144,0.00008741689,0.00019690915],"category_scores_gemma":[0.00010205748,0.00012457908,0.000069333255,0.0018243501,0.0000551536,0.00025525872,0.00010248396,0.00026716676,0.000004432721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008258284,0.0009038438,0.98543614,0.000045682627,0.00013078049,0.000041834577,0.008703282,0.0025487056,0.0009527157,0.00017073505,0.00001103977,0.00022939603],"study_design_scores_gemma":[0.011197595,0.000176438,0.98318404,0.000175657,0.00008823433,0.000001249776,0.00080367306,0.0026601078,0.0012576272,0.00035411245,0.00000633361,0.00009492807],"about_ca_topic_score_codex":0.06265151,"about_ca_topic_score_gemma":0.008450395,"teacher_disagreement_score":0.054201115,"about_ca_system_score_codex":0.00018719662,"about_ca_system_score_gemma":0.0001921308,"threshold_uncertainty_score":0.9435904},"labels":[],"label_agreement":null},{"id":"W4322012252","doi":"10.1016/j.esmoop.2023.100808","title":"78P Electronic tool for high grade adverse event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Odds ratio; Adverse effect; Internal medicine; Odds; Gynecology; Logistic regression","score_opus":0.18092098499228404,"score_gpt":0.49887079803873235,"score_spread":0.3179498130464483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322012252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91754067,0.00007284189,0.00014263942,0.076865405,0.0015587866,0.003524187,0.000024292327,0.00006583361,0.0002053387],"genre_scores_gemma":[0.9888832,0.00071669,0.00027135882,0.0012380999,0.0006280931,0.0002951525,0.00039293387,0.000034267418,0.0075402227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542016,0.0005090463,0.0026199222,0.00055378105,0.00032163007,0.00057548704],"domain_scores_gemma":[0.9960402,0.001988692,0.0013585996,0.0003345524,0.00011153362,0.00016638408],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015841285,0.0001599622,0.0009785705,0.00009943476,0.00011426871,0.000018059649,0.0002410321,0.00050563534,0.001028373],"category_scores_gemma":[0.009842264,0.00012038879,0.00024994143,0.00034182798,0.00018271247,0.00007141035,0.0003402977,0.0005449966,0.000039820097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042756656,0.0011890637,0.61784047,0.00078777986,0.0009591894,0.00053237786,0.0012117493,0.00030766227,0.00076762174,0.01915275,0.056878317,0.29609737],"study_design_scores_gemma":[0.010156832,0.00045254928,0.80487734,0.0003773779,0.00022236154,0.000013083302,0.00015852427,0.0035150407,0.00072796585,0.0093960725,0.16982111,0.00028174563],"about_ca_topic_score_codex":0.0013299491,"about_ca_topic_score_gemma":0.0068224203,"teacher_disagreement_score":0.29581565,"about_ca_system_score_codex":0.00043440363,"about_ca_system_score_gemma":0.0009997543,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4323570004","doi":"10.1016/j.esmoop.2023.100937","title":"79MO Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (DosE FIndiNg Extensions) study","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Consolidated Standards of Reporting Trials; Delphi method; Clinical trial; Protocol (science); Delphi; Medicine; Citation; Checklist; Medical physics; Medical education; Alternative medicine; Family medicine; Psychology; Computer science; Library science; Pathology; Artificial intelligence","score_opus":0.8720176792740006,"score_gpt":0.6405684192663532,"score_spread":0.23144926000764743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323570004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9120172,0.00021434439,0.0013026411,0.077255435,0.002341283,0.0054146647,0.00053613784,0.000092631155,0.0008256377],"genre_scores_gemma":[0.98263586,0.00022147775,0.007162955,0.0066226507,0.00072081416,0.0007947409,0.00014057205,0.000073568764,0.0016273871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99027777,0.0014933011,0.006500986,0.0010213092,0.00015927835,0.0005473661],"domain_scores_gemma":[0.9795224,0.01659819,0.0027693568,0.0006679942,0.00020069745,0.00024136566],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.080468334,0.0002868602,0.0017201384,0.0004477996,0.0010220805,0.00056343107,0.0008402171,0.00018981443,0.0002713964],"category_scores_gemma":[0.044886142,0.0002793463,0.00023470349,0.00037304626,0.00017951726,0.0004085091,0.00063022366,0.00035698048,0.0009271037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007284765,0.0009782935,0.62986267,0.00015504453,0.0015402448,0.00005822829,0.008085189,0.0002632858,0.000013045573,0.15569843,0.19614369,0.0064733815],"study_design_scores_gemma":[0.017567815,0.0005670179,0.7462842,0.00035166304,0.000111011854,0.000036413454,0.009184256,0.025315914,0.0000041123044,0.014845249,0.18485695,0.0008754361],"about_ca_topic_score_codex":0.0010225191,"about_ca_topic_score_gemma":0.000566716,"teacher_disagreement_score":0.14085318,"about_ca_system_score_codex":0.00019946696,"about_ca_system_score_gemma":0.00039957295,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W4324143593","doi":"10.1016/j.esmoop.2023.101155","title":"Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer survivorship and care","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Anxiety; Depression (economics); Mindfulness; Guideline; Medicine; Clinical psychology; Cancer; Psychiatry; Population; Clinical Practice; Psychology; Internal medicine; Physical therapy","score_opus":0.03869775150564856,"score_gpt":0.4239034952803956,"score_spread":0.38520574377474703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324143593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678928,0.00021044626,0.000013273844,0.008927341,0.0012500455,0.00084605586,0.000031186988,0.00006217062,0.020766674],"genre_scores_gemma":[0.98130095,0.0031837942,0.00060645887,0.012615526,0.00039280206,0.00014625725,0.00017569946,0.00003137651,0.0015471535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866205,0.00010888456,0.0004429482,0.00035453032,0.0002360561,0.00019553116],"domain_scores_gemma":[0.9990219,0.00015436194,0.00010098948,0.00026686658,0.00032254495,0.00013333448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007653225,0.00010583398,0.00026678,0.000054230397,0.00004701897,0.00003831965,0.0001502746,0.00011692609,0.00023312369],"category_scores_gemma":[0.0013340832,0.00008655729,0.000040336654,0.0003376723,0.000033771357,0.00026110958,0.0003518333,0.00026495775,0.000051111965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046739014,0.00012087439,0.8067853,0.000023228908,0.000021803187,0.00002727072,0.00051820686,0.0000026977086,0.000002426504,0.00001781732,0.109905586,0.08210742],"study_design_scores_gemma":[0.0026474518,0.00008894926,0.64678985,0.00020510757,0.000049024773,0.000005332364,0.0007963994,0.00022945282,0.00005282648,0.00002363467,0.34900337,0.000108612985],"about_ca_topic_score_codex":0.037136402,"about_ca_topic_score_gemma":0.022046976,"teacher_disagreement_score":0.23909777,"about_ca_system_score_codex":0.00005219715,"about_ca_system_score_gemma":0.00012434373,"threshold_uncertainty_score":0.9957981},"labels":[],"label_agreement":null},{"id":"W4353071698","doi":"10.1016/j.esmoop.2023.101051","title":"30P Bone fragility in patients with adrenocortical carcinoma undergoing mitotane therapy","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Mitotane; Adrenocortical carcinoma; Fragility; Medicine; Carcinoma; Oncology; Internal medicine; Chemistry","score_opus":0.024410025083677848,"score_gpt":0.2801928866869096,"score_spread":0.25578286160323177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353071698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994569,0.000031745818,0.0000079179,0.000942256,0.00006836842,0.0007625462,0.000005458356,0.000049956278,0.0035627685],"genre_scores_gemma":[0.99790645,0.000005161621,0.000148236,0.0004143846,0.000052145027,0.000035790188,0.000086215,0.00002181424,0.0013297967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988824,0.000048746748,0.00022191263,0.00029088045,0.000255278,0.000300763],"domain_scores_gemma":[0.9993915,0.00008610995,0.00004355901,0.00029768678,0.0000486141,0.00013251904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019004852,0.00013141907,0.00029644064,0.00008463922,0.00006117191,0.000025919093,0.00015293251,0.00005634503,0.00040788704],"category_scores_gemma":[0.000060624316,0.000091069574,0.000035704365,0.0005069348,0.000058122438,0.000106329586,0.00012438293,0.00020288488,0.00020055765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001478589,0.00026681332,0.99220556,0.000019217321,0.000026916956,0.001477402,0.00029633418,0.000008485492,0.0000036386482,0.000113113245,0.0009264025,0.0031775495],"study_design_scores_gemma":[0.005493221,0.00058393175,0.9926393,0.00008830016,0.0000119444,0.00004800389,0.0000830986,0.00007619888,0.00015507937,0.00020345837,0.00049460505,0.00012282665],"about_ca_topic_score_codex":0.00076053676,"about_ca_topic_score_gemma":0.00036714118,"teacher_disagreement_score":0.0040146317,"about_ca_system_score_codex":0.000054729106,"about_ca_system_score_gemma":0.00015013997,"threshold_uncertainty_score":0.4466077},"labels":[],"label_agreement":null},{"id":"W4366156895","doi":"10.1016/j.esmoop.2023.101214","title":"Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; European Society for Medical Oncology; Astellas Pharma; Oncolytics Biotech; Svenska Sällskapet för Medicinsk Forskning; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Celgene; G1 Therapeutics; Instituto de Salud Carlos III; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Metastatic breast cancer; Meta-analysis; Breast cancer; Oncology; Hormone receptor; Internal medicine; Medicine; Value (mathematics); Cancer; Statistics; Mathematics","score_opus":0.0579265093594468,"score_gpt":0.3651085097397053,"score_spread":0.3071820003802585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366156895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010768155,0.9925243,0.0000038892567,0.00018304778,0.00002389256,0.0049556945,0.0022434986,0.000007605101,0.000047304133],"genre_scores_gemma":[0.00027312894,0.99365133,0.00009967997,0.00009417129,0.000017987768,0.0047228434,0.0007817147,0.000060411065,0.0002987169],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99694866,0.00075908867,0.0010770479,0.00074495113,0.00020071489,0.0002695378],"domain_scores_gemma":[0.9980844,0.00019370616,0.00086794136,0.0006402275,0.0001414444,0.00007227852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006682104,0.000572341,0.0076528247,0.00021008399,0.000051450905,0.00004540584,0.00059999584,0.0001289203,0.000052020816],"category_scores_gemma":[0.00016073589,0.00038175727,0.0011260133,0.0010699201,0.00010524808,0.000009960563,0.000720473,0.00013905708,0.000021616881],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017492493,0.000113842834,0.00006574519,0.58099514,0.4162459,0.000014396998,0.000045132052,0.0000029683201,2.644941e-7,0.000058124966,0.00041074687,0.0020302641],"study_design_scores_gemma":[0.00020382079,0.00006403595,0.0005615443,0.03044294,0.9664594,0.000033780965,0.000024708837,4.44224e-7,0.0000034106272,0.000009048144,0.0017853617,0.00041151186],"about_ca_topic_score_codex":0.0034227662,"about_ca_topic_score_gemma":0.0015461992,"teacher_disagreement_score":0.5505522,"about_ca_system_score_codex":0.000080925194,"about_ca_system_score_gemma":0.0002537512,"threshold_uncertainty_score":0.99986345},"labels":[],"label_agreement":null},{"id":"W4376613505","doi":"10.1016/j.esmoop.2023.101505","title":"165P Introduction of Magseed in the DGH setting: No inferiority to wire localisation","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Ductal carcinoma; Breast cancer; Surgery; Radiology; Cancer; Internal medicine","score_opus":0.02618504176217914,"score_gpt":0.3116581822500918,"score_spread":0.28547314048791267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824966,0.0000019196905,0.000026255564,0.013334768,0.0004990555,0.000627905,0.000005223788,0.00002614688,0.002982109],"genre_scores_gemma":[0.99813086,0.000003555013,0.0002947646,0.00013704559,0.00057871715,0.000022702145,0.00011904359,0.0000064470382,0.00070688233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993908,0.00006205565,0.00018118472,0.0001312196,0.0001287457,0.00010600733],"domain_scores_gemma":[0.999656,0.000028775818,0.00005021872,0.0001750853,0.000060719252,0.000029162467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006213155,0.000057476675,0.0001365071,0.00010346353,0.000041999192,0.000021712127,0.00011183425,0.00005118007,0.00012059318],"category_scores_gemma":[0.0000774947,0.000040035873,0.000021884061,0.00044339834,0.000030794046,0.000119385564,0.000060125098,0.00011536558,0.00018512178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001640435,0.00026060126,0.26877242,0.00030067572,0.00011143577,0.000046320125,0.008378496,0.00016264066,0.009955708,0.0031148365,0.14223443,0.565022],"study_design_scores_gemma":[0.0010400268,0.00015803857,0.9737379,0.000086246044,0.000035260095,0.0012370856,0.0015034479,0.00037447523,0.0024543493,0.00036263678,0.01891264,0.00009787868],"about_ca_topic_score_codex":0.0010268253,"about_ca_topic_score_gemma":0.00022591489,"teacher_disagreement_score":0.7049655,"about_ca_system_score_codex":0.00003079795,"about_ca_system_score_gemma":0.00004795528,"threshold_uncertainty_score":0.23794277},"labels":[],"label_agreement":null},{"id":"W4376613513","doi":"10.1016/j.esmoop.2023.101504","title":"164P Adjuvant radiation therapy amongst immigrant and Canadian-born/long-term resident women with breast cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University","funders":"McMaster University","keywords":"Medicine; Breast cancer; Immigration; Mastectomy; Demography; Breast-conserving surgery; Cohort; Retrospective cohort study; Cancer; Socioeconomic status; Population; Radiation therapy; Internal medicine; Gynecology; Environmental health","score_opus":0.01650930865033263,"score_gpt":0.2947519935859524,"score_spread":0.27824268493561977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850482,0.0010305977,4.3715298e-7,0.011877746,0.000107495,0.0011829985,0.00013706791,0.000030307188,0.00058514904],"genre_scores_gemma":[0.98684543,0.008613409,0.0000063854222,0.0010232863,0.00013078027,0.0010662947,0.000096614785,0.000033965604,0.0021838269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892545,0.000023910681,0.0001499749,0.00033067673,0.00019264015,0.0003773514],"domain_scores_gemma":[0.9992182,0.00002694293,0.000058700403,0.00027021137,0.000043067605,0.0003828644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014937439,0.00016350597,0.00029810605,0.00013067927,0.00013871296,0.00011559173,0.00011330857,0.000048183047,0.0008658076],"category_scores_gemma":[0.000003803437,0.00011436968,0.000024219566,0.00027697912,0.000046143712,0.00013974146,0.000042732518,0.000083430175,0.00005030952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006003534,0.000064466374,0.88557297,0.00002098971,0.00030587215,0.0004073437,0.0022364715,0.0000069926236,0.000036178106,0.000027518134,0.007358833,0.103362],"study_design_scores_gemma":[0.0037048287,0.00032538996,0.9852742,0.00019167508,0.000053342188,0.00005123974,0.00023998141,0.000010614308,0.00034905144,0.0000105477,0.009643463,0.00014566426],"about_ca_topic_score_codex":0.71737856,"about_ca_topic_score_gemma":0.6759436,"teacher_disagreement_score":0.103216335,"about_ca_system_score_codex":0.00065342215,"about_ca_system_score_gemma":0.00053343584,"threshold_uncertainty_score":0.9479986},"labels":[],"label_agreement":null},{"id":"W4376613526","doi":"10.1016/j.esmoop.2023.101342","title":"118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary","funders":"Chinese Academy of Medical Sciences; AstraZeneca; Les Laboratories Pierre Fabre; Academy of Medical Sciences; Chinese Academy of Sciences; Cancer Research Institute","keywords":"Medicine; Breast cancer; Cumulative incidence; Stage (stratigraphy); Population; Internal medicine; Cancer registry; Epidemiology; Hormone therapy; Incidence (geometry); Oncology; Adjuvant therapy; Cohort; Cancer","score_opus":0.015835592691497,"score_gpt":0.31287438802178574,"score_spread":0.29703879533028876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652654,0.0000017547902,2.4292714e-7,0.0006900311,0.00024904346,0.00060047983,0.0014176276,0.000008225814,0.0005060274],"genre_scores_gemma":[0.9924137,0.0016516267,0.000015871778,0.00014760044,0.000069718895,0.0002895635,0.00028422268,0.000032726803,0.0050949673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846315,0.00015424629,0.00032195897,0.0005735307,0.00014417635,0.0003429183],"domain_scores_gemma":[0.9991999,0.00013276441,0.00016089978,0.00032770023,0.000054009713,0.00012470769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010322632,0.0002708457,0.00039437035,0.00004308501,0.00012536377,0.000045446508,0.00022682983,0.000078392055,0.00007178178],"category_scores_gemma":[0.000036755646,0.00021588047,0.00006439339,0.0001407482,0.00008754688,0.000013602314,0.00040630696,0.00009733646,0.0000077165805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014685642,0.00013719957,0.9942961,0.000005093056,0.00046042417,0.000018111881,0.0001618994,0.000011352099,3.1351753e-8,0.000005517239,0.0012611361,0.003496286],"study_design_scores_gemma":[0.002912655,0.00015400264,0.9952949,0.000030543924,0.000064338936,2.5704736e-7,0.00011595874,0.000003891144,0.00011340678,0.0000104628625,0.0010695155,0.00023001415],"about_ca_topic_score_codex":0.9999215,"about_ca_topic_score_gemma":0.9999548,"teacher_disagreement_score":0.00458894,"about_ca_system_score_codex":0.00025214444,"about_ca_system_score_gemma":0.00024379048,"threshold_uncertainty_score":0.88033503},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":true,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4376613563","doi":"10.1016/j.esmoop.2023.101385","title":"196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Samsung; Genentech; Daiichi-Sankyo; Eisai; Novartis Pharmaceuticals Corporation; Ascentage Pharma; Argenx; Syndax Pharmaceuticals; Mirati Therapeutics; Les Laboratories Pierre Fabre; TG Therapeutics; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; G1 Therapeutics; Ipsen Biopharmaceuticals; Celgene; Carrick Therapeutics; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Letrozole; Adjuvant; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Cancer; Breast cancer; Oncology; Aromatase","score_opus":0.026123771770422327,"score_gpt":0.30380116496314485,"score_spread":0.27767739319272255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963526,0.0010162477,0.0000720266,0.0010103657,0.000031437412,0.0012581489,0.00018739965,0.00002216628,0.00004961351],"genre_scores_gemma":[0.99688107,0.0011855836,0.0012467206,0.00025029355,0.000018537597,0.00009477494,0.00017797656,0.000036713383,0.00010834618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998528,0.00009649734,0.00037482023,0.00042836845,0.00025608233,0.00031625174],"domain_scores_gemma":[0.9990242,0.00026640415,0.00014203406,0.00032438737,0.00005921795,0.00018375998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029024802,0.0002232645,0.0005431257,0.00014349594,0.00005049654,0.000023039118,0.00019570661,0.000032961987,0.00008335834],"category_scores_gemma":[0.000110382425,0.00017625473,0.000025073452,0.00045325558,0.000162618,0.00023023617,0.00017126485,0.00020765407,0.0000064915307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013841379,0.0005434913,0.904622,0.00009566041,0.00014451532,0.00017461719,0.0020711436,0.00056932657,0.00010850825,0.000027187347,0.000015724496,0.07778643],"study_design_scores_gemma":[0.020239163,0.00046912444,0.97495186,0.00083247724,0.00004844478,0.000003235158,0.00010907207,0.0006591027,0.00023278005,0.0007004515,0.0015616176,0.0001926936],"about_ca_topic_score_codex":0.001828255,"about_ca_topic_score_gemma":0.0015023616,"teacher_disagreement_score":0.07759374,"about_ca_system_score_codex":0.00012137389,"about_ca_system_score_gemma":0.00011849666,"threshold_uncertainty_score":0.71874595},"labels":[],"label_agreement":null},{"id":"W4376613623","doi":"10.1016/j.esmoop.2023.101409","title":"220P Oral selective estrogen receptor degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: A systematic review and meta-analysis of randomized control trials","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Randomized controlled trial; Estrogen receptor; Breast cancer; Selective estrogen receptor modulator; Metastatic breast cancer; Fulvestrant; Cancer; Cochrane Library","score_opus":0.22772770467136944,"score_gpt":0.4902644295594634,"score_spread":0.262536724888094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004855569,0.9255903,0.00021589725,0.0017306911,0.00009886833,0.065307096,0.00698306,0.000031515217,0.000037723457],"genre_scores_gemma":[0.00007183413,0.93185586,0.0014804642,0.0007617788,0.0000641056,0.06320441,0.0011422124,0.00010791431,0.0013113954],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98953164,0.005668355,0.0031617722,0.0008614717,0.00037606078,0.00040072162],"domain_scores_gemma":[0.9846095,0.010795348,0.0032170822,0.00038464248,0.0007194964,0.00027395238],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0071392106,0.00083165214,0.039506614,0.000690146,0.00012706334,0.00009298345,0.0003737741,0.0001690034,0.00094566133],"category_scores_gemma":[0.00266464,0.0005031316,0.0056899874,0.0023821844,0.00012419872,0.00017234351,0.00010863225,0.00025398144,0.00002631687],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011794645,0.00011540544,6.9575174e-7,0.21410373,0.76825976,0.000008770762,0.00029207102,0.00000413785,9.703931e-7,0.000038824943,0.0025547403,0.0028262367],"study_design_scores_gemma":[0.04933394,0.00032917788,0.0000013200798,0.024072908,0.92454547,0.000027403541,0.00014456308,0.00001992874,0.000008200569,0.000017164708,0.0011318263,0.0003680988],"about_ca_topic_score_codex":0.0043211333,"about_ca_topic_score_gemma":0.0003117178,"teacher_disagreement_score":0.19003083,"about_ca_system_score_codex":0.00051308033,"about_ca_system_score_gemma":0.00071824825,"threshold_uncertainty_score":0.99996763},"labels":[],"label_agreement":null},{"id":"W4376613634","doi":"10.1016/j.esmoop.2023.101463","title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; PharmaMar; Eisai; Clovis Oncology; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Relay Therapeutics; Gilead Sciences; Veracyte; Pfizer; Oncolytics Biotech","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Internal medicine; Oncology; Clinical trial; Cancer; Gastroenterology","score_opus":0.045698589555339356,"score_gpt":0.33968918892926603,"score_spread":0.2939905993739267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370695,0.0002906602,0.000025061521,0.003321425,0.00042685974,0.0042964993,0.004393747,0.000055851793,0.003482973],"genre_scores_gemma":[0.996002,0.00072599726,0.0010405775,0.00015385155,0.000265596,0.00030814175,0.00018456971,0.00007381825,0.0012454579],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963028,0.00048227038,0.0013298839,0.0006946429,0.0006680019,0.0005224072],"domain_scores_gemma":[0.99673015,0.0007773441,0.0010404015,0.0005581248,0.0005935574,0.00030043803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012658192,0.00042588823,0.0015368343,0.00033076058,0.00008948881,0.00002085219,0.00045905137,0.00024289126,0.000600427],"category_scores_gemma":[0.0006973567,0.00038970762,0.00017203503,0.0011398759,0.00078103004,0.00044242293,0.00038157884,0.00049680483,0.000005800787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5962059,0.0026477645,0.029385928,0.0007472857,0.0025560975,0.00021001049,0.023919115,0.00017512194,0.012334273,0.0003860713,0.0061469236,0.32528552],"study_design_scores_gemma":[0.16866201,0.003455836,0.74089503,0.0027055074,0.00031656,0.000045228786,0.0068776575,0.00007394297,0.07218148,0.0020466386,0.002032208,0.00070789206],"about_ca_topic_score_codex":0.028172225,"about_ca_topic_score_gemma":0.004991609,"teacher_disagreement_score":0.7115091,"about_ca_system_score_codex":0.00026834873,"about_ca_system_score_gemma":0.0011682317,"threshold_uncertainty_score":0.99985546},"labels":[],"label_agreement":null},{"id":"W4376613679","doi":"10.1016/j.esmoop.2023.101323","title":"99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Daiichi-Sankyo; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Daiichi Sankyo Europe; AstraZeneca","keywords":"Biology; Oncology; KEGG; Proportional hazards model; Cancer research; Gene expression; Gene; Internal medicine; Transcriptome; Medicine; Genetics","score_opus":0.00802498974315066,"score_gpt":0.25938981151331925,"score_spread":0.2513648217701686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747103,0.000101770835,0.000094700896,0.0001123413,0.0000620249,0.0009439507,0.0011898188,0.000009133521,0.000015245654],"genre_scores_gemma":[0.9978636,0.000426621,0.00014270285,0.000018782748,0.000048961534,0.0005626303,0.00085592613,0.00004119103,0.00003956871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982584,0.00013696885,0.0003887572,0.0006654893,0.00023077297,0.00031957484],"domain_scores_gemma":[0.9992767,0.000042985845,0.00020354633,0.00028360155,0.0001181091,0.00007505079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000072360555,0.00037284967,0.00065376546,0.0002815511,0.00007213978,0.00003755014,0.00016408808,0.00011741709,0.000040407293],"category_scores_gemma":[0.00001075901,0.00029064217,0.0000748298,0.00049736706,0.00010035125,0.000046654783,0.00033381724,0.00008036577,0.0000013356536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008217647,0.0007075268,0.9668567,0.0000389074,0.0015359933,0.00005100429,0.0095170075,0.0015763366,0.008475675,3.767353e-7,0.000028963545,0.0029938642],"study_design_scores_gemma":[0.005879604,0.00076280383,0.9563387,0.0002325306,0.00033245786,0.0000012855711,0.0012629348,0.00008278999,0.034813505,0.0000035415417,0.0000036715742,0.00028618216],"about_ca_topic_score_codex":0.0055640438,"about_ca_topic_score_gemma":0.04641534,"teacher_disagreement_score":0.040851295,"about_ca_system_score_codex":0.00037367822,"about_ca_system_score_gemma":0.00016141993,"threshold_uncertainty_score":0.9999546},"labels":[],"label_agreement":null},{"id":"W4376613717","doi":"10.1016/j.esmoop.2023.101290","title":"66P Digital profiling of immune biomarkers: Relation to anthracycline benefit","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Queen's University; University of British Columbia","funders":"","keywords":"Cyclophosphamide; Breast cancer; Oncology; Immune system; Anthracycline; Medicine; Epirubicin; Internal medicine; Chemotherapy; Immunology; Cancer","score_opus":0.03478004766884513,"score_gpt":0.3375019741374314,"score_spread":0.30272192646858626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848229,0.00012822455,0.00006871858,0.0029040403,0.00023542815,0.0010207511,0.000044120545,0.00007369369,0.0107021155],"genre_scores_gemma":[0.99524754,0.00007277462,0.0010196484,0.00016767159,0.00006152693,0.000035725345,0.00028520156,0.000024694133,0.0030852372],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990316,0.000009919804,0.0003877568,0.00021050598,0.0001839048,0.00017631506],"domain_scores_gemma":[0.99939454,0.000054166463,0.000103549406,0.00031809995,0.00006715061,0.00006252399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038711223,0.000101664766,0.00024729068,0.00015539695,0.000057524005,0.00005448659,0.00019715208,0.000062965126,0.0002475818],"category_scores_gemma":[0.00010537385,0.00008773986,0.0000947457,0.00073379773,0.000042469124,0.00026048732,0.0001724761,0.00006645531,0.00014407355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016500682,0.00063825294,0.13220866,0.00030230495,0.001372174,0.000097765886,0.0020343391,0.00006947088,0.3939817,0.00068523054,0.009681953,0.4424275],"study_design_scores_gemma":[0.003990126,0.0006752897,0.85414666,0.0005774588,0.000056150973,0.0000215551,0.0007396974,0.0003225453,0.119016856,0.0002887026,0.019925093,0.00023984147],"about_ca_topic_score_codex":0.0005706743,"about_ca_topic_score_gemma":0.000024953086,"teacher_disagreement_score":0.721938,"about_ca_system_score_codex":0.00004727242,"about_ca_system_score_gemma":0.000063142805,"threshold_uncertainty_score":0.35779276},"labels":[],"label_agreement":null},{"id":"W4376613759","doi":"10.1016/j.esmoop.2023.101506","title":"166P A mono-institutional experience of field-in-field 3D-CRT planning in breast radiotherapy with FAST and FAST-forward protocols","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Radiation therapy; Nuclear medicine; Breast cancer; Breast-conserving surgery; Radiology; Cancer; Mastectomy; Internal medicine","score_opus":0.017409620918420472,"score_gpt":0.32821964693735184,"score_spread":0.3108100260189314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930916,0.00008424272,0.0005189503,0.0008373461,0.000030290572,0.0033292414,0.000022875514,0.000009787317,0.0020757061],"genre_scores_gemma":[0.99462694,0.00004354865,0.00092630513,0.00020869354,0.000037151196,0.003976413,0.00002171996,0.000009391466,0.00014982252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934214,0.000020089694,0.00013442813,0.00025938055,0.00008175367,0.00016217641],"domain_scores_gemma":[0.99973047,0.000018953091,0.000044098644,0.00015718896,0.00002062425,0.000028651228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007542588,0.000110590256,0.00016929502,0.000047100784,0.00004633235,0.000021915479,0.00017835993,0.000059764876,0.00002254185],"category_scores_gemma":[0.000011676986,0.00008411933,0.000014685678,0.00013676957,0.00005878254,0.0000133603035,0.00015868816,0.0000548037,0.0000013026465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013886876,0.00010007179,0.97673714,0.00003193468,0.00007561425,0.00004889142,0.0019849467,0.0005235721,0.0032762743,0.000084872,0.00047982804,0.015268177],"study_design_scores_gemma":[0.0042318227,0.0006675045,0.95367,0.0004112016,0.000006992269,0.00009016814,0.0013947146,0.00023589481,0.033324566,0.000030240555,0.0056353738,0.00030150494],"about_ca_topic_score_codex":0.0012786674,"about_ca_topic_score_gemma":0.0005634887,"teacher_disagreement_score":0.03004829,"about_ca_system_score_codex":0.00001814213,"about_ca_system_score_gemma":0.00007353253,"threshold_uncertainty_score":0.3430287},"labels":[],"label_agreement":null},{"id":"W4376613834","doi":"10.1016/j.esmoop.2023.101571","title":"LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche; Eisai; Sanofi; Daiichi-Sankyo; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Internal medicine; Cyclophosphamide; Oncology; Adjuvant; Neoadjuvant therapy; Capecitabine; Placebo; Population; Breast cancer; Gastroenterology; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","score_opus":0.03329605026677972,"score_gpt":0.35987509302728204,"score_spread":0.3265790427605023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988985,0.000112519054,0.000035177796,0.0005780088,0.00021841557,0.008587884,0.0012080229,0.000016254507,0.000258727],"genre_scores_gemma":[0.99290574,0.00014144238,0.00011577123,0.00016122653,0.000057159996,0.003543806,0.00056011014,0.00006283412,0.0024519416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643326,0.00060366606,0.0009043538,0.0009038872,0.0005681662,0.00058669166],"domain_scores_gemma":[0.9978528,0.00016390787,0.0008748649,0.0007296926,0.00025644322,0.00012231784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009678893,0.0005311138,0.0017038811,0.00017187551,0.00034439424,0.00013467776,0.0011992669,0.00012300686,0.00027675135],"category_scores_gemma":[0.00017144575,0.00033387006,0.00031598145,0.0012595727,0.00016906041,0.000047293768,0.0008175197,0.00019088158,0.0000039348115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9629312,0.0014734198,0.0132536525,0.000011935795,0.0067283176,0.000011222652,0.00084586244,0.0010835074,0.0017693955,0.000002237428,0.0025985944,0.009290655],"study_design_scores_gemma":[0.939201,0.0016501475,0.048270013,0.00012248296,0.0013964411,0.0000012459474,0.0002662044,0.0030595514,0.0054273824,0.0000059586428,0.00015706547,0.00044248806],"about_ca_topic_score_codex":0.01828023,"about_ca_topic_score_gemma":0.004822812,"teacher_disagreement_score":0.03501636,"about_ca_system_score_codex":0.00026287526,"about_ca_system_score_gemma":0.0006015568,"threshold_uncertainty_score":0.9999113},"labels":[],"label_agreement":null},{"id":"W4376613897","doi":"10.1016/j.esmoop.2023.101392","title":"203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia","funders":"Yonsei University College of Medicine; Merck Sharp and Dohme; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Universitat de Barcelona; Medizinischen Hochschule Hannover; Hacettepe Üniversitesi; Gilead Sciences; Merck; AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Metastatic breast cancer; Taxane; Eribulin; Breast cancer; Population; Vinorelbine; Cancer; Chemotherapy; Cisplatin","score_opus":0.09030039216248577,"score_gpt":0.4620253913515751,"score_spread":0.37172499918908936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991773,0.00019397383,0.0020339608,0.00039315745,0.000379581,0.0024888767,0.002565276,0.000065816,0.0001063567],"genre_scores_gemma":[0.99650145,0.00012567769,0.001018785,0.0001412924,0.00015380647,0.00067990256,0.00091910554,0.00006944981,0.00039054162],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958963,0.0012665768,0.0010191711,0.00084404706,0.0005295793,0.00044431622],"domain_scores_gemma":[0.99659795,0.001871342,0.00046898404,0.00063060736,0.00020432027,0.00022681824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018321518,0.00035969313,0.0018209332,0.0003511031,0.000076141034,0.000043537675,0.0004932146,0.00015613061,0.0015824522],"category_scores_gemma":[0.0003462522,0.00029531153,0.00033909536,0.0021995823,0.00024969265,0.00044681603,0.00030923134,0.00045742962,0.0000438105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.573763,0.008731153,0.20300484,0.0004560358,0.0149379205,0.0006818562,0.0040092524,0.0020743539,0.042827312,0.000041308896,0.0029481852,0.14652476],"study_design_scores_gemma":[0.27956122,0.0011364571,0.65490687,0.0014038612,0.0026001886,0.000008785502,0.0010097334,0.0010929841,0.055703375,0.0010235632,0.00092016865,0.0006327903],"about_ca_topic_score_codex":0.03620589,"about_ca_topic_score_gemma":0.0026621176,"teacher_disagreement_score":0.45190203,"about_ca_system_score_codex":0.00028136527,"about_ca_system_score_gemma":0.0003257047,"threshold_uncertainty_score":0.9999499},"labels":[],"label_agreement":null},{"id":"W4377966316","doi":"10.1016/j.esmoop.2023.101558","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Genentech; Foundation Medicine; Sierra Oncology; Daiichi Sankyo Europe; Servier; FibroGen; Astellas Pharma; Eisai; Daiichi-Sankyo; European Society for Medical Oncology; Monash University; Natera; Seagen; Pfizer; Incyte; Azərbaycan Milli Elmlər Akademiyası; Boehringer Ingelheim Japan; Ipsen; Japanese Society of Medical Oncology; BeiGene; Sanofi; Amgen; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Colorectal cancer; Medicine; Clinical Practice; Oncology; Internal medicine; Cancer; Family medicine","score_opus":0.16010647211181903,"score_gpt":0.463078024038618,"score_spread":0.3029715519267989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377966316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672406,0.0015162182,0.000011885399,0.024120905,0.0004610729,0.0053220047,0.00037110917,0.000036881054,0.0009193345],"genre_scores_gemma":[0.98545086,0.0057084467,0.0022956212,0.0009173648,0.00010074919,0.0041448795,0.00012487161,0.00003418083,0.0012230031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880356,0.000060679205,0.00042316967,0.00030662306,0.00020097429,0.00020499481],"domain_scores_gemma":[0.99769944,0.0011532721,0.00020681342,0.00019180315,0.00067256344,0.000076080905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034661533,0.00018639583,0.000554433,0.000036461548,0.00018573325,0.000031471096,0.00011382648,0.00003477807,0.000055082488],"category_scores_gemma":[0.0011655855,0.0000917168,0.00009727874,0.00022555556,0.00011232262,0.000113715716,0.00012694037,0.00005764373,0.0000035510184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01050189,0.0009400131,0.5974406,0.000048028767,0.004845253,0.000024868823,0.0015152558,0.000006583319,0.0000010096851,0.00006624473,0.034682687,0.34992757],"study_design_scores_gemma":[0.012632195,0.0055457046,0.8379771,0.00010111393,0.0022910584,0.0000027422832,0.0017827539,0.0000903022,0.00008663247,0.000022722792,0.1393507,0.000116974785],"about_ca_topic_score_codex":0.006202138,"about_ca_topic_score_gemma":0.009128222,"teacher_disagreement_score":0.3498106,"about_ca_system_score_codex":0.000085067964,"about_ca_system_score_gemma":0.00021453715,"threshold_uncertainty_score":0.9375819},"labels":[],"label_agreement":null},{"id":"W4378904074","doi":"10.1016/j.esmoop.2023.101567","title":"The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Amgen Astellas Biopharma; Chugai Pharmaceutical; Flatiron Health; EMD Serono; AstraZeneca; Alnylam Pharmaceuticals; Genentech; Pancreatic Cancer Action Network; Ipsen; Sumitomo Dainippon Pharma Oncology; Nordic Pharma Group; Falk Foundation; Shionogi; Astellas Pharma; Samsung; Eisai; Sirtex Medical; Cancer Research UK; Plexxikon; Seagen; GlaxoSmithKline; Advanced Accelerator Applications; BeiGene; Momenta Pharmaceuticals; Daiichi Sankyo Europe; Agios Pharmaceuticals; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Mirati Therapeutics; Boston Scientific Corporation; Karyopharm Therapeutics; Array BioPharma; Exelixis; Celgene; National Cancer Institute; Incyte; Servier; Halozyme; Kyowa Hakko Kirin; Sanofi; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Amgen; Les Laboratories Pierre Fabre","keywords":"Hepatocellular carcinoma; Medicine; Cirrhosis; Expert opinion; Gastrointestinal cancer; Liver cancer; General surgery; Cancer; Internal medicine; Intensive care medicine; Gastroenterology; Oncology; Colorectal cancer","score_opus":0.223973563722923,"score_gpt":0.391251917489142,"score_spread":0.167278353766219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378904074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051456114,0.98908544,0.000009323575,0.0022128585,0.0013676233,0.0056296363,0.00044084873,0.00004076311,0.00069895625],"genre_scores_gemma":[0.00068919506,0.99152756,0.00033404934,0.000077082426,0.00028538884,0.0026998587,0.002203303,0.00009695331,0.002086642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971648,0.00047918945,0.0008050581,0.00070789806,0.0004257666,0.00041733135],"domain_scores_gemma":[0.99742347,0.00083828793,0.0005062738,0.000955752,0.00009434591,0.00018189916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061622437,0.00056146004,0.001273921,0.00012434355,0.0005048502,0.00016702373,0.00085682503,0.00007877885,0.00040773881],"category_scores_gemma":[0.000030343275,0.00031816802,0.0003754865,0.0004732942,0.00018001742,0.000066832676,0.0008750492,0.00056637684,0.00006782856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116923584,0.00018774235,0.039544158,0.0025304118,0.0011913881,0.0001357253,0.00012301642,7.966828e-8,3.9916205e-7,0.0004652594,0.027066233,0.92863864],"study_design_scores_gemma":[0.000961169,0.00017562532,0.0028445378,0.0319675,0.0011668042,0.000021221731,0.000154372,0.00015601917,0.000017639526,0.00004012537,0.96221715,0.00027780907],"about_ca_topic_score_codex":0.004228001,"about_ca_topic_score_gemma":0.00055168563,"teacher_disagreement_score":0.9351509,"about_ca_system_score_codex":0.00020134641,"about_ca_system_score_gemma":0.0002982178,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W4381848427","doi":"10.1016/j.esmoop.2023.101587","title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Reflex; Lung cancer; Intensive care medicine; Biomarker; Medical physics; Pathology; Internal medicine","score_opus":0.18011234910227428,"score_gpt":0.4606255245699017,"score_spread":0.28051317546762744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381848427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94688517,0.00013950377,0.00014767906,0.03603108,0.0001977903,0.011994488,0.00078551105,0.000060768685,0.0037580186],"genre_scores_gemma":[0.9806062,0.00003828937,0.0081893625,0.0023895463,0.000054718963,0.007627139,0.0005785552,0.000021859107,0.0004943197],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99936765,0.000032144962,0.00019242156,0.00020208686,0.000055892953,0.00014979529],"domain_scores_gemma":[0.99831355,0.0013573787,0.00007231754,0.00010558631,0.00011714075,0.00003404111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027105425,0.000086062435,0.00012549716,0.00006787813,0.00029081467,0.0000647178,0.000039020557,0.000030885316,0.00006653056],"category_scores_gemma":[0.0002533295,0.00006271009,0.000022717475,0.00015860941,0.000033925382,0.000040065133,0.000027239921,0.000035708184,0.000002200874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016280665,0.00067161873,0.2030379,0.00057402666,0.0016850674,0.00018791837,0.027108118,0.00056068646,0.032625753,0.00964771,0.6901975,0.032075617],"study_design_scores_gemma":[0.06320261,0.0033154807,0.78117746,0.0011207977,0.0013701045,0.00007317135,0.048910923,0.036658168,0.035515968,0.010492456,0.017051099,0.0011117416],"about_ca_topic_score_codex":0.0019173402,"about_ca_topic_score_gemma":0.0023430504,"teacher_disagreement_score":0.6731464,"about_ca_system_score_codex":0.000103125385,"about_ca_system_score_gemma":0.00030981385,"threshold_uncertainty_score":0.28984576},"labels":[],"label_agreement":null},{"id":"W4383162923","doi":"10.1016/j.esmoop.2023.101592","title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Astellas Pharma; Eisai; Seagen; Gilead Sciences; Servier; Instituto de Salud Carlos III; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Confidence interval; Meta-analysis; Odds ratio; Hormone receptor; Cancer","score_opus":0.26727533271768683,"score_gpt":0.5170282764841014,"score_spread":0.2497529437664146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383162923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.053806e-7,0.9800712,9.497492e-7,0.0008372303,0.000026781845,0.017697724,0.00090473524,0.000021941582,0.0004386485],"genre_scores_gemma":[0.000008339712,0.9859412,0.00008146412,0.00022239154,0.000022808676,0.010126105,0.00016081825,0.00010851521,0.003328363],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941734,0.0015151524,0.0020537658,0.0008014118,0.00089020364,0.00056607235],"domain_scores_gemma":[0.996442,0.00080151885,0.0008365086,0.0013614311,0.00024883222,0.00030969884],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037848311,0.0005213364,0.016932769,0.000688976,0.000033703098,0.00008454538,0.0008590144,0.00021494659,0.0018523758],"category_scores_gemma":[0.0009395924,0.00032764673,0.0015263727,0.003994373,0.00010577991,0.000081271246,0.0006873399,0.00065996486,0.00012407177],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045659162,0.00006147973,0.000112594396,0.89690226,0.09879481,0.00010266676,0.00003685433,7.8646167e-7,3.7902077e-9,0.000023313662,0.00072560785,0.003235066],"study_design_scores_gemma":[0.0001468897,0.000038351187,0.00011778072,0.34992856,0.6304096,0.000054822696,0.000012695714,0.000007476841,4.2389594e-8,0.0000054609322,0.019080797,0.00019752282],"about_ca_topic_score_codex":0.019630916,"about_ca_topic_score_gemma":0.0022038522,"teacher_disagreement_score":0.5469737,"about_ca_system_score_codex":0.00045597224,"about_ca_system_score_gemma":0.0020707916,"threshold_uncertainty_score":0.99991757},"labels":[],"label_agreement":null},{"id":"W4385173573","doi":"10.1016/j.esmoop.2023.101613","title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Internal medicine; Breast cancer; Incidence (geometry); Asymptomatic; Cardiotoxicity; Oncology; Gastroenterology; Lung cancer; Cancer; Chemotherapy","score_opus":0.15007037871251086,"score_gpt":0.4438841884306995,"score_spread":0.2938138097181886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385173573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005011231,0.98837924,0.0000126554005,0.00022950459,0.000020135352,0.010276948,0.0009359617,0.0000141216115,0.00008132784],"genre_scores_gemma":[0.0030547043,0.9928483,0.000037661834,0.0001462236,0.00002238746,0.0035477595,0.00010051939,0.000072523384,0.00016994441],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99587464,0.0008863678,0.0012987831,0.0008014793,0.00079369504,0.00034501473],"domain_scores_gemma":[0.9975537,0.00033232538,0.00063762267,0.00081249885,0.00028105424,0.00038280588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015366981,0.00048848224,0.009260753,0.0005113717,0.00004755442,0.00009828954,0.00054986536,0.00011555218,0.00027959683],"category_scores_gemma":[0.00045392042,0.00030241584,0.00073335785,0.0018570814,0.00021550826,0.00015975986,0.0006200779,0.00046827944,0.0000037002424],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006140503,0.00016517469,0.0009108498,0.93147016,0.06333018,0.00012534784,0.00008519596,8.7518043e-7,1.2920631e-8,0.0000030338756,0.00012177176,0.0037259967],"study_design_scores_gemma":[0.0003847027,0.00016420978,0.0006809692,0.41208407,0.5857162,0.000038268485,0.00002240574,0.000015230709,1.339316e-7,0.0000021051765,0.0006117361,0.00027996372],"about_ca_topic_score_codex":0.007439215,"about_ca_topic_score_gemma":0.004370385,"teacher_disagreement_score":0.522386,"about_ca_system_score_codex":0.0007633747,"about_ca_system_score_gemma":0.0010544196,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W4385651875","doi":"10.1016/j.esmoop.2023.101615","title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Concordance; Medicine; Immunohistochemistry; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer","score_opus":0.09067429760705649,"score_gpt":0.4811611636940519,"score_spread":0.3904868660869954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385651875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728186,0.000056702826,8.257934e-7,0.009057585,0.00011569241,0.0028713455,0.00022227659,0.00002441749,0.00036928328],"genre_scores_gemma":[0.9950495,0.00070095016,0.000053456475,0.00031172016,0.00004553047,0.0004416371,0.000004067203,0.000019957832,0.0033732273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984415,0.00025564482,0.0002749724,0.00040773686,0.00035297195,0.0002671317],"domain_scores_gemma":[0.99894965,0.00021191464,0.00008527408,0.0004875368,0.00014112952,0.00012448906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013697722,0.00015063927,0.0004316645,0.000038964085,0.0001790782,0.00008697207,0.00038455476,0.00004074793,0.00030139845],"category_scores_gemma":[0.00054668775,0.000072927025,0.000031097334,0.00027064516,0.0002638711,0.00006476301,0.00073102105,0.00023979787,0.000034997276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032151237,0.00022007513,0.9865823,0.000054293578,0.000090168876,0.00006494735,0.0025674712,5.0107917e-7,0.000026761172,0.000013181692,0.00059364055,0.009465175],"study_design_scores_gemma":[0.000982305,0.0008009247,0.9968019,0.00016594428,0.00012715218,0.000028317523,0.0007740252,0.000035185785,0.000031745396,0.000051547242,0.0001251524,0.00007581044],"about_ca_topic_score_codex":0.0021890562,"about_ca_topic_score_gemma":0.00055608805,"teacher_disagreement_score":0.010219618,"about_ca_system_score_codex":0.00011452164,"about_ca_system_score_gemma":0.00010388793,"threshold_uncertainty_score":0.3309213},"labels":[],"label_agreement":null},{"id":"W4387402119","doi":"10.1016/j.esmoop.2023.101886","title":"76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Kazan Federal University","keywords":"Metastasis; Neutrophil extracellular traps; CXC chemokine receptors; Lung cancer; Cancer research; Biology; Adenocarcinoma; Cancer; Chemokine; Flow cytometry; Immune system; Lung; Immunology; Medicine; Pathology; Chemokine receptor; Internal medicine; Inflammation","score_opus":0.023456665180682866,"score_gpt":0.31420880309617616,"score_spread":0.2907521379154933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9477103,0.03671705,0.0007328276,0.0038569262,0.0029767323,0.0045868163,0.0001927,0.0002688304,0.0029578444],"genre_scores_gemma":[0.993681,0.0003287731,0.00014126868,0.00009216712,0.000022133583,0.0003089153,0.00028659083,0.000031997504,0.005107115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856347,0.00025671918,0.00048352376,0.00026108167,0.000062300256,0.00037293325],"domain_scores_gemma":[0.9990753,0.00009895716,0.00032807197,0.00037664128,0.0000981276,0.0000229201],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006063891,0.00017906973,0.00040418163,0.00014734753,0.00017994594,0.0000364474,0.0005888142,0.00015314814,0.0012990133],"category_scores_gemma":[0.000032080912,0.00015488101,0.00009151428,0.00030608504,0.00016262208,0.00039402285,0.00014583043,0.00021814018,0.00021998057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008673158,0.00021378433,0.007108786,0.00047931564,0.00095129415,0.000046752095,0.0034450751,0.00087613787,0.8943356,0.0017901025,0.05018447,0.039701324],"study_design_scores_gemma":[0.00883016,0.0003680167,0.03323489,0.0007327533,0.0004068746,0.000048257734,0.0005820072,0.0015677875,0.8293452,0.0007850124,0.12344226,0.00065673474],"about_ca_topic_score_codex":0.0008394795,"about_ca_topic_score_gemma":0.00010297851,"teacher_disagreement_score":0.0732578,"about_ca_system_score_codex":0.00007000042,"about_ca_system_score_gemma":0.00014421948,"threshold_uncertainty_score":0.99961394},"labels":[],"label_agreement":null},{"id":"W4387402137","doi":"10.1016/j.esmoop.2023.101876","title":"66P Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor microenvironment; Glioma; Cancer research; Microglia; Monocyte; Downregulation and upregulation; Chemistry; Biology; Population; Cell culture; Cell biology; Immunology; Biochemistry; Inflammation; Gene; Tumor cells; Medicine; Genetics","score_opus":0.014908265323234035,"score_gpt":0.2753468143502024,"score_spread":0.2604385490269684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489117,0.0021277305,0.000004375851,0.00024542608,0.00043069533,0.00030197998,0.00001029436,0.0000295291,0.001958814],"genre_scores_gemma":[0.9930194,0.00034821875,0.00006595887,0.00005188922,0.000009448199,0.000032619322,0.0000267317,0.000013804277,0.00643194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992502,0.0001336442,0.00021373983,0.00019355993,0.000020918154,0.00018798407],"domain_scores_gemma":[0.9995765,0.00007625656,0.00008415262,0.00022912338,0.000026938698,0.0000069960197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002968281,0.00009156005,0.0002514126,0.00013326417,0.000054899974,0.000013795196,0.0002695792,0.0001241598,0.0008758355],"category_scores_gemma":[0.00004380029,0.00008741832,0.000023935938,0.00028831718,0.00014910032,0.00011992087,0.00037241686,0.00011819958,0.0003232916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030472604,0.000044933986,0.005678183,0.00002696053,0.00009951979,0.000007431137,0.0013784452,0.00003850673,0.97041714,0.0013003297,0.0050725024,0.015631333],"study_design_scores_gemma":[0.0010876404,0.000051728464,0.38232097,0.000029471877,0.000011968751,0.000008571133,0.00015772955,0.000007838659,0.59417367,0.0004212499,0.021644158,0.000084996005],"about_ca_topic_score_codex":0.0007735688,"about_ca_topic_score_gemma":0.00027579445,"teacher_disagreement_score":0.3766428,"about_ca_system_score_codex":0.000012683785,"about_ca_system_score_gemma":0.000031884458,"threshold_uncertainty_score":0.9589785},"labels":[],"label_agreement":null},{"id":"W4387402146","doi":"10.1016/j.esmoop.2023.102022","title":"173P Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor microenvironment; Medicine; Colorectal cancer; Myeloid; Immune system; Metastasis; Immunology; Cancer; Internal medicine; Cancer research; Oncology","score_opus":0.029429117823138787,"score_gpt":0.3084441759101499,"score_spread":0.2790150580870111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603415,0.00032442785,0.0000019688912,0.00027721163,0.00013391035,0.00089492573,0.00004174666,0.0000834595,0.0022082177],"genre_scores_gemma":[0.99791765,0.0005508878,0.00029438705,0.00019263779,0.000036423455,0.00023634259,0.00005901419,0.000026801634,0.0006858523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883115,0.000104391416,0.00022562548,0.0003351289,0.00019539159,0.00030833186],"domain_scores_gemma":[0.9994843,0.00008975321,0.000097401826,0.00015373601,0.000056477576,0.00011830833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005857924,0.00015227405,0.00032165466,0.00015182764,0.0001013996,0.00006620243,0.000170895,0.00010750485,0.00025277145],"category_scores_gemma":[0.000117884796,0.00015299222,0.000050292103,0.0005010765,0.00005565975,0.00022769798,0.0003467754,0.00016054284,0.000073300806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005186712,0.00013527335,0.9882428,0.00012645418,0.00012856146,0.0003438863,0.00046462842,0.000011954021,0.0023373351,0.00001842597,0.004857598,0.0028144068],"study_design_scores_gemma":[0.0021897107,0.000049509374,0.9782575,0.0002325084,0.00014485375,0.0000039309007,0.00015047529,0.0025175863,0.015477226,0.000044468292,0.00076105655,0.00017118543],"about_ca_topic_score_codex":0.0020268655,"about_ca_topic_score_gemma":0.00086244644,"teacher_disagreement_score":0.0131398905,"about_ca_system_score_codex":0.00026476313,"about_ca_system_score_gemma":0.000112481895,"threshold_uncertainty_score":0.62388414},"labels":[],"label_agreement":null},{"id":"W4387402149","doi":"10.1016/j.esmoop.2023.101987","title":"137P Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Lymphoblastic Leukemia; Event (particle physics); Medicine; Cancer research; Oncology; Leukemia; Internal medicine; Physics","score_opus":0.03518190690563943,"score_gpt":0.3248304217885291,"score_spread":0.2896485148828897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850875,0.000041771542,0.00066735625,0.0004987343,0.0008769821,0.0014999965,0.000090380876,0.00021683138,0.011020409],"genre_scores_gemma":[0.988125,0.00035264925,0.000987104,0.00015879866,0.00081180246,0.00011725393,0.0002289081,0.00012324558,0.009095203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964484,0.00019449042,0.00064702664,0.00072068104,0.0010597914,0.0009296383],"domain_scores_gemma":[0.99791455,0.00040849196,0.00014573356,0.0010157317,0.00014856896,0.0003669413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012562671,0.00032410517,0.0005872496,0.00071761204,0.00017276252,0.00013925339,0.001126144,0.0002760668,0.0003231131],"category_scores_gemma":[0.0006561241,0.00030522753,0.00012314251,0.002375961,0.0000859425,0.00043502706,0.0017241648,0.00046531652,0.0010236512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006011589,0.0014520531,0.6920874,0.0015165088,0.0008378786,0.01255005,0.0025614814,0.014787628,0.015023448,0.0006178125,0.24807177,0.0044823615],"study_design_scores_gemma":[0.038655274,0.00088492053,0.7235577,0.00035170614,0.0007806373,0.00043528387,0.0005156615,0.22745076,0.002822682,0.000752478,0.0030079507,0.00078496477],"about_ca_topic_score_codex":0.0032958118,"about_ca_topic_score_gemma":0.0002867775,"teacher_disagreement_score":0.24506383,"about_ca_system_score_codex":0.003463306,"about_ca_system_score_gemma":0.003521792,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W4387402172","doi":"10.1016/j.esmoop.2023.101897","title":"87P Macrophage ontogeny underlies functional programs and drives brain tumor progression","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Biology; Tumor microenvironment; Microglia; Cytotoxic T cell; Dendritic cell; Haematopoiesis; Immunology; Cancer research; Progenitor cell; Chemokine; Major histocompatibility complex; Monocyte; Macrophage; Tumor progression; Bone marrow; Immunotherapy; Immune system; Stem cell; Cancer; Inflammation; Cell biology; In vitro","score_opus":0.033323002147533164,"score_gpt":0.3053476582211081,"score_spread":0.27202465607357496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771645,0.003945087,0.000052778858,0.0027945037,0.0027440893,0.0016633774,0.000020369402,0.00037596468,0.011239293],"genre_scores_gemma":[0.940325,0.00007053374,0.0003300129,0.00039307703,0.000052934964,0.00028398164,0.00033067126,0.000034662367,0.058179084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989018,0.00014579156,0.0001885506,0.00035655082,0.00004469754,0.0003626545],"domain_scores_gemma":[0.99949217,0.00011091104,0.00008097225,0.00025782106,0.000036072393,0.000022048367],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035556752,0.00016124289,0.00020811404,0.00006786785,0.00034941564,0.00009968264,0.00035315304,0.00013227931,0.0013031389],"category_scores_gemma":[0.000049490533,0.00013444273,0.00004219993,0.00019010421,0.00035496237,0.00017157145,0.00071158115,0.00023303897,0.0014166845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011295326,0.00047900862,0.068474315,0.00014101148,0.0007321526,0.00018329268,0.0034058194,0.000014200614,0.24098723,0.008839902,0.31594682,0.3596667],"study_design_scores_gemma":[0.0027148693,0.00042461816,0.20462763,0.00016364189,0.000033792247,0.0001602849,0.0010706264,0.000011050208,0.064287856,0.0015144955,0.7245687,0.0004223904],"about_ca_topic_score_codex":0.00019475317,"about_ca_topic_score_gemma":0.00016206664,"teacher_disagreement_score":0.4086219,"about_ca_system_score_codex":0.00003719866,"about_ca_system_score_gemma":0.000083937106,"threshold_uncertainty_score":0.9996098},"labels":[],"label_agreement":null},{"id":"W4387402176","doi":"10.1016/j.esmoop.2023.101867","title":"57P Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Nemzeti Kutatási, Fejlesztési és Innovaciós Alap","keywords":"KRAS; Germline; Lung cancer; Genetic testing; Germline mutation; Medicine; Oncology; Cancer; Internal medicine; Family history; Mutation; Cancer research; Biology; Gene; Genetics; Colorectal cancer","score_opus":0.01727020581761593,"score_gpt":0.3250007477688046,"score_spread":0.30773054195118865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980314,0.00015275487,0.000077824865,0.0006568017,0.000118460914,0.00037171823,0.00014505337,0.0000050587605,0.00044093796],"genre_scores_gemma":[0.9957569,0.0019516359,0.00046437557,0.0004862033,0.00011587343,0.00007495505,0.00018698,0.000022610713,0.0009404151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992356,0.000022612767,0.0002238445,0.00030309494,0.00004360353,0.0001712711],"domain_scores_gemma":[0.99956214,0.00006808355,0.000077361656,0.00016656489,0.000038921375,0.00008694479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019868417,0.00011568148,0.00020891646,0.000034190452,0.00005552407,0.0000805157,0.00014536777,0.000081278136,0.000011531724],"category_scores_gemma":[0.00006754506,0.000102313454,0.000021595353,0.00007699008,0.00006141594,0.0000044590333,0.00031685975,0.00009129869,0.0000035427504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073494084,0.000059021528,0.993415,0.000031101976,0.00003832732,0.000028004797,0.00011458326,0.00003604683,0.0021219456,0.00002350641,0.0013175831,0.002741358],"study_design_scores_gemma":[0.0013896014,0.0001268122,0.9928334,0.000030683426,0.00003384744,0.0000033436504,0.00005871029,0.00054377917,0.0012324583,0.000019143721,0.003554975,0.0001732887],"about_ca_topic_score_codex":0.00085789466,"about_ca_topic_score_gemma":0.0034363861,"teacher_disagreement_score":0.0025784913,"about_ca_system_score_codex":0.000009366906,"about_ca_system_score_gemma":0.0001439073,"threshold_uncertainty_score":0.41722214},"labels":[],"label_agreement":null},{"id":"W4387402208","doi":"10.1016/j.esmoop.2023.101896","title":"86P Regulation of cancer progression through the gut microbiome and immuno-nutrition","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Obesity; Cancer; Microbiome; Gut flora; Dysbiosis; Biology; Immune system; Colorectal cancer; Immunology; Internal medicine; Bioinformatics; Medicine; Physiology; Endocrinology; Genetics","score_opus":0.025555787202839374,"score_gpt":0.39430330062532565,"score_spread":0.3687475134224863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954704,0.0018603762,0.000008339857,0.0011120051,0.00004982631,0.0006383621,0.000054876935,0.0000052684327,0.0008005343],"genre_scores_gemma":[0.99627006,0.0018916468,0.000105392326,0.00003288532,0.000046343157,0.00017980204,0.00030989037,0.000007181271,0.0011568267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996064,0.000030071731,0.000071649396,0.00013147874,0.00006104701,0.000099367084],"domain_scores_gemma":[0.9997495,0.000004839408,0.000038092192,0.0001584793,0.000034187284,0.00001489069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007873028,0.000048401205,0.00005676638,0.000013177769,0.00008148717,0.000030173034,0.00013156235,0.000037261485,0.00003233858],"category_scores_gemma":[0.000007785241,0.000032542357,0.000019602368,0.00010273854,0.00006123293,0.0000070050482,0.0002227462,0.000024454137,0.0000056157996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027211392,0.000071402865,0.0039388714,0.00004059747,0.00009650019,0.000001532095,0.00013657681,0.0000053431622,0.9607816,0.00007657373,0.016278781,0.018300125],"study_design_scores_gemma":[0.0014036208,0.00023223613,0.096062355,0.00008446489,0.000015005649,0.0000040906784,0.00008358333,0.00001386308,0.7674913,0.00064435834,0.13388158,0.00008355716],"about_ca_topic_score_codex":0.0024333964,"about_ca_topic_score_gemma":0.0006531715,"teacher_disagreement_score":0.19329031,"about_ca_system_score_codex":0.000009914946,"about_ca_system_score_gemma":0.000035688434,"threshold_uncertainty_score":0.36785838},"labels":[],"label_agreement":null},{"id":"W4387402365","doi":"10.1016/j.esmoop.2023.101683","title":"37P NET-mediated radio-resistance in early-stage non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre; McGill University","funders":"","keywords":"Stage (stratigraphy); Lung cancer; Resistance (ecology); Oncology; Medicine; Internal medicine; Biology; Ecology","score_opus":0.018454719119439796,"score_gpt":0.33735191911043033,"score_spread":0.31889719999099053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93297994,0.000589445,0.000021466472,0.0022003197,0.00033863308,0.0017052097,0.000118188604,0.000082725805,0.06196405],"genre_scores_gemma":[0.8678791,0.00037197047,0.00045441263,0.00050087355,0.00009765034,0.0005715112,0.00024033381,0.000041581294,0.12984255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998985,0.00002532889,0.00020902515,0.0003079047,0.00014820557,0.00032455754],"domain_scores_gemma":[0.9994068,0.00005844876,0.000064150605,0.00029516907,0.000043668955,0.000131754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013216904,0.00014201905,0.00026785373,0.000119135475,0.00007843887,0.000058456404,0.0002112574,0.00006696563,0.00055272406],"category_scores_gemma":[0.000019485165,0.00012304063,0.00004453074,0.00060078036,0.000025626017,0.00013215846,0.00009797207,0.00014439915,0.00025109007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027937925,0.00027623432,0.90750843,0.00029569914,0.00025645475,0.0009072963,0.0074986885,0.00023483286,0.00048671465,0.00017850855,0.08126337,0.0008143953],"study_design_scores_gemma":[0.004946075,0.000060616458,0.917249,0.00026880528,0.00012888739,8.020348e-7,0.00024529974,0.0005023815,0.0007158059,0.000025125639,0.07567422,0.00018297668],"about_ca_topic_score_codex":0.01680039,"about_ca_topic_score_gemma":0.014325787,"teacher_disagreement_score":0.06787851,"about_ca_system_score_codex":0.00026879777,"about_ca_system_score_gemma":0.0003897139,"threshold_uncertainty_score":0.9897468},"labels":[],"label_agreement":null},{"id":"W4387402439","doi":"10.1016/j.esmoop.2023.101669","title":"23P Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Heparanase; Cancer research; Metastasis; Gene knockdown; Adenocarcinoma; Tumor microenvironment; Immune system; Biology; Cancer; Flow cytometry; Lung cancer; Immunology; Cell culture; Medicine; Pathology; Genetics","score_opus":0.02184632214610117,"score_gpt":0.32737679775068146,"score_spread":0.3055304756045803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939606,0.00005642161,0.0040705395,0.0001720553,0.00018436597,0.001138761,0.0001768948,0.00001127278,0.00022905598],"genre_scores_gemma":[0.9957623,0.0000116240335,0.00037659836,0.00004180926,0.000061618564,0.000118851785,0.0011078477,0.000029956434,0.0024894301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902076,0.000036594887,0.00022455245,0.00030560145,0.0001820245,0.0002304818],"domain_scores_gemma":[0.9993245,0.000014662092,0.00009518122,0.00034210813,0.00017191262,0.000051633637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027524872,0.00009644,0.000113206675,0.00006185126,0.00007650506,0.000054808435,0.0005548955,0.00009739268,0.00004992309],"category_scores_gemma":[0.00010701026,0.000085524545,0.00007211742,0.0001448634,0.00004696316,0.000011124586,0.00038257954,0.00005011421,0.000040514846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035685027,0.00014008835,0.026823167,0.00007098532,0.000110994064,7.2811514e-7,0.0000683273,0.00009448758,0.96530133,0.0001604909,0.005830013,0.0010425152],"study_design_scores_gemma":[0.0017128959,0.0005366261,0.30164242,0.000013509038,0.00002089486,0.0000015024224,0.000057378384,0.0015434388,0.68667996,0.00029690412,0.007308726,0.00018573913],"about_ca_topic_score_codex":0.00010734812,"about_ca_topic_score_gemma":0.000008044458,"teacher_disagreement_score":0.27862138,"about_ca_system_score_codex":0.000013573267,"about_ca_system_score_gemma":0.000081948354,"threshold_uncertainty_score":0.34875897},"labels":[],"label_agreement":null},{"id":"W4387402628","doi":"10.1016/j.esmoop.2023.101891","title":"81P Single-cell spatial landscape of NSCLC reveals subtype specific immune features","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University","funders":"","keywords":"Mass cytometry; Immune system; Adenocarcinoma; Biology; Tumor microenvironment; Lung cancer; Cell; Cancer research; Context (archaeology); Flow cytometry; Cell type; Pathology; Immunology; Cancer; Medicine; Phenotype; Gene; Genetics","score_opus":0.03213982978182304,"score_gpt":0.2851381018444327,"score_spread":0.25299827206260966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.881504,0.0024925848,0.000014970627,0.0024938416,0.0008656016,0.0010519943,0.00003905684,0.00009737998,0.11144057],"genre_scores_gemma":[0.97499776,0.00047449907,0.00018522533,0.00022215743,0.00020580002,0.000015437841,0.00014382674,0.00003075366,0.023724522],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99899566,0.0000445311,0.0002941824,0.00022788011,0.00021536724,0.00022236988],"domain_scores_gemma":[0.9992581,0.00006553657,0.00012907188,0.00043355246,0.00005883366,0.00005487898],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003995654,0.00013011074,0.00035168443,0.00011116943,0.000058815433,0.000043351323,0.0003029124,0.00009508667,0.0019439459],"category_scores_gemma":[0.000026222579,0.00010593083,0.00011876239,0.0004286438,0.00006262659,0.000069925234,0.0001397554,0.00012904007,0.00018485167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009316532,0.00045498772,0.021274779,0.00019517953,0.00027279262,0.0001431799,0.0011166686,0.0000029052162,0.58852273,0.00009096758,0.31835312,0.060256153],"study_design_scores_gemma":[0.0059490046,0.000810259,0.68016696,0.0003465323,0.00005745339,0.000033379,0.00036326205,0.0000080861,0.15649687,0.00009309244,0.15543091,0.00024417893],"about_ca_topic_score_codex":0.001673717,"about_ca_topic_score_gemma":0.00014624323,"teacher_disagreement_score":0.6588922,"about_ca_system_score_codex":0.00003291113,"about_ca_system_score_gemma":0.000077103265,"threshold_uncertainty_score":0.9989684},"labels":[],"label_agreement":null},{"id":"W4387406894","doi":"10.1016/j.esmoop.2023.101878","title":"68P The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Myelopoiesis; Reprogramming; Cancer research; Progenitor cell; CCR2; Tumor microenvironment; Biology; Immunophenotyping; Monocyte; Myeloid; Bone marrow; Monocytosis; Flow cytometry; Immunology; Pathology; Immune system; Medicine; Stem cell; Chemokine; Cell biology; Chemokine receptor; Cell","score_opus":0.01647164423249159,"score_gpt":0.30104143655232796,"score_spread":0.28456979231983637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387406894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977535,0.00020192798,2.451012e-7,0.00044070493,0.000038167724,0.0008815639,0.0000031217505,0.00001292778,0.0006678264],"genre_scores_gemma":[0.9996311,0.000019725261,0.00006385899,0.000018400557,0.0000074414093,0.00016676573,0.0000029922312,0.000011095071,0.00007861038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916184,0.00004262534,0.00033507938,0.00016225441,0.00014015063,0.00015802565],"domain_scores_gemma":[0.9993562,0.00013819906,0.00011328677,0.00034145842,0.000025481206,0.000025357054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005054099,0.00007731905,0.0003515734,0.00016035404,0.000016358454,0.000012520392,0.0001828873,0.000037575668,0.000016250506],"category_scores_gemma":[0.0001413004,0.00004820781,0.00005626323,0.00047445446,0.00002484644,0.00004922364,0.00019841471,0.0000709167,0.00001617555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004539315,0.00020384355,0.9719357,0.00006827981,0.000039426588,0.00009221243,0.0010690152,0.000023515979,0.0027750456,0.00022179593,0.000026579139,0.023499224],"study_design_scores_gemma":[0.0021614546,0.00026267392,0.9530953,0.00069628475,0.000037898353,0.000020847017,0.0047365525,0.00035136534,0.038235243,0.00012661528,0.00021438718,0.00006134975],"about_ca_topic_score_codex":0.010375448,"about_ca_topic_score_gemma":0.0015833243,"teacher_disagreement_score":0.035460196,"about_ca_system_score_codex":0.000047268088,"about_ca_system_score_gemma":0.000042656633,"threshold_uncertainty_score":0.99621457},"labels":[],"label_agreement":null},{"id":"W4387406895","doi":"10.1016/j.esmoop.2023.101887","title":"77P Obesity-induced monocyte rewiring to enhance colorectal cancer liver metastasis","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Colorectal cancer; Metastasis; Monocyte; Medicine; Cancer; Obesity; Cancer research; Oncology; Internal medicine","score_opus":0.029537766296983067,"score_gpt":0.33727398738899134,"score_spread":0.30773622109200827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387406895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912187,0.0005151454,0.000100074234,0.0003814781,0.0039516427,0.0005757289,0.000056469005,0.000035997335,0.003164802],"genre_scores_gemma":[0.9791609,0.0017380136,0.0006491951,0.0009877494,0.0060603023,0.00045694306,0.00008944995,0.00005401213,0.010803409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987191,0.000062600164,0.000178143,0.0005257477,0.00013635961,0.0003780782],"domain_scores_gemma":[0.9993346,0.000011807854,0.00005955744,0.00036181684,0.00007494268,0.00015733005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002965081,0.0001769485,0.00024923743,0.00006214144,0.00014053748,0.00008759314,0.0005650648,0.00010560542,0.00016395554],"category_scores_gemma":[0.00007052821,0.00017855033,0.000090477915,0.00029879925,0.000024521894,0.000013169459,0.0007623433,0.000097271026,0.00025033025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024418798,0.00004451935,0.0009037976,0.000020850368,0.00016790071,0.0000018488284,0.00039044183,0.00013161852,0.7984889,0.000069774156,0.15533574,0.044200417],"study_design_scores_gemma":[0.00020729766,0.000060632086,0.012867997,0.0000152562625,0.000026054817,0.0000021723658,0.000054402608,0.00001571747,0.49518326,0.000010228027,0.491365,0.0001919932],"about_ca_topic_score_codex":0.0039115595,"about_ca_topic_score_gemma":0.0050332965,"teacher_disagreement_score":0.33602923,"about_ca_system_score_codex":0.000036197856,"about_ca_system_score_gemma":0.00015686292,"threshold_uncertainty_score":0.7281071},"labels":[],"label_agreement":null},{"id":"W4387407257","doi":"10.1016/j.esmoop.2023.101884","title":"74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Shota Rustaveli National Science Foundation; National Science Foundation","keywords":"Immune system; Gut flora; Weight gain; Cancer; Microbiome; Obesity; Overweight; Biology; Immunology; FOXP3; Immunity; Internal medicine; Medicine; Endocrinology; Bioinformatics; Body weight","score_opus":0.020085235390278976,"score_gpt":0.3143288653952752,"score_spread":0.29424363000499626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387407257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397254,0.000101067235,0.000026684826,0.0040657907,0.00011389994,0.0008629183,0.00004795516,0.000030240688,0.0007789306],"genre_scores_gemma":[0.9965386,0.000094798444,0.0006652622,0.00096017326,0.000104442595,0.000044551613,0.00015261823,0.000023487251,0.0014160664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987212,0.00022359271,0.00019326177,0.0004221988,0.00007529717,0.00036447204],"domain_scores_gemma":[0.99915034,0.000027385551,0.000078555924,0.00058542093,0.000062681276,0.000095595664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007486591,0.00018239483,0.00020751549,0.000021646734,0.0005076536,0.0001187579,0.00028886506,0.00011255412,0.000028388065],"category_scores_gemma":[0.000087542874,0.00013042199,0.000056506608,0.00020064121,0.00012667966,0.000010095913,0.0015956186,0.00017570941,0.0000793094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016888551,0.0000897639,0.0025972216,0.00004324501,0.00003946003,0.000016390844,0.00064084865,0.000010201157,0.97990984,0.00005104523,0.015557991,0.0008751232],"study_design_scores_gemma":[0.00046195064,0.00039279225,0.32951382,0.000078415826,0.000018659663,0.00008247598,0.0003233797,0.00002329707,0.55694336,0.0001768912,0.11170448,0.00028047033],"about_ca_topic_score_codex":0.0014114439,"about_ca_topic_score_gemma":0.0010807209,"teacher_disagreement_score":0.42296648,"about_ca_system_score_codex":0.000019412626,"about_ca_system_score_gemma":0.00008692354,"threshold_uncertainty_score":0.53184545},"labels":[],"label_agreement":null},{"id":"W4387407582","doi":"10.1016/j.esmoop.2023.102006","title":"157P PCM4EU academy: An educational program for precision oncology","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; BeiGene; Eisai Canada; Centre Léon Bérard; Daiichi Sankyo Europe; Servier; Eisai; Basilea Pharmaceutica; Genentech; Institut Gustave-Roussy; PharmaMar; European Society for Medical Oncology; Pfizer; Incyte; Boston Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Amgen; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Reimbursement; Oncology; Medical education; Portfolio; Clinical trial; Internal medicine; Medicine; Psychology; Health care; Political science","score_opus":0.050071421314818634,"score_gpt":0.432178044634972,"score_spread":0.3821066233201534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387407582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677007,0.0002189712,0.0003858742,0.011556268,0.0011347472,0.0034513501,0.0002782915,0.000050519517,0.015223279],"genre_scores_gemma":[0.94955605,0.0008530873,0.021280564,0.0032957538,0.0026975085,0.003198178,0.0056488863,0.00008980048,0.013380158],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992597,0.00002532282,0.00014091049,0.00031572508,0.00005660175,0.00020173073],"domain_scores_gemma":[0.99953467,0.00006383223,0.000053105985,0.00019953531,0.00005576985,0.00009310114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002767354,0.00008560744,0.00010537864,0.00002974229,0.000100749516,0.00007060287,0.00043354332,0.00015658673,0.00006781372],"category_scores_gemma":[0.00017320077,0.00008552263,0.000045020122,0.00008559853,0.00003396434,0.0000057626635,0.0003176845,0.000054487442,0.00005779935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044825106,0.000580975,0.0024503032,0.000021431457,0.00007741959,0.0000016852168,0.00016137035,0.00025594703,0.021691922,0.006173675,0.52210027,0.4460368],"study_design_scores_gemma":[0.0005937316,0.00082250393,0.015116235,0.0000052245045,0.000011075626,0.0000036251486,0.00004074463,0.00020730957,0.010468149,0.0035022923,0.9690959,0.00013322177],"about_ca_topic_score_codex":0.000080624006,"about_ca_topic_score_gemma":0.00024719557,"teacher_disagreement_score":0.44699565,"about_ca_system_score_codex":0.000026993432,"about_ca_system_score_gemma":0.00033398316,"threshold_uncertainty_score":0.34875116},"labels":[],"label_agreement":null},{"id":"W4388247185","doi":"10.1016/j.esmoop.2023.102049","title":"Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma","year":2023,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Sirtex Medical; Eisai; Ipsen; BeiGene; Sociedad Española de Oncología Médica; Incyte; Horizon 2020 Framework Programme; Boston Scientific Corporation; AstraZeneca; Mylan; Servier; European Commission; Pfizer; Amgen","keywords":"Fibroblast growth factor receptor; Cancer research; PI3K/AKT/mTOR pathway; Medicine; Cancer; Protein kinase B; Intrahepatic Cholangiocarcinoma; Oncology; Internal medicine; Fibroblast growth factor; Receptor; Biology; Signal transduction; Genetics","score_opus":0.043969944904116695,"score_gpt":0.3597103993650207,"score_spread":0.315740454460904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388247185","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069957026,0.0010164775,0.000006665036,0.0011850714,0.9724391,0.004855347,0.00094966294,0.00030189694,0.012250065],"genre_scores_gemma":[0.0073019,0.00013553284,0.0005882478,0.00030325804,0.94637936,0.0025578463,0.0032559603,0.0004990719,0.038978793],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643844,0.00007063898,0.00078381645,0.0011800724,0.00070937414,0.00081767526],"domain_scores_gemma":[0.99725753,0.0010846711,0.00027956074,0.00083628914,0.00031980447,0.00022213753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090820686,0.00062338676,0.0015955793,0.00037768396,0.00013843365,0.00022961122,0.0008220429,0.00094161177,0.00017777832],"category_scores_gemma":[0.001448796,0.00058024033,0.0004098277,0.0004826049,0.00010519345,0.00020745248,0.0008888515,0.0011615774,0.00016615672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083990465,0.00012649014,0.0030313176,0.0008892773,0.00033769055,0.00019389504,0.0009258363,3.1022864e-7,0.000014329207,0.000027900955,0.99184227,0.0017707855],"study_design_scores_gemma":[0.0070199,0.000693735,0.032736592,0.0006908434,0.0002443965,0.00000725934,0.00038877147,0.000011614233,0.00012501271,0.000112442205,0.95738757,0.000581852],"about_ca_topic_score_codex":0.0019264409,"about_ca_topic_score_gemma":0.0073972805,"teacher_disagreement_score":0.03445468,"about_ca_system_score_codex":0.00039553986,"about_ca_system_score_gemma":0.001220827,"threshold_uncertainty_score":0.9996649},"labels":[],"label_agreement":null},{"id":"W4388325995","doi":"10.1016/j.esmoop.2023.102058","title":"On finding acceptance","year":2023,"lang":"en","type":"letter","venue":"ESMO Open","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Feeling; Mentorship; Psychology; Medical education; Workforce; Medicine; Social psychology; Political science; Law","score_opus":0.39240252589444596,"score_gpt":0.5293103077383241,"score_spread":0.13690778184387814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388325995","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020904193,0.00001856619,0.0000073994743,0.88089556,0.00065823045,0.0012597773,0.000030406542,0.00007150347,0.116849504],"genre_scores_gemma":[0.00022867012,0.00015054444,0.000084774096,0.8240552,0.0035761695,0.00010794297,0.00037946977,0.00007086695,0.17134637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684525,0.00009997165,0.0002567852,0.00041618536,0.0010780342,0.0013037607],"domain_scores_gemma":[0.9964366,0.00082894077,0.00007237157,0.00059911376,0.000060178972,0.002002821],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012347584,0.00020018345,0.00052479486,0.00019905806,0.00010245498,0.00009548361,0.00062800554,0.000638038,0.00418839],"category_scores_gemma":[0.03209464,0.00014998896,0.00008183479,0.00030368625,0.00006147999,0.00006919756,0.000287324,0.0036819305,0.008286637],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007643048,0.000017100861,0.00003585396,0.00036090758,0.000030420937,0.004191292,0.000035001787,5.515595e-8,0.0000010511114,0.00003128953,0.97604924,0.01917136],"study_design_scores_gemma":[0.000826629,0.00043226077,0.0012609542,0.0014493747,0.000016807327,0.000019709481,0.000007264038,0.000006622355,0.00002708171,0.00029220388,0.9955313,0.0001297986],"about_ca_topic_score_codex":0.0006847704,"about_ca_topic_score_gemma":0.000031556956,"teacher_disagreement_score":0.056840375,"about_ca_system_score_codex":0.0003220835,"about_ca_system_score_gemma":0.0043435493,"threshold_uncertainty_score":0.99861664},"labels":[],"label_agreement":null},{"id":"W4388840640","doi":"10.1016/j.esmoop.2023.102047","title":"Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sleep and related disorders","field":"Psychology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Insomnia; Guideline; Medicine; Clinical Practice; First line therapy; Population; Chronic insomnia; Intensive care medicine; Psychiatry; Family medicine; Oncology; Sleep disorder; Pathology; Environmental health","score_opus":0.03309259223051882,"score_gpt":0.4296957238549652,"score_spread":0.3966031316244464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388840640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7389438,0.000089564266,0.000020504684,0.012915135,0.0026733975,0.001313015,0.000030369729,0.00013658372,0.24387759],"genre_scores_gemma":[0.9411051,0.0012959001,0.00337965,0.034692276,0.00045168202,0.0007668667,0.0006924209,0.00019326658,0.017422816],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981748,0.00026240604,0.0005817382,0.00044133622,0.00020152002,0.000338235],"domain_scores_gemma":[0.99883366,0.00026959213,0.00018412994,0.0004162975,0.00020204998,0.00009426016],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000672049,0.0001418125,0.00024785337,0.00010754788,0.00006659154,0.0000415791,0.00051508297,0.00023081161,0.0018276293],"category_scores_gemma":[0.0004788392,0.000109481116,0.000038465474,0.0007040482,0.000070606184,0.00024199032,0.00020397943,0.00044148572,0.0022971837],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010279316,0.0009896697,0.5103289,0.0000027180702,0.00038817822,0.000109282875,0.0011526474,0.000108210836,5.157833e-8,0.0007700112,0.41957706,0.065545335],"study_design_scores_gemma":[0.009422277,0.00026139643,0.46145976,0.000048429814,0.000084995314,0.0000018935066,0.001240577,0.000085088985,7.1743443e-7,0.00009902627,0.52708316,0.00021266437],"about_ca_topic_score_codex":0.022604031,"about_ca_topic_score_gemma":0.0041968664,"teacher_disagreement_score":0.22645478,"about_ca_system_score_codex":0.000030413266,"about_ca_system_score_gemma":0.000091668924,"threshold_uncertainty_score":0.99908483},"labels":[],"label_agreement":null},{"id":"W4389067002","doi":"10.1016/j.esmoop.2023.102045","title":"Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Instituto de Salud Carlos III; Horizon 2020 Framework Programme; European Commission","keywords":"Alveolar soft part sarcoma; Medicine; Internal medicine; Soft tissue sarcoma; Immunotherapy; Retrospective cohort study; Sarcoma; Progressive disease; Oncology; Confidence interval; Surgery; Disease; Cancer; Pathology","score_opus":0.02896856907271544,"score_gpt":0.3037014069650634,"score_spread":0.274732837892348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389067002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853604,0.0004823621,6.358622e-7,0.004422159,0.00023747224,0.0011491139,0.00013670661,0.00007025292,0.008140889],"genre_scores_gemma":[0.9972231,0.00014356073,0.00034481398,0.000104386076,0.0001498963,0.00012739455,0.0004934928,0.000037426034,0.0013759793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786574,0.00008096194,0.00083660317,0.00055273034,0.0003373623,0.00032660097],"domain_scores_gemma":[0.998265,0.0003874889,0.0002830169,0.0008754105,0.00007045556,0.00011860285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066009164,0.00021689461,0.0006888644,0.00018567317,0.000058201447,0.00003918534,0.00032209491,0.00011355011,0.00017389088],"category_scores_gemma":[0.0010296558,0.00018647211,0.00020965045,0.0008115547,0.00009051517,0.0001153519,0.00042453528,0.0002807396,0.000247674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037302566,0.0028002074,0.94981384,0.000037533835,0.0005565427,0.0017858591,0.002511463,0.000022553118,0.0017464883,0.00021163323,0.026162928,0.0106206825],"study_design_scores_gemma":[0.012148,0.00018596854,0.94905835,0.0008376665,0.0000849343,0.0000076312435,0.00031148572,0.000031114465,0.030152066,0.0004107667,0.00661394,0.0001580635],"about_ca_topic_score_codex":0.017985672,"about_ca_topic_score_gemma":0.0011000959,"teacher_disagreement_score":0.028405577,"about_ca_system_score_codex":0.00025606915,"about_ca_system_score_gemma":0.00013516119,"threshold_uncertainty_score":0.98855364},"labels":[],"label_agreement":null},{"id":"W4390776701","doi":"10.1016/j.esmoop.2023.102195","title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Nausea and vomiting management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; University of Ottawa","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; Helsinn; American Society of Clinical Oncology; World Health Organization; AstraZeneca; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Nausea; Guideline; Vomiting; Medicine; Radiation therapy; Chemotherapy-induced nausea and vomiting; Chemotherapy; Oncology; Internal medicine; Antiemetic","score_opus":0.03764434434872091,"score_gpt":0.3675748876269092,"score_spread":0.32993054327818827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390776701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616583,0.0045790086,0.0042437394,0.02457222,0.00019986443,0.002994566,0.000014655566,0.00005054071,0.0016871063],"genre_scores_gemma":[0.9829789,0.0025194767,0.007814996,0.0012869734,0.00028366334,0.00009077688,0.000025547746,0.000047100813,0.004952579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920756,0.000027695201,0.00026597094,0.0002601491,0.00009925072,0.00013937615],"domain_scores_gemma":[0.99952376,0.0001420918,0.00006635464,0.00018130094,0.000038338963,0.000048154943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00098605,0.00011431896,0.00023216702,0.000060445156,0.00009301578,0.00013708149,0.000094519106,0.000047535454,0.000079955375],"category_scores_gemma":[0.000047331778,0.00007811035,0.0000370988,0.00009834661,0.000049402406,0.00011665892,0.00011419595,0.00008421571,0.0000011316492],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013844811,0.00020322436,0.009573797,0.0020243153,0.0022531927,0.000033151347,0.0018889892,0.000004603431,0.022091936,0.011166785,0.06557213,0.8838034],"study_design_scores_gemma":[0.019732008,0.002303763,0.111342564,0.0023986737,0.0013437619,0.00015493367,0.001435635,0.03676724,0.024806522,0.006667167,0.79232514,0.0007225721],"about_ca_topic_score_codex":0.00021136795,"about_ca_topic_score_gemma":0.000047305843,"teacher_disagreement_score":0.88308084,"about_ca_system_score_codex":0.00001557222,"about_ca_system_score_gemma":0.000031256317,"threshold_uncertainty_score":0.31852478},"labels":[],"label_agreement":null},{"id":"W4391506607","doi":"10.1016/j.esmoop.2023.102226","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bayer Yakuhin; Sierra Oncology; Eli Lilly Japan; Pfizer Japan; Novartis Pharma; INCLIVA Instituto de Investigación Sanitaria; Ipsen; Teijin Pharma; Japanese Society of Medical Oncology; Otsuka Pharmaceutical; Daiichi Sankyo Europe; Veracyte; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Natera; Daiichi-Sankyo; MacroGenics; AstraZeneca; Genentech; Sysmex Corporation; Astellas Pharma; Eisai; FibroGen; Fondazione Beretta; BeiGene; Mirati Therapeutics; Hellenic Society of Medical Oncology; Pharmacyclics; Exelixis; Kissei; Pfizer; American Association for Cancer Research; Servier; Incyte; JST-Mirai Program; Astellas Foundation for Research on Metabolic Disorders; Gilead Sciences; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Sanofi; Amgen; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; SymBio Pharmaceuticals Limited; American Society of Clinical Oncology; Foundation Medicine; GlaxoSmithKline; Seagen; Relay Therapeutics","keywords":"Medicine; Cancer; Clinical Practice; Intensive care medicine; Internal medicine; Oncology; Family medicine","score_opus":0.12312810847628576,"score_gpt":0.4420520611936647,"score_spread":0.31892395271737894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391506607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57231486,0.020983739,0.0023263171,0.36047727,0.006161739,0.026081191,0.0005964942,0.00024652597,0.01081185],"genre_scores_gemma":[0.96395856,0.0099216495,0.009386094,0.0044674636,0.00059465,0.0018612399,0.00012251206,0.00006403832,0.009623772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989087,0.000032484673,0.00040441524,0.00029212455,0.00019344913,0.00016881974],"domain_scores_gemma":[0.9985878,0.0006175149,0.00012723528,0.00026467798,0.0003342038,0.000068563306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003719024,0.00015072434,0.00034805643,0.000056763904,0.00006917728,0.000076783246,0.00015306052,0.000040651645,0.00012657896],"category_scores_gemma":[0.0005809834,0.00007750784,0.000093296425,0.000235121,0.0000525979,0.0001756203,0.000110806126,0.0000769384,0.0000033947326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011821917,0.00019605526,0.44404042,0.00006566556,0.0009936272,0.000010178369,0.00017095586,0.0000030870797,9.751032e-8,0.000134851,0.09527354,0.45792934],"study_design_scores_gemma":[0.004649275,0.0011304432,0.47019014,0.00015581283,0.0014466757,0.000001920401,0.000320193,0.00011102382,0.000006834371,0.000011371616,0.52190936,0.00006699208],"about_ca_topic_score_codex":0.0037590442,"about_ca_topic_score_gemma":0.0013554848,"teacher_disagreement_score":0.45786235,"about_ca_system_score_codex":0.00006757099,"about_ca_system_score_gemma":0.00017740605,"threshold_uncertainty_score":0.5682575},"labels":[],"label_agreement":null},{"id":"W4391527398","doi":"10.1016/j.esmoop.2024.102233","title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; Canada Excellence Research Chairs, Government of Canada; Innovent Biologics; Incyte; Exelixis; AstraZeneca; Amgen; Pfizer; Daiichi Sankyo Europe; Actuate Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Meta-analysis; Breast cancer; Confidence interval; Observational study; Cochrane Library; Cancer; Clinical trial; Hazard ratio; Population","score_opus":0.10351902282538446,"score_gpt":0.4221861749337481,"score_spread":0.31866715210836366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391527398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013616271,0.97159916,0.0000136200215,0.0035144067,0.000042205247,0.013397392,0.011209972,0.00003822989,0.00018364028],"genre_scores_gemma":[0.00008362169,0.9857508,0.00036363752,0.0017982116,0.000049003866,0.007098208,0.0020024576,0.00014657862,0.0027074637],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.992895,0.0024063662,0.002184829,0.0014402341,0.00051473605,0.000558836],"domain_scores_gemma":[0.997004,0.0005540789,0.0008706814,0.0010296839,0.0001448877,0.00039669138],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001986587,0.0012468409,0.018747961,0.00075545715,0.00013098415,0.00029285735,0.00059273944,0.00023835253,0.006191993],"category_scores_gemma":[0.00018285004,0.0007079962,0.003994171,0.0019696322,0.00010563521,0.00022091945,0.00047386225,0.0007254725,0.000112900205],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007532895,0.0002060163,0.000002540431,0.64180297,0.3497948,0.00036159722,0.00009302928,6.607397e-8,2.3371053e-8,0.00018407348,0.0022876014,0.0052597495],"study_design_scores_gemma":[0.00041744416,0.00013028277,0.000027924316,0.096913226,0.8828326,0.00041765836,0.00003929962,6.686367e-7,5.2470676e-7,0.000018130755,0.018664433,0.0005378043],"about_ca_topic_score_codex":0.0066423253,"about_ca_topic_score_gemma":0.0019241315,"teacher_disagreement_score":0.54488975,"about_ca_system_score_codex":0.00068584643,"about_ca_system_score_gemma":0.00052933296,"threshold_uncertainty_score":0.9999725},"labels":[],"label_agreement":null},{"id":"W4392014388","doi":"10.1016/j.esmoop.2024.102254","title":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Principia Biopharma; Loxo Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Astellas Pharma; Cancer Research UK; Seagen; MacroGenics; Ascentage Pharma; Menarini Group; F-star Therapeutics; Symphogen; Moderna; Pfizer; Innovent Biologics; Incyte; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; GlaxoSmithKline; Tizona Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Novartis Farmacéutica; Alexion Pharmaceuticals; Servier; Gilead Sciences; Sanofi; Helsinn Therapeutics; Amgen; Jounce Therapeutics; LAM Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Onyx Pharmaceuticals; Eli Lilly and Company","keywords":"Monoclonal antibody; Antibody; Solid tumor; Dosing; Cancer research; Medicine; Monoclonal; Internal medicine; Immunology; Cancer","score_opus":0.013214786902607927,"score_gpt":0.3212640118319691,"score_spread":0.3080492249293612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392014388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950339,0.00013978714,7.105732e-7,0.000464168,0.00020024093,0.0028222965,0.00001533505,0.000019496087,0.0013040187],"genre_scores_gemma":[0.99907535,0.0000114077375,0.000030761894,0.00015089451,0.000031410113,0.00014576975,0.000017139537,0.000033372216,0.00050390424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985534,0.00006889529,0.00045076094,0.0003565966,0.00033457042,0.0002357553],"domain_scores_gemma":[0.99929583,0.000036136727,0.00009624658,0.00048462918,0.000043090247,0.00004408212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032205065,0.00017667738,0.0003894576,0.00014190622,0.000073241834,0.00004889165,0.0003433824,0.000046866015,0.00022396578],"category_scores_gemma":[0.000021578868,0.00011029194,0.000057684283,0.0006569244,0.00008707761,0.00019249042,0.00017096991,0.00025449906,0.000004912733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031665117,0.017064083,0.8924798,0.00051018206,0.00050621765,0.00037819767,0.022444334,0.00008283034,0.0018617713,0.000065648244,0.0022905234,0.030651296],"study_design_scores_gemma":[0.043146115,0.0069948463,0.9370839,0.0029630568,0.00006953928,0.0000054180337,0.0018430516,0.00006775911,0.0029532593,0.00003651063,0.0045863343,0.0002501957],"about_ca_topic_score_codex":0.0024587752,"about_ca_topic_score_gemma":0.005828758,"teacher_disagreement_score":0.044604115,"about_ca_system_score_codex":0.00020316897,"about_ca_system_score_gemma":0.00014745582,"threshold_uncertainty_score":0.4497575},"labels":[],"label_agreement":null},{"id":"W4392246441","doi":"10.1016/j.esmoop.2024.102358","title":"30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Basilea Pharmaceutica; PharmaMar; European Society for Medical Oncology; Pfizer; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Eisai Canada; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Blocking (statistics); Bifunctional; Medicine; Cancer research; Blocking antibody; Antibody; Immunology; Chemistry; Computer science","score_opus":0.020554862663627372,"score_gpt":0.31619361572736215,"score_spread":0.29563875306373477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392246441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437654,0.0011940608,0.000004166629,0.00068188604,0.00023072648,0.0019169978,0.00004844975,0.00002612346,0.0015210413],"genre_scores_gemma":[0.99840647,0.00010384096,0.00041813188,0.000056061446,0.00013554125,0.00012153373,0.000098183766,0.00003547337,0.0006247801],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99799836,0.000045575354,0.0007517592,0.00048235222,0.0004462825,0.00027567722],"domain_scores_gemma":[0.9992131,0.00009767319,0.00019209246,0.00034435358,0.00009441222,0.00005835429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007385117,0.0002486403,0.0005806064,0.0003701011,0.000063995634,0.00003737425,0.0002251688,0.00010964276,0.00013835673],"category_scores_gemma":[0.00003966849,0.00019082884,0.00010199266,0.00084202376,0.00012388089,0.0003195428,0.00017316308,0.00029135396,0.0000032917635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44416842,0.008536345,0.3190948,0.0035880771,0.0019979766,0.004042048,0.047585655,0.00050177606,0.15412952,0.00040803498,0.0028206413,0.013126701],"study_design_scores_gemma":[0.024947673,0.015264151,0.90262586,0.007634132,0.000116454416,0.00022004911,0.009951081,0.00020888404,0.036124285,0.00013071325,0.0023816875,0.0003950588],"about_ca_topic_score_codex":0.00491582,"about_ca_topic_score_gemma":0.006317617,"teacher_disagreement_score":0.583531,"about_ca_system_score_codex":0.00017307232,"about_ca_system_score_gemma":0.00038296139,"threshold_uncertainty_score":0.77817744},"labels":[],"label_agreement":null},{"id":"W4392246465","doi":"10.1016/j.esmoop.2024.102273","title":"44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"","keywords":"KRAS; Pembrolizumab; Medicine; Cancer research; Internal medicine; Oncology; Cancer; Colorectal cancer; Immunotherapy","score_opus":0.04750845522952496,"score_gpt":0.4015019755190461,"score_spread":0.35399352028952114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392246465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929882,0.00033752614,4.3511736e-7,0.0018451643,0.000068973626,0.0023926191,0.000029304541,0.000017460718,0.0023202735],"genre_scores_gemma":[0.99916047,0.000020289337,0.000029531499,0.00007855819,0.000031521286,0.00031255124,0.00009012832,0.00001549601,0.0002614377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872464,0.00015127822,0.00034541512,0.00038010982,0.0002294679,0.00016906571],"domain_scores_gemma":[0.9995454,0.0001654595,0.000051669005,0.00016732539,0.00003761974,0.00003253984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006547456,0.00014885403,0.00034856785,0.00013910713,0.000066068525,0.00010832522,0.00009350109,0.000029412275,0.000044481956],"category_scores_gemma":[0.00012617242,0.00008883786,0.000014233874,0.00047256262,0.00004300087,0.000146746,0.00016405393,0.00022352127,0.000005403465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0907473,0.010673213,0.53978,0.000111055844,0.0008797562,0.0051387358,0.18902478,0.00015774222,0.0006622123,0.00012127315,0.0019524661,0.16075142],"study_design_scores_gemma":[0.058498796,0.006830841,0.9166414,0.0011180046,0.00011486118,0.000013151178,0.010114731,0.005855909,0.00026909637,0.00021206535,0.00015867263,0.00017246594],"about_ca_topic_score_codex":0.016848495,"about_ca_topic_score_gemma":0.040386014,"teacher_disagreement_score":0.37686136,"about_ca_system_score_codex":0.00024037862,"about_ca_system_score_gemma":0.00017052035,"threshold_uncertainty_score":0.9896984},"labels":[],"label_agreement":null},{"id":"W4392246504","doi":"10.1016/j.esmoop.2024.102352","title":"21P Polymerase theta inhibition in homologous recombination-deficient prostate cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Homologous recombination; Homologous chromosome; Prostate cancer; Polymerase; Recombination; Cancer research; Biology; Cancer; Chemistry; Genetics; DNA; Gene","score_opus":0.03352979029464611,"score_gpt":0.3799532532632377,"score_spread":0.3464234629685916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392246504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532511,0.004594438,0.0000021798228,0.015317339,0.0003552651,0.0015757601,0.000048062997,0.00005878377,0.024797058],"genre_scores_gemma":[0.964232,0.0011825941,0.000026895936,0.00024455314,0.00004477199,0.00050943356,0.00015712183,0.000021828322,0.033580773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99903446,0.000047413378,0.00016979931,0.00030604022,0.0001895017,0.00025280702],"domain_scores_gemma":[0.99965835,0.000033676693,0.00002018818,0.00016849421,0.000042004114,0.0000772883],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028555814,0.00010571213,0.00016689704,0.00019105744,0.000063996034,0.00013365131,0.000074879004,0.000043325203,0.0009404514],"category_scores_gemma":[0.000016986398,0.000076358236,0.00003913503,0.00043453326,0.000054440996,0.00019191758,0.00011921936,0.00020626625,0.00015479715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035274602,0.003732962,0.15820588,0.0015576483,0.0007016812,0.017509956,0.01773186,0.00012607065,0.010767886,0.012176796,0.07674204,0.6972197],"study_design_scores_gemma":[0.029562175,0.0038435222,0.41994184,0.008802902,0.0004294848,0.000638325,0.0026452064,0.0045298133,0.3359426,0.020224215,0.17193395,0.0015059861],"about_ca_topic_score_codex":0.004607469,"about_ca_topic_score_gemma":0.00057503907,"teacher_disagreement_score":0.69571376,"about_ca_system_score_codex":0.00034150956,"about_ca_system_score_gemma":0.0004033576,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4392384788","doi":"10.1016/j.esmoop.2024.102388","title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Aptitude Health; Oncolytics Biotech; Seagen; Puma Biotechnology; Daiichi-Sankyo; Genentech; Veracyte; Pfizer; Incyte; Queen Mary University of London; Clovis Oncology; Astellas Pharma; Eisai; Jazz Pharmaceuticals; National Institutes of Health; Natera; Baxalta; Amgen; Ariad Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre","keywords":"Breast cancer; Medicine; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Trastuzumab; Cohort; Regimen; Human Epidermal Growth Factor Receptor 2; Stage (stratigraphy); Clinical endpoint; Survival analysis; Cancer; Clinical trial","score_opus":0.013372703807049923,"score_gpt":0.30783930790961056,"score_spread":0.29446660410256065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392384788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705813,0.00094704295,0.000015956288,0.00034330803,0.00006286084,0.0007192114,0.027165443,0.000003908009,0.00016095935],"genre_scores_gemma":[0.991734,0.00053888565,0.000041889278,0.00013615789,0.000047901838,0.00024295985,0.0072125015,0.000018571027,0.000027131724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980924,0.0002796734,0.00045656826,0.0005822121,0.00026246597,0.0003266832],"domain_scores_gemma":[0.99898165,0.00010178981,0.00019384,0.0005336978,0.00014190748,0.000047087855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022293646,0.0002583025,0.0006953488,0.00027019923,0.000053459324,0.00005505788,0.00063914544,0.00009244359,0.000071182905],"category_scores_gemma":[0.0000106100115,0.00019641788,0.00020848475,0.002683648,0.00015570778,0.000021527589,0.00045915853,0.00012628689,0.0000017786291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003281062,0.00028373805,0.97542584,0.00004538747,0.00889548,0.00002192243,0.00086083007,0.012026151,0.00003026416,0.0000386178,0.0009870649,0.0010566004],"study_design_scores_gemma":[0.00062301604,0.000103995546,0.9943213,0.0001349228,0.003182719,0.0000025912652,0.00031547857,0.00057759305,0.00011994363,0.000008158012,0.00042318812,0.00018713095],"about_ca_topic_score_codex":0.22164814,"about_ca_topic_score_gemma":0.16050462,"teacher_disagreement_score":0.061143514,"about_ca_system_score_codex":0.000120453056,"about_ca_system_score_gemma":0.00015776123,"threshold_uncertainty_score":0.854814},"labels":[],"label_agreement":null},{"id":"W4392880574","doi":"10.1016/j.esmoop.2024.102452","title":"62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sunitinib; Imatinib; GiST; Stromal tumor; Exon; Medicine; Stromal cell; Internal medicine; Cancer research; Oncology; Cancer; Biology; Gene; Genetics","score_opus":0.015241067141243797,"score_gpt":0.2817250521485034,"score_spread":0.2664839850072596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392880574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959715,0.000049485807,0.00030872834,0.00023280487,0.000008765023,0.002222534,0.00028713784,0.000094780626,0.0008242368],"genre_scores_gemma":[0.97564584,0.000008938912,0.021632602,0.00002861324,0.000021691962,0.00017572749,0.002187334,0.000063026186,0.00023624978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997328,0.0001802785,0.00046841995,0.000863484,0.000546368,0.00061345374],"domain_scores_gemma":[0.99850416,0.0002730632,0.00015817035,0.00037465556,0.00025169112,0.00043824682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029264088,0.00045721568,0.00082048815,0.0003954063,0.00013873728,0.00032440358,0.00017713201,0.000027257021,0.00043100942],"category_scores_gemma":[0.0001241216,0.0003030153,0.000047187677,0.0009511685,0.00022825059,0.00050533196,0.00016193575,0.00041047588,0.0000065040726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014938997,0.00042682388,0.9802732,0.0000847005,0.0006365107,0.0023826144,0.00016512629,0.00013517673,0.000030218183,0.00004960576,0.000022120666,0.00085489836],"study_design_scores_gemma":[0.014001346,0.0076881074,0.9717492,0.00262838,0.000993578,0.00029677694,0.00035076405,0.0017958584,0.00013386978,0.000015357089,0.000052633965,0.00029415978],"about_ca_topic_score_codex":0.007840238,"about_ca_topic_score_gemma":0.0058188625,"teacher_disagreement_score":0.021323875,"about_ca_system_score_codex":0.00018634227,"about_ca_system_score_gemma":0.0002749887,"threshold_uncertainty_score":0.9999422},"labels":[],"label_agreement":null},{"id":"W4392888805","doi":"10.1016/j.esmoop.2024.102525","title":"136P Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer HealthCare","keywords":"Trk receptor; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.0313283833075118,"score_gpt":0.3258445661640823,"score_spread":0.2945161828565705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392888805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438513,0.0065113087,0.00002332537,0.002869942,0.00028317104,0.002915028,0.00014569228,0.000041249932,0.0028251677],"genre_scores_gemma":[0.99383676,0.0027195143,0.0002273446,0.00015412194,0.00024683902,0.0003959816,0.00009234551,0.000034660392,0.0022924342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990074,0.000017434953,0.0002312134,0.00037572315,0.00016853074,0.0001997115],"domain_scores_gemma":[0.9993669,0.00017393283,0.00006251989,0.00020219553,0.00009814616,0.00009632306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010051174,0.00019463511,0.00042082064,0.00008174116,0.0001336308,0.000038913164,0.00008777157,0.000055898538,0.00014412066],"category_scores_gemma":[0.000038577462,0.00012496475,0.00007773572,0.00023063328,0.000043932963,0.00008932578,0.00011758085,0.00007424517,0.0000074106933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009279173,0.0010942577,0.59486485,0.00078922795,0.0013671252,0.00005778491,0.0058131013,0.000021898099,0.00003720377,0.00010038107,0.010412544,0.37616247],"study_design_scores_gemma":[0.020952905,0.0075124945,0.78737766,0.000834122,0.0012032186,0.000015800448,0.00020968309,0.000090587426,0.0013609168,0.000047911733,0.18010695,0.00028776602],"about_ca_topic_score_codex":0.0033918156,"about_ca_topic_score_gemma":0.0027302965,"teacher_disagreement_score":0.3758747,"about_ca_system_score_codex":0.00014352662,"about_ca_system_score_gemma":0.00015893539,"threshold_uncertainty_score":0.5127433},"labels":[],"label_agreement":null},{"id":"W4392888807","doi":"10.1016/j.esmoop.2024.102507","title":"118P Influence of radiotherapy dose on pattern of local recurrence for clival and spinal chordoma treated with proton/photon radiotherapy","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Radiation therapy; Medicine; Chordoma; Proton therapy; Radiology; Nuclear medicine","score_opus":0.022972764907719424,"score_gpt":0.3410772699091753,"score_spread":0.3181045050014559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392888807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456406,0.0008296596,0.0002947575,0.00031546853,0.000027346126,0.0037732495,0.000044220807,0.0000197337,0.00013149813],"genre_scores_gemma":[0.9975956,0.0005299514,0.0008159979,0.00015438447,0.000028313203,0.00068122125,0.000018033315,0.00003428561,0.00014221344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899584,0.000034286586,0.00026674094,0.00035243615,0.00018026776,0.00017044904],"domain_scores_gemma":[0.99940926,0.000077896024,0.0000954601,0.00026730247,0.00006409183,0.00008600702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016106093,0.00018902656,0.0004760896,0.000085459316,0.000030768202,0.00003525379,0.00013506385,0.000053463,0.000060129292],"category_scores_gemma":[0.000007334994,0.00012467203,0.000059859034,0.00017035299,0.00016919983,0.00011985317,0.000020091458,0.00009886791,0.0000015630125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016730346,0.0020483471,0.54865324,0.0017100659,0.0011979296,0.0002824208,0.0010665132,0.00004448862,0.0021341024,0.000359123,0.00038906428,0.42538434],"study_design_scores_gemma":[0.01419759,0.027026957,0.83830607,0.0055244565,0.00022063659,0.00015008252,0.000063626,0.0009759563,0.108325906,0.00007308641,0.004844407,0.0002912519],"about_ca_topic_score_codex":0.0026588226,"about_ca_topic_score_gemma":0.000057036086,"teacher_disagreement_score":0.4250931,"about_ca_system_score_codex":0.000066944755,"about_ca_system_score_gemma":0.00010728011,"threshold_uncertainty_score":0.5083978},"labels":[],"label_agreement":null},{"id":"W4392970390","doi":"10.1016/j.esmoop.2024.102946","title":"Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review","year":2024,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute; European Society for Medical Oncology; World Health Organization","keywords":"Workforce; Business; Psychological intervention; Capacity building; Health care; Workforce planning; SWOT analysis; Workload; Systematic review; Medicine; Nursing; MEDLINE; Economic growth; Marketing; Political science; Economics","score_opus":0.1247386254063085,"score_gpt":0.5126302968166273,"score_spread":0.3878916714103188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392970390","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001848224,0.9806029,0.00027358875,0.00047568107,0.00055786705,0.01747815,0.00024243016,0.000015750462,0.00035176906],"genre_scores_gemma":[0.0000058674414,0.9903759,0.0020564175,0.00091665593,0.0002947454,0.0045928922,0.00001781974,0.000049686758,0.0016900562],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867195,0.00012644839,0.0005965831,0.00031415466,0.00009826027,0.00019259339],"domain_scores_gemma":[0.99839157,0.0005036504,0.00047026764,0.00043311328,0.00015407165,0.000047316284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024440858,0.000292967,0.0031457248,0.00005408297,0.00012560727,0.00003409394,0.00043676537,0.0002029332,0.0000065665513],"category_scores_gemma":[0.00013155467,0.0001476906,0.00043017595,0.00023926818,0.0002181622,0.00007180312,0.00013053948,0.00024953173,7.1707206e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016269902,0.00000752562,6.264772e-7,0.965895,0.00052251754,6.4516047e-7,0.00031048866,4.7337932e-7,1.6092741e-7,0.005374942,0.002373698,0.025497634],"study_design_scores_gemma":[0.00027020645,0.00007429142,3.5537758e-7,0.49361157,0.0077182017,0.000060344155,0.00013415715,0.0000026933997,9.091433e-7,0.0005181721,0.49750403,0.000105080326],"about_ca_topic_score_codex":0.00014739274,"about_ca_topic_score_gemma":0.0000893391,"teacher_disagreement_score":0.49513033,"about_ca_system_score_codex":0.00024347786,"about_ca_system_score_gemma":0.0011024937,"threshold_uncertainty_score":0.60226476},"labels":[],"label_agreement":null},{"id":"W4393165834","doi":"10.1016/j.esmoop.2024.102582","title":"3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University; Institute of Cancer Research; Montreal General Hospital; BC Cancer Agency","funders":"Janssen Biotech","keywords":"Osimertinib; Chemotherapy; Oncology; Medicine; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.01046002646336001,"score_gpt":0.38087481027381986,"score_spread":0.37041478381045984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393165834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353493,0.0013929894,0.00005969385,0.0075799203,0.0002217496,0.002561742,0.00007964582,0.00009733412,0.0044719693],"genre_scores_gemma":[0.9940458,0.0003687327,0.0018911159,0.0016112764,0.00005129336,0.0004793579,0.0002594376,0.000065283675,0.0012276879],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981631,0.0000571353,0.0004768493,0.0005916144,0.0003996659,0.00031161413],"domain_scores_gemma":[0.9990666,0.00007020382,0.00013213957,0.00050925155,0.000097429736,0.0001243545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020232695,0.00028377734,0.0006976119,0.00050594803,0.000055947712,0.000089431735,0.00022036326,0.00012826228,0.001140042],"category_scores_gemma":[0.000021529031,0.00019451685,0.0002313517,0.0012757462,0.00006527432,0.00022193324,0.00007785612,0.00020906063,0.000029896491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027751062,0.0023321605,0.045248125,0.0003361658,0.005210171,0.00070782687,0.0078067076,0.00014429308,0.010708387,0.00023920629,0.000721304,0.8987946],"study_design_scores_gemma":[0.024880923,0.005159409,0.848433,0.0072396044,0.0036177218,0.00003212738,0.00072651904,0.008798874,0.06611458,0.00016715248,0.03401309,0.00081695936],"about_ca_topic_score_codex":0.0004730482,"about_ca_topic_score_gemma":0.00020345084,"teacher_disagreement_score":0.89797765,"about_ca_system_score_codex":0.00038395327,"about_ca_system_score_gemma":0.00033119408,"threshold_uncertainty_score":0.999773},"labels":[],"label_agreement":null},{"id":"W4393166351","doi":"10.1016/j.esmoop.2024.102985","title":"LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Perioperative; Oncology; Internal medicine; Phases of clinical research; Surgery; Clinical trial; Cancer; Immunotherapy","score_opus":0.04397265782353947,"score_gpt":0.38708020047345953,"score_spread":0.34310754264992005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393166351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335546,0.00006369602,0.000028013232,0.002298636,0.00027066423,0.003553785,0.000022491935,0.000057685236,0.010349592],"genre_scores_gemma":[0.9836952,0.000018324006,0.00020864575,0.00089415873,0.00011214473,0.00020855015,0.0000696636,0.00004282829,0.0147504825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796,0.00015850677,0.0004707474,0.00060103973,0.00048453434,0.00032517922],"domain_scores_gemma":[0.99890983,0.00021527488,0.00008278665,0.0006094129,0.000081959566,0.000100727724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000649933,0.00026287817,0.0006712568,0.0000870185,0.00014154988,0.00036253437,0.00047461272,0.000050354985,0.0008227172],"category_scores_gemma":[0.000072986746,0.00013151472,0.00007410476,0.00050640176,0.000109195316,0.0003724094,0.0003930003,0.00044551012,0.000085867294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004017874,0.0012733828,0.97722936,0.000014110024,0.0006909268,0.00026332217,0.0035785188,0.0000047222593,3.1484163e-7,0.000057009656,0.0052079763,0.0076625138],"study_design_scores_gemma":[0.039394654,0.0036602842,0.93883693,0.00025526708,0.0003389264,0.0000015313138,0.0045435466,0.00012365835,0.0000058576643,0.000008417068,0.012641417,0.00018953082],"about_ca_topic_score_codex":0.014618864,"about_ca_topic_score_gemma":0.014045627,"teacher_disagreement_score":0.03839242,"about_ca_system_score_codex":0.00013585127,"about_ca_system_score_gemma":0.00022517264,"threshold_uncertainty_score":0.9919429},"labels":[],"label_agreement":null},{"id":"W4393166394","doi":"10.1016/j.esmoop.2024.102652","title":"73P Correlation between diet, microbiome composition and clinical outcomes in patients with non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Microbiome; Lung cancer; Correlation; Composition (language); Internal medicine; Oncology; Medicine; Biology; Bioinformatics; Mathematics","score_opus":0.028353929379090963,"score_gpt":0.334799487108363,"score_spread":0.306445557729272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393166394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967809,0.00034301844,0.000070042515,0.000382025,0.0001925802,0.0008639015,0.000062883824,0.000011894481,0.0012928018],"genre_scores_gemma":[0.9986254,0.00006396259,0.00037626695,0.0001552822,0.000060632257,0.000030156192,0.00015108615,0.000015609323,0.00052158855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919105,0.000045645193,0.00027597666,0.00026154678,0.00009799006,0.00012780755],"domain_scores_gemma":[0.99963576,0.000091856775,0.000049008042,0.00011950537,0.000043490032,0.000060392038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024426638,0.000115026734,0.00037558036,0.00006866992,0.00004991995,0.000057630663,0.000047698228,0.00005179497,0.00005614366],"category_scores_gemma":[0.000006183436,0.00007871258,0.000044094777,0.000118426884,0.00004142034,0.00009830071,0.00012460002,0.00016563304,0.0000117207055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017130739,0.00009722018,0.996037,0.000108584274,0.00014856883,0.000024033334,0.00020172508,9.533372e-7,0.000008035438,0.0000071577447,0.001140396,0.0020550026],"study_design_scores_gemma":[0.0023597998,0.00036161227,0.9955697,0.00032602088,0.0003494484,0.0000010359172,0.000035424608,0.00010156168,0.000040847717,0.0000025828667,0.0007515524,0.00010041683],"about_ca_topic_score_codex":0.0007755319,"about_ca_topic_score_gemma":0.00023146784,"teacher_disagreement_score":0.0021884923,"about_ca_system_score_codex":0.00005238537,"about_ca_system_score_gemma":0.000047435416,"threshold_uncertainty_score":0.3209806},"labels":[],"label_agreement":null},{"id":"W4393166419","doi":"10.1016/j.esmoop.2024.102758","title":"184P A framework to support implementation of low-dose computed tomography (LDCT) lung cancer screening: Research methodology and opportunities for impact","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computed tomography; Lung cancer; Medicine; Lung cancer screening; Medical physics; Radiology; Oncology","score_opus":0.35674599722669986,"score_gpt":0.5770725381971785,"score_spread":0.22032654097047866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393166419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467774,0.0039061732,0.011385064,0.02818454,0.0005050114,0.007513246,0.0008023935,0.00007391318,0.0008522702],"genre_scores_gemma":[0.97166556,0.00046044827,0.025295682,0.0006821545,0.00015255316,0.0012760984,0.00016974637,0.0000339987,0.0002637321],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986812,0.00016278918,0.0002708555,0.0003432987,0.00022869119,0.00031317445],"domain_scores_gemma":[0.9984685,0.0008442895,0.000045446977,0.00022549288,0.000210203,0.00020603836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013551828,0.00013442087,0.00039193634,0.0003435941,0.00008969484,0.00010854202,0.0001410632,0.000073307965,0.00072893646],"category_scores_gemma":[0.00004743958,0.00010407817,0.00010628457,0.00035173676,0.00007157069,0.00012484886,0.00019878325,0.00014530134,0.0000013142086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020617729,0.000333662,0.28285798,0.0022900272,0.004138905,0.0002376373,0.010640633,0.00003465989,0.000312569,0.011900519,0.24003513,0.44515648],"study_design_scores_gemma":[0.0074984417,0.010137277,0.8881055,0.0054330127,0.001464347,0.000070926646,0.008373839,0.0012500387,0.015891943,0.0031650073,0.0580229,0.00058677705],"about_ca_topic_score_codex":0.008959963,"about_ca_topic_score_gemma":0.0008804335,"teacher_disagreement_score":0.6052475,"about_ca_system_score_codex":0.00015756997,"about_ca_system_score_gemma":0.00051923346,"threshold_uncertainty_score":0.9976395},"labels":[],"label_agreement":null},{"id":"W4394769738","doi":"10.1016/j.esmoop.2024.102974","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Samsung; Society for Immunotherapy of Cancer; Pfizer Japan; Sun Pharma; European Society for Medical Oncology; Fondazione Beretta; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Novartis; Bayer Yakuhin; Veracyte; Boehringer Ingelheim Japan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Roche; Intas Pharmaceuticals; Relay Therapeutics; Amgen; Pfizer; Institute for Oil Sands Innovation, University of Alberta; AstraZeneca","keywords":"Reimbursement; Breast cancer; Medicine; Family medicine; China; Alternative medicine; South asia; Clinical Practice; Clinical trial; Cancer; Internal medicine; Health care; Political science; Pathology","score_opus":0.05948405414798169,"score_gpt":0.4030207663022943,"score_spread":0.3435367121543126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394769738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262249,0.012962853,0.00027074717,0.051480237,0.0012795461,0.0041349,0.0027840608,0.00003425274,0.00082851975],"genre_scores_gemma":[0.991769,0.0040605585,0.0014704155,0.0006316324,0.00027185978,0.0012282585,0.00012303752,0.00003337301,0.00041186015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902546,0.00004798064,0.00027878644,0.00038899682,0.00009913882,0.000159663],"domain_scores_gemma":[0.9989488,0.00017131513,0.000105408064,0.0002819224,0.00044530552,0.000047248155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017271408,0.0001802813,0.0002311108,0.00001401598,0.00010994486,0.00006703432,0.00018777355,0.00007192509,0.000017129065],"category_scores_gemma":[0.0001587209,0.00009910412,0.00008198863,0.00006813398,0.000104390456,0.000017977676,0.0001708176,0.00004159763,0.0000016130073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033643893,0.0005154353,0.5621056,0.000035483456,0.0038692672,0.0000046768605,0.00038468998,0.000005789405,0.000011539175,0.00011199262,0.03104279,0.39854833],"study_design_scores_gemma":[0.003245189,0.000855174,0.74787456,0.000089703404,0.000668373,0.0000055623823,0.00021451377,0.00000915634,0.00041353438,0.000013338276,0.24646416,0.00014675208],"about_ca_topic_score_codex":0.006448117,"about_ca_topic_score_gemma":0.0034380981,"teacher_disagreement_score":0.3984016,"about_ca_system_score_codex":0.000028091014,"about_ca_system_score_gemma":0.00015481898,"threshold_uncertainty_score":0.97476673},"labels":[],"label_agreement":null},{"id":"W4394835388","doi":"10.1016/j.esmoop.2024.102992","title":"ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council; EMD Serono; Ipsen; Syöpäsäätiö; European Society for Medical Oncology; Incyte; Finnish Cancer Institute; Cilag; Astellas Pharma; Associazione Italiana di Oncologia Medica; Association canadienne des infirmières en oncologie; Medtronic; Daiichi Sankyo Europe; Sanofi; Les Laboratories Pierre Fabre; AstraZeneca; Veracyte; Pfizer","keywords":"Psychosocial; Medicine; Quality of life (healthcare); Finance; Family medicine; Business; Nursing; Psychiatry","score_opus":0.04935127432807665,"score_gpt":0.29647715933403007,"score_spread":0.24712588500595342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394835388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97369313,0.000675327,0.00012440087,0.00129855,0.00024930693,0.00070304825,0.0002214465,0.000008411295,0.023026373],"genre_scores_gemma":[0.9976347,0.0005276003,0.00032356876,0.000706339,0.000027291091,0.00009067591,0.000006048109,0.000017732556,0.0006660333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906343,0.0000102022495,0.0003683774,0.00031426648,0.00003601084,0.00020773006],"domain_scores_gemma":[0.9995787,0.000040502964,0.0001357132,0.00019173617,0.000014565484,0.00003874128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034962158,0.00012720171,0.00027336506,0.00008951981,0.00006361431,0.00011198973,0.00024400001,0.000043200373,0.00029538246],"category_scores_gemma":[0.000015689984,0.00010217408,0.0000271011,0.00014194389,0.00007416336,0.00023366889,0.00015172773,0.000108212844,0.00002431784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066366803,0.00021661146,0.5191041,0.00013706209,0.00024178078,0.000020730746,0.0012781438,0.00027704352,5.073981e-7,0.4152105,0.011652276,0.051197585],"study_design_scores_gemma":[0.0012697554,0.00016398203,0.9477761,0.00039431662,0.000005488317,1.44444e-7,0.00005861939,0.00026613995,0.00005041276,0.003832875,0.045982745,0.00019943313],"about_ca_topic_score_codex":0.0044616847,"about_ca_topic_score_gemma":0.00068865356,"teacher_disagreement_score":0.428672,"about_ca_system_score_codex":0.0000922552,"about_ca_system_score_gemma":0.000028710714,"threshold_uncertainty_score":0.67447627},"labels":[],"label_agreement":null},{"id":"W4395020893","doi":"10.1016/j.esmoop.2024.103004","title":"Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi; AstraZeneca","keywords":"Medicine; Internal medicine; Discontinuation; Retrospective cohort study; Oncology; Lung cancer; Adverse effect; Cancer; Cohort; Kidney cancer; Progression-free survival; Chemotherapy","score_opus":0.01840575878252875,"score_gpt":0.3167468201235399,"score_spread":0.2983410613410111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395020893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793876,0.00326528,0.0000032807532,0.014328692,0.00047166622,0.00095999264,0.00002358156,0.00003564102,0.0015242692],"genre_scores_gemma":[0.9934311,0.0034484733,0.00003599083,0.0006580096,0.000052427902,0.00010818308,0.00003889479,0.000023417655,0.0022035022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990751,0.000033347096,0.0003044345,0.00025147415,0.0001383527,0.00019729811],"domain_scores_gemma":[0.9996539,0.000027423674,0.00003229607,0.00022119995,0.000027092652,0.00003811292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005969025,0.00012544416,0.00023827856,0.000083085106,0.00006667372,0.00009837057,0.00019608457,0.0000651935,0.0005739944],"category_scores_gemma":[0.000008750117,0.0000787885,0.000040189898,0.000577816,0.00010012601,0.00008538334,0.000063654734,0.00023812664,0.00001225933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073786397,0.0002698909,0.6253703,0.00026977307,0.0021591496,0.000625542,0.010408272,0.0000034119462,0.12293927,0.00018568344,0.011077631,0.21931243],"study_design_scores_gemma":[0.0031774347,0.00018774136,0.8481821,0.0016839042,0.00013124669,0.00015289901,0.00031727293,0.00021878869,0.039839994,0.00004753492,0.10584546,0.00021566407],"about_ca_topic_score_codex":0.013489794,"about_ca_topic_score_gemma":0.0009852648,"teacher_disagreement_score":0.22281176,"about_ca_system_score_codex":0.00012810808,"about_ca_system_score_gemma":0.00019717947,"threshold_uncertainty_score":0.9930795},"labels":[],"label_agreement":null},{"id":"W4396607282","doi":"10.1016/j.esmoop.2024.102964","title":"The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Stichting Tegen Kanker; Fonds De La Recherche Scientifique - FNRS; Gilead Sciences","keywords":"Pembrolizumab; Medicine; Immunotherapy; Oncology; Cancer; Breast cancer; Triple-negative breast cancer; Internal medicine","score_opus":0.013643132587179488,"score_gpt":0.29238551692852194,"score_spread":0.27874238434134246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396607282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433595,0.0006484501,0.00022607557,0.00085714564,0.00005846022,0.0021695753,0.001491168,0.000025050953,0.00018812118],"genre_scores_gemma":[0.9984449,0.00017921143,0.00037866458,0.00012536238,0.000028462202,0.00030515212,0.00013783984,0.000039506325,0.00036090554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988045,0.00004811124,0.000252482,0.00042798943,0.00024123384,0.00022566579],"domain_scores_gemma":[0.99911505,0.00020286265,0.00012670753,0.00029132984,0.00019380137,0.00007022862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020899439,0.00021170334,0.0005110179,0.00022606007,0.00019651884,0.00018125222,0.00018404168,0.00005184033,0.00017094257],"category_scores_gemma":[0.000017661114,0.00011293806,0.00011527025,0.001345029,0.00017596787,0.00016767376,0.00004330097,0.0000805267,4.4321268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07027316,0.00009581806,0.8215988,0.000028222214,0.028710283,0.000006201287,0.0025607138,0.0000060942602,0.0006067874,0.000021895972,0.00034335253,0.07574863],"study_design_scores_gemma":[0.007365489,0.000931228,0.986906,0.0004958501,0.0017705096,0.000002934588,0.00051680504,0.00019447481,0.0012755577,0.000017427727,0.00034774415,0.00017598702],"about_ca_topic_score_codex":0.04444474,"about_ca_topic_score_gemma":0.014831046,"teacher_disagreement_score":0.16530715,"about_ca_system_score_codex":0.00029747232,"about_ca_system_score_gemma":0.00017405025,"threshold_uncertainty_score":0.9619184},"labels":[],"label_agreement":null},{"id":"W4396901591","doi":"10.1016/j.esmoop.2024.103007","title":"Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents","year":2024,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Johnson and Johnson","keywords":"Context (archaeology); Social media; Key (lock); Psychology; Medicine; Computer science; World Wide Web","score_opus":0.07138869323734366,"score_gpt":0.45122562909439967,"score_spread":0.379836935857056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396901591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012029184,0.99572283,1.3158446e-7,0.00034944768,0.000054187323,0.0018348369,0.0006297141,0.0000059071995,0.00020001412],"genre_scores_gemma":[0.008601963,0.98965245,0.00003575495,0.000049698454,0.00010749967,0.00039655852,0.0010502635,0.000025428679,0.00008035897],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99822474,0.00011647532,0.0008510493,0.00047436124,0.00016836727,0.0001650403],"domain_scores_gemma":[0.99915147,0.00007993036,0.0003843086,0.00017529089,0.00011898146,0.00009004799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033865828,0.00031229272,0.0026353246,0.0005983699,0.00004373664,0.00008807347,0.00010081132,0.00014035955,0.00008732046],"category_scores_gemma":[0.00010522138,0.00021829394,0.00018066166,0.00135915,0.000109374414,0.00005749978,0.00019536683,0.00024694842,9.0652566e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038657403,0.00013878196,0.0015792256,0.07365029,0.0022181545,0.000051066298,0.0028342134,5.2223825e-8,4.1612824e-7,0.00047210007,0.0003000207,0.918717],"study_design_scores_gemma":[0.0017945472,0.00090917153,0.047344428,0.5464254,0.19294633,0.00007502406,0.00054984406,0.00003077965,0.000006064128,0.0028276413,0.20585966,0.0012311093],"about_ca_topic_score_codex":0.0012369208,"about_ca_topic_score_gemma":0.0011167992,"teacher_disagreement_score":0.9174859,"about_ca_system_score_codex":0.0001373113,"about_ca_system_score_gemma":0.00027038928,"threshold_uncertainty_score":0.89017683},"labels":[],"label_agreement":null},{"id":"W4397006824","doi":"10.1016/j.esmoop.2024.103160","title":"88P Bilateral mastectomy and breast cancer mortality","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Mastectomy; Breast cancer; Medicine; Oncology; Cancer; Obstetrics; Internal medicine","score_opus":0.019264975655241396,"score_gpt":0.33408691461012097,"score_spread":0.3148219389548796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397006824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913073,0.0018728923,0.00001638931,0.002093007,0.000282454,0.00021994284,0.00024924063,0.000021010434,0.003937732],"genre_scores_gemma":[0.99771315,0.00034768358,0.00008947958,0.0002383151,0.00021596954,0.00010521381,0.000043847806,0.000016404882,0.0012299382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993888,0.000018025557,0.00007865996,0.00032029898,0.00005345008,0.0001407578],"domain_scores_gemma":[0.9997464,0.0000039886772,0.0000136435565,0.00017175457,0.000020560994,0.00004364811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058761994,0.00011357505,0.00010518763,0.000014173949,0.0000603898,0.000111268484,0.00013334441,0.000047304347,0.00016299702],"category_scores_gemma":[0.000002308162,0.000088541325,0.000029929111,0.00005248548,0.000058138667,0.000008221084,0.0003581425,0.00004215671,0.000014605794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029873115,0.00012719783,0.88556206,0.00018050137,0.0019717242,0.00010993215,0.00052764855,0.000015084097,0.012832948,0.0007334738,0.028104728,0.069536],"study_design_scores_gemma":[0.00043858972,0.0000319044,0.9427296,0.00005542525,0.000066169836,0.00007581331,0.00003381104,0.00001746509,0.007768617,0.00014207169,0.04846322,0.00017730102],"about_ca_topic_score_codex":0.004156464,"about_ca_topic_score_gemma":0.0013745794,"teacher_disagreement_score":0.0693587,"about_ca_system_score_codex":0.000018513896,"about_ca_system_score_gemma":0.000053655134,"threshold_uncertainty_score":0.6283358},"labels":[],"label_agreement":null},{"id":"W4397006918","doi":"10.1016/j.esmoop.2024.103243","title":"221P Incidence and survival after brain metastases among patients with stage I-III breast cancer: A population-based study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Instituto de Salud Carlos III; Seagen; Pfizer","keywords":"Stage (stratigraphy); Breast cancer; Incidence (geometry); Oncology; Medicine; Internal medicine; Cancer; Population; Biology; Environmental health","score_opus":0.013357523343352959,"score_gpt":0.30528183574030116,"score_spread":0.2919243123969482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397006918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605685,0.00014751905,0.000060506176,0.0008769555,0.000100874204,0.0019355533,0.000697732,0.000039277176,0.00008471261],"genre_scores_gemma":[0.99790496,0.0000024389817,0.00032942122,0.00030323846,0.000040133695,0.00037813425,0.00025652166,0.00003332898,0.0007518461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865025,0.00013808855,0.00020965411,0.00044235,0.00035831667,0.00020135456],"domain_scores_gemma":[0.9992831,0.00014353888,0.000052823718,0.00029728893,0.00006750031,0.00015577629],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003390674,0.00020871822,0.00034984536,0.00009050578,0.0000886198,0.00020741271,0.00010082655,0.000024759725,0.0010585627],"category_scores_gemma":[0.00001654322,0.0001372569,0.00004083327,0.00023878049,0.00004254179,0.00028654598,0.00012162319,0.00011396623,0.000010633122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006378629,0.0005234737,0.9934895,0.000058773272,0.00041081192,0.00031424372,0.00024751006,0.000025133819,3.2622316e-7,0.000033857337,0.0001622963,0.0040962053],"study_design_scores_gemma":[0.0038811534,0.0005505776,0.99387914,0.00028313862,0.0004428142,0.0000032340856,0.0002527121,0.00012897239,0.0000068516765,0.0000103543425,0.00040224518,0.00015879642],"about_ca_topic_score_codex":0.042136293,"about_ca_topic_score_gemma":0.013619029,"teacher_disagreement_score":0.028517265,"about_ca_system_score_codex":0.00008765901,"about_ca_system_score_gemma":0.00015035372,"threshold_uncertainty_score":0.9998546},"labels":[],"label_agreement":null},{"id":"W4397006962","doi":"10.1016/j.esmoop.2024.103273","title":"252P Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase III randomized trials (RCT) in metastatic breast cancer (MBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Censoring (clinical trials); Randomized controlled trial; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Breast cancer; Progression-free survival; Overall survival; Cancer; Pathology","score_opus":0.05797926994222724,"score_gpt":0.4893996818491113,"score_spread":0.43142041190688407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397006962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863132,0.0006240523,0.00032582457,0.0018041338,0.0002500649,0.005983555,0.00045248523,0.000019251132,0.0042274054],"genre_scores_gemma":[0.9986363,0.00009484929,0.00041239502,0.000028325481,0.000016408094,0.0006738264,0.000057969486,0.000012687812,0.00006724232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99835414,0.0003393192,0.00082141184,0.00013208503,0.00022113525,0.00013191298],"domain_scores_gemma":[0.9971677,0.0022209827,0.00028948806,0.00020131808,0.000081721606,0.000038794424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022696801,0.0001406464,0.0010652076,0.00021372677,0.000023227512,0.00004429004,0.00016165774,0.00002672262,0.0003906433],"category_scores_gemma":[0.0011188746,0.0000684129,0.0001817076,0.00034994693,0.000076631004,0.00029664463,0.000066740664,0.00012483879,0.0000027826406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49257302,0.003717815,0.015869875,0.0016370314,0.011186319,0.00015382475,0.13134733,0.011006372,0.0010589146,0.00767253,0.001955494,0.32182148],"study_design_scores_gemma":[0.76372594,0.0018021871,0.055049524,0.022129009,0.0033167133,0.000032221873,0.006093946,0.13273454,0.01011769,0.004521584,0.000047767455,0.00042891235],"about_ca_topic_score_codex":0.00978981,"about_ca_topic_score_gemma":0.0005235954,"teacher_disagreement_score":0.32139257,"about_ca_system_score_codex":0.00025603652,"about_ca_system_score_gemma":0.00046025089,"threshold_uncertainty_score":0.99680406},"labels":[],"label_agreement":null},{"id":"W4397007022","doi":"10.1016/j.esmoop.2024.103282","title":"261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Durvalumab; Medicine; Chemotherapy; Metastatic melanoma; Docetaxel; Internal medicine; Oncology; Radiology; Immunotherapy; Cancer","score_opus":0.0240032643173013,"score_gpt":0.335595626129557,"score_spread":0.3115923618122557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898342,0.00062986877,0.000099202545,0.001048845,0.00046195879,0.006785533,0.00046611973,0.000079004916,0.0005952487],"genre_scores_gemma":[0.9956026,0.0004504707,0.0003229284,0.00046985692,0.00008474581,0.000843531,0.0001682382,0.00013909957,0.0019185458],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957022,0.0003935433,0.0011932575,0.0011027119,0.0009171512,0.000691119],"domain_scores_gemma":[0.99801093,0.00016373931,0.00035105878,0.0008821746,0.00033575748,0.00025632512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005828113,0.00066860346,0.001416205,0.0004548067,0.00017479366,0.00021067106,0.00074360106,0.00008657663,0.0044673905],"category_scores_gemma":[0.00004567673,0.00045548455,0.00016858862,0.0016546032,0.0002396953,0.0006637625,0.00020538586,0.0005734742,0.0000208658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5100307,0.024385178,0.027870405,0.0010325118,0.00538512,0.001034245,0.01376991,0.00008178585,0.0003244002,0.000053139483,0.0061595677,0.40987307],"study_design_scores_gemma":[0.51109266,0.038292784,0.4086646,0.0074973973,0.0018184416,0.0007919291,0.010169187,0.003321268,0.0034658718,0.00008628256,0.012681684,0.0021178997],"about_ca_topic_score_codex":0.03314261,"about_ca_topic_score_gemma":0.0162644,"teacher_disagreement_score":0.40775517,"about_ca_system_score_codex":0.00093854626,"about_ca_system_score_gemma":0.0017816991,"threshold_uncertainty_score":0.9997897},"labels":[],"label_agreement":null},{"id":"W4397007234","doi":"10.1016/j.esmoop.2024.103146","title":"159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Standard of care; Adjuvant; Oncology; Cancer; Immunotherapy; Nivolumab","score_opus":0.009822913088877542,"score_gpt":0.31407478498026575,"score_spread":0.3042518718913882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830936,0.0066348123,0.00002398928,0.000552145,0.00030286532,0.0026296563,0.0061646476,0.000030036674,0.0005682392],"genre_scores_gemma":[0.9959574,0.001769638,0.00011984436,0.000041066287,0.00009713979,0.0007428244,0.00057787384,0.00009151811,0.0006027267],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967888,0.0002347448,0.0008104117,0.0012142396,0.00040154177,0.00055026996],"domain_scores_gemma":[0.9984241,0.000079203506,0.00029840102,0.000757289,0.0002557575,0.00018520874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017489205,0.0006680817,0.0013023884,0.00016457264,0.00017263154,0.00009715144,0.00053754664,0.00020444562,0.00017013635],"category_scores_gemma":[0.0000328538,0.00055516715,0.00019613314,0.0004132313,0.00028088104,0.000053862503,0.0006017243,0.00017860314,0.0000034298014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08781601,0.01949728,0.31075874,0.001687531,0.015674101,0.001095021,0.056433998,0.00022617383,0.031323664,0.00027515148,0.016245514,0.45896682],"study_design_scores_gemma":[0.23531814,0.041206684,0.27766037,0.0037332517,0.0042194403,0.00039043056,0.08219665,0.0002997801,0.33044598,0.00028864498,0.02007595,0.0041646813],"about_ca_topic_score_codex":0.05585494,"about_ca_topic_score_gemma":0.043611504,"teacher_disagreement_score":0.45480213,"about_ca_system_score_codex":0.00038788366,"about_ca_system_score_gemma":0.000554526,"threshold_uncertainty_score":0.99969},"labels":[],"label_agreement":null},{"id":"W4397007282","doi":"10.1016/j.esmoop.2024.103202","title":"180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Centre Hospitalier Universitaire Vaudois","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Radiology; Cancer; Immunotherapy","score_opus":0.05708297713041971,"score_gpt":0.4125401569395417,"score_spread":0.355457179809122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8632454,0.0050440496,0.051630482,0.007865353,0.004748684,0.061938513,0.001791524,0.00056030025,0.0031756721],"genre_scores_gemma":[0.97158366,0.0005237093,0.008018713,0.00034985403,0.00061118917,0.0060921283,0.00013424689,0.00027532305,0.0124111455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637425,0.00014644813,0.0011960629,0.00091765233,0.0005981247,0.0007674344],"domain_scores_gemma":[0.9973265,0.0007644138,0.00048376576,0.0006519535,0.00044250058,0.00033084975],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086541,0.0006021477,0.0017883645,0.00031996417,0.00024088641,0.0002057528,0.0005886618,0.00010757648,0.0033584924],"category_scores_gemma":[0.00013996585,0.00042709967,0.00042665948,0.0009760837,0.00027191668,0.0010366847,0.00014768454,0.00042765515,0.00001631854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81365657,0.00070852245,0.0000053820636,0.0003451538,0.0016306565,0.000086060536,0.0011717856,0.00019740325,0.0036164445,0.00020463469,0.0006075082,0.17776985],"study_design_scores_gemma":[0.9394705,0.002937281,0.000040624913,0.0022726632,0.0007023917,0.00016285872,0.0005249916,0.001789097,0.041234534,0.001089359,0.00925159,0.00052410207],"about_ca_topic_score_codex":0.003275558,"about_ca_topic_score_gemma":0.00039735602,"teacher_disagreement_score":0.17724575,"about_ca_system_score_codex":0.0005623738,"about_ca_system_score_gemma":0.002012115,"threshold_uncertainty_score":0.9998181},"labels":[],"label_agreement":null},{"id":"W4397007298","doi":"10.1016/j.esmoop.2024.103338","title":"280P Outcomes of women with early-stage triple-negative breast cancer (TNBC) in connection with age and other socio-demographic factors: A population based cohort study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatoon Medical Imaging; University of Saskatchewan","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Cohort; Medicine; Connection (principal bundle); Demography; Population; Stage (stratigraphy); Oncology; Triple negative; Cancer; Gynecology; Internal medicine; Environmental health; Biology; Sociology","score_opus":0.019516205927045262,"score_gpt":0.31873658817177236,"score_spread":0.2992203822447271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966424,0.000037261198,0.00009984213,0.0002786221,0.000045611716,0.0026445314,0.00009055184,0.000054246855,0.00010692354],"genre_scores_gemma":[0.99866337,0.000003707052,0.00017422187,0.00012586422,0.000022461989,0.0005452536,0.000012717416,0.00005474106,0.00039766027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873626,0.0000977172,0.00023969868,0.00039964332,0.00028604435,0.00024063227],"domain_scores_gemma":[0.99941695,0.00010362136,0.00011781365,0.00021742583,0.000058704907,0.00008546464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003171542,0.00022299378,0.0005682621,0.00023945616,0.000054698292,0.000059726033,0.00009184486,0.000055022316,0.00029541992],"category_scores_gemma":[0.00001311905,0.00014436348,0.000026614307,0.00051363505,0.0001166744,0.00034189387,0.000033120567,0.000190729,7.695998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027744968,0.00019190641,0.98711884,0.00007893323,0.00059266755,0.00005733407,0.008006629,0.000068151174,0.000030351903,0.00003730467,0.0000015319358,0.0010418718],"study_design_scores_gemma":[0.0065895105,0.00075355597,0.9857026,0.00035852907,0.000109510496,0.000007023989,0.006051147,0.000053218046,0.00005705751,0.00007071825,0.00006730762,0.00017985111],"about_ca_topic_score_codex":0.06010482,"about_ca_topic_score_gemma":0.017193783,"teacher_disagreement_score":0.042911038,"about_ca_system_score_codex":0.0003975071,"about_ca_system_score_gemma":0.00013268214,"threshold_uncertainty_score":0.9594534},"labels":[],"label_agreement":null},{"id":"W4397007301","doi":"10.1016/j.esmoop.2024.103220","title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Japanese Society of Medical Oncology; Daewoong Pharmaceutical Company; Chugai Pharmaceutical; Seagen; Radius Health; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Immunotherapy; Cancer; Polymerase","score_opus":0.04492359654625794,"score_gpt":0.33558879898993604,"score_spread":0.2906652024436781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95125854,0.0029578565,0.009769526,0.011467115,0.0035009384,0.014580937,0.00073511107,0.0010094739,0.004720488],"genre_scores_gemma":[0.9596414,0.0010740486,0.008181576,0.008741322,0.0008756815,0.0065092063,0.0012426971,0.0006400651,0.013094005],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926797,0.00028438374,0.0019272451,0.0022339178,0.0014673065,0.0014074509],"domain_scores_gemma":[0.9957716,0.00041715582,0.000680502,0.0018291263,0.0006504454,0.0006511973],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006331427,0.0014040871,0.002497629,0.0005910351,0.00042652752,0.00091033423,0.00089611945,0.00047173162,0.006215059],"category_scores_gemma":[0.00012773919,0.0010365834,0.000574681,0.0011450456,0.00037162635,0.0013416819,0.00022568836,0.0011312678,0.00022043382],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61398643,0.003658763,0.003343382,0.0027497632,0.017201269,0.0036946756,0.034206174,0.001875063,0.002342561,0.00093007647,0.121770546,0.19424129],"study_design_scores_gemma":[0.30755496,0.015820848,0.025001802,0.0070127607,0.0033711244,0.0028238036,0.0027769636,0.019303298,0.0187287,0.0023494181,0.5898689,0.005387405],"about_ca_topic_score_codex":0.003446145,"about_ca_topic_score_gemma":0.0008229856,"teacher_disagreement_score":0.46809837,"about_ca_system_score_codex":0.003250182,"about_ca_system_score_gemma":0.004885531,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W4397007318","doi":"10.1016/j.esmoop.2024.103354","title":"297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; University Health Network; CancerCare Manitoba; Ottawa Hospital; Health Sciences Centre; University of Saskatchewan; Centre Hospitalier de l’Université de Montréal; Université Laval; Princess Margaret Cancer Centre; Dalhousie University; University of British Columbia; Hôpital Maisonneuve-Rosemont; Sunnybrook Health Science Centre; McGill University Health Centre","funders":"","keywords":"Perspective (graphical); Psychological intervention; Delphi; Breast cancer; Delphi method; Medicine; Dermatology; Medical physics; Cancer; Computer science; Internal medicine; Artificial intelligence; Nursing","score_opus":0.040749464071860475,"score_gpt":0.389119983552802,"score_spread":0.3483705194809415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007318","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22219807,0.0064461525,0.0004776809,0.70467216,0.0025035369,0.012464714,0.003037601,0.00029608648,0.047904003],"genre_scores_gemma":[0.99552,0.00008362496,0.0003265924,0.0022407605,0.00018250833,0.0008079439,0.00013279117,0.000030791205,0.00067501876],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990773,0.00006455534,0.00022265667,0.00028036206,0.00012723161,0.00022784845],"domain_scores_gemma":[0.99928224,0.00017444909,0.00004018845,0.00017984612,0.0001321006,0.00019119335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022196292,0.00012190722,0.00022122024,0.00038399515,0.000113373404,0.00015080962,0.00013464244,0.00009614927,0.00030234744],"category_scores_gemma":[0.00017376555,0.00011988786,0.00011441587,0.00025414667,0.000033772663,0.00013698262,0.000020923995,0.00017787395,0.00004712366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070569356,0.0004886233,0.01636657,0.00093788217,0.00090423506,0.00069229875,0.019050917,0.0019518598,0.00015364328,0.1040426,0.7687333,0.08597233],"study_design_scores_gemma":[0.0097966585,0.00091812253,0.8359212,0.0063629462,0.00024931677,0.00042432596,0.0033410464,0.06911648,0.000744137,0.0032500343,0.06907769,0.00079802494],"about_ca_topic_score_codex":0.5997316,"about_ca_topic_score_gemma":0.7151828,"teacher_disagreement_score":0.8195546,"about_ca_system_score_codex":0.0017449174,"about_ca_system_score_gemma":0.00095776166,"threshold_uncertainty_score":0.4888885},"labels":[],"label_agreement":null},{"id":"W4397007360","doi":"10.1016/j.esmoop.2024.103115","title":"127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Atezolizumab; Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","score_opus":0.051704810733827496,"score_gpt":0.41411049754855733,"score_spread":0.36240568681472984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95598364,0.00067904766,0.000016998447,0.023829404,0.0010161501,0.0051207715,0.0010130437,0.00007188387,0.012269073],"genre_scores_gemma":[0.9876044,0.0003791358,0.000064726,0.00041865866,0.00068859465,0.0006075981,0.000055544973,0.00011342649,0.010067965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99578756,0.00039444136,0.00097062363,0.0009109854,0.001159863,0.0007765058],"domain_scores_gemma":[0.99809897,0.00025547357,0.00018342867,0.000956159,0.00021999725,0.00028594537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012281562,0.00041688734,0.0008944388,0.0002562385,0.00017089138,0.00023285075,0.0011582249,0.00018464387,0.0029748124],"category_scores_gemma":[0.00014855673,0.00028108357,0.00031545974,0.0011862752,0.00035415657,0.0003401297,0.00042345838,0.0011425456,0.000074837706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43637872,0.0040132655,0.0018392247,0.00048563973,0.0010124579,0.0015793748,0.012471284,0.00004686016,0.004554007,0.00055433187,0.11295619,0.42410865],"study_design_scores_gemma":[0.6153115,0.0100652,0.18578105,0.010809216,0.0004089309,0.0010790341,0.0014643667,0.0030757503,0.033829723,0.0005321154,0.13624224,0.0014008782],"about_ca_topic_score_codex":0.065205,"about_ca_topic_score_gemma":0.003615269,"teacher_disagreement_score":0.42270777,"about_ca_system_score_codex":0.0016753853,"about_ca_system_score_gemma":0.0034267437,"threshold_uncertainty_score":0.9999641},"labels":[],"label_agreement":null},{"id":"W4397007490","doi":"10.1016/j.esmoop.2024.103097","title":"109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Invasive lobular carcinoma; Endocrine system; Adjuvant therapy; Medicine; Adjuvant; Oncology; Gynecology; Internal medicine; Breast cancer; Cancer; Hormone; Invasive ductal carcinoma","score_opus":0.06478760111655238,"score_gpt":0.4140119191026694,"score_spread":0.34922431798611697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96051687,0.02401203,0.00010964596,0.0067931744,0.0004943372,0.0039981934,0.0011806733,0.000078787976,0.0028162692],"genre_scores_gemma":[0.99025667,0.0012711991,0.0010340572,0.0005506072,0.00027324236,0.00051784306,0.000649368,0.00003299226,0.005414047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894446,0.000022253162,0.00026204775,0.00044291755,0.00012840958,0.0001999077],"domain_scores_gemma":[0.9991689,0.00031774363,0.000050277624,0.00025843023,0.0001046181,0.000100031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010969262,0.00017751307,0.00036486197,0.00005439563,0.00013814498,0.000106865475,0.00010784748,0.00003086386,0.0001042921],"category_scores_gemma":[0.000098427845,0.00012279295,0.000042672516,0.0000876483,0.000064903346,0.00018473672,0.00011168255,0.00007737088,0.000018599232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02557436,0.002934544,0.0080399765,0.00082199776,0.018115569,0.0036992577,0.060599957,0.000021068221,0.018054368,0.0034375584,0.29819062,0.56051075],"study_design_scores_gemma":[0.15375286,0.011157478,0.030701337,0.0017568992,0.003357509,0.00013894588,0.0055500153,0.0006068185,0.044870626,0.0050963117,0.7421718,0.0008394038],"about_ca_topic_score_codex":0.003169012,"about_ca_topic_score_gemma":0.00051324815,"teacher_disagreement_score":0.55967134,"about_ca_system_score_codex":0.000108630455,"about_ca_system_score_gemma":0.00027862738,"threshold_uncertainty_score":0.5007351},"labels":[],"label_agreement":null},{"id":"W4397007641","doi":"10.1016/j.esmoop.2024.103081","title":"75P A multicenter physician survey evaluating Ki-67 use in breast cancer management in Canada","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Family medicine; Breast cancer; Multicenter study; Cancer; Oncology; Internal medicine","score_opus":0.18120745501085675,"score_gpt":0.42823314284730674,"score_spread":0.24702568783645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928219,0.00019058118,0.0000055850464,0.001563233,0.00030927997,0.0008112445,0.000077098026,0.000011779543,0.004209329],"genre_scores_gemma":[0.99569947,0.000048071925,0.0002741553,0.0030363174,0.000055816992,0.000114169525,0.000033895183,0.00001772625,0.00072036753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986418,0.00010449475,0.00025205882,0.00033329125,0.00035464438,0.00031372893],"domain_scores_gemma":[0.999566,0.00006936667,0.0000310326,0.00020804655,0.00004826605,0.000077259676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064704806,0.00012438356,0.00022680116,0.00007822101,0.000026668464,0.00012174333,0.00021649744,0.000024086012,0.00028448598],"category_scores_gemma":[0.000029129349,0.00011173942,0.000024133613,0.00043085942,0.0000119875,0.00033358447,0.00020873001,0.00020400513,0.000021610147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028225975,0.000028454362,0.9455262,0.00007719851,0.000062765845,0.0007736652,0.00022994366,0.000489228,0.000016656864,0.000031649684,0.0064125895,0.046069387],"study_design_scores_gemma":[0.0009828064,0.000017687384,0.9851381,0.0015667311,0.000029401339,0.000005786823,0.00048342702,0.009884403,0.000023662555,0.000009829177,0.0017361076,0.00012203153],"about_ca_topic_score_codex":0.9974909,"about_ca_topic_score_gemma":0.99815357,"teacher_disagreement_score":0.045947354,"about_ca_system_score_codex":0.0014537079,"about_ca_system_score_gemma":0.0008287087,"threshold_uncertainty_score":0.45566013},"labels":[],"label_agreement":null},{"id":"W4397007666","doi":"10.1016/j.esmoop.2024.103102","title":"114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Oncology; Chemotherapy; Fixed-dose combination; Breast cancer; Pharmacology; Internal medicine; Cancer","score_opus":0.014165103925520332,"score_gpt":0.33089731714571946,"score_spread":0.3167322132201991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405605,0.00093221216,0.000099645855,0.00039720297,0.000083027364,0.003941794,0.00043182724,0.0000055776245,0.00005267059],"genre_scores_gemma":[0.9987168,0.00056432036,0.000036697013,0.000046286066,0.000022043336,0.00032701332,0.00012324621,0.000026121572,0.00013750714],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986314,0.00014898324,0.00037903007,0.00052349624,0.00013460498,0.0001824798],"domain_scores_gemma":[0.9992999,0.00010313638,0.00017325401,0.00025047,0.00012816905,0.000045106648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002204037,0.00023391056,0.00059999427,0.00008930892,0.00017216492,0.00011476189,0.00028190564,0.00007817646,0.000017915512],"category_scores_gemma":[0.000021694175,0.00017526663,0.00007574965,0.0003567307,0.00013609516,0.0000284777,0.00031393033,0.00007728661,1.3113723e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35742638,0.017249726,0.20170186,0.0004236651,0.027563073,0.00008639403,0.03780933,0.00074373593,0.0326389,0.000050286657,0.00023999649,0.32406667],"study_design_scores_gemma":[0.14865336,0.0022092748,0.83907247,0.00022554694,0.0018797135,0.00004263173,0.0010162177,0.0013604971,0.005218051,0.000006485764,0.000026964253,0.00028877982],"about_ca_topic_score_codex":0.007814986,"about_ca_topic_score_gemma":0.007929233,"teacher_disagreement_score":0.6373706,"about_ca_system_score_codex":0.0001686122,"about_ca_system_score_gemma":0.0001491454,"threshold_uncertainty_score":0.99879205},"labels":[],"label_agreement":null},{"id":"W4397007854","doi":"10.1016/j.esmoop.2024.103035","title":"27P Impact of chemotherapy (CT) use and stromal tumor-infiltrating lymphocytes (sTILs) in stage I triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Triple-negative breast cancer; Stage (stratigraphy); Triple negative; Stromal cell; Chemotherapy; Breast cancer; Medicine; Oncology; Cancer; Pathology; Internal medicine; Biology","score_opus":0.028841999122971765,"score_gpt":0.34957971962111506,"score_spread":0.3207377204981433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966127,0.0010572494,0.000005953196,0.00040028038,0.000108037406,0.00080687634,0.00034322706,0.000028187666,0.0006374492],"genre_scores_gemma":[0.9977025,0.00050278485,0.00025954205,0.00022752663,0.000071818286,0.000049455102,0.000014995324,0.00003536454,0.0011360325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988778,0.00005424136,0.0003368131,0.00031402442,0.00016669383,0.0002504153],"domain_scores_gemma":[0.99941224,0.00015625503,0.000096207594,0.00020596545,0.000046363344,0.00008295616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030622867,0.0002025072,0.00041654977,0.00013398929,0.000041616207,0.00017120784,0.00014816673,0.000039424613,0.0017190377],"category_scores_gemma":[0.000035776986,0.00015231423,0.00011479287,0.00038678467,0.0001285871,0.00048104828,0.00005728713,0.00015299949,0.0000022633683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015297769,0.00031682133,0.8363314,0.00047460108,0.0015956404,0.00065726065,0.004665973,0.000051517203,0.056469508,0.00013635232,0.0031816293,0.08082148],"study_design_scores_gemma":[0.006597418,0.00042571747,0.97590697,0.0011012704,0.000039734397,0.00016038172,0.00047651966,0.0012105219,0.013139913,0.000023360059,0.0007190177,0.00019915194],"about_ca_topic_score_codex":0.09624132,"about_ca_topic_score_gemma":0.0023678166,"teacher_disagreement_score":0.13957554,"about_ca_system_score_codex":0.00042808152,"about_ca_system_score_gemma":0.0007294133,"threshold_uncertainty_score":0.99919355},"labels":[],"label_agreement":null},{"id":"W4397008063","doi":"10.1016/j.esmoop.2024.103019","title":"10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute on the Environment, University of Minnesota; Veracyte; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Eisai; Astellas Pharma; Oncolytics Biotech; Relay Therapeutics; Seagen; MacroGenics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sanofi; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Biomarker; Neoadjuvant therapy; Oncology; Endocrine system; Mutation; Internal medicine; Medicine; Biology; Cancer; Genetics; Hormone; Breast cancer; Gene","score_opus":0.04233489190041899,"score_gpt":0.3595692542732487,"score_spread":0.3172343623728297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397008063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924355,0.0005413495,0.0000027534631,0.0023432565,0.00019947547,0.004088737,0.000018984392,0.000020385753,0.00034951596],"genre_scores_gemma":[0.99794257,0.00005458651,0.00009066742,0.00016524526,0.00004952928,0.00016970604,0.000008997461,0.000021616774,0.0014970572],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99888575,0.00022007272,0.00023590171,0.00030824548,0.00021632844,0.00013371592],"domain_scores_gemma":[0.9992386,0.00025757172,0.000042109124,0.0003467134,0.000032159653,0.00008280974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005164525,0.00013150949,0.00025737679,0.00009125916,0.000060903873,0.00007591844,0.00012542907,0.000030270023,0.0001310753],"category_scores_gemma":[0.00019550619,0.00007739292,0.00003147129,0.0002544536,0.000043525095,0.00008545132,0.00023816711,0.00009256009,0.000011180366],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50602764,0.002915464,0.013547336,0.0001714323,0.002194872,0.0025013175,0.039877437,0.000008988931,0.0147846965,0.00014313539,0.016036442,0.40179124],"study_design_scores_gemma":[0.29318416,0.016063571,0.61693853,0.0006774809,0.00062374875,0.0006346383,0.004282331,0.0006706218,0.007533725,0.00017907938,0.05884064,0.0003714354],"about_ca_topic_score_codex":0.0020877544,"about_ca_topic_score_gemma":0.00027093999,"teacher_disagreement_score":0.60339123,"about_ca_system_score_codex":0.00014797677,"about_ca_system_score_gemma":0.00026617345,"threshold_uncertainty_score":0.31560743},"labels":[],"label_agreement":null},{"id":"W4399361514","doi":"10.1016/j.esmoop.2024.103466","title":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; Chugai Pharmaceutical; Seagen; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Novartis; Daiichi-Sankyo; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Palbociclib; Hormone receptor; Docetaxel; Gynecology; Chemotherapy; Cancer; Metastatic breast cancer","score_opus":0.009595296794721674,"score_gpt":0.2882959797367978,"score_spread":0.27870068294207617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949076,0.0003192537,0.000015624395,0.00052739633,0.00007793376,0.003077234,0.0008431628,0.000039673057,0.00019208422],"genre_scores_gemma":[0.9959223,0.00049851986,0.0015042363,0.00012804972,0.000039525967,0.0010423553,0.0003218062,0.00011420055,0.00042900397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975926,0.0001686828,0.0005526677,0.0007367677,0.00048458288,0.00046468372],"domain_scores_gemma":[0.99882007,0.000110519984,0.00025481283,0.00040791312,0.00026351205,0.00014319042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011244343,0.00049717433,0.00092856365,0.00027586837,0.0000460189,0.00005334048,0.00022227257,0.000073218755,0.0005695913],"category_scores_gemma":[0.000012175504,0.00032281392,0.000055206903,0.00088946876,0.00019498197,0.0005534291,0.00010798289,0.00029355998,0.000010557007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05374476,0.002419385,0.91795146,0.00007060065,0.000996154,0.000117419215,0.0029937674,0.00010458896,0.00021183101,0.000011143146,0.00004497852,0.021333907],"study_design_scores_gemma":[0.030489074,0.0067103663,0.95355105,0.0014772746,0.00023527241,0.0000054316192,0.00019031297,0.000023711911,0.006715605,0.000054188196,0.00018057603,0.00036714473],"about_ca_topic_score_codex":0.06031082,"about_ca_topic_score_gemma":0.01569804,"teacher_disagreement_score":0.04461278,"about_ca_system_score_codex":0.0010161917,"about_ca_system_score_gemma":0.00027071594,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4399361815","doi":"10.1016/j.esmoop.2024.103488","title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; AstraZeneca; Incyte; Amgen","keywords":"Medicine; Cohort; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Progression-free survival; Retrospective cohort study; Surgery; Gastroenterology; Overall survival; Clinical trial","score_opus":0.14684467515984387,"score_gpt":0.404070658401311,"score_spread":0.25722598324146717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214705,0.0010733877,0.0000016533743,0.0015221535,0.00031233943,0.0018364643,0.00019353318,0.00004450273,0.0228689],"genre_scores_gemma":[0.99647367,0.00002763745,0.000482002,0.00031375213,0.00021963893,0.00016317368,0.00023418944,0.000038994178,0.0020469523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979427,0.0001167364,0.00058832555,0.0007538306,0.0003222925,0.00027610763],"domain_scores_gemma":[0.9987513,0.00016652538,0.00008572613,0.0007912379,0.00007664948,0.00012855047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053326716,0.00023253773,0.00064505276,0.00015340697,0.000079583995,0.0002538424,0.00093514833,0.00008164232,0.00022023528],"category_scores_gemma":[0.000096111435,0.00019235286,0.000039743143,0.0005137442,0.000048996048,0.00048492488,0.0008360172,0.00035488367,0.00006320512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009785416,0.015390229,0.70197105,0.00027384024,0.0015049615,0.004499205,0.09666254,0.000012120652,0.002629564,0.0004964137,0.13692786,0.0298468],"study_design_scores_gemma":[0.02084925,0.0028713008,0.9636696,0.00053003256,0.0001989334,0.000015544196,0.0046766372,0.0002602822,0.00062810484,0.00019677778,0.005844364,0.00025917462],"about_ca_topic_score_codex":0.03705204,"about_ca_topic_score_gemma":0.010745398,"teacher_disagreement_score":0.26169854,"about_ca_system_score_codex":0.00009343821,"about_ca_system_score_gemma":0.00023502135,"threshold_uncertainty_score":0.9693603},"labels":[],"label_agreement":null},{"id":"W4399799721","doi":"10.1016/j.esmoop.2024.103606","title":"Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; University of Alberta; University of Calgary","funders":"National Cancer Institute; European Society for Medical Oncology","keywords":"Renal cell carcinoma; Medicine; Oncology; Lymphocyte; Internal medicine; Renal carcinoma","score_opus":0.021611642478399064,"score_gpt":0.2583214882515631,"score_spread":0.23670984577316403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399799721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914003,0.0010017282,0.00025310463,0.0007543567,0.00037677187,0.003141502,0.0021405711,0.000040300707,0.00089135923],"genre_scores_gemma":[0.9931454,0.000050485618,0.003436678,0.0002192786,0.000050678704,0.0003796498,0.00239279,0.00007172586,0.000253282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965186,0.00030297608,0.0010972033,0.00077745755,0.0009275471,0.00037618133],"domain_scores_gemma":[0.9968582,0.0012853574,0.00050495093,0.00084263185,0.0003856753,0.00012320188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013442043,0.00037383713,0.00053551723,0.00022744038,0.00013186784,0.00021312057,0.0008461788,0.000055742155,0.0003048571],"category_scores_gemma":[0.00040404894,0.00027184872,0.0001100383,0.0005062265,0.00025477,0.0005044327,0.0003317706,0.0002988807,0.000032620934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03433366,0.004528601,0.9249878,0.0021689618,0.0021414063,0.0015535881,0.009969407,0.00056021777,0.0050644083,0.00016691857,0.010178386,0.004346627],"study_design_scores_gemma":[0.019244403,0.0007438218,0.94970214,0.0018343697,0.0009356035,0.000008566379,0.00046564575,0.0074860947,0.017224062,0.00011466765,0.001791029,0.0004496161],"about_ca_topic_score_codex":0.0037791098,"about_ca_topic_score_gemma":0.0006202128,"teacher_disagreement_score":0.0247143,"about_ca_system_score_codex":0.0004957758,"about_ca_system_score_gemma":0.0008901811,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W4399799741","doi":"10.1016/j.esmoop.2024.103484","title":"Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bone health and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Prostate cancer; Consensus conference; Bone health; Management of prostate cancer; Medicine; Cancer; Internal medicine; Osteoporosis; Bone mineral","score_opus":0.025234520605777026,"score_gpt":0.37922913173815953,"score_spread":0.3539946111323825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399799741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97091275,0.014667253,0.0000036769106,0.009263798,0.00007917895,0.0022273287,0.00002140282,0.000028135082,0.002796495],"genre_scores_gemma":[0.98689115,0.010900208,0.0005301071,0.00044247982,0.000010074321,0.00014536058,0.00006181369,0.000011025065,0.0010077725],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99927115,0.0000487299,0.00019109894,0.00024644408,0.00007686362,0.00016570187],"domain_scores_gemma":[0.999714,0.000017125632,0.000037626287,0.000073819996,0.000010597901,0.00014678955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019341506,0.000093466406,0.00020587431,0.00007956424,0.00007860621,0.00012345408,0.000016005139,0.000024578252,0.000009195786],"category_scores_gemma":[0.0000014600554,0.00007973714,0.000007704718,0.00008241738,0.000045532717,0.00010391459,0.000059885428,0.000069354406,0.0000019048446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004690372,0.0011257754,0.32857895,0.02147351,0.0008953914,0.003570372,0.010356194,0.000007952422,0.00023505536,0.04579333,0.011920133,0.57135296],"study_design_scores_gemma":[0.008176951,0.0014968127,0.96534324,0.0045659654,0.00015640547,0.00031444288,0.0013399877,0.00075650396,0.0000841863,0.004875439,0.012680681,0.00020941033],"about_ca_topic_score_codex":0.0060135387,"about_ca_topic_score_gemma":0.0026467317,"teacher_disagreement_score":0.6367643,"about_ca_system_score_codex":0.0000672844,"about_ca_system_score_gemma":0.00016613667,"threshold_uncertainty_score":0.9090712},"labels":[],"label_agreement":null},{"id":"W4399926328","doi":"10.1016/j.esmoop.2024.103537","title":"37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"GlaxoSmithKline","keywords":"Endometrial cancer; Oncology; Medicine; Internal medicine; Overall survival; Chemotherapy; Gynecology; Cancer","score_opus":0.03420991255425919,"score_gpt":0.35121528693626825,"score_spread":0.31700537438200904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399926328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687595,0.015007603,0.00001287698,0.0043935142,0.0014909733,0.0053925063,0.00019559302,0.000045340716,0.0047021317],"genre_scores_gemma":[0.979187,0.014601401,0.0002648879,0.0030096532,0.0003892547,0.0012645896,0.00031618972,0.00008144506,0.00088558637],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973252,0.00030182148,0.00056361145,0.0006587212,0.0005897156,0.0005609719],"domain_scores_gemma":[0.9986345,0.00071428757,0.0000899109,0.00034735602,0.000035287805,0.00017864958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009140515,0.00033116268,0.00084342575,0.0002865899,0.00004917439,0.0002030812,0.0003462396,0.00013562311,0.0007688212],"category_scores_gemma":[0.00024324207,0.00020289657,0.000116747644,0.0014006833,0.00006549145,0.00026774354,0.00015691573,0.00048400543,0.000011359251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51414764,0.0020837677,0.008121471,0.00053932326,0.0007042235,0.0011183744,0.002661975,0.000016377584,0.0014458046,0.0007436122,0.0047575226,0.4636599],"study_design_scores_gemma":[0.6159534,0.0068110297,0.0358829,0.0010379375,0.00031571116,0.00002448665,0.0004861218,0.0000751619,0.0027437399,0.00089661166,0.3349317,0.0008412168],"about_ca_topic_score_codex":0.009428015,"about_ca_topic_score_gemma":0.0018193334,"teacher_disagreement_score":0.4628187,"about_ca_system_score_codex":0.0009294714,"about_ca_system_score_gemma":0.00057345885,"threshold_uncertainty_score":0.9971683},"labels":[],"label_agreement":null},{"id":"W4399926559","doi":"10.1016/j.esmoop.2024.103538","title":"38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"","keywords":"Endometrial cancer; Oncology; Internal medicine; Progression-free survival; Medicine; Overall survival; Cancer; DNA mismatch repair; Gynecology","score_opus":0.07310603800379314,"score_gpt":0.3678890593812957,"score_spread":0.29478302137750256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399926559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844733,0.006351283,0.0000013409415,0.0038323845,0.00074993924,0.003792163,0.00019443112,0.000016044838,0.0005891406],"genre_scores_gemma":[0.99759835,0.00081615994,0.0004786563,0.00021012271,0.00012815384,0.000576979,0.000085366126,0.000013906224,0.00009228157],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976677,0.00044428857,0.0006719893,0.00053805165,0.00044538343,0.00023260161],"domain_scores_gemma":[0.99855244,0.0008441642,0.00013048826,0.0003666338,0.000028221411,0.00007806755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011303689,0.00018911221,0.0005639327,0.0001662193,0.000052627034,0.00005438615,0.00024311757,0.000118060474,0.00004440546],"category_scores_gemma":[0.0014716424,0.00009406023,0.00006719555,0.0008615822,0.000122046484,0.000113008144,0.00037786624,0.0003336075,3.419207e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5007296,0.003920092,0.32936108,0.00062849425,0.00032113562,0.0009885426,0.0055510197,0.00004407591,0.00047870824,0.0016374036,0.0020663703,0.1542735],"study_design_scores_gemma":[0.16177471,0.0022264626,0.8217807,0.0021242574,0.00021363639,0.000016003392,0.00034156317,0.0002599254,0.00025207686,0.0020562662,0.0086636115,0.00029077497],"about_ca_topic_score_codex":0.0055179424,"about_ca_topic_score_gemma":0.0062024323,"teacher_disagreement_score":0.49241963,"about_ca_system_score_codex":0.00022283703,"about_ca_system_score_gemma":0.00019409695,"threshold_uncertainty_score":0.8341515},"labels":[],"label_agreement":null},{"id":"W4399926566","doi":"10.1016/j.esmoop.2024.103539","title":"39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; LEO Pharma; Eisai; Cilag; Novocure; Astellas Pharma; Clovis Oncology; Amgen; Pfizer; MorphoSys; PharmaMar; Mersana Therapeutics; Fujirebio US; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Lenvatinib; Medicine; Oncology; Chemotherapy; Internal medicine; Endometrial cancer; Gynecology; Cancer; Immunotherapy","score_opus":0.08448183385298305,"score_gpt":0.43783779156860636,"score_spread":0.35335595771562334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399926566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9399029,0.011259994,0.00020658682,0.009225388,0.0056441673,0.024999157,0.00073963695,0.0005245986,0.0074975505],"genre_scores_gemma":[0.9569085,0.011458102,0.00060845935,0.0025072466,0.0028530685,0.0072933296,0.0004962715,0.0002322491,0.01764274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959537,0.000116691095,0.0009912167,0.001305437,0.0008107552,0.0008222438],"domain_scores_gemma":[0.9972084,0.0010352947,0.00024444287,0.0007934225,0.00027814286,0.00044029913],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069925137,0.00071447756,0.0015576605,0.00044488386,0.0003214965,0.0003042118,0.0007460885,0.00022449164,0.011142879],"category_scores_gemma":[0.00050109054,0.000487349,0.000417405,0.0018029769,0.00008921005,0.0004272877,0.0002050522,0.00049887795,0.00014956246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20044278,0.0073292153,0.00043309265,0.00025530704,0.0019739443,0.00015808821,0.0011237464,0.000008077837,0.00034669222,0.00010837951,0.0069835004,0.7808372],"study_design_scores_gemma":[0.3205167,0.023900576,0.0007055554,0.0005416266,0.00051232526,0.000026593973,0.00023069141,0.0001710947,0.011255983,0.0003116013,0.6411821,0.0006451218],"about_ca_topic_score_codex":0.0038017568,"about_ca_topic_score_gemma":0.00136315,"teacher_disagreement_score":0.7801921,"about_ca_system_score_codex":0.0006606636,"about_ca_system_score_gemma":0.0007786781,"threshold_uncertainty_score":0.9997578},"labels":[],"label_agreement":null},{"id":"W4400032038","doi":"10.1016/j.esmoop.2024.103604","title":"Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer Canada; Rehabilitation Research and Development Service; Nestlé Health Science; Canadian Institutes of Health Research; Danone; Government of Alberta; Pfizer; Bristol-Myers Squibb; Alberta Health Services; AstraZeneca; University of Alberta; Ipsen; U.S. Department of Veterans Affairs","keywords":"Colorectal cancer; Randomized controlled trial; Prime (order theory); Medicine; Cancer; Internal medicine; Muscle protein; Oncology; Physical therapy; Skeletal muscle; Mathematics","score_opus":0.06229601727810243,"score_gpt":0.376462414951293,"score_spread":0.3141663976731906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400032038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616606,0.000024332714,0.000058140253,0.00427255,0.00011864746,0.033255357,0.00016325232,0.00001694828,0.00043012408],"genre_scores_gemma":[0.995245,0.000001932396,0.0012261455,0.0002890435,0.00006212702,0.0030016003,0.00006925525,0.000015838174,0.00008910177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787307,0.00065696274,0.0007933433,0.0002733253,0.0002495406,0.00015377754],"domain_scores_gemma":[0.998899,0.00047027337,0.00020687246,0.00017804504,0.00015670298,0.00008912549],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029049364,0.00012893652,0.0010616598,0.00010389465,0.000048671252,0.00003687129,0.00016274047,0.00003983583,0.0010056887],"category_scores_gemma":[0.00090466585,0.00007659936,0.00007977738,0.00028588166,0.00007081911,0.00011776677,0.00008876445,0.00022373103,0.000004402919],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9797128,0.00064841215,0.012639742,0.000113061695,0.00010366575,0.0000014326162,0.00069172797,7.3407756e-7,0.0016319363,0.00017778033,0.00009870031,0.0041800495],"study_design_scores_gemma":[0.8938638,0.0014897836,0.09753467,0.0018463369,0.00009551868,1.3751479e-7,0.00006003119,0.00013888227,0.0042947424,0.0004483884,0.00013682274,0.00009086774],"about_ca_topic_score_codex":0.024156367,"about_ca_topic_score_gemma":0.002869652,"teacher_disagreement_score":0.08584894,"about_ca_system_score_codex":0.00019434703,"about_ca_system_score_gemma":0.00045093917,"threshold_uncertainty_score":0.99990755},"labels":[],"label_agreement":null},{"id":"W4400171210","doi":"10.1016/j.esmoop.2024.103618","title":"An assessment of the attitudes, knowledge, and education regarding the health care needs of LGBTQ patients with cancer: results of an ESMO/SIOPE global survey","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"LGBTQ Health, Identity, and Policy","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"European Society for Medical Oncology; European Society for Paediatric Oncology","keywords":"Family medicine; Medicine; Medical education; Psychology; Gerontology","score_opus":0.03787920765319025,"score_gpt":0.4855369856019824,"score_spread":0.44765777794879213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400171210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688597,0.0018166236,0.0000037894729,0.0009176736,0.0012289133,0.0009949679,0.00082948676,0.000009755453,0.025339102],"genre_scores_gemma":[0.9985896,0.0001796412,0.00007437011,0.00014009378,0.00010042852,0.000037164085,0.00014802502,0.000015885762,0.0007148406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979627,0.00095497165,0.00043039862,0.00024733858,0.00020295064,0.00020165014],"domain_scores_gemma":[0.99848187,0.000097172284,0.00030123256,0.0007044025,0.00031860484,0.000096720934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011270168,0.0001256924,0.00028149318,0.00006699253,0.00017373753,0.00006472165,0.00064572506,0.00007007025,0.000034844314],"category_scores_gemma":[0.000029996138,0.000075265685,0.000030935083,0.0005530163,0.00014063381,0.00020627015,0.00016289233,0.00015472574,0.0000014780655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019913318,0.0004049856,0.947385,0.00060606183,0.000075744734,1.151386e-7,0.007689327,0.0000074163677,5.088551e-7,0.003569605,0.010038551,0.030023519],"study_design_scores_gemma":[0.0007815643,0.00057504076,0.9949394,0.00020573733,0.00004443298,0.000001164913,0.00096598815,0.0000082799215,0.000003708068,0.00007753849,0.0023205767,0.00007659545],"about_ca_topic_score_codex":0.4264117,"about_ca_topic_score_gemma":0.19433066,"teacher_disagreement_score":0.23208103,"about_ca_system_score_codex":0.00020420215,"about_ca_system_score_gemma":0.0021242884,"threshold_uncertainty_score":0.8203707},"labels":[],"label_agreement":null},{"id":"W4400929921","doi":"10.1016/j.esmoop.2024.103646","title":"Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Incyte; Mirati Therapeutics; Jounce Therapeutics; Regeneron Pharmaceuticals; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tremelimumab; Durvalumab; Head and neck squamous-cell carcinoma; Medicine; CTLA-4; Oncology; PD-L1; Immunotherapy; Cytotoxic T cell; Internal medicine; Cancer research; Head and neck cancer; T cell; Immunology; Cancer; Immune system; Ipilimumab; Nivolumab; Biology","score_opus":0.04684865456165723,"score_gpt":0.38269544008808287,"score_spread":0.33584678552642566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400929921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962186,0.00069210114,0.000009786093,0.00037295467,0.00012579544,0.0021225347,0.000028918093,0.000012898422,0.0004164134],"genre_scores_gemma":[0.99937254,0.00010840079,0.00016305874,0.00006342116,0.000015675725,0.000027257745,0.000011439498,0.000020300702,0.00021789115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866295,0.0002132935,0.00041521306,0.00038414262,0.00016094118,0.00016347996],"domain_scores_gemma":[0.9993391,0.00021761606,0.00008003396,0.00024579198,0.000030397645,0.00008704891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071463507,0.0001601919,0.00052820577,0.00009052154,0.000037631125,0.000051099014,0.00009468596,0.00003929311,0.000076654025],"category_scores_gemma":[0.000031293086,0.00011497583,0.00004889101,0.00021044129,0.00013055369,0.00014423007,0.00010765236,0.00023108147,0.0000017316762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30096132,0.01510527,0.4936641,0.00078561937,0.0004087401,0.0006618766,0.004203075,4.2567063e-7,0.000510587,0.0000060824796,0.00025198536,0.18344095],"study_design_scores_gemma":[0.10358849,0.024729447,0.8675109,0.0003220751,0.0003354462,0.000028686469,0.00085435447,0.0013222944,0.00040276337,0.0000036852887,0.0007347643,0.00016709915],"about_ca_topic_score_codex":0.0030560782,"about_ca_topic_score_gemma":0.0032911103,"teacher_disagreement_score":0.37384683,"about_ca_system_score_codex":0.00006024133,"about_ca_system_score_gemma":0.00015037102,"threshold_uncertainty_score":0.46885782},"labels":[],"label_agreement":null},{"id":"W4401354990","doi":"10.1016/j.esmoop.2024.103647","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"Eli Lilly Japan; Sirtex Medical; Ipsen; Kaohsiung Medical University Chung-Ho Memorial Hospital; Teijin Pharma; Japanese Society of Medical Oncology; European Society for Medical Oncology; Health Promotion Administration, Ministry of Health and Welfare; Kaohsiung Medical University; Chunghwa Telecom Laboratories; ReShape Lifesciences; Genentech; Veracyte; Astellas Pharma; Eisai; Fondazione Beretta; BeiGene; Handok; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Chugai Pharmaceutical; Abbott Japan; AstraZeneca; Invitae; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Halozyme; Exelixis; Sanofi; Relay Therapeutics; Amgen; Rakuten Medical; Celgene; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biliary tract cancer; Cancer; Medicine; Biliary tract; Clinical Practice; General surgery; Internal medicine; Family medicine; Gemcitabine","score_opus":0.14140697288649354,"score_gpt":0.44509703658777094,"score_spread":0.3036900637012774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401354990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7849927,0.04913872,0.00009220452,0.15122041,0.0021593347,0.00819217,0.0006139996,0.00008731822,0.0035031275],"genre_scores_gemma":[0.9861943,0.0074693263,0.0015408975,0.0020361475,0.00036213858,0.0012078497,0.000056614597,0.000036253765,0.0010964803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885154,0.00004328138,0.00041401893,0.00035035828,0.00017549028,0.00016528608],"domain_scores_gemma":[0.99812716,0.0009517304,0.00010570026,0.00028762387,0.00045501319,0.000072789226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003500948,0.00017473908,0.000420507,0.00003354393,0.0001032575,0.000057447363,0.00012931823,0.000058089296,0.000056435754],"category_scores_gemma":[0.00062451104,0.00008710121,0.00012082287,0.00013199334,0.00009461061,0.00018695235,0.00008833929,0.00010452069,0.000002347974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016803364,0.00043702617,0.6230867,0.00008306716,0.0015408781,0.000021547214,0.0011208302,7.6731646e-7,6.036833e-7,0.000044776792,0.08004056,0.29194292],"study_design_scores_gemma":[0.0036828027,0.0013060466,0.6258607,0.00023728996,0.0013600411,0.0000052022547,0.00067251245,0.000040058654,0.000039975497,0.000011297453,0.36669675,0.000087302826],"about_ca_topic_score_codex":0.0048259506,"about_ca_topic_score_gemma":0.0026503527,"teacher_disagreement_score":0.2918556,"about_ca_system_score_codex":0.00006050808,"about_ca_system_score_gemma":0.00027494656,"threshold_uncertainty_score":0.72954255},"labels":[],"label_agreement":null},{"id":"W4401412460","doi":"10.1016/j.esmoop.2024.103667","title":"TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Trabectedin; Liposarcoma; Leiomyosarcoma; Sarcoma; Medicine; Soft tissue sarcoma; Oncology; Internal medicine; Radiology; Pathology","score_opus":0.028335226051422087,"score_gpt":0.3206105531349532,"score_spread":0.2922753270835311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401412460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049234,0.002447931,0.0000049822756,0.0023221246,0.00033428098,0.0030829245,0.0003876385,0.00008764903,0.0008401226],"genre_scores_gemma":[0.99800587,0.00023360974,0.00020507831,0.00012280566,0.00010866908,0.00026541017,0.0006936174,0.00006963156,0.00029529008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969022,0.00031653678,0.00092276325,0.00092814193,0.00047175025,0.0004585602],"domain_scores_gemma":[0.9983628,0.00042893624,0.00014578881,0.0007953565,0.00006177335,0.00020538493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004038234,0.000457615,0.00091580226,0.00021674353,0.00018569996,0.00020981258,0.0005301954,0.00014158693,0.00036609685],"category_scores_gemma":[0.00008059929,0.00029378015,0.00015381153,0.00068424916,0.00015645153,0.0002533786,0.00057616364,0.00046918134,0.000022626798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013103172,0.04948983,0.71517074,0.00020579749,0.002779539,0.004905604,0.017371526,0.0000013240829,0.013888396,0.00046915948,0.007009871,0.17560507],"study_design_scores_gemma":[0.03261788,0.0068141753,0.9484339,0.0009916512,0.00058795884,0.000051457908,0.0019520915,0.00061505893,0.004156081,0.00019249866,0.0032478373,0.00033942063],"about_ca_topic_score_codex":0.01257179,"about_ca_topic_score_gemma":0.0062125055,"teacher_disagreement_score":0.23326318,"about_ca_system_score_codex":0.000119316064,"about_ca_system_score_gemma":0.000080305406,"threshold_uncertainty_score":0.9999514},"labels":[],"label_agreement":null},{"id":"W4402050099","doi":"10.1016/j.esmoop.2024.103688","title":"Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer","year":2024,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Cancer pain; Medicine; Cancer; Immune system; Opioid; Immune checkpoint; Oncology; Internal medicine; Immunotherapy; Immunology; Receptor","score_opus":0.029793070968903067,"score_gpt":0.33040109581377497,"score_spread":0.3006080248448719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402050099","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013085735,0.99319774,4.597266e-7,0.00016620684,0.0006412661,0.0020605936,0.0001452838,0.000008358746,0.0024715082],"genre_scores_gemma":[0.00423015,0.9939574,0.0000064230517,0.00007315283,0.00018708744,0.000418761,0.00026966954,0.000055399578,0.0008019345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984062,0.00023889824,0.00050521287,0.00033424725,0.00033127857,0.0001841902],"domain_scores_gemma":[0.9992129,0.00009912522,0.0001778073,0.00038917302,0.00006800295,0.000052947496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009249055,0.00028743717,0.0012929641,0.00009821089,0.000026054031,0.000061058134,0.00029081077,0.00014095247,0.00012781292],"category_scores_gemma":[0.000041872405,0.00014674298,0.0001724252,0.00042401478,0.00008014947,0.000056226472,0.00028062324,0.00047435466,0.0000055724768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011550363,0.00012786372,0.0045194435,0.024002634,0.0003482629,0.00004108822,0.0019237481,1.0243057e-7,4.5668664e-8,0.000079963116,0.0014569475,0.9673844],"study_design_scores_gemma":[0.0007337015,0.00029474118,0.008258653,0.03487697,0.0010684404,0.000007401923,0.0005685139,5.396458e-7,0.0000013537043,0.000011211614,0.9539239,0.00025460395],"about_ca_topic_score_codex":0.019463325,"about_ca_topic_score_gemma":0.009118026,"teacher_disagreement_score":0.96712977,"about_ca_system_score_codex":0.00010819212,"about_ca_system_score_gemma":0.00044386165,"threshold_uncertainty_score":0.98706615},"labels":[],"label_agreement":null},{"id":"W4402496964","doi":"10.1016/j.esmoop.2024.103689","title":"Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"National Cancer Institute; Ministero della Salute","keywords":"Fibrosarcoma; Sarcoma; Medicine; Retrospective cohort study; Epithelioid sarcoma; Rare disease; Pathology; Disease","score_opus":0.035645951304997245,"score_gpt":0.31207974434448466,"score_spread":0.2764337930394874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402496964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318285,0.010030774,0.000023990468,0.002642077,0.00030675041,0.002935448,0.00022985625,0.00011559794,0.0005326671],"genre_scores_gemma":[0.9977509,0.00026431665,0.0008933718,0.0003000503,0.00019621693,0.00026356507,0.0001230872,0.000087839195,0.000120700795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726784,0.00021670992,0.00062699494,0.00089509203,0.0005634925,0.00042984588],"domain_scores_gemma":[0.9978548,0.00072566397,0.00015628309,0.00094087434,0.00005631644,0.00026601934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000388554,0.00043244977,0.00081723003,0.000115703,0.00031352203,0.00037318777,0.0005112259,0.00007880373,0.00019464271],"category_scores_gemma":[0.00014536142,0.0002856657,0.00023033802,0.00051884854,0.00023597854,0.00033745557,0.000422222,0.00039001455,0.000028303868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004447037,0.0013510477,0.97197783,0.00009647388,0.00051687437,0.0005183547,0.0016929664,0.0000024403616,0.0012550228,0.0005886768,0.00036939664,0.021186205],"study_design_scores_gemma":[0.0033526614,0.00061037164,0.9872105,0.0022744061,0.000519894,0.000022705728,0.0017461684,0.00004444311,0.0017893456,0.0009746831,0.0011626832,0.0002921392],"about_ca_topic_score_codex":0.0015663826,"about_ca_topic_score_gemma":0.00033793715,"teacher_disagreement_score":0.020894065,"about_ca_system_score_codex":0.00020693529,"about_ca_system_score_gemma":0.00006964648,"threshold_uncertainty_score":0.9999595},"labels":[],"label_agreement":null},{"id":"W4402620846","doi":"10.1016/j.esmoop.2024.103714","title":"Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Tata Memorial Centre; National Health and Medical Research Council; Medical Research Council; Associazione Italiana per la Ricerca sul Cancro; Korea Health Industry Development Institute; Cancer Australia; European Society for Medical Oncology; National Breast Cancer Foundation","keywords":"Histology; Breast cancer; Medicine; Oncology; Cancer; Germline; Internal medicine; Family history; Biology; Gene; Genetics","score_opus":0.019809949338518953,"score_gpt":0.3655796768933542,"score_spread":0.34576972755483526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402620846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965956,0.0002267958,0.00008354251,0.0011487347,0.00092361984,0.00022501092,0.00020386993,0.00000488843,0.00058788713],"genre_scores_gemma":[0.99843544,0.0001447075,0.00044607435,0.00035498122,0.00010942792,0.000053263335,0.000019842555,0.000018285811,0.00041797204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991672,0.000045196193,0.00028297177,0.00031570497,0.000051293253,0.00013763434],"domain_scores_gemma":[0.9996299,0.00002651195,0.00004749885,0.0001966449,0.00004116112,0.000058254398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002487252,0.0000921955,0.00022067664,0.000052892865,0.000024203187,0.0000367561,0.00024023578,0.0000784998,0.000055094475],"category_scores_gemma":[0.00008710905,0.00008798354,0.000040886865,0.000097751574,0.00007867666,0.000006290713,0.00032760893,0.00009214551,0.0000038041253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006075068,0.000015679336,0.98505664,0.000020748526,0.00008595282,0.000010715706,0.0001318697,0.0000089205805,0.002351874,0.0000726519,0.0010967006,0.011087495],"study_design_scores_gemma":[0.0002425964,0.000054875123,0.99036324,0.00003763288,0.000028934524,0.00003258024,0.00014595332,0.0000557095,0.0009842358,0.000024208382,0.007907075,0.00012295422],"about_ca_topic_score_codex":0.0016828798,"about_ca_topic_score_gemma":0.003361412,"teacher_disagreement_score":0.01096454,"about_ca_system_score_codex":0.00007085788,"about_ca_system_score_gemma":0.00028417807,"threshold_uncertainty_score":0.35878646},"labels":[],"label_agreement":null},{"id":"W4403327461","doi":"10.1016/j.esmoop.2024.103931","title":"Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar","year":2024,"lang":"en","type":"review","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Samsung; Genentech; Incyte; F. Hoffmann-La Roche; Eisai; Daiichi Sankyo Europe; Sanofi; Servier; Takeda Oncology; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Raising (metalworking); Colorectal cancer; Bar (unit); Medicine; Oncology; Cancer; Internal medicine; Engineering; Geography; Materials science; Metallurgy; Mechanical engineering","score_opus":0.12646508830824668,"score_gpt":0.4654175603828325,"score_spread":0.3389524720745858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403327461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027892538,0.9909152,4.3751172e-7,0.00034376635,0.00025863506,0.0017035718,0.000094784154,0.000014337833,0.0038800258],"genre_scores_gemma":[0.006480292,0.9920724,0.0002305922,0.000110350215,0.000034713405,0.00052545423,0.00002494142,0.00004946245,0.0004718099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801105,0.00018360227,0.00091451156,0.00044125438,0.00021963022,0.0002299569],"domain_scores_gemma":[0.9982839,0.0010336225,0.00034446365,0.00022761905,0.000044563927,0.000065819535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075747387,0.00035743977,0.0027311083,0.00012552037,0.00007980678,0.00006661887,0.00027150862,0.00010767634,0.000078685654],"category_scores_gemma":[0.00042917507,0.00018034448,0.00030394606,0.00027166578,0.00015063635,0.000060586386,0.0005930865,0.0005528017,0.000016508106],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014493626,0.00010925356,0.0053265984,0.0054685683,0.0024558217,0.00015570872,0.0014212431,1.7822978e-7,1.2634582e-7,0.00013925359,0.00050561683,0.9842727],"study_design_scores_gemma":[0.0014719832,0.0009497026,0.009828918,0.033251654,0.009839363,0.00008450377,0.00041691633,0.000005092181,9.4654865e-7,0.00013940765,0.9436681,0.0003433881],"about_ca_topic_score_codex":0.0024178685,"about_ca_topic_score_gemma":0.0018405257,"teacher_disagreement_score":0.98392934,"about_ca_system_score_codex":0.00023037638,"about_ca_system_score_gemma":0.0007237141,"threshold_uncertainty_score":0.73542345},"labels":[],"label_agreement":null},{"id":"W4403455062","doi":"10.1016/j.esmoop.2024.103938","title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; Meso Scale Diagnostics; Gilead Sciences; American College of Radiology Imaging Network; Roche; Canadian Cancer Society; GlaxoSmithKline; AstraZeneca; Novartis; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Cancer","score_opus":0.07178304164162665,"score_gpt":0.3880955706819111,"score_spread":0.31631252904028445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403455062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940227,0.00005804491,0.000010177147,0.0017263249,0.0000784832,0.003113333,0.00023451244,0.000010595606,0.00074583106],"genre_scores_gemma":[0.9982758,0.00004762751,0.000115588075,0.00013254849,0.000024689136,0.00059373403,0.000070370006,0.000033816315,0.0007058149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974989,0.0003086933,0.00049315486,0.0005075809,0.00083014864,0.00036151955],"domain_scores_gemma":[0.9990271,0.00016473242,0.00012485517,0.00038849434,0.00021316131,0.00008168455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075147225,0.00019813646,0.0006544931,0.00040048547,0.00003423595,0.0000799472,0.00045273485,0.00008709348,0.00030747417],"category_scores_gemma":[0.00007149371,0.00011617777,0.000056882287,0.0039750626,0.00016742593,0.00026156474,0.00013137236,0.00054899446,0.000006276839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029898664,0.0008092867,0.94073844,0.00012925285,0.00032555067,0.00014976236,0.0032293664,0.00048203193,0.00001595277,0.000056871708,0.00009666804,0.024068182],"study_design_scores_gemma":[0.02433991,0.0017463658,0.9689511,0.0029325038,0.00018272409,0.0000032106414,0.00022198985,0.0011685179,0.00016108314,0.000016223283,0.00012345522,0.00015290116],"about_ca_topic_score_codex":0.066816345,"about_ca_topic_score_gemma":0.1445673,"teacher_disagreement_score":0.07775094,"about_ca_system_score_codex":0.0010763204,"about_ca_system_score_gemma":0.0015887772,"threshold_uncertainty_score":0.9393978},"labels":[],"label_agreement":null},{"id":"W4403505143","doi":"10.1016/j.esmoop.2024.103937","title":"Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?","year":2024,"lang":"en","type":"letter","venue":"ESMO Open","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medac; BeiGene; Ipsen; Incyte; Eisai; Sanofi; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Servier; Amgen","keywords":"Refractory (planetary science); Primary (astronomy); Cancer research; Medicine; Internal medicine; Oncology; Biology; Astrobiology; Physics; Astrophysics","score_opus":0.020583778102275685,"score_gpt":0.2860546329042308,"score_spread":0.2654708548019551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403505143","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6942853,0.00012534668,0.0000062020627,0.28662238,0.00047293934,0.0039729606,0.0007421557,0.00004110155,0.013731652],"genre_scores_gemma":[0.19003998,0.00018003154,0.001331156,0.66820425,0.0047498075,0.0026419626,0.010131829,0.00095198816,0.121769],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960829,0.0006197668,0.00036614478,0.0012541473,0.000906,0.0007710563],"domain_scores_gemma":[0.9974919,0.00012121194,0.000117837466,0.0017734095,0.0002497699,0.0002458872],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000791969,0.00053453277,0.00040886737,0.00019082415,0.00022883466,0.00034849322,0.0023772344,0.00064357586,0.00020628585],"category_scores_gemma":[0.0002053833,0.00036677602,0.00013778739,0.0002815963,0.00010888241,0.000014439222,0.0034781664,0.0013627155,0.0008663121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026840423,0.00007891255,0.001907288,0.000103118735,0.00023597438,0.00014070295,0.00029782974,0.0000013077603,0.006151359,0.0000012117983,0.9874221,0.00097615673],"study_design_scores_gemma":[0.00068987283,0.0019288056,0.08346157,0.00025583841,0.000038515496,0.000004286761,0.000036732657,2.7618682e-7,0.0010889128,0.0000060984985,0.91200215,0.00048696718],"about_ca_topic_score_codex":0.0007358926,"about_ca_topic_score_gemma":0.00020338755,"teacher_disagreement_score":0.5042453,"about_ca_system_score_codex":0.00017765409,"about_ca_system_score_gemma":0.00047449832,"threshold_uncertainty_score":0.9999116},"labels":[],"label_agreement":null},{"id":"W4403537554","doi":"10.1016/j.esmoop.2024.103910","title":"173P NRF2 levels in high grade serous ovarian cancer: Characterization and treatment","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Serous ovarian cancer; Serous fluid; Cancer; Oncology; Ovarian cancer; Medicine; Internal medicine","score_opus":0.05150485959038524,"score_gpt":0.335412370547508,"score_spread":0.28390751095712274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705919,0.0006963009,0.000035512738,0.025598837,0.00046345624,0.0013501701,0.00018506186,0.000052645708,0.0010260905],"genre_scores_gemma":[0.99352586,0.0017275134,0.0002511745,0.0004670772,0.0002073296,0.00051862665,0.0001841699,0.000027021755,0.0030912156],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991756,0.00002912971,0.00017208376,0.00035526537,0.00009561403,0.00017230223],"domain_scores_gemma":[0.99964994,0.000028725935,0.000027252934,0.00018683942,0.000014145548,0.00009307487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081075734,0.00015022706,0.0002838249,0.000083614956,0.000043021195,0.0001578648,0.00006191611,0.000059016627,0.0005488681],"category_scores_gemma":[0.0000040859195,0.0001138203,0.000029278115,0.00018660421,0.0000181355,0.00017767788,0.00005324383,0.00006556472,0.000036308797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019704043,0.00091188814,0.33320606,0.00015409615,0.0006955384,0.0013826495,0.002574025,0.000009068846,0.001185501,0.008161532,0.00088565977,0.650637],"study_design_scores_gemma":[0.0027462754,0.0003356742,0.93126833,0.00041707623,0.00014752534,0.000031492542,0.000021818718,0.00013119294,0.0021943783,0.00011691475,0.06247379,0.00011550218],"about_ca_topic_score_codex":0.017245332,"about_ca_topic_score_gemma":0.0023955202,"teacher_disagreement_score":0.65052146,"about_ca_system_score_codex":0.00043282728,"about_ca_system_score_gemma":0.00019580261,"threshold_uncertainty_score":0.98929894},"labels":[],"label_agreement":null},{"id":"W4403537557","doi":"10.1016/j.esmoop.2024.103901","title":"163TiP Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Glycomics Network; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Smoothened; Hedgehog; Hedgehog signaling pathway; Medicine; Mutation; Cancer research; Internal medicine; Oncology; Biology; Genetics; Gene","score_opus":0.03419798114909415,"score_gpt":0.31847057907966986,"score_spread":0.2842725979305757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965798,0.00024611072,0.0001959795,0.000052896867,0.00019792584,0.0023541248,0.00007643094,0.000051367268,0.000245318],"genre_scores_gemma":[0.9975072,0.000017369064,0.0014724265,0.00006750928,0.000044393633,0.0002770537,0.00023475573,0.00005232184,0.00032696236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979788,0.00017550171,0.00054190384,0.0007425307,0.00024465795,0.00031657962],"domain_scores_gemma":[0.99897856,0.000046652574,0.00019097408,0.00038450083,0.00031303318,0.000086272834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031950252,0.00031929708,0.0004485841,0.00013471516,0.00024740084,0.00018037368,0.00046035607,0.00012582507,0.000021360262],"category_scores_gemma":[0.000336312,0.0002490183,0.000022743425,0.000437184,0.00014177432,0.00007850108,0.0008788304,0.00011690649,0.0000022551797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063071135,0.016395831,0.005008955,0.00015181156,0.00031216946,0.00009998523,0.0045477003,0.00018055338,0.9527275,0.000017626984,0.00084324536,0.0134075135],"study_design_scores_gemma":[0.024007542,0.025041923,0.0050032577,0.0013112923,0.00009040833,0.000007216498,0.0016769368,0.00018775268,0.9396029,0.00003897338,0.0023714197,0.0006603394],"about_ca_topic_score_codex":0.00015850565,"about_ca_topic_score_gemma":0.00071920094,"teacher_disagreement_score":0.017700428,"about_ca_system_score_codex":0.000060436625,"about_ca_system_score_gemma":0.00021619638,"threshold_uncertainty_score":0.9999962},"labels":[],"label_agreement":null},{"id":"W4403537582","doi":"10.1016/j.esmoop.2024.103782","title":"36P Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Department of Science and Technology, Ministry of Science and Technology, India; Manipal Academy of Higher Education","keywords":"Doxorubicin; Abacavir; Cancer research; Breast cancer; Pharmacology; Medicine; Oncology; Cancer; Chemistry; Internal medicine; Chemotherapy; Virology; Human immunodeficiency virus (HIV)","score_opus":0.014124335237422302,"score_gpt":0.30913402494697145,"score_spread":0.29500968970954916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97343874,0.00023162768,0.0000964169,0.01773441,0.00009053485,0.0005500998,0.00009306306,0.000043383105,0.007721724],"genre_scores_gemma":[0.9974676,0.000059812803,0.00004274588,0.00074571255,0.000104413935,0.000033655233,0.00006111415,0.000016765085,0.0014681795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990787,0.000059265378,0.00029008166,0.00022876619,0.00019230547,0.00015090396],"domain_scores_gemma":[0.9995567,0.00006327484,0.00005552,0.0002160473,0.00004924607,0.000059178175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029408856,0.000111723144,0.0002414859,0.00014937029,0.000044889694,0.00006653832,0.00012141964,0.000058321864,0.0016479533],"category_scores_gemma":[0.000009946783,0.00007253371,0.0001242527,0.000551404,0.00007184378,0.00015295591,0.00010120739,0.00020439873,0.00017447292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006766541,0.0013222975,0.0075593544,0.00069946155,0.0006143968,0.0006427566,0.0024801134,0.00041933337,0.90369385,0.0016266016,0.034578536,0.045686632],"study_design_scores_gemma":[0.004761993,0.00014302794,0.33028194,0.0095793335,0.0005723011,0.00018711419,0.0011251703,0.00590031,0.64207715,0.00072781777,0.0041719116,0.00047192868],"about_ca_topic_score_codex":0.0057009077,"about_ca_topic_score_gemma":0.00046895444,"teacher_disagreement_score":0.32272258,"about_ca_system_score_codex":0.00006354538,"about_ca_system_score_gemma":0.000090086054,"threshold_uncertainty_score":0.99926466},"labels":[],"label_agreement":null},{"id":"W4403537585","doi":"10.1016/j.esmoop.2024.103818","title":"77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Medical Research Council; Genentech; Sierra Oncology; Astellas Pharma; Eisai; Prostate Cancer UK; Cancer Research UK; National Center for Advancing Translational Sciences; Wellcome Trust; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Amgen; Pfizer; Vertex Pharmaceuticals; National Institutes of Health; Menarini Silicon Biosystems","keywords":"Prostate cancer; MCL1; Cancer; Medicine; Prostate; Cancer research; Internal medicine; Biology; Genetics; Gene","score_opus":0.0645400951627398,"score_gpt":0.3920523083365812,"score_spread":0.32751221317384144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405072,0.019072415,0.0029861326,0.0139152305,0.0006013887,0.007130413,0.000142439,0.00022149744,0.0154233035],"genre_scores_gemma":[0.993104,0.00021302441,0.00078194716,0.00014580601,0.00008021294,0.0004982842,0.00019226645,0.000037308764,0.0049471785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989635,0.00004278421,0.00019157714,0.00033590116,0.0001797193,0.00028655145],"domain_scores_gemma":[0.99955904,0.000083583676,0.000038533883,0.00012033694,0.00011655529,0.000081955404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033455266,0.0001422063,0.00019335389,0.00006647208,0.00018812035,0.0007655466,0.00011108286,0.0000440848,0.000106463674],"category_scores_gemma":[0.000026273645,0.0001077817,0.000041167463,0.0001585383,0.0000734762,0.0004191851,0.00007742471,0.00014941834,0.000005415684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023431368,0.001005774,0.01357763,0.004628353,0.002683571,0.00093314686,0.019576533,0.00008824799,0.57073486,0.04331934,0.010154794,0.33095458],"study_design_scores_gemma":[0.025197674,0.006510245,0.032498166,0.004381843,0.0013288773,0.0001586139,0.022201603,0.019323898,0.74240184,0.044413064,0.09961891,0.0019652923],"about_ca_topic_score_codex":0.0006322011,"about_ca_topic_score_gemma":0.000069011985,"teacher_disagreement_score":0.3289893,"about_ca_system_score_codex":0.00010254561,"about_ca_system_score_gemma":0.00042101878,"threshold_uncertainty_score":0.7382183},"labels":[],"label_agreement":null},{"id":"W4403537638","doi":"10.1016/j.esmoop.2024.103754","title":"8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Precision medicine; Drug; Lung; Oncology; Medical physics; Internal medicine; Pharmacology; Pathology","score_opus":0.04747564389814995,"score_gpt":0.4132002471207954,"score_spread":0.36572460322264544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5940246,0.006681041,0.00039105542,0.037428007,0.002069887,0.0073375,0.00009132573,0.00017864797,0.35179794],"genre_scores_gemma":[0.9494019,0.0005358772,0.002893325,0.000896203,0.00047270788,0.0004044817,0.00009654153,0.00004448157,0.045254473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989672,0.000015853399,0.000305883,0.00027615394,0.00026040876,0.00017450225],"domain_scores_gemma":[0.9991,0.0002851695,0.00005446222,0.00035096644,0.00009212153,0.000117276766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020976507,0.00014916385,0.00027759193,0.0000897604,0.00014797944,0.00004193344,0.00017194387,0.00003049317,0.0004463203],"category_scores_gemma":[0.00008795699,0.00007434798,0.000053205516,0.00040357726,0.000042367126,0.000114816714,0.00007728076,0.000057642053,0.000034526256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034090775,0.0002755559,0.007953586,0.00016053983,0.0007863356,0.00017350691,0.034636937,0.00043927864,0.0014030308,0.0007351352,0.20177332,0.75132185],"study_design_scores_gemma":[0.003694351,0.0024911086,0.028595569,0.0032368863,0.0013426928,0.000059301958,0.0029028335,0.0032130803,0.0043379785,0.0003509712,0.94956845,0.0002067791],"about_ca_topic_score_codex":0.029988883,"about_ca_topic_score_gemma":0.0015173609,"teacher_disagreement_score":0.7511151,"about_ca_system_score_codex":0.00094477955,"about_ca_system_score_gemma":0.0004545253,"threshold_uncertainty_score":0.97647053},"labels":[],"label_agreement":null},{"id":"W4403537732","doi":"10.1016/j.esmoop.2024.103761","title":"15P Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont","funders":"Agence Nationale de la Recherche","keywords":"Breast cancer; Germline; Medicine; Oncology; Internal medicine; Genome-wide association study; HER2 negative; Cancer; Genetics; Biology; Single-nucleotide polymorphism; Genotype; Gene; Metastatic breast cancer","score_opus":0.004940847877152026,"score_gpt":0.24988186243845573,"score_spread":0.2449410145613037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662095,0.00015956657,0.000007952771,0.000045641907,0.000050424955,0.00047931375,0.0025154904,0.0000034339155,0.000117220836],"genre_scores_gemma":[0.99918437,0.00010421561,0.00010163227,0.000013566519,0.000013675356,0.00008670443,0.00045213598,0.000013133674,0.00003059012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990454,0.00005288556,0.00023408832,0.00038065322,0.0001472047,0.00013979632],"domain_scores_gemma":[0.99940467,0.000050204886,0.00012802,0.00016362709,0.0002123823,0.000041108622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007215078,0.00015907625,0.0003510151,0.00010317581,0.000031291067,0.00001668325,0.00012305476,0.000053632008,0.00003795996],"category_scores_gemma":[0.00003838023,0.00011625876,0.00005021965,0.00042113825,0.00012307665,0.00001617728,0.00023228327,0.000048873524,3.1983052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057485787,0.00022873539,0.99355346,0.000032303255,0.0021497381,0.0000010666098,0.00057351246,0.0001072636,0.000034579454,0.0000030160927,0.000073165436,0.0026682797],"study_design_scores_gemma":[0.0011439256,0.00034821566,0.99289966,0.00028736208,0.00040126633,2.4199943e-7,0.000068318834,0.000095318464,0.004587723,0.0000037367092,0.00003752121,0.00012669741],"about_ca_topic_score_codex":0.006084444,"about_ca_topic_score_gemma":0.005614802,"teacher_disagreement_score":0.0045531434,"about_ca_system_score_codex":0.000046197252,"about_ca_system_score_gemma":0.0000632239,"threshold_uncertainty_score":0.91978997},"labels":[],"label_agreement":null},{"id":"W4403537762","doi":"10.1016/j.esmoop.2024.103926","title":"164TiP MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Glycomics Network; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Scrum; Glycomics; Omics; Computer science; Computational biology; Biology; Bioinformatics; Software; Operating system; Software development; Glycan; Molecular biology","score_opus":0.05409124199152692,"score_gpt":0.33933741572096904,"score_spread":0.2852461737294421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369305,0.00047784645,0.001300851,0.0005159208,0.00014902261,0.0022754834,0.00006893596,0.000027372058,0.0014915211],"genre_scores_gemma":[0.9962331,0.00013645974,0.0017779483,0.00021072682,0.00008488756,0.00020714857,0.0000685591,0.00003048257,0.0012506661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855995,0.00008177426,0.00022892762,0.0006289719,0.00021240444,0.0002879898],"domain_scores_gemma":[0.99934363,0.000060572856,0.000045698896,0.00034765637,0.00007947833,0.00012296997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057497894,0.00024772345,0.00019421476,0.00008104743,0.00052807055,0.00072591234,0.0003522097,0.00013500827,0.00003724763],"category_scores_gemma":[0.00018154096,0.00016981759,0.0000483622,0.0001572989,0.0003115576,0.000038128972,0.00070596003,0.000333418,0.000028224425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010551611,0.008331685,0.51823133,0.0005143696,0.00440375,0.0013027511,0.013222628,0.0015235259,0.14957225,0.057473652,0.011049292,0.22382317],"study_design_scores_gemma":[0.03025694,0.0057239314,0.5199731,0.00097197684,0.00030824917,0.0009226185,0.013283457,0.16730313,0.14527866,0.0017749928,0.11060116,0.0036017646],"about_ca_topic_score_codex":0.00045962952,"about_ca_topic_score_gemma":0.00092794123,"teacher_disagreement_score":0.22022142,"about_ca_system_score_codex":0.00004844182,"about_ca_system_score_gemma":0.00023033444,"threshold_uncertainty_score":0.6999989},"labels":[],"label_agreement":null},{"id":"W4403537774","doi":"10.1016/j.esmoop.2024.103864","title":"125P Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medulloblastoma; RNA-Seq; Copy-number variation; Computational biology; Biology; Computer science; Genetics; Gene; Gene expression; Transcriptome; Genome","score_opus":0.030903135932091468,"score_gpt":0.30492653483087906,"score_spread":0.2740233988987876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7253587,0.0007411917,0.2632886,0.0003494123,0.0005185268,0.0007756496,0.008555122,0.000017972347,0.0003948247],"genre_scores_gemma":[0.98794836,0.00054361863,0.0050268373,0.000056753797,0.0001323468,0.000057170306,0.0061357603,0.000020117212,0.00007905681],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991369,0.0000347967,0.00021401452,0.00045908426,0.00005270661,0.00010247794],"domain_scores_gemma":[0.9989476,0.00013291383,0.00012643969,0.0006496363,0.00009603267,0.000047368867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024562833,0.000099939214,0.00016652184,0.00006013904,0.000079121055,0.00013077391,0.00031448956,0.000111123365,0.00007856416],"category_scores_gemma":[0.00015209625,0.0001015931,0.00006184661,0.0002415752,0.000037197682,0.000012063437,0.00017756116,0.000055182223,0.000005060929],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013804515,0.00025458098,0.024998952,0.000060249913,0.0033667844,0.0000015050178,0.00019280516,0.0006447786,0.8840438,0.0016694334,0.012045138,0.0713415],"study_design_scores_gemma":[0.0016952073,0.00036159286,0.14312544,0.000029965988,0.0026163233,0.0000012015959,0.00009166438,0.37787026,0.23021717,0.0012307918,0.24224165,0.0005187207],"about_ca_topic_score_codex":0.0022168015,"about_ca_topic_score_gemma":0.0076359757,"teacher_disagreement_score":0.65382665,"about_ca_system_score_codex":0.00002470701,"about_ca_system_score_gemma":0.00013643337,"threshold_uncertainty_score":0.42610538},"labels":[],"label_agreement":null},{"id":"W4403537808","doi":"10.1016/j.esmoop.2024.103837","title":"97P Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University of British Columbia Hospital; BC Cancer Agency","funders":"","keywords":"Pancreatic ductal adenocarcinoma; Germline; Oncology; Internal medicine; Medicine; Population; Pancreatic cancer; Cancer research; Biology; Cancer; Genetics; Gene; Environmental health","score_opus":0.030636000484484286,"score_gpt":0.37519230797114644,"score_spread":0.34455630748666216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340713,0.00010209623,0.00021144179,0.00078863703,0.00011114507,0.0017512747,0.00006293776,0.000030080708,0.0035352455],"genre_scores_gemma":[0.9921035,0.0000149625985,0.005751482,0.00016917917,0.000039915998,0.00019216863,0.00035170245,0.000039042334,0.0013380016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978677,0.00018590166,0.0005813084,0.00044338958,0.0005563824,0.0003653224],"domain_scores_gemma":[0.99875605,0.00038134184,0.00010840644,0.00046778083,0.00013104243,0.00015537356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064867985,0.00021953679,0.0008992459,0.00029303588,0.00005916732,0.00005057009,0.00028426916,0.0001242035,0.0010154867],"category_scores_gemma":[0.00018048106,0.00015407565,0.00008698624,0.00045615545,0.000077327444,0.00017401099,0.00014001665,0.00031115348,0.000038100156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027562067,0.0007591708,0.99676865,0.0002582588,0.00026720058,0.000358497,0.00013810597,0.000015790507,0.00004583414,0.00046562692,0.00012177832,0.0005254504],"study_design_scores_gemma":[0.004437126,0.0011095303,0.98577964,0.00051891606,0.00032481627,0.00001992457,0.000055535154,0.0074042864,0.000015543621,0.00013562896,0.000042175707,0.00015689761],"about_ca_topic_score_codex":0.004185955,"about_ca_topic_score_gemma":0.0006607265,"teacher_disagreement_score":0.010989047,"about_ca_system_score_codex":0.00030908876,"about_ca_system_score_gemma":0.000990714,"threshold_uncertainty_score":0.9998977},"labels":[],"label_agreement":null},{"id":"W4403538115","doi":"10.1016/j.esmoop.2024.103813","title":"69P Next generation sequencing in colorectal cancer: Association of BRAF, KRAS mutations with right sided cancers, mucinous disease, lymphovascular/perineural invasion and microsatellite instability","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Allison University; Upper River Valley Hospital","funders":"","keywords":"Microsatellite instability; KRAS; Lymphovascular invasion; Perineural invasion; Colorectal cancer; Medicine; Cancer; Disease; Oncology; Adenocarcinoma; Internal medicine; Microsatellite; Biology; Metastasis; Genetics; Allele; Gene","score_opus":0.039737253383547264,"score_gpt":0.2973723839211062,"score_spread":0.25763513053755893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403538115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942429,0.0031124358,0.0000059966274,0.0007964534,0.00014387713,0.0010881101,0.000076102035,0.000026733878,0.0005073862],"genre_scores_gemma":[0.99795425,0.001053053,0.00018743132,0.00008485624,0.000061442064,0.00026639018,0.0001471502,0.000016810614,0.0002286179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892116,0.000066857756,0.00025917543,0.00036604246,0.00021070825,0.00017606196],"domain_scores_gemma":[0.99952877,0.00008613242,0.00007739727,0.00011219054,0.00011557929,0.00007991944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019738234,0.00015354523,0.00032950033,0.00008627271,0.00011697482,0.00010292369,0.000057082554,0.000049189515,0.000087413966],"category_scores_gemma":[0.000071408176,0.00011578143,0.000048938644,0.00034372153,0.00006503104,0.00033603175,0.000076583296,0.00009488956,0.0000013032056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011511911,0.00014998089,0.9301394,0.00045223147,0.00061186485,0.00031407966,0.0076921033,0.0008543783,0.036198307,0.000119968005,0.00017413707,0.022142308],"study_design_scores_gemma":[0.0027435785,0.0004345204,0.96217954,0.0005722394,0.00038561205,0.000027651027,0.000455444,0.0057510696,0.02638466,0.00006759551,0.00078066316,0.0002174333],"about_ca_topic_score_codex":0.044458583,"about_ca_topic_score_gemma":0.10456416,"teacher_disagreement_score":0.060105577,"about_ca_system_score_codex":0.0028620886,"about_ca_system_score_gemma":0.0011230953,"threshold_uncertainty_score":0.96190447},"labels":[],"label_agreement":null},{"id":"W4404096478","doi":"10.1016/j.esmoop.2024.103976","title":"What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Government of Ontario; Ontario Institute for Cancer Research","keywords":"Context (archaeology); Cancer drugs; Medicine; Value (mathematics); Cancer; Perception; Intensive care medicine; Computer science; Psychology; Internal medicine; Machine learning; Biology; Neuroscience","score_opus":0.03627364547336505,"score_gpt":0.3554973760055262,"score_spread":0.3192237305321612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404096478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794976,0.008813309,0.0000371976,0.0005485687,0.0008027729,0.0009858428,0.0005432824,0.0000062651466,0.008765152],"genre_scores_gemma":[0.9906738,0.0081051,0.00045964538,0.00019792725,0.000052593645,0.00017504387,0.0000059299714,0.000022952529,0.00030704102],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99797165,0.000059666283,0.001200544,0.0004557522,0.00007105205,0.00024130584],"domain_scores_gemma":[0.9981432,0.0005135988,0.00076797366,0.00043258842,0.00009085558,0.00005181228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017238647,0.00021555013,0.0010322438,0.00030935256,0.00005982782,0.000101769416,0.0006618811,0.00012844903,0.00034848115],"category_scores_gemma":[0.00011734971,0.00019287721,0.00012502025,0.0003685831,0.00033854588,0.0006341928,0.00024448615,0.00022962419,0.000005503482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003227523,0.0010645479,0.23721611,0.00042496287,0.0006040793,0.0000027769322,0.08728896,0.0016468131,0.00009473835,0.5350173,0.00066291855,0.135654],"study_design_scores_gemma":[0.0031166205,0.0012772126,0.88344085,0.0014021972,0.0001519591,0.0000021750222,0.07086909,0.0012835395,0.0022213988,0.024206107,0.011464432,0.00056442636],"about_ca_topic_score_codex":0.057804715,"about_ca_topic_score_gemma":0.014813446,"teacher_disagreement_score":0.64622474,"about_ca_system_score_codex":0.00020127867,"about_ca_system_score_gemma":0.0001743485,"threshold_uncertainty_score":0.94846946},"labels":[],"label_agreement":null},{"id":"W4404408828","doi":"10.1016/j.esmoop.2024.103978","title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"","keywords":"Bespoke; Melanoma; Residual; Residual risk; Medicine; Internal medicine; Oncology; Dermatology; Cancer research; Computer science; Business; Algorithm","score_opus":0.00788301094561676,"score_gpt":0.2580673376940029,"score_spread":0.25018432674838614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404408828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687743,0.0005652679,0.0012819672,0.000066983026,0.00025870927,0.00047256768,0.000383052,0.0000035559012,0.00009045257],"genre_scores_gemma":[0.99889106,0.00017304812,0.0002983838,0.00003919816,0.0000923102,0.00009235814,0.00029222918,0.000020703945,0.000100717065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931455,0.000024580933,0.00016862855,0.00029375768,0.00006706534,0.00013143929],"domain_scores_gemma":[0.99960905,0.000025463492,0.000044604763,0.00021441292,0.00004921367,0.000057263063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013146644,0.00009160968,0.00010776892,0.00004621198,0.000029420984,0.000048399714,0.0001854089,0.000061671766,0.000007980062],"category_scores_gemma":[0.00014684649,0.000084514366,0.000055553188,0.0000689723,0.000024912237,0.000005144289,0.00018172161,0.000047382266,0.0000032701664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045956247,0.0008199674,0.78571516,0.00043464848,0.00047239842,0.00009125794,0.00019827804,0.0030670331,0.11128525,0.0022658166,0.005764241,0.085290305],"study_design_scores_gemma":[0.0020502252,0.0010915715,0.5817621,0.00007911259,0.000122053556,8.5378207e-7,0.00001600242,0.00033660614,0.38853112,0.0021406547,0.023547135,0.00032261494],"about_ca_topic_score_codex":0.0011271007,"about_ca_topic_score_gemma":0.0014332444,"teacher_disagreement_score":0.27724588,"about_ca_system_score_codex":0.000024105168,"about_ca_system_score_gemma":0.000099604295,"threshold_uncertainty_score":0.3446396},"labels":[],"label_agreement":null},{"id":"W4405050504","doi":"10.1016/j.esmoop.2024.103972","title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; XBiotech; EMD Serono; Genentech; National Institutes of Health; HCA Healthcare; Pfizer; Incyte; Moderna; Revolution Medicines; Gilead Sciences; National Cancer Institute; Vertex Pharmaceuticals; F. Hoffmann-La Roche; Eli Lilly and Company; AstraZeneca; Jounce Therapeutics; Celgene; Array BioPharma; Astellas Pharma; TG Therapeutics; Seagen; Agios Pharmaceuticals","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Medicine; Urothelial cancer; Internal medicine; Urology; Phase (matter); Bladder cancer; Cancer; Chemistry; Immunotherapy; Nivolumab","score_opus":0.0958352596985449,"score_gpt":0.4042303405836028,"score_spread":0.3083950808850579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701455,0.0024310523,0.0047543775,0.008820093,0.0012210553,0.0070270924,0.0023103447,0.00011460114,0.0031758358],"genre_scores_gemma":[0.98877937,0.000059438677,0.0012640613,0.0012605042,0.0009768591,0.0010414955,0.0004918468,0.00005495344,0.0060714926],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985353,0.00008751323,0.00034345163,0.0004942166,0.00025650687,0.0002830182],"domain_scores_gemma":[0.9990082,0.00025370752,0.00005875839,0.0005140607,0.000051531824,0.00011375271],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027217687,0.00024227533,0.0005815718,0.00010288425,0.00026404808,0.00023081928,0.00038357993,0.000057099787,0.0022938203],"category_scores_gemma":[0.000034917102,0.00014588455,0.000483405,0.00046993888,0.00005916221,0.0001504156,0.00009200665,0.00015701719,0.00006660426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48564342,0.0064057484,0.003031535,0.00015479597,0.048878934,0.0008303361,0.013846547,0.000055540422,0.0011625456,0.0033197678,0.106512025,0.33015883],"study_design_scores_gemma":[0.4822514,0.015098516,0.005552967,0.00013349389,0.028750861,0.00003299289,0.00045910617,0.0074272975,0.0065657184,0.005602032,0.44742814,0.0006974765],"about_ca_topic_score_codex":0.010063307,"about_ca_topic_score_gemma":0.00065870024,"teacher_disagreement_score":0.3409161,"about_ca_system_score_codex":0.00010439914,"about_ca_system_score_gemma":0.00048768576,"threshold_uncertainty_score":0.99861825},"labels":[],"label_agreement":null},{"id":"W4405050900","doi":"10.1016/j.esmoop.2024.104073","title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Open label; Internal medicine; Oncology; Randomized controlled trial; Immunotherapy; Cancer","score_opus":0.03543818598914407,"score_gpt":0.3104221155019698,"score_spread":0.27498392951282574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96938986,0.0014099434,0.0001533388,0.0013715178,0.0007639303,0.017138954,0.0008783841,0.00008716913,0.008806896],"genre_scores_gemma":[0.9834637,0.00007455855,0.0032534478,0.00024347419,0.00043424428,0.0016122559,0.002144851,0.00013863329,0.008634825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962931,0.00021724809,0.0008937715,0.0013551734,0.0006243407,0.0006163531],"domain_scores_gemma":[0.9966484,0.0012630698,0.00034868182,0.0011472543,0.00024905332,0.00034357613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007428909,0.00056630705,0.0011084473,0.00010846109,0.0007892863,0.0006235193,0.0007709864,0.00021023277,0.00015981049],"category_scores_gemma":[0.00032430023,0.0003622962,0.0001502425,0.00032207614,0.0001648659,0.0008465771,0.00076389743,0.00055851234,0.00004529036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.959418,0.00235714,0.00014169751,0.00007753447,0.0005103807,0.00024033675,0.0015414992,0.000021921125,0.00018527229,0.000052221294,0.018447923,0.017006071],"study_design_scores_gemma":[0.9298271,0.022694865,0.0014254379,0.00040473105,0.0013708038,0.000024443778,0.0003133609,0.0016934866,0.0013273119,0.00014536736,0.040292453,0.000480642],"about_ca_topic_score_codex":0.004391379,"about_ca_topic_score_gemma":0.00041363173,"teacher_disagreement_score":0.029590907,"about_ca_system_score_codex":0.000972998,"about_ca_system_score_gemma":0.0011643778,"threshold_uncertainty_score":0.9998829},"labels":[],"label_agreement":null},{"id":"W4405475772","doi":"10.1016/j.esmoop.2024.104003","title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; Kasturba Medical College, Manipal; Incyte; Eisai; Ipsen; BeiGene; Merck KGaA; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Interim; Biliary tract cancer; Guideline; Biliary tract; Medicine; Clinical Practice; Interim analysis; Cancer; Internal medicine; General surgery; Clinical trial; Family medicine; Pathology; Geography","score_opus":0.10617497590124042,"score_gpt":0.4643638996670465,"score_spread":0.3581889237658061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405475772","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10445652,0.010497936,0.00021085238,0.4135188,0.0038743543,0.0029752166,0.00009521672,0.00013715141,0.46423396],"genre_scores_gemma":[0.96716046,0.0051429817,0.0025060393,0.019246394,0.0005433171,0.00017630741,0.000029029812,0.000038956467,0.005156499],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998603,0.00008518066,0.000541651,0.00034744566,0.00025840465,0.0001643333],"domain_scores_gemma":[0.99899554,0.0002693785,0.000093121555,0.0004851282,0.00009790804,0.000058948564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011867757,0.00014265595,0.00031880732,0.000042202922,0.000056439017,0.00006381802,0.0003404855,0.000047702157,0.001051844],"category_scores_gemma":[0.00008989013,0.000082822364,0.00014640964,0.00019663537,0.000090784066,0.00015063421,0.0004042216,0.00031337934,0.00015245013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081733114,0.0004595424,0.0045659007,0.00023549321,0.0021676195,0.00068814575,0.0005684803,0.0000033726242,0.00001162068,0.0057882746,0.8373562,0.14733802],"study_design_scores_gemma":[0.0006714359,0.00029923793,0.06583077,0.00073502597,0.00063987926,0.000027923117,0.00088720577,0.00010026352,0.0002108341,0.00013605897,0.9303597,0.00010164723],"about_ca_topic_score_codex":0.0011967535,"about_ca_topic_score_gemma":0.000087384964,"teacher_disagreement_score":0.862704,"about_ca_system_score_codex":0.00006115807,"about_ca_system_score_gemma":0.00010594296,"threshold_uncertainty_score":0.99986136},"labels":[],"label_agreement":null},{"id":"W4405575375","doi":"10.1016/j.esmoop.2024.104074","title":"Corrigendum to “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer”","year":2024,"lang":"en","type":"erratum","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biliary tract cancer; Medicine; Clinical Practice; Biliary tract; Internal medicine; Oncology; Cancer; General surgery; Intensive care medicine; Family medicine","score_opus":0.15782388274875644,"score_gpt":0.4350156302361033,"score_spread":0.2771917474873469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405575375","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022899542,0.21455394,0.00010988329,0.413463,0.21967748,0.05925534,0.012905368,0.00031940802,0.056816053],"genre_scores_gemma":[0.077480644,0.11194418,0.008330592,0.030569118,0.015875991,0.023214163,0.0049448023,0.00086241536,0.7267781],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731874,0.000081561,0.00093260536,0.0008708366,0.00043281144,0.00036341624],"domain_scores_gemma":[0.9967563,0.00055416446,0.0004234265,0.00074538484,0.0013080817,0.00021261735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050244614,0.0005320346,0.001348598,0.00010981001,0.00018435725,0.000105664134,0.0004115775,0.0003002305,0.00008497849],"category_scores_gemma":[0.0015271142,0.00028836154,0.00030560003,0.00026746083,0.00013203226,0.00014357947,0.00033963332,0.0005033987,0.000009270978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021391287,0.00046103826,0.06582272,0.00020358126,0.002506834,0.00003600484,0.0009127432,2.8173432e-7,5.3964566e-8,0.000008957033,0.8507526,0.077156074],"study_design_scores_gemma":[0.003513222,0.002950734,0.27220446,0.0009840253,0.0041743647,0.0000074293775,0.000801182,0.000010129348,0.0000050680537,0.000006761195,0.7151021,0.00024054572],"about_ca_topic_score_codex":0.013353581,"about_ca_topic_score_gemma":0.015342707,"teacher_disagreement_score":0.66996205,"about_ca_system_score_codex":0.00021623982,"about_ca_system_score_gemma":0.0012440822,"threshold_uncertainty_score":0.99995685},"labels":[],"label_agreement":null},{"id":"W4406108792","doi":"10.1016/j.esmoop.2024.104099","title":"A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?","year":2025,"lang":"en","type":"review","venue":"ESMO Open","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Intensive care medicine; Medicine; Cancer; Taxonomy (biology); Biology; Internal medicine; Ecology","score_opus":0.17204104008031654,"score_gpt":0.42312933532410496,"score_spread":0.2510882952437884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406108792","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021737195,0.9538836,0.0000023555006,0.02657851,0.00038805808,0.011545318,0.0033691798,0.0000046644254,0.0020546208],"genre_scores_gemma":[0.010214557,0.9813854,0.000023223072,0.0023700055,0.00006453575,0.001303778,0.0001783379,0.000031408275,0.0044287546],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975016,0.00042454447,0.000800989,0.0003648656,0.00056774967,0.00034022538],"domain_scores_gemma":[0.99554706,0.00154687,0.0013617196,0.0010353604,0.00043223545,0.0000767771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055796,0.00042704254,0.0019142992,0.000056521054,0.0001986729,0.000058832655,0.0013289585,0.00014504288,0.00046405994],"category_scores_gemma":[0.0005328663,0.00013724821,0.00058009644,0.00041690798,0.00027636008,0.00008893741,0.0012787116,0.0002731303,0.0000012605988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000344363,0.00068993313,0.17984743,0.026512584,0.011978549,0.0000038263443,0.035084885,0.000008590193,0.000005021365,0.0002097094,0.21055536,0.53475976],"study_design_scores_gemma":[0.00061957794,0.00013184814,0.0011519659,0.052528825,0.0018755659,2.1793294e-7,0.003191994,3.4477884e-7,0.0011539956,0.000008086109,0.9392068,0.00013081261],"about_ca_topic_score_codex":0.02131157,"about_ca_topic_score_gemma":0.021315295,"teacher_disagreement_score":0.7286514,"about_ca_system_score_codex":0.00028075938,"about_ca_system_score_gemma":0.0009844571,"threshold_uncertainty_score":0.99654317},"labels":[],"label_agreement":null},{"id":"W4406268174","doi":"10.1016/j.esmoop.2024.104107","title":"Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; National Cancer Institute; Celgene; Agilent Technologies; Bristol-Myers Squibb","keywords":"Gastroesophageal Junction; Medicine; Cancer; Internal medicine; Nivolumab; Gastroenterology; Oncology; Adenocarcinoma; Immunotherapy","score_opus":0.009857846797699509,"score_gpt":0.31018671636702405,"score_spread":0.30032886956932453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406268174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504405,0.0007108507,0.00010330611,0.0010107824,0.0002685176,0.0025712205,0.000009520501,0.000020566824,0.00026118846],"genre_scores_gemma":[0.99777126,0.00038035322,0.000060416238,0.00039655517,0.00002821607,0.0005297867,0.000028536855,0.000013755693,0.0007911176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989931,0.000089133035,0.0002267848,0.00028571548,0.00021850306,0.00018676388],"domain_scores_gemma":[0.99949706,0.000028809853,0.00013372605,0.00021078614,0.00009860656,0.000031009436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023234192,0.0001556934,0.00024320812,0.00022596946,0.0002843255,0.00006349149,0.00012997753,0.000038316062,0.00014778794],"category_scores_gemma":[0.00001000069,0.00010266408,0.000024526591,0.0008810322,0.000061774175,0.00031165552,0.00006860543,0.0001906831,5.4256026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010297381,0.0015810659,0.5897164,0.000012171747,0.00018081887,0.0000021811727,0.00046410205,0.000018844687,0.000087724446,0.0000047648928,0.00043658138,0.39719796],"study_design_scores_gemma":[0.034937598,0.0042538624,0.95761245,0.00015594992,0.00011496535,0.0000013351497,0.0008725893,0.00008803625,0.00010176143,0.000013047058,0.001766636,0.00008176709],"about_ca_topic_score_codex":0.0067678667,"about_ca_topic_score_gemma":0.002846011,"teacher_disagreement_score":0.3971162,"about_ca_system_score_codex":0.00036758857,"about_ca_system_score_gemma":0.0001712745,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W4407227498","doi":"10.1016/j.esmoop.2024.104121","title":"Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Swedish Orphan Biovitrum; European Society for Medical Oncology; Eisai; Seagen; Incyte; Multinational Association of Supportive Care in Cancer; American Society of Clinical Oncology; AstraZeneca; European SocieTy for Radiotherapy and Oncology; Regeneron Pharmaceuticals; Medpace; Associazione Italiana di Oncologia Medica; Gilead Sciences; Sanofi; Celgene; Adenoid Cystic Carcinoma Research Foundation; Pfizer","keywords":"Guideline; Medicine; Malignancy; Clinical Practice; Intensive care medicine; Internal medicine; Physical therapy; Pathology","score_opus":0.08541978819751062,"score_gpt":0.49211599382109794,"score_spread":0.4066962056235873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407227498","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40398914,0.0024921913,0.00061900227,0.43268278,0.0031590518,0.007864365,0.00011128237,0.00014899802,0.14893319],"genre_scores_gemma":[0.7060028,0.007664926,0.07483233,0.12592249,0.0017898986,0.002941127,0.0005312586,0.00011091873,0.0802043],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981223,0.00018638506,0.00078966137,0.0004891262,0.000104506515,0.00030802595],"domain_scores_gemma":[0.9964892,0.0026044704,0.00013308554,0.0003387891,0.0001951189,0.00023931592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011844331,0.00018665312,0.00075300963,0.000054713782,0.00012796774,0.000048619673,0.0001672297,0.00022136135,0.00027472663],"category_scores_gemma":[0.00270338,0.00013682987,0.00015630016,0.00014089938,0.0000917251,0.0001527732,0.00019388285,0.00015712816,0.00003668613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004726104,0.0023392274,0.16044591,0.0000619857,0.0005339635,0.00039337832,0.0001312083,5.823053e-7,0.000018962795,0.008980646,0.44680652,0.3755615],"study_design_scores_gemma":[0.011269312,0.002557141,0.038876902,0.00012189098,0.00047034668,0.00004432441,0.00007520045,0.00006237441,0.0002966395,0.0003482615,0.9457526,0.00012497806],"about_ca_topic_score_codex":0.0010423262,"about_ca_topic_score_gemma":0.00039470778,"teacher_disagreement_score":0.4989461,"about_ca_system_score_codex":0.00010354421,"about_ca_system_score_gemma":0.0005781516,"threshold_uncertainty_score":0.55797607},"labels":[],"label_agreement":null},{"id":"W4408218433","doi":"10.1016/j.esmoop.2025.104192","title":"34P Investigating the potential of auger electron-emitting radionuclide-labelled Hsp90 inhibitors in the treatment of cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"The Wellcome Trust DBT India Alliance; Department of Biotechnology, Ministry of Science and Technology, India; Wellcome Trust","keywords":"Radionuclide; Electron; Cancer; Radiochemistry; Medicine; Nuclear physics; Chemistry; Internal medicine; Physics","score_opus":0.0165180221479791,"score_gpt":0.34539096793013285,"score_spread":0.32887294578215376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408218433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939633,0.0011105327,0.000023603541,0.0017863894,0.000049604863,0.0009701905,0.0000060051793,0.0000017864852,0.0020886154],"genre_scores_gemma":[0.9979709,0.00033565835,0.00019716423,0.00014905084,0.000075639735,0.00022601632,0.000015630727,0.000009722035,0.0010202574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988699,0.00023813118,0.00029827887,0.00021347331,0.00015368439,0.00022653228],"domain_scores_gemma":[0.9993925,0.000053201733,0.00008405246,0.00038475523,0.00006225083,0.000023257513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061241485,0.00010375365,0.00017434312,0.000043801178,0.0001067467,0.000029099287,0.00056994933,0.00008454658,0.00002265757],"category_scores_gemma":[0.00014214392,0.00006116117,0.00006586641,0.00026693178,0.00012358188,0.0000044287663,0.00020506096,0.000106581974,8.8856996e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010555727,0.00020637007,0.01858293,0.000035823938,0.00015945967,0.0000030612273,0.00075197,0.00030573385,0.9610716,0.00029020334,0.0011461185,0.017341154],"study_design_scores_gemma":[0.0008825109,0.00027396413,0.006355636,0.0000630942,0.000018943487,0.0000011145856,0.0002815491,0.00016488663,0.9806958,0.00017375099,0.011022439,0.00006635682],"about_ca_topic_score_codex":0.0063021667,"about_ca_topic_score_gemma":0.0011694893,"teacher_disagreement_score":0.019624136,"about_ca_system_score_codex":0.000045408342,"about_ca_system_score_gemma":0.0003315949,"threshold_uncertainty_score":0.9527033},"labels":[],"label_agreement":null},{"id":"W4408220345","doi":"10.1016/j.esmoop.2025.104187","title":"29P BRCA1 reversion mutations confer a fitness benefit to PARP inhibitor-resistant subclones in high grade serous ovarian cancer models","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Reversion; PARP inhibitor; Serous ovarian cancer; Ovarian cancer; Serous fluid; Genetics; Biology; Cancer research; Mutation; Cancer; Medicine; Oncology; Internal medicine; Poly ADP ribose polymerase; DNA; Phenotype; Gene; Polymerase","score_opus":0.0445721061994778,"score_gpt":0.35147407901348515,"score_spread":0.30690197281400733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408220345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473854,0.00027815707,0.0012347784,0.041160922,0.0007721686,0.0024358297,0.00019912451,0.000084860265,0.006448764],"genre_scores_gemma":[0.98441285,0.00011451023,0.00153003,0.00503405,0.00013112948,0.0008581955,0.00012644906,0.00003510402,0.0077576684],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99826074,0.0000743652,0.00047088327,0.000534198,0.00030427793,0.00035552104],"domain_scores_gemma":[0.9989444,0.00008659751,0.00009318332,0.00050523225,0.0002017466,0.00016880906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002891357,0.00023099635,0.0004896952,0.0003077742,0.00016733655,0.00010056046,0.000338852,0.00015018637,0.0006335919],"category_scores_gemma":[0.00003346533,0.00022714125,0.000067878835,0.0008522353,0.00006226737,0.00032422904,0.00020065818,0.00024948016,0.00004074716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026686478,0.005184584,0.16818587,0.0019141051,0.0020533286,0.0017814407,0.024731645,0.0988703,0.08110379,0.35050124,0.20981216,0.02917505],"study_design_scores_gemma":[0.0441542,0.0008139838,0.6281673,0.00953792,0.00043863978,0.000052590458,0.0021586774,0.003516402,0.086924456,0.08743222,0.13488306,0.0019205929],"about_ca_topic_score_codex":0.037462004,"about_ca_topic_score_gemma":0.012085102,"teacher_disagreement_score":0.45998138,"about_ca_system_score_codex":0.0006008307,"about_ca_system_score_gemma":0.00050767337,"threshold_uncertainty_score":0.96894765},"labels":[],"label_agreement":null},{"id":"W4408220906","doi":"10.1016/j.esmoop.2025.104176","title":"20P Tumor markers evolution in pts treated with TCE and association with radiologic response","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Sierra Oncology; Ipsen; Daiichi Sankyo Europe; Gilead Sciences; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; MacroGenics; Pfizer; Incyte; BeiGene; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Exelixis; Sanofi; Relay Therapeutics; Amgen; Celgene","keywords":"Association (psychology); Internal medicine; Medicine; Oncology; Psychology; Psychotherapist","score_opus":0.012902910709983919,"score_gpt":0.2961474526705894,"score_spread":0.2832445419606055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408220906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808836,0.00018215203,0.000063485284,0.008782096,0.000029459492,0.0004272975,0.0000021357516,0.000024913441,0.009604861],"genre_scores_gemma":[0.9880624,0.000022128657,0.00062293577,0.0009382243,0.000007826765,0.000049136906,0.000009076374,0.0000044712237,0.010283834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918795,0.0002675065,0.00010732052,0.00019799083,0.00009115875,0.0001481054],"domain_scores_gemma":[0.99942994,0.00032296462,0.000051991003,0.00010915795,0.000045831417,0.000040110248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009952446,0.00008236953,0.00024421385,0.000087475455,0.00006670428,0.000013850776,0.00005408086,0.00005151507,0.0000192853],"category_scores_gemma":[0.000898522,0.000051313044,0.000008103752,0.00024345239,0.00010469919,0.000050924173,0.000044629513,0.00016655686,0.0000048955712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059989747,0.000043984237,0.98648137,0.000015694754,0.00007371313,0.00021467122,0.00013014357,0.0000019657643,0.00011349575,0.000027063877,0.0064774198,0.00042148517],"study_design_scores_gemma":[0.0032514904,0.0004710161,0.9938592,0.0003117648,0.000081127924,0.00005135354,0.00029907183,0.000088523615,0.00006602899,0.000039759238,0.0014212229,0.000059497837],"about_ca_topic_score_codex":0.0008200732,"about_ca_topic_score_gemma":0.00020507994,"teacher_disagreement_score":0.007843872,"about_ca_system_score_codex":0.00016986455,"about_ca_system_score_gemma":0.000115026996,"threshold_uncertainty_score":0.20924851},"labels":[],"label_agreement":null},{"id":"W4408221171","doi":"10.1016/j.esmoop.2025.104221","title":"61P Targeting ATR and PKMYT1 to overcome carboplatin resistance in triple-negative breast cancer patient-derived models","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre; Jewish General Hospital","funders":"","keywords":"Triple-negative breast cancer; Carboplatin; Breast cancer; Medicine; Triple negative; Oncology; Cancer; Internal medicine; Cancer research; Chemotherapy; Cisplatin","score_opus":0.011635760681426398,"score_gpt":0.3053877772091159,"score_spread":0.2937520165276895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408221171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900335,0.0005582247,0.00011949682,0.001224563,0.000099832185,0.0008515543,0.00013642572,0.000006501877,0.006969909],"genre_scores_gemma":[0.9940054,0.00007310065,0.0013281013,0.00033995297,0.000044022236,0.0002201607,0.0000346687,0.000019738225,0.003934854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866414,0.00013427378,0.00025250408,0.00049856736,0.00014302756,0.00030751256],"domain_scores_gemma":[0.99943626,0.000028643579,0.000053867356,0.00027465736,0.000106894666,0.00009969048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023142103,0.00015422587,0.00021393968,0.00009143574,0.00011218484,0.00006793681,0.00031310934,0.00010988039,0.000033772674],"category_scores_gemma":[0.00014598695,0.00015882296,0.000031614174,0.00027572797,0.00006542284,0.000017587823,0.00064735586,0.00015226663,0.0000039631723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025141658,0.0001762072,0.007857757,0.0001187995,0.00014793332,0.000044579632,0.003824446,0.0015542342,0.9150432,0.0003909645,0.06277298,0.0055547385],"study_design_scores_gemma":[0.0045367866,0.00021656623,0.03850697,0.00057739357,0.000020821533,0.0000051192824,0.0009913488,0.0009955335,0.929671,0.0010359877,0.022569966,0.0008725312],"about_ca_topic_score_codex":0.0061212005,"about_ca_topic_score_gemma":0.014048851,"teacher_disagreement_score":0.040203016,"about_ca_system_score_codex":0.00011672747,"about_ca_system_score_gemma":0.00023143236,"threshold_uncertainty_score":0.9253465},"labels":[],"label_agreement":null},{"id":"W4408562453","doi":"10.1016/j.esmoop.2025.104497","title":"Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Gilead Sciences; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Palbociclib; Letrozole; Medicine; Gynecology; Internal medicine; Cancer; Breast cancer","score_opus":0.03697220638522724,"score_gpt":0.3806589555226792,"score_spread":0.34368674913745195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408562453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126744,0.00039805242,0.000035780908,0.0012968378,0.00083464244,0.0033888437,0.000032843916,0.000023947247,0.0027216088],"genre_scores_gemma":[0.998422,0.00001025448,0.00008571924,0.00040611255,0.000023981585,0.00009675949,0.000022728798,0.000021055828,0.00091136695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968249,0.00078476925,0.0013960908,0.0003024139,0.00046432283,0.0002274587],"domain_scores_gemma":[0.9969903,0.0005353067,0.0013107276,0.00092222996,0.00015790612,0.00008350274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013825761,0.00019760036,0.0012869876,0.0000923254,0.00006792599,0.000005691078,0.00037765072,0.00011320442,0.00012903023],"category_scores_gemma":[0.0012921138,0.000129504,0.00028252404,0.0005304447,0.00019707649,0.00006799877,0.00021733598,0.00024766446,0.000002026898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7214604,0.0014862047,0.039184857,0.0021193316,0.003079347,0.000011285861,0.0035100586,0.00016717798,0.009352431,0.0031382015,0.0018105184,0.2146802],"study_design_scores_gemma":[0.41242823,0.012531812,0.38027483,0.002818799,0.00045857308,0.000007424655,0.0005975538,0.000052451454,0.18633817,0.0014804115,0.0026571758,0.0003545658],"about_ca_topic_score_codex":0.004503536,"about_ca_topic_score_gemma":0.00016310133,"teacher_disagreement_score":0.34108996,"about_ca_system_score_codex":0.000149929,"about_ca_system_score_gemma":0.0007553517,"threshold_uncertainty_score":0.68080294},"labels":[],"label_agreement":null},{"id":"W4408563004","doi":"10.1016/j.esmoop.2025.104506","title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck; Pfizer","keywords":"Javelin; Urothelial carcinoma; Avelumab; Medicine; Oncology; Carcinoma; Term (time); Urology; Internal medicine; Bladder cancer; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.03674774194139571,"score_gpt":0.33897801224876994,"score_spread":0.30223027030737426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408563004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753013,0.00019087002,0.000577331,0.007664442,0.0017620724,0.010967659,0.00049861585,0.00003833462,0.002999379],"genre_scores_gemma":[0.9835594,0.00005552323,0.00040626005,0.0038672534,0.0002519193,0.0014958802,0.00031154117,0.000046282417,0.010005931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813265,0.000066894245,0.00054318336,0.00057672645,0.00024938615,0.00043117037],"domain_scores_gemma":[0.9986605,0.00034049095,0.0001248978,0.00065026135,0.00013622385,0.00008762358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019633594,0.0003168473,0.00064947293,0.00007479985,0.0001750531,0.000080124344,0.00056318,0.00013370876,0.0005462045],"category_scores_gemma":[0.00027153693,0.00018595319,0.00019898973,0.000207665,0.00007334236,0.00016083643,0.00025127636,0.00022128578,0.000043510187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049498454,0.0016194653,0.90432847,0.000049971335,0.00039564847,0.000031755953,0.0007435931,0.000008389957,0.000006733916,0.00008259099,0.0079158945,0.035319027],"study_design_scores_gemma":[0.20046286,0.000590755,0.7925533,0.00022147305,0.00021148418,6.3284483e-7,0.00004990665,0.000026944444,0.00036415845,0.00034007634,0.0049962397,0.00018214974],"about_ca_topic_score_codex":0.0036918474,"about_ca_topic_score_gemma":0.004269718,"teacher_disagreement_score":0.15096441,"about_ca_system_score_codex":0.00022568824,"about_ca_system_score_gemma":0.00035549566,"threshold_uncertainty_score":0.7582951},"labels":[],"label_agreement":null},{"id":"W4408602445","doi":"10.1016/j.esmoop.2025.104496","title":"How we treat patients with metastatic uveal melanoma","year":2025,"lang":"en","type":"review","venue":"ESMO Open","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melanoma; Metastatic melanoma; Medicine; Oncology; Dermatology; Internal medicine; Cancer research","score_opus":0.04631508802085058,"score_gpt":0.3622912821502412,"score_spread":0.3159761941293906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408602445","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018754714,0.9695521,0.000006195635,0.00049737457,0.00016312684,0.0042515197,0.0001313692,0.000027429862,0.025352132],"genre_scores_gemma":[0.000032335745,0.9252521,0.0011233352,0.00010719577,0.000035273548,0.00048550792,0.0016969141,0.000044769997,0.07122259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985985,0.00020544762,0.00025940198,0.00047897798,0.00019766476,0.0002600061],"domain_scores_gemma":[0.9988601,0.00015881499,0.00021638993,0.0005737907,0.000062006795,0.00012885849],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009360222,0.00043575212,0.0022441873,0.0001570538,0.000095135496,0.00007878706,0.00034358472,0.00020619543,0.00024131457],"category_scores_gemma":[0.000053053136,0.00024890303,0.00025730877,0.00027185958,0.000059337537,0.000116496354,0.0002148908,0.0002858317,0.00019582176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009760919,0.0006041298,0.0020991652,0.008782179,0.0023977805,0.00060779526,0.000021678448,8.047555e-9,4.4745577e-10,0.00009089295,0.003984712,0.98131406],"study_design_scores_gemma":[0.003638508,0.0009748878,0.00062661996,0.013953649,0.011082722,0.000044801818,0.000008068472,7.438276e-8,3.613003e-7,0.000025337267,0.9694436,0.0002013706],"about_ca_topic_score_codex":0.00008331867,"about_ca_topic_score_gemma":0.00007941395,"teacher_disagreement_score":0.98111266,"about_ca_system_score_codex":0.0001939521,"about_ca_system_score_gemma":0.0007447972,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4408736548","doi":"10.1016/j.esmoop.2025.104317","title":"162MO Long-term development of 12- and 15-year-old offspring after maternal cancer during pregnancy: A prospective multicentre cohort study","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Offspring; Medicine; Prospective cohort study; Pregnancy; Obstetrics; Term (time); Cohort; Cohort study; Cancer; Pediatrics; Internal medicine; Biology; Genetics","score_opus":0.013335055091233766,"score_gpt":0.31029011519707295,"score_spread":0.29695506010583916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408736548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571574,0.00033544426,0.000008916425,0.000041414918,0.00014788355,0.0027854869,0.000007847415,0.000016776421,0.00094050006],"genre_scores_gemma":[0.99370307,0.00009412628,0.00023019749,0.000023746172,0.000026517358,0.0005129376,0.0000019654963,0.000016841814,0.0053906133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989787,0.000015818663,0.00028028188,0.0003438156,0.0001844864,0.00019689795],"domain_scores_gemma":[0.99955505,0.000009753621,0.000082382634,0.00021829754,0.00006276051,0.00007178173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007804394,0.00014854094,0.00035357222,0.00007393416,0.00007262431,0.00005151348,0.000128905,0.00004002688,0.0003475916],"category_scores_gemma":[0.0000100439565,0.00012367767,0.000028745277,0.00009292792,0.00003341263,0.000108096785,0.00038358913,0.00012143874,0.0000036510278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073545455,0.00021928035,0.9907434,0.0002809806,0.00042350517,0.00007480971,0.0033774008,9.1842765e-7,0.00013976086,0.0000036718873,0.00000816169,0.0039926306],"study_design_scores_gemma":[0.003404808,0.000048445134,0.9836708,0.0020840862,0.00015240915,0.0000031537384,0.000275898,0.0000039244132,0.010192383,0.000002164381,0.000043712636,0.00011826972],"about_ca_topic_score_codex":0.0040421328,"about_ca_topic_score_gemma":0.012712501,"teacher_disagreement_score":0.010052622,"about_ca_system_score_codex":0.00023183493,"about_ca_system_score_gemma":0.00016878294,"threshold_uncertainty_score":0.70938736},"labels":[],"label_agreement":null},{"id":"W4408736954","doi":"10.1016/j.esmoop.2025.104326","title":"18TiP Maintenance cabozantinib in children, adolescents and young adults with unresectable osteosarcoma: The phase II, randomized, open-label CabOSTar trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cabozantinib; Open label; Osteosarcoma; Randomized controlled trial; Medicine; Oncology; Pediatrics; Internal medicine; Cancer; Cancer research","score_opus":0.017999235159252315,"score_gpt":0.31993752399335396,"score_spread":0.3019382888341016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408736954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97366863,0.001470731,0.00000792788,0.003792507,0.00019372474,0.013809614,0.00004112644,0.000019448064,0.0069962787],"genre_scores_gemma":[0.993979,0.0004592665,0.00030741523,0.0012407474,0.00005699756,0.0014767254,0.00007887759,0.000027624284,0.0023733866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979605,0.0002638828,0.00048199092,0.00058571197,0.0002635886,0.00044434163],"domain_scores_gemma":[0.9988335,0.00018773675,0.00015438418,0.0006092127,0.000096018404,0.00011915235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010339799,0.0003018245,0.0010103924,0.000111504334,0.00032138155,0.00029231785,0.00067859015,0.00008225589,0.00006707506],"category_scores_gemma":[0.00026876546,0.00016692857,0.00005759711,0.00043570282,0.00020340261,0.00025528242,0.00091263425,0.0002920672,0.000008746839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7815654,0.006372053,0.19446066,0.000036995792,0.0004285918,0.00019501125,0.0005456558,6.2373147e-7,0.0000045822558,0.0009494692,0.003936721,0.011504217],"study_design_scores_gemma":[0.9316274,0.001188481,0.062787294,0.0018971491,0.00032403623,0.00008529966,0.00028386305,0.000096071795,0.00021524848,0.00008077689,0.0012292159,0.00018519085],"about_ca_topic_score_codex":0.025323473,"about_ca_topic_score_gemma":0.00478733,"teacher_disagreement_score":0.15006195,"about_ca_system_score_codex":0.000077153505,"about_ca_system_score_gemma":0.00027175373,"threshold_uncertainty_score":0.98116696},"labels":[],"label_agreement":null},{"id":"W4408875879","doi":"10.1016/j.esmoop.2025.104535","title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Cabinet Office, Government of Japan; Swine Innovation Porc; Japan Agency for Medical Research and Development","keywords":"Cancer; Geography; Medicine; Computational biology; Biology; Genetics","score_opus":0.037584939178826916,"score_gpt":0.38092394197700374,"score_spread":0.3433390027981768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408875879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958686,0.0015864843,0.0007018959,0.0008073727,0.00015756596,0.00022498782,0.0000397629,0.0000017714815,0.0006115634],"genre_scores_gemma":[0.99672,0.0016827265,0.000722237,0.00022382231,0.000043613723,0.00001193455,0.0004047901,0.0000054804095,0.00018535998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938554,0.00004994513,0.00022478754,0.00024038577,0.000043143227,0.00005619968],"domain_scores_gemma":[0.99960953,0.00001558188,0.00007437274,0.00022207787,0.00006227447,0.000016183325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017231605,0.00005844677,0.00010782955,0.000047731603,0.00001634071,0.00002344164,0.00024194978,0.00008999721,0.000013598293],"category_scores_gemma":[0.000041415056,0.000062398416,0.000012820886,0.000057160494,0.00005857507,0.00000991014,0.0006512271,0.000052145322,5.0570975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006226145,0.00010884839,0.66660655,0.000049142218,0.00039467006,0.00000199951,0.00007056797,0.0014754353,0.22109745,0.0007874915,0.005814185,0.10297102],"study_design_scores_gemma":[0.002019946,0.000049006292,0.9359491,0.00006321401,0.00003157144,0.000003390193,0.000056096396,0.005168655,0.015217697,0.00036324852,0.040959414,0.00011869552],"about_ca_topic_score_codex":0.00026553072,"about_ca_topic_score_gemma":0.0005406169,"teacher_disagreement_score":0.26934248,"about_ca_system_score_codex":0.000007283363,"about_ca_system_score_gemma":0.00007548725,"threshold_uncertainty_score":0.25445336},"labels":[],"label_agreement":null},{"id":"W4408898205","doi":"10.1016/j.esmoop.2024.104014","title":"OP02-5 Three-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer with Korean subset","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Biliary tract cancer; Chemotherapy; Biliary tract; Topaz; Internal medicine; Medicine; Oncology; Cancer; Chemistry; Gemcitabine; Mineralogy","score_opus":0.030257379840549423,"score_gpt":0.34175605056931935,"score_spread":0.3114986707287699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408898205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226063,0.000826207,0.000021536498,0.0028971988,0.00005974165,0.0012636061,0.0001238108,0.000009931563,0.0025373183],"genre_scores_gemma":[0.99893373,0.00027885032,0.00004507734,0.00029836025,0.00004978913,0.0000847132,0.000047856447,0.000012884924,0.0002487169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886554,0.00009200216,0.0002862409,0.00037001708,0.00022320422,0.00016301325],"domain_scores_gemma":[0.99914867,0.00017459942,0.000083223196,0.00048601325,0.000063747844,0.000043749493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036533302,0.00016954626,0.0007095677,0.00010615304,0.00008968961,0.00003609517,0.00026562033,0.000039950468,0.00021697063],"category_scores_gemma":[0.000020020887,0.0001022074,0.00006760236,0.0007991903,0.0000989458,0.00008089226,0.00014475465,0.00017346944,5.9259116e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038237288,0.0006950167,0.9823465,0.000014323221,0.0022168318,0.000030135445,0.004795567,0.000018450897,0.00001791946,0.000019627993,0.00048660094,0.0055353204],"study_design_scores_gemma":[0.018677056,0.00041578157,0.97207487,0.0000830297,0.0011911547,7.5966165e-7,0.006648453,0.00012959697,0.00010769596,0.000027202323,0.00053717184,0.0001072428],"about_ca_topic_score_codex":0.110632755,"about_ca_topic_score_gemma":0.2465217,"teacher_disagreement_score":0.13588895,"about_ca_system_score_codex":0.00009483362,"about_ca_system_score_gemma":0.00019760107,"threshold_uncertainty_score":0.8952896},"labels":[],"label_agreement":null},{"id":"W4408898399","doi":"10.1016/j.esmoop.2024.104046","title":"PP338 A novel phosphatidylserine-targeting small molecule drug conjugate (T-1201) for cancer therapy","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Conjugate; Phosphatidylserine; Cancer therapy; Drug; Cancer; Small molecule; Cancer research; Medicine; Pharmacology; Combinatorial chemistry; Chemistry; Internal medicine; Biochemistry; Mathematics","score_opus":0.02996969612285281,"score_gpt":0.3093277538783463,"score_spread":0.2793580577554935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408898399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96028566,0.016342858,0.0028983455,0.0042638457,0.0021596886,0.0027523304,0.00011465966,0.000102427584,0.011080193],"genre_scores_gemma":[0.94912565,0.0006964288,0.00067947624,0.0018304973,0.00003860424,0.00067205046,0.00032529698,0.00002976775,0.046602245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990136,0.00005430465,0.0002911422,0.00031469783,0.000017260616,0.0003089988],"domain_scores_gemma":[0.99944645,0.000090938,0.000097062395,0.00024988648,0.00010252476,0.0000131432125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032964157,0.00017232212,0.00030371532,0.000052684853,0.0002883484,0.000068280446,0.00050099497,0.00011836357,0.00070154393],"category_scores_gemma":[0.000041326002,0.00014970433,0.000094924566,0.00012788716,0.00006539409,0.00015361221,0.00021207548,0.00012176055,0.000038813945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007589973,0.0002486631,0.0015987906,0.000029245568,0.0005280517,4.3546174e-7,0.00046556798,0.000039434428,0.9186262,0.004303821,0.03363684,0.039763954],"study_design_scores_gemma":[0.0031293319,0.000042184827,0.0041390513,0.000056679226,0.000021104011,8.872688e-7,0.00007149698,0.000077326695,0.6092085,0.00013935739,0.38296533,0.00014870359],"about_ca_topic_score_codex":0.0032129602,"about_ca_topic_score_gemma":0.0003012098,"teacher_disagreement_score":0.3493285,"about_ca_system_score_codex":0.000045951754,"about_ca_system_score_gemma":0.00013368246,"threshold_uncertainty_score":0.76814145},"labels":[],"label_agreement":null},{"id":"W4410424571","doi":"10.1016/j.esmoop.2025.105051","title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Genentech; Ipsen; Servier; Astellas Pharma; Eisai; Daiichi-Sankyo; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Medicine; Antibody; Programmed cell death 1; Monoclonal; Cancer research; PD-L1; Oncology; Immunology; Immunotherapy; Internal medicine; Cancer","score_opus":0.014801016748825375,"score_gpt":0.30766719638374646,"score_spread":0.29286617963492106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410424571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582624,0.00014182509,0.000011095348,0.00020456257,0.000056901725,0.0034810186,0.000012271106,0.000019223477,0.0002468834],"genre_scores_gemma":[0.9991521,0.00007414393,0.00028934688,0.000079347825,0.00000563699,0.00013027852,0.00016606573,0.000028852483,0.000074200034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807125,0.000098641154,0.0005759995,0.00055051345,0.00034312747,0.00036043616],"domain_scores_gemma":[0.9991683,0.000038430502,0.00020292374,0.00040755575,0.00011772189,0.000065062944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386842,0.00028905508,0.0007987818,0.00043227733,0.00010196719,0.000075508324,0.00026708416,0.0000954549,0.000019166806],"category_scores_gemma":[0.000017220385,0.0002304203,0.000028408005,0.0008509355,0.00015426152,0.0004480659,0.00012724992,0.00019024464,4.1463977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007188028,0.0043179397,0.9836506,0.00014449643,0.0001428632,0.00008372658,0.0014095453,0.00006960652,0.00095101347,0.000058075137,0.000009519544,0.0019745645],"study_design_scores_gemma":[0.046425983,0.00391216,0.943867,0.0012561489,0.0000638832,0.0000046839496,0.0012496706,0.00008087129,0.0027689934,0.000032304026,0.00008205665,0.00025624508],"about_ca_topic_score_codex":0.009448296,"about_ca_topic_score_gemma":0.026978957,"teacher_disagreement_score":0.039783623,"about_ca_system_score_codex":0.00012197558,"about_ca_system_score_gemma":0.00013473783,"threshold_uncertainty_score":0.99714786},"labels":[],"label_agreement":null},{"id":"W4410455596","doi":"10.1016/j.esmoop.2025.105020","title":"448P Real-world data: Hepatitis B prophylaxis in breast cancer patients, cancer centre experience","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatitis C virus research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Breast cancer; Cancer; Internal medicine; Oncology; Hepatitis B; Family medicine","score_opus":0.053518956048650805,"score_gpt":0.4155989881430812,"score_spread":0.3620800320944304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519062,0.00013286217,0.000005003442,0.0070389872,0.00045363922,0.0023211264,0.001181832,0.000044200446,0.036916144],"genre_scores_gemma":[0.9799321,0.002780937,0.00017824676,0.0008489331,0.00010162855,0.00054137845,0.0002585745,0.000030952244,0.015327245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977176,0.00013372557,0.0003936355,0.00071968447,0.00050239335,0.00053296046],"domain_scores_gemma":[0.9983968,0.000059894643,0.00007897441,0.0010390361,0.00023883735,0.00018643735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025465086,0.00019313222,0.0004442165,0.0002704077,0.00010789623,0.00012742363,0.0011059501,0.00006784401,0.00318209],"category_scores_gemma":[0.00013055086,0.00017188667,0.000030538715,0.0013276583,0.00016516041,0.0005430298,0.0014588642,0.0003784979,0.00008393181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018905265,0.00023953078,0.87888557,0.000078116704,0.000040040006,0.000058751397,0.0005625206,0.0000023390087,0.000018702296,0.00009858345,0.025208501,0.09461832],"study_design_scores_gemma":[0.0013842025,0.00004466241,0.9035275,0.0006345818,0.000014269441,4.444728e-7,0.00007628822,0.00034546063,0.00028697352,0.000012342179,0.09351837,0.00015490918],"about_ca_topic_score_codex":0.70341486,"about_ca_topic_score_gemma":0.6219065,"teacher_disagreement_score":0.094463415,"about_ca_system_score_codex":0.00074717373,"about_ca_system_score_gemma":0.0010094898,"threshold_uncertainty_score":0.9977291},"labels":[],"label_agreement":null},{"id":"W4410455631","doi":"10.1016/j.esmoop.2025.104995","title":"423P Role of individualized intervention(s) on quality of life (QOL) and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer (EBC): MyChoice, a prospective multicenter trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Saskatoon Medical Imaging; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Breast cancer; Quality of life (healthcare); Stage (stratigraphy); Adjuvant; Intervention (counseling); Multicenter trial; Gynecology; Oncology; Randomized controlled trial; Endocrine system; Cancer; Internal medicine; Multicenter study; Nursing; Hormone","score_opus":0.029504717847214673,"score_gpt":0.37209205964876635,"score_spread":0.3425873418015517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402285,0.0001551832,0.000009246182,0.00022627387,0.00012450517,0.003253728,0.00025014352,0.0000108068725,0.0019472913],"genre_scores_gemma":[0.99729776,0.000054519103,0.000053167776,0.00027774775,0.00003553162,0.0011304169,0.000009265362,0.0000144707,0.0011271101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984265,0.00018755136,0.00050571474,0.00036577662,0.00029554762,0.00021888348],"domain_scores_gemma":[0.99910855,0.0000804538,0.00021402977,0.0003070628,0.00017494921,0.000114955124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050834025,0.00016890708,0.00065645645,0.00014717288,0.000024673967,0.000032016964,0.00022540745,0.00004416979,0.0005199804],"category_scores_gemma":[0.0000725529,0.00012886718,0.00004035915,0.00035504167,0.00006891547,0.00012438236,0.00018066626,0.00017061892,0.0000012961706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2572682,0.001008995,0.7158424,0.00019711854,0.00032548246,0.000003312921,0.009058638,0.0000032779549,0.00074134115,0.00022364361,0.000034002842,0.015293556],"study_design_scores_gemma":[0.0784855,0.0044198735,0.909985,0.0008974056,0.000026212936,4.5956023e-7,0.0025336405,0.0000034520738,0.0029279524,0.000045924022,0.00055274623,0.00012180827],"about_ca_topic_score_codex":0.08697547,"about_ca_topic_score_gemma":0.04182763,"teacher_disagreement_score":0.1941426,"about_ca_system_score_codex":0.00015120761,"about_ca_system_score_gemma":0.0002267111,"threshold_uncertainty_score":0.9756565},"labels":[],"label_agreement":null},{"id":"W4410455677","doi":"10.1016/j.esmoop.2025.104985","title":"414TiP Phase I/II study (Duravelo-1) of zelenectide pevedotin, a Bicycle Toxin Conjugate: Additional cohort (B-8) in patients with advanced breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Astellas Pharma; Eisai; Plexxikon; Seagen; Bayer HealthCare; G1 Therapeutics; Chugai Pharmaceutical; NGM Biopharmaceuticals; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Syndax Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Centre Léon Bérard; MacroGenics; Celldex Therapeutics; Sanofi; Exelixis; Array BioPharma; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Merck KGaA; Celgene; Carrick Therapeutics; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Breast cancer; Conjugate; Cohort; Toxin; Medicine; Oncology; Internal medicine; Cancer; Microbiology; Biology; Mathematics","score_opus":0.01195093419835612,"score_gpt":0.35579513805209734,"score_spread":0.3438442038537412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097705,0.0000119435545,0.000007618499,0.0010749734,0.000024147124,0.0019167737,0.0010755928,0.000015945405,0.004895979],"genre_scores_gemma":[0.99691916,0.0000049916935,0.0002194892,0.00038242605,0.000024791603,0.0008260141,0.00040942823,0.000012029381,0.0012016554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896413,0.000026040056,0.0003066094,0.00031988262,0.00020688992,0.00017645252],"domain_scores_gemma":[0.9993065,0.00007033155,0.00008690211,0.00026896867,0.00016739946,0.000099926714],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010851427,0.00013595102,0.00032690287,0.000051342056,0.00009313416,0.000013293367,0.00020908593,0.000041071908,0.0034338946],"category_scores_gemma":[0.000046044326,0.0001141802,0.000028440101,0.00042909605,0.00008103747,0.00011175382,0.0001167508,0.00018616432,0.000005840058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00475774,0.011125182,0.962773,0.00010023563,0.00035820738,0.000016434766,0.00014507413,0.0000660895,0.0026584377,0.00015730342,0.0065178014,0.011324463],"study_design_scores_gemma":[0.014936035,0.00043937215,0.9659402,0.0002630458,0.00011713732,0.0000035295855,0.00012028788,0.000052138366,0.015259832,0.000034826488,0.0027051428,0.00012847368],"about_ca_topic_score_codex":0.0003013077,"about_ca_topic_score_gemma":0.000098429504,"teacher_disagreement_score":0.012601394,"about_ca_system_score_codex":0.000101067635,"about_ca_system_score_gemma":0.0002555221,"threshold_uncertainty_score":0.9974771},"labels":[],"label_agreement":null},{"id":"W4410455776","doi":"10.1016/j.esmoop.2025.104922","title":"351P Real-world (RW) analysis of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Alanine aminotransferase; Metastatic breast cancer; Alanine; Medicine; Internal medicine; Breast cancer; Alanine transaminase; Gastroenterology; Cancer; Oncology; Biology; Biochemistry; Amino acid","score_opus":0.014352393836994859,"score_gpt":0.31418076628660285,"score_spread":0.29982837244960797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366164,0.000053695225,0.0014083252,0.00095040485,0.0000337025,0.002048316,0.0006693928,0.000061868785,0.001112657],"genre_scores_gemma":[0.9947274,0.000103660896,0.0012406356,0.0004968721,0.000016459802,0.00044351528,0.0010064512,0.00006554167,0.0018995084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972487,0.00016188437,0.0007939462,0.0007393084,0.00053711917,0.00051900436],"domain_scores_gemma":[0.99831206,0.0001229658,0.00022589536,0.0006773912,0.00048398823,0.00017770301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025785845,0.00048296683,0.0014039307,0.0010198009,0.00009374943,0.000046141962,0.000343221,0.00006629339,0.00066688505],"category_scores_gemma":[0.000012733303,0.0003611821,0.00012581568,0.0045071905,0.00020676086,0.00050407666,0.0000453917,0.000287312,0.0000043318364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01359677,0.0012258943,0.95840067,0.00021872319,0.0048854635,0.000074496165,0.000812578,0.0039077913,0.0007701544,0.00028789698,0.00003978239,0.015779775],"study_design_scores_gemma":[0.016351935,0.0006529697,0.9692259,0.00085529493,0.0046096244,0.0000044297917,0.00019409355,0.00075655535,0.0067555844,0.000028893764,0.00019509718,0.00036962933],"about_ca_topic_score_codex":0.039779663,"about_ca_topic_score_gemma":0.088595845,"teacher_disagreement_score":0.04881618,"about_ca_system_score_codex":0.00052345154,"about_ca_system_score_gemma":0.00039861846,"threshold_uncertainty_score":0.999884},"labels":[],"label_agreement":null},{"id":"W4410455818","doi":"10.1016/j.esmoop.2025.104916","title":"345P Pooled safety analysis of sacituzumab govitecan (SG) in metastatic breast cancer (mBC), including data from patients (pts) treated in NA/EU and Asia","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead Sciences","keywords":"Metastatic breast cancer; Medicine; Pooled analysis; Internal medicine; Cancer; Oncology; Breast cancer","score_opus":0.047449307139542186,"score_gpt":0.3689127274295066,"score_spread":0.3214634202899644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992234,0.000689776,0.000007912028,0.0008099965,0.00004381439,0.000759991,0.0024304749,0.000008248984,0.0030157669],"genre_scores_gemma":[0.9979639,0.0003361314,0.00012917722,0.0001585175,0.000005649629,0.00007565282,0.0010961933,0.000009856281,0.00022490833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861956,0.0000875416,0.000452334,0.00047583508,0.00017115693,0.00019359896],"domain_scores_gemma":[0.99919015,0.00012662905,0.00012102874,0.00044342544,0.00006579347,0.00005295884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019218588,0.00018375835,0.00094319537,0.00041176888,0.00006432044,0.000028985167,0.00026830408,0.00004129417,0.00033444905],"category_scores_gemma":[0.00007124743,0.0001454778,0.000048198322,0.0014696555,0.00005771153,0.00017759264,0.0007648667,0.00011053403,0.0000010645354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016465894,0.00043922948,0.9534775,0.00003454545,0.003683007,0.00002740598,0.0006370348,0.000025986094,0.000040010338,0.000025601652,0.00018845509,0.039774626],"study_design_scores_gemma":[0.005932532,0.000094948395,0.98805726,0.00033039172,0.002844356,3.4239258e-7,0.0004813794,0.0016520268,0.00010692322,0.00003283112,0.00035620225,0.00011082494],"about_ca_topic_score_codex":0.19134544,"about_ca_topic_score_gemma":0.22250225,"teacher_disagreement_score":0.0396638,"about_ca_system_score_codex":0.0005186276,"about_ca_system_score_gemma":0.00013719765,"threshold_uncertainty_score":0.81403947},"labels":[],"label_agreement":null},{"id":"W4410455898","doi":"10.1016/j.esmoop.2025.104875","title":"303MO Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto; Ottawa Hospital; University Health Network","funders":"","keywords":"Metastatic breast cancer; Medicine; Chemotherapy; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.061661054827280605,"score_gpt":0.42850645695208844,"score_spread":0.3668454021248078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802142,0.000049366612,0.0014172235,0.0061988668,0.00008891052,0.0044045877,0.0016445135,0.000035178204,0.0059471987],"genre_scores_gemma":[0.9905143,0.000025511341,0.004753856,0.0007661944,0.000117164804,0.00070208445,0.00038494408,0.000023606979,0.0027123555],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988348,0.000022780288,0.00039591943,0.00035617422,0.00017912485,0.00021118818],"domain_scores_gemma":[0.99903077,0.00012759119,0.00017527713,0.000384359,0.00017316153,0.000108870314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019245749,0.00016486972,0.00040726457,0.000033209275,0.0001049179,0.000046944107,0.00029876153,0.000051794494,0.00023672897],"category_scores_gemma":[0.00007414209,0.00012778176,0.00007188259,0.0002551223,0.00010187406,0.000117723815,0.000058662845,0.00013936793,0.000002182193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7084607,0.019538129,0.001578786,0.0013687303,0.0015942515,0.0000166435,0.0004936341,0.00002735218,0.04897557,0.0005501796,0.060212504,0.15718354],"study_design_scores_gemma":[0.5698,0.0013690309,0.0030980697,0.00097181275,0.00091988675,0.00001429098,0.00009882544,0.001137986,0.3378021,0.00019486753,0.08425336,0.00033974583],"about_ca_topic_score_codex":0.00023698756,"about_ca_topic_score_gemma":0.000010779012,"teacher_disagreement_score":0.28882656,"about_ca_system_score_codex":0.00007290473,"about_ca_system_score_gemma":0.0003019113,"threshold_uncertainty_score":0.5210789},"labels":[],"label_agreement":null},{"id":"W4410455900","doi":"10.1016/j.esmoop.2025.104879","title":"307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Quality of life (healthcare); Adverse effect; Phase (matter); Medicine; Family medicine; Quality (philosophy); Gerontology; Internal medicine; Nursing; Philosophy; Chemistry","score_opus":0.4159915797025908,"score_gpt":0.4920141183729708,"score_spread":0.07602253867038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936651,0.00007934263,0.00032367406,0.0022389053,0.00025392624,0.001974386,0.00034420317,0.000013742943,0.0011066925],"genre_scores_gemma":[0.9980706,0.000004987041,0.0002286124,0.0012643406,0.000042789823,0.00009731495,0.00011626044,0.000012222206,0.00016286949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925202,0.0010753864,0.005584203,0.00047142484,0.00014289662,0.00020586155],"domain_scores_gemma":[0.99154836,0.0018758338,0.005341658,0.0010033894,0.00010586819,0.0001248875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009647266,0.00016981525,0.0017177778,0.00042764633,0.00021352999,0.00003168146,0.00056754146,0.00013671402,0.00008389576],"category_scores_gemma":[0.0063034813,0.00017593794,0.00024146347,0.0010535856,0.00007684172,0.00052065274,0.00020372275,0.00013937667,0.000013737544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005143738,0.00037479494,0.9632456,0.00014661164,0.0012262149,6.328907e-8,0.0017483957,0.00016563454,0.0000010955587,0.03203225,0.00043327463,0.000111714886],"study_design_scores_gemma":[0.01708254,0.000111429654,0.9685513,0.00007472028,0.00030093582,3.916219e-8,0.0011619077,0.0016180776,0.000010600849,0.010704758,0.00021650862,0.00016721875],"about_ca_topic_score_codex":0.006300764,"about_ca_topic_score_gemma":0.0006898691,"teacher_disagreement_score":0.021327494,"about_ca_system_score_codex":0.00017110759,"about_ca_system_score_gemma":0.00030959566,"threshold_uncertainty_score":0.9524912},"labels":[],"label_agreement":null},{"id":"W4410455950","doi":"10.1016/j.esmoop.2025.104772","title":"218P Treatment patterns, overall survival (OS), and healthcare resource utilization (HCRU) among patients with HER2-positive (HER2+), high- or intermediate-risk, early-stage breast cancer (eBC) in Canada","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Calgary; AstraZeneca (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Breast cancer; Overall survival; Internal medicine; Cancer","score_opus":0.019693295668072066,"score_gpt":0.24280660012365876,"score_spread":0.2231133044555867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909293,0.00016477273,0.000049377955,0.00076079083,0.00036016415,0.00091748394,0.00465,0.0000099708695,0.0021581093],"genre_scores_gemma":[0.99616027,0.0009932725,0.00001680809,0.00061973266,0.000050219493,0.000131956,0.00017724611,0.000034027038,0.0018164675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835354,0.000052809963,0.00055002293,0.00058324164,0.00004826234,0.0004120966],"domain_scores_gemma":[0.9991163,0.00006673129,0.00033218233,0.0002910697,0.00004988697,0.00014384383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017912907,0.00027121048,0.0006225028,0.00013973002,0.00014309361,0.00017243258,0.00029310622,0.00010026027,0.0003673306],"category_scores_gemma":[0.000023094764,0.00025034053,0.000031176034,0.00017314158,0.00005653033,0.00050109194,0.00016613709,0.00018259726,0.0000069015305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000515783,0.00008021181,0.98806316,0.000031196203,0.000087308,0.000009931692,0.00048309827,0.00010775989,8.9464685e-9,0.0014128978,0.00037016536,0.00883851],"study_design_scores_gemma":[0.0028408074,0.00020926414,0.99009335,0.00019133194,0.000011491043,2.4061413e-7,0.00019173736,0.00013622404,0.000008136305,0.00013708384,0.0058899806,0.00029035535],"about_ca_topic_score_codex":0.99580866,"about_ca_topic_score_gemma":0.9953677,"teacher_disagreement_score":0.008548155,"about_ca_system_score_codex":0.0020156053,"about_ca_system_score_gemma":0.00060929457,"threshold_uncertainty_score":0.9999949},"labels":[],"label_agreement":null},{"id":"W4410463538","doi":"10.1016/j.esmoop.2025.104671","title":"117P PIK3CA mutational status concordance between plasma and tumor in HER2+ advanced breast cancer (ABC) patients (pts) of ALPHABET (GEICAM/2017-01_IBCSG 62-20_BIG 18-04) trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Ipsen; Universitat de València; PharmaMar; Astellas Pharma; Seagen; Sociedad Española de Oncología Médica; BeiGene; Mersana Therapeutics; AstraZeneca España; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Dana-Farber Cancer Institute; McGill University; Merck KGaA; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer","keywords":"Concordance; Breast cancer; Oncology; Internal medicine; Medicine; Alphabet; Cancer; HER2 negative; Metastatic breast cancer","score_opus":0.022531783675793643,"score_gpt":0.3512807230497896,"score_spread":0.32874893937399596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410463538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163485,0.00035738904,0.00009135251,0.0010295048,0.00054840447,0.0024565107,0.0010146664,0.000036571848,0.0028307268],"genre_scores_gemma":[0.99503016,0.000089014626,0.002230906,0.00057813927,0.00018773187,0.0004716934,0.0002145196,0.000046469184,0.001151384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744546,0.00011916093,0.000791996,0.0006538782,0.00045285645,0.0005366717],"domain_scores_gemma":[0.99840903,0.00026901104,0.00040194148,0.00042590292,0.0002916349,0.0002024897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026742733,0.000348085,0.00097031024,0.00021725219,0.00010832958,0.000044031716,0.0003889852,0.00010676587,0.00042711975],"category_scores_gemma":[0.00016337913,0.00032960693,0.00007768698,0.0005087036,0.00032515408,0.0005205505,0.00029529998,0.00034227682,0.000010872719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055960685,0.00077624846,0.757882,0.00027687065,0.00040585917,0.00004144455,0.00080781867,0.0001689115,0.0002845762,0.00042767604,0.00076246774,0.18220547],"study_design_scores_gemma":[0.0926513,0.00062862836,0.88980347,0.00082040374,0.000106040825,0.000011014947,0.0002494509,0.00006262449,0.0011543692,0.0007049475,0.013500264,0.00030746558],"about_ca_topic_score_codex":0.003176204,"about_ca_topic_score_gemma":0.0009846344,"teacher_disagreement_score":0.18189801,"about_ca_system_score_codex":0.00044301827,"about_ca_system_score_gemma":0.0009644635,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4410463909","doi":"10.1016/j.esmoop.2025.104766","title":"212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; Ipsen; Eisai; Pfizer; Ministero della Salute; Incyte; Teva Pharmaceutical Industries; Gilead Sciences; Amgen; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine; Gynecology; Postmenopausal women; Adjuvant; Breast cancer; Cancer; Biology","score_opus":0.023663144756867982,"score_gpt":0.36959615737085977,"score_spread":0.3459330126139918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410463909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99144673,0.0020558308,0.000015246088,0.0024077282,0.000026322801,0.0026902948,0.00056785607,0.000008160675,0.00078185357],"genre_scores_gemma":[0.99721575,0.0009885372,0.00006694915,0.00030923763,0.000011345813,0.00097356143,0.000028551269,0.000022307066,0.00038376285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861413,0.00023448573,0.0002212619,0.00041010772,0.00019600704,0.00032398282],"domain_scores_gemma":[0.9989702,0.00022168548,0.00013096098,0.00036768956,0.0001824506,0.00012702677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027824778,0.00025914118,0.0008693758,0.0003281701,0.000092738126,0.000031039566,0.00016456204,0.000045649977,0.00009814999],"category_scores_gemma":[0.000009990086,0.0001620658,0.000038502458,0.00081492856,0.00021906034,0.00019596043,0.00007237988,0.00012821631,1.0325121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1865342,0.0021000553,0.4451496,0.00019701937,0.026763711,0.00039168462,0.20842479,0.0017978807,0.0037522158,0.0064172987,0.000011623949,0.11845991],"study_design_scores_gemma":[0.023802739,0.0038875,0.96120864,0.00016216667,0.00058169744,0.000016761598,0.008717361,0.000046791214,0.00073365483,0.000053622007,0.00063720794,0.00015185797],"about_ca_topic_score_codex":0.6976329,"about_ca_topic_score_gemma":0.51655376,"teacher_disagreement_score":0.51605904,"about_ca_system_score_codex":0.0012677757,"about_ca_system_score_gemma":0.00088459876,"threshold_uncertainty_score":0.66088516},"labels":[],"label_agreement":null},{"id":"W4410464113","doi":"10.1016/j.esmoop.2025.104744","title":"190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of Birmingham; Veracyte","keywords":"Breast cancer; Oncology; Medicine; Cancer; Internal medicine","score_opus":0.11278990042249279,"score_gpt":0.4610803198658805,"score_spread":0.3482904194433877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410464113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763364,0.00016454789,0.00008750302,0.00042620246,0.000079572594,0.0013242878,0.00018133993,0.0000038584085,0.0000990406],"genre_scores_gemma":[0.99796313,0.000049934137,0.0012918998,0.00015377601,0.000029640583,0.00025526492,0.000030452527,0.000009728133,0.00021617312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982571,0.000378613,0.0004418808,0.00057008094,0.00013621003,0.00021613351],"domain_scores_gemma":[0.9989836,0.000101762766,0.0001393122,0.0006532414,0.00008767415,0.00003438265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038959776,0.00022919486,0.00060578994,0.00006933675,0.00009586989,0.0000514222,0.0004629034,0.0000883079,0.000031393916],"category_scores_gemma":[0.0000405875,0.00014537587,0.00033186108,0.00032790552,0.00013765407,0.000010002128,0.00027182972,0.000067238914,9.57994e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087355025,0.0037747181,0.9892723,0.000004062043,0.0037572447,0.000005305134,0.0008254612,0.00038341494,0.000037984762,0.0000024456936,0.000021496118,0.0010420344],"study_design_scores_gemma":[0.0042953272,0.00045026737,0.99240834,0.000009539102,0.0012561295,0.0000011940817,0.0010155804,0.00023802381,0.00015636059,0.0000021385515,0.000040653584,0.00012645965],"about_ca_topic_score_codex":0.033602912,"about_ca_topic_score_gemma":0.014599348,"teacher_disagreement_score":0.019003564,"about_ca_system_score_codex":0.00010838971,"about_ca_system_score_gemma":0.00014356946,"threshold_uncertainty_score":0.9728324},"labels":[],"label_agreement":null},{"id":"W4410611436","doi":"10.1016/j.esmoop.2025.105110","title":"Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"National Cancer Institute; Loxo Oncology; Bayer HealthCare; Bayer Corporation; Bayer","keywords":"Trk receptor; Cancer; Line (geometry); Fusion; Medicine; Internal medicine; Neurotrophin","score_opus":0.01762276124513903,"score_gpt":0.3755784067848174,"score_spread":0.3579556455396784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410611436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98101205,0.00021513704,0.000074507174,0.0026537608,0.000114456096,0.004296499,0.00013661398,0.00001375305,0.011483245],"genre_scores_gemma":[0.98849136,0.00028990195,0.00079720863,0.00020778748,0.000022390628,0.00050823955,0.00018456481,0.000011284797,0.009487287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995363,0.000007757365,0.00012918867,0.00017373127,0.000062803476,0.00009024688],"domain_scores_gemma":[0.99959826,0.00007534536,0.00005346215,0.00014227818,0.000085742875,0.000044898086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028225506,0.000091865986,0.00021930938,0.000037285623,0.000107007145,0.000011835202,0.000042634078,0.000028668343,0.0001257846],"category_scores_gemma":[0.000020577963,0.00005669785,0.000024958958,0.00009700385,0.000022727361,0.000044930184,0.000033858614,0.00002091176,0.0000014115908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016599065,0.0037023677,0.6008496,0.0002161857,0.0018548988,0.000005577612,0.0020254203,0.00008494666,0.000019286781,0.0007883887,0.0024522748,0.37140197],"study_design_scores_gemma":[0.046781935,0.0041528614,0.80628484,0.0006804101,0.0010693854,9.677403e-7,0.00007544488,0.000026866206,0.0013287264,0.00009513212,0.13940218,0.00010124207],"about_ca_topic_score_codex":0.004260333,"about_ca_topic_score_gemma":0.0016598487,"teacher_disagreement_score":0.3713007,"about_ca_system_score_codex":0.00013248691,"about_ca_system_score_gemma":0.0001926506,"threshold_uncertainty_score":0.64403766},"labels":[],"label_agreement":null},{"id":"W4410840498","doi":"10.1016/j.esmoop.2025.105065","title":"Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Eisai Canada; Otsuka Pharmaceutical; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Sanofi; Exelixis; Moderna; F. Hoffmann-La Roche; Taiho Pharmaceutical; Boston Scientific Corporation; Ipsen; BeiGene; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Pembrolizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Cancer; Sorafenib; Immunotherapy","score_opus":0.18335039971298422,"score_gpt":0.37988705921614,"score_spread":0.1965366595031558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410840498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818976,0.0010171012,0.000038052938,0.0016458853,0.00017611113,0.007284366,0.00017654622,0.000021828462,0.0014503567],"genre_scores_gemma":[0.99725616,0.0000798497,0.00024079633,0.0000823539,0.000015095505,0.000567427,0.0002961099,0.000031121333,0.0014310696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631125,0.00042637356,0.0018740614,0.00057878485,0.00046122412,0.00034831397],"domain_scores_gemma":[0.9963054,0.00074819854,0.001148559,0.0012787471,0.0003673948,0.00015171253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008041072,0.00036939557,0.0023898913,0.00035798197,0.00020491329,0.00001462648,0.0005196209,0.0001496922,0.00019677906],"category_scores_gemma":[0.00050215254,0.00026426523,0.00075056794,0.0017787706,0.00012925087,0.000090344554,0.00025335394,0.0001370812,0.0000025281563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01257311,0.003325053,0.96811664,0.00041855834,0.0077206283,0.000006642691,0.003408306,0.00022818478,0.00012248366,0.0005026483,0.00008832232,0.003489419],"study_design_scores_gemma":[0.09441754,0.015372088,0.84770423,0.00032259952,0.009570639,0.0000012307875,0.0035220815,0.011547839,0.016214637,0.00009787672,0.0008499275,0.00037931616],"about_ca_topic_score_codex":0.03881303,"about_ca_topic_score_gemma":0.005758283,"teacher_disagreement_score":0.12041242,"about_ca_system_score_codex":0.00034914108,"about_ca_system_score_gemma":0.0010635238,"threshold_uncertainty_score":0.9999809},"labels":[],"label_agreement":null},{"id":"W4411017374","doi":"10.1016/j.esmoop.2025.105286","title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; EMD Serono; Genentech; National Cancer Institute; Gilead Sciences; Servier; Sociedad Española de Oncología Médica; Astellas Pharma; University of Toronto; Canadian Cancer Society; Seagen; PTC Therapeutics; Celgene; Conquer Cancer Foundation; Princess Margaret Cancer Foundation; Breast Cancer Research Foundation; Sanofi; GlaxoSmithKline; Pfizer; Symphogen; American Society of Clinical Oncology; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Canadian Association of Medical Oncologists; Susan G. Komen for the Cure; Amgen","keywords":"Epigenomics; Identification (biology); Breast cancer; Computational biology; Cancer; Stage (stratigraphy); DNA methylation; genomic DNA; Biology; Oncology; DNA; Medicine; Genetics; Gene","score_opus":0.04882968378360836,"score_gpt":0.3169911366718874,"score_spread":0.26816145288827903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959484,0.0010497797,0.0010552427,0.00016227843,0.00008324975,0.0013370587,0.00028236653,0.0000010598626,0.0000805661],"genre_scores_gemma":[0.9992732,0.000061394196,0.00015454752,0.00009894476,0.000028618304,0.00028159752,0.000070284004,0.00001086094,0.000020576517],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991872,0.000058570564,0.00033748808,0.0002369225,0.00007520752,0.00010463136],"domain_scores_gemma":[0.9991529,0.00015153486,0.00023860906,0.00026100737,0.00017954502,0.00001642055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005617926,0.000088652945,0.00015901981,0.000044981243,0.000057952984,0.000032863278,0.00023370876,0.00003516524,0.000007138026],"category_scores_gemma":[0.00012857546,0.00008186627,0.0000400885,0.00007144416,0.00007943195,0.0000045863844,0.00013927501,0.0000358679,2.3303616e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045136493,0.00014440814,0.11162785,0.00033490692,0.00018248038,5.701218e-7,0.0003616093,0.14353879,0.72985196,0.00093505863,0.000111102134,0.012459906],"study_design_scores_gemma":[0.0014272027,0.000039499115,0.84628636,0.000051834595,0.00011191132,9.430178e-7,0.00022983717,0.035323367,0.115843214,0.00026947868,0.00031349575,0.00010287733],"about_ca_topic_score_codex":0.0021474021,"about_ca_topic_score_gemma":0.0009213606,"teacher_disagreement_score":0.7346585,"about_ca_system_score_codex":0.000048833983,"about_ca_system_score_gemma":0.00037777438,"threshold_uncertainty_score":0.33384097},"labels":[],"label_agreement":null},{"id":"W4411017560","doi":"10.1016/j.esmoop.2025.105120","title":"Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; University of California, San Francisco; Eisai; Daiichi-Sankyo; Veracyte; Genentech; NSABP Foundation; Les Laboratories Pierre Fabre; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Seagen; Roche","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Quality of life (healthcare); Adjuvant; Randomized controlled trial; Internal medicine; Cancer; Adjuvant therapy; Endocrine system; Gynecology; Metastatic breast cancer; Hormone","score_opus":0.031208791184765088,"score_gpt":0.3602247273950173,"score_spread":0.3290159362102522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691666,0.0013095954,0.000058081274,0.0052987286,0.000175776,0.0047985334,0.00007017308,0.000016941976,0.0013555109],"genre_scores_gemma":[0.99573296,0.0014788941,0.0003186206,0.0011443335,0.00009247881,0.00080741744,0.000012534168,0.000027196362,0.00038553734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971234,0.00080968643,0.0009106075,0.00041491888,0.00042044497,0.00032095108],"domain_scores_gemma":[0.9979518,0.00088026177,0.00037118685,0.0005713505,0.0001501451,0.000075244556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014771136,0.00028568378,0.0016805197,0.00017828257,0.0000456623,0.000035653993,0.0004549298,0.00008668164,0.000117564465],"category_scores_gemma":[0.00019485819,0.00017071681,0.000116971234,0.0005900926,0.0004161309,0.00019477856,0.00014742235,0.00034962798,8.709343e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8317622,0.0004960517,0.12896518,0.00014349284,0.00039915307,0.0000146475695,0.0028924095,0.000015176631,0.00020267523,0.0006060751,0.000035714846,0.03446723],"study_design_scores_gemma":[0.62322897,0.00027602268,0.37373576,0.00047299947,0.000045407098,0.000010639224,0.00041844984,0.000016172951,0.00030206316,0.00057172705,0.0007787794,0.00014300579],"about_ca_topic_score_codex":0.026936466,"about_ca_topic_score_gemma":0.008341453,"teacher_disagreement_score":0.24477056,"about_ca_system_score_codex":0.000086234926,"about_ca_system_score_gemma":0.00058546726,"threshold_uncertainty_score":0.97954327},"labels":[],"label_agreement":null},{"id":"W4411135651","doi":"10.1016/j.esmoop.2025.105125","title":"Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Bayer Yakuhin; MSD K.K.; Chugai Pharmaceutical; Pfizer Japan; EMD Serono; AstraZeneca; Genentech; Council of Scientific and Industrial Research, India; Sierra Oncology; Sanofi K.K.; INCLIVA Instituto de Investigación Sanitaria; Exelixis; International Atomic Energy Agency; PharmaMar; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Novocure; Seoul National University; Indian Council of Medical Research; Intas Pharmaceuticals; Seagen; European SocieTy for Radiotherapy and Oncology; Glenmark Pharmaceuticals; The Wellcome Trust DBT India Alliance; Seoul National University Hospital; MacroGenics; Sociedad Española de Oncología Médica; BeiGene; Actuate Therapeutics; Ribon Therapeutics; Sysmex Corporation; Mersana Therapeutics; Amgen; Astellas Pharma; Deciphera Pharmaceuticals; Clovis Oncology; Natera; Regeneron Pharmaceuticals; Boehringer Ingelheim Japan; Gilead Sciences; Taiho Pharmaceutical; EQRx; F. Hoffmann-La Roche; Servier; Eisai; FibroGen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; American Society of Clinical Oncology; Hellenic Society of Medical Oncology; Sanofi; Pfizer; Celgene","keywords":"Guideline; Reimbursement; Medicine; Family medicine; China; Political science; Health care; Pathology","score_opus":0.030895119361079686,"score_gpt":0.37895786669597414,"score_spread":0.34806274733489445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411135651","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24326946,0.0059562456,0.024660708,0.56086475,0.0058535812,0.06452526,0.0017661875,0.00022068842,0.092883125],"genre_scores_gemma":[0.8808282,0.0034900547,0.09897867,0.010982304,0.00023989017,0.0024826387,0.00021630233,0.000060789374,0.0027211236],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984342,0.00007568696,0.0006342866,0.00041657023,0.00023778158,0.00020148748],"domain_scores_gemma":[0.99804187,0.0007255762,0.00028733947,0.0005291925,0.00033430159,0.00008174606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007028862,0.0001806599,0.0004459712,0.00004156962,0.00013047263,0.000050962142,0.00023773682,0.00007899224,0.00013686021],"category_scores_gemma":[0.00017335979,0.00010670702,0.000077275996,0.0002085364,0.00008746005,0.00013166058,0.0002023685,0.00013148847,0.0000029184143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013933662,0.0035364055,0.285173,0.0002496154,0.0077813887,0.00010298196,0.00025980748,0.000052206055,9.993838e-7,0.014044613,0.099671416,0.5751939],"study_design_scores_gemma":[0.0207923,0.0006604188,0.5936188,0.00038851943,0.002038368,7.460461e-7,0.00020128791,0.00010397935,0.00004214995,0.00008373644,0.38198128,0.00008842259],"about_ca_topic_score_codex":0.0040057637,"about_ca_topic_score_gemma":0.00061421073,"teacher_disagreement_score":0.63755876,"about_ca_system_score_codex":0.00008245608,"about_ca_system_score_gemma":0.00024335388,"threshold_uncertainty_score":0.6055543},"labels":[],"label_agreement":null},{"id":"W4411229260","doi":"10.1016/j.esmoop.2025.105303","title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Genentech; Sun Pharma; Natera; Relay Therapeutics; Seagen; MacroGenics; Puma Biotechnology; Loxo Oncology; Ribon Therapeutics; BeiGene; Mersana Therapeutics; Les Laboratories Pierre Fabre; Astellas Pharma; Eisai; Jazz Pharmaceuticals; F. Hoffmann-La Roche; AstraZeneca; Invitae; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Medicine; Oncology; HER2 negative; Internal medicine; Cancer; Metastatic breast cancer","score_opus":0.013185224983119479,"score_gpt":0.3310736711880635,"score_spread":0.31788844620494405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411229260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788796,0.007993111,0.00018418666,0.006883678,0.00008779468,0.002618002,0.00008361274,0.000020970525,0.0032490694],"genre_scores_gemma":[0.9839956,0.012756369,0.0019462114,0.00057364634,0.000006638006,0.00023253972,0.000020010275,0.000019363732,0.0004496069],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99884313,0.00009682016,0.0003509705,0.0003558354,0.00015145875,0.00020180213],"domain_scores_gemma":[0.99945104,0.00008930904,0.00012330747,0.00019874667,0.00009453245,0.000043049753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025301118,0.00019164519,0.0005208497,0.00018767637,0.000046842706,0.000022813343,0.00013681583,0.000057453355,0.00006453307],"category_scores_gemma":[0.000009823146,0.00017605825,0.000021430207,0.00056238944,0.00016808718,0.00037242193,0.0002512301,0.00015652791,6.2057717e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010601318,0.00076214486,0.18695818,0.001466775,0.0006078653,0.00009410978,0.005176598,0.00021790918,0.000550268,0.008537436,0.000035316287,0.7849921],"study_design_scores_gemma":[0.01346793,0.000100115976,0.9746002,0.0042046746,0.000050705556,0.000014221739,0.0017662788,0.000110122055,0.001196074,0.003681557,0.00065352395,0.00015457551],"about_ca_topic_score_codex":0.005068208,"about_ca_topic_score_gemma":0.0038035936,"teacher_disagreement_score":0.78764206,"about_ca_system_score_codex":0.00025067414,"about_ca_system_score_gemma":0.000065391134,"threshold_uncertainty_score":0.76616484},"labels":[],"label_agreement":null},{"id":"W4411628399","doi":"10.1016/j.esmoop.2025.105332","title":"70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Nab-paclitaxel; Paclitaxel; Medicine; Ovarian cancer; Internal medicine; Oncology; Chemotherapy; Cancer","score_opus":0.025907286003502127,"score_gpt":0.324439035187439,"score_spread":0.2985317491839369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411628399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92636555,0.00057781115,0.00029157914,0.0012444489,0.0013278053,0.001761346,0.0036927557,0.000100379584,0.06463834],"genre_scores_gemma":[0.99008185,0.00007950706,0.0020801418,0.00046974764,0.00011028493,0.00018481271,0.0001955609,0.000037773647,0.0067603528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99587476,0.0004251989,0.0014888463,0.0009997558,0.0005091274,0.0007023157],"domain_scores_gemma":[0.99788564,0.00036359587,0.00046036363,0.00091346545,0.00019033742,0.00018659097],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020556422,0.00043463975,0.001013345,0.0003016594,0.0002942148,0.0002647917,0.0012776924,0.00021199956,0.0032534706],"category_scores_gemma":[0.000240329,0.00038456233,0.0001450287,0.00070575357,0.00022680272,0.0007236161,0.00040846015,0.00042240715,0.00014043976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021765044,0.0015827538,0.0007178992,0.00073210057,0.00025521475,0.0005898346,0.0065786433,0.0001481273,0.9174077,0.028110825,0.017916568,0.0041953074],"study_design_scores_gemma":[0.04441677,0.0012503848,0.024211807,0.0020035293,0.00023808125,0.0000413075,0.0018228426,0.00042065175,0.8477832,0.015658913,0.06071827,0.0014342493],"about_ca_topic_score_codex":0.023771217,"about_ca_topic_score_gemma":0.00926962,"teacher_disagreement_score":0.06962449,"about_ca_system_score_codex":0.00018506704,"about_ca_system_score_gemma":0.0006906393,"threshold_uncertainty_score":0.99986064},"labels":[],"label_agreement":null},{"id":"W4411628428","doi":"10.1016/j.esmoop.2025.105273","title":"146P Malignant bowel obstruction (MBO) symptom monitoring through artificial intelligence (AI) based automated calls in gynecologic cancers","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bowel obstruction; Internal medicine; Pathology; Radiology","score_opus":0.029995895288466013,"score_gpt":0.37430060265291226,"score_spread":0.34430470736444624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411628428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95797914,0.00015246627,0.014887515,0.012143894,0.003150603,0.0013156389,0.0000045461297,0.00037955356,0.009986641],"genre_scores_gemma":[0.9901682,0.000051407944,0.007305231,0.0017747995,0.00013048483,0.000085422274,0.000021240414,0.000020283225,0.00044290908],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983907,0.00010687628,0.00047635927,0.00043121044,0.00021470305,0.00038017283],"domain_scores_gemma":[0.9992842,0.00015160003,0.00010054737,0.0003021573,0.00006846266,0.0000930283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005553143,0.00018413362,0.0003848797,0.00015782085,0.00014531652,0.00012523169,0.00036104288,0.00013878183,0.00019248851],"category_scores_gemma":[0.0006247164,0.00016276022,0.000062078536,0.0005330941,0.00011464794,0.00018305311,0.00015102387,0.0005707089,0.000025766183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010116573,0.00073774066,0.53946584,0.0006277381,0.00037739583,0.0012193227,0.0024232445,0.1081629,0.014234351,0.012038785,0.007543564,0.31215748],"study_design_scores_gemma":[0.0010855774,0.00017505843,0.3392612,0.0014270261,0.00010623123,0.000020697446,0.00073702954,0.62979734,0.018612165,0.0041670413,0.0042636106,0.00034702258],"about_ca_topic_score_codex":0.010237673,"about_ca_topic_score_gemma":0.00021744471,"teacher_disagreement_score":0.52163446,"about_ca_system_score_codex":0.00061123393,"about_ca_system_score_gemma":0.000582781,"threshold_uncertainty_score":0.99635327},"labels":[],"label_agreement":null},{"id":"W4411642994","doi":"10.1016/j.esmoop.2025.105252","title":"126TiP REJOICE-Ovarian02: A phase Ib/II study of raludotatug deruxtecan (R-DXd) with other anticancer agents in participants (pts) with relapsed ovarian cancer (OC) after platinum-based chemotherapy","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Ovarian cancer; Chemotherapy; Medicine; Internal medicine; Oncology; Platinum; Cancer; Chemistry","score_opus":0.050804593430607815,"score_gpt":0.38529900125410677,"score_spread":0.33449440782349893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411642994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876344,0.00015779331,0.00014737867,0.004112077,0.00012715491,0.0049628993,0.00007453483,0.00003934513,0.0027443666],"genre_scores_gemma":[0.9897025,0.000035960893,0.0021199125,0.0033104932,0.00005515234,0.0030654722,0.000017797376,0.00008878268,0.0016039232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716896,0.00016698419,0.0006541358,0.00087834225,0.00050033676,0.0006312469],"domain_scores_gemma":[0.99826556,0.000095725874,0.000286666,0.0009878948,0.00015518583,0.00020897042],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042695118,0.00046113713,0.0010635298,0.00026885435,0.00012674912,0.00007767914,0.00034235272,0.00011931974,0.002266335],"category_scores_gemma":[0.000024506964,0.00032321372,0.00007324802,0.0010078601,0.00013129222,0.00018936372,0.000107083564,0.00027687455,0.0000081071385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026552804,0.013278262,0.93719023,0.00015176901,0.0018454021,0.00043290964,0.0039540823,0.00023457133,0.00010033157,0.000098296,0.00090572215,0.015255591],"study_design_scores_gemma":[0.11915448,0.0059510954,0.8592055,0.0025612295,0.0009791023,0.000004657637,0.00064667827,0.00037468996,0.003339531,0.000039715815,0.0073152357,0.00042811487],"about_ca_topic_score_codex":0.027538445,"about_ca_topic_score_gemma":0.037520118,"teacher_disagreement_score":0.09260168,"about_ca_system_score_codex":0.00042321102,"about_ca_system_score_gemma":0.0011316562,"threshold_uncertainty_score":0.999922},"labels":[],"label_agreement":null},{"id":"W4411643018","doi":"10.1016/j.esmoop.2025.105199","title":"69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; AbbVie; European Commission; Seagen; Merck; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sociedad Española de Oncología Médica; Eisai Canada; BeiGene; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Oncology; Ovarian carcinomas; Biomarker; Ovarian cancer; Internal medicine; Medicine; Phases of clinical research; Epithelial ovarian cancer; Ovarian carcinoma; Biology; Cancer; Toxicity","score_opus":0.06490799290462351,"score_gpt":0.3777180111971781,"score_spread":0.3128100182925546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411643018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496871,0.0004531968,0.00063538074,0.017107192,0.0018474282,0.017254328,0.003943006,0.00018050721,0.008891815],"genre_scores_gemma":[0.98862094,0.000036292695,0.003116735,0.0008547226,0.00024428236,0.0019458409,0.00091012235,0.00006783294,0.0042032306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966494,0.00012426254,0.0007580927,0.0012425444,0.00038084638,0.0008448771],"domain_scores_gemma":[0.9975654,0.00026607572,0.00020936584,0.0010079136,0.00048988377,0.00046138835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006838613,0.0004967403,0.00090217433,0.0003816178,0.00060283893,0.00024101538,0.00049187714,0.0001433642,0.0001453068],"category_scores_gemma":[0.0005414166,0.00043124234,0.00027577693,0.0010430749,0.000042643194,0.00021064325,0.00050271983,0.00023840023,0.000028295568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10970753,0.08227001,0.11705568,0.0008365827,0.020127786,0.0008515329,0.043773104,0.00008677586,0.011593086,0.0038624925,0.3043375,0.3054979],"study_design_scores_gemma":[0.19000283,0.028388869,0.24375363,0.0016439089,0.0042620557,0.000038632825,0.014215448,0.00067687547,0.008704289,0.00007192466,0.5068661,0.0013754385],"about_ca_topic_score_codex":0.0051888577,"about_ca_topic_score_gemma":0.0014183805,"teacher_disagreement_score":0.30412248,"about_ca_system_score_codex":0.00085730234,"about_ca_system_score_gemma":0.00097327126,"threshold_uncertainty_score":0.9998139},"labels":[],"label_agreement":null},{"id":"W4411643311","doi":"10.1016/j.esmoop.2025.105200","title":"71O Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): Opportunities for targeted treatment strategies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Serous ovarian cancer; Antibody-drug conjugate; Serous fluid; Ovarian cancer; Medicine; Conjugate; Cancer research; Drug; Antibody; Targeted therapy; Oncology; Monoclonal antibody; Internal medicine; Cancer; Immunology; Pharmacology","score_opus":0.0628592540817787,"score_gpt":0.3691242001253307,"score_spread":0.30626494604355203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411643311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9204941,0.0046040607,0.00048484147,0.04121086,0.0018280477,0.012412721,0.0010312379,0.0002402421,0.017693913],"genre_scores_gemma":[0.9760842,0.0019972979,0.0090730805,0.00094798784,0.00016412354,0.0035258536,0.0010414142,0.00005245517,0.0071135927],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817,0.00009581371,0.0004840578,0.00060278614,0.00017686884,0.0004704529],"domain_scores_gemma":[0.99903196,0.00012443858,0.00015231283,0.0004425742,0.00010471221,0.00014397781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023891623,0.00036816875,0.0007675387,0.00018953926,0.00019856617,0.00021645623,0.00024150465,0.00012437695,0.0003360886],"category_scores_gemma":[0.000019288731,0.00028429404,0.000120839046,0.0002181027,0.00006635005,0.00034819974,0.00012755573,0.00013207697,0.0000053704325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012541202,0.016758861,0.61486995,0.004116853,0.0076067047,0.0038474826,0.011832578,0.0039795125,0.04207664,0.15578695,0.061232146,0.06535116],"study_design_scores_gemma":[0.051356636,0.0020574182,0.18450627,0.0055792457,0.0012066648,0.00001806046,0.012913467,0.0011332178,0.5802096,0.011198768,0.14850648,0.0013141448],"about_ca_topic_score_codex":0.014268233,"about_ca_topic_score_gemma":0.0020023196,"teacher_disagreement_score":0.53813297,"about_ca_system_score_codex":0.00056149205,"about_ca_system_score_gemma":0.0013252875,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W4411643312","doi":"10.1016/j.esmoop.2025.105187","title":"58TiP ASCENT-GYN-01 (GOG-3104/ENGOT-en26): A randomized, phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with endometrial cancer (EC) after platinum-based chemotherapy and immunotherapy","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Gilead Sciences","keywords":"Medicine; Endometrial cancer; Gynecology; Cancer; Internal medicine","score_opus":0.015804454985232246,"score_gpt":0.3299195637676139,"score_spread":0.31411510878238164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411643312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98814154,0.0008666243,0.000029733776,0.00023441305,0.00018588814,0.009264155,0.00012698563,0.00002008447,0.0011306053],"genre_scores_gemma":[0.9962256,0.00037925882,0.00014529937,0.0005922236,0.000092354574,0.00206541,0.000062737265,0.000048470203,0.00038864554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971427,0.0002945952,0.00096884574,0.0006342476,0.0005758356,0.00038377545],"domain_scores_gemma":[0.9979163,0.00072505424,0.00048626607,0.0005764123,0.00016524781,0.00013073845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003387949,0.00048933533,0.0024302003,0.00056023785,0.00006894426,0.00004605909,0.0002614295,0.00011765669,0.00043642544],"category_scores_gemma":[0.000088612265,0.000328474,0.00022982666,0.0013689232,0.00017770074,0.00015902668,0.00006354854,0.00015593141,0.0000014348383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6842865,0.01876294,0.16004847,0.00009596922,0.00239008,0.000017409182,0.0018532163,0.000014821893,0.0001243602,0.000008949561,0.000026927572,0.1323704],"study_design_scores_gemma":[0.8584725,0.013512969,0.11901891,0.00047432756,0.0006868481,3.4449707e-7,0.00024015036,0.000041352043,0.0062736683,0.000017416985,0.0010142889,0.0002471915],"about_ca_topic_score_codex":0.029458968,"about_ca_topic_score_gemma":0.0024741634,"teacher_disagreement_score":0.17418608,"about_ca_system_score_codex":0.00058675,"about_ca_system_score_gemma":0.00036186658,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W4412440980","doi":"10.1016/j.esmoop.2025.105509","title":"The use of machine learning models to predict progression-free survival and overall survival outcomes from waterfall plots in randomized clinical trials (MAP-OUTCOMES)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Waterfall; Clinical endpoint; Confidence interval; Medicine; Randomized controlled trial; Progression-free survival; Logistic regression; Waterfall model; Artificial intelligence; Machine learning; Internal medicine; Statistics; Oncology; Overall survival; Computer science; Mathematics; Software; Cartography","score_opus":0.1472286405677557,"score_gpt":0.4280689458158332,"score_spread":0.2808403052480775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412440980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9304025,0.0005440198,0.0075050886,0.05201969,0.0021051716,0.00551974,0.000057397,0.00010134392,0.0017450422],"genre_scores_gemma":[0.9794734,0.00080637424,0.011873008,0.0022954142,0.00015701125,0.0002231501,0.00012022754,0.00007328225,0.00497814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99129754,0.0049888087,0.0021283482,0.0005714217,0.00061014097,0.0004037431],"domain_scores_gemma":[0.97445303,0.023968192,0.00044857705,0.0007544611,0.00010296119,0.0002727599],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02509921,0.00031271085,0.0032488615,0.00016755958,0.00016985004,0.0002536331,0.00076541264,0.00017615485,0.000058211288],"category_scores_gemma":[0.04557074,0.00016624053,0.00037378253,0.00016418955,0.0002835272,0.00023416028,0.0013665924,0.0010434226,0.0000039350666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04169929,0.00031548963,0.90945,0.000051277602,0.0010543838,0.000043770964,0.0004905806,0.0013147182,0.00003247844,0.0022157468,0.0019257981,0.041406453],"study_design_scores_gemma":[0.33028632,0.0002878642,0.39545602,0.0014815506,0.0007220971,0.0000024056683,0.00014097708,0.24697796,0.000037977443,0.006579508,0.01760336,0.00042395387],"about_ca_topic_score_codex":0.010723679,"about_ca_topic_score_gemma":0.0007260067,"teacher_disagreement_score":0.513994,"about_ca_system_score_codex":0.00004155093,"about_ca_system_score_gemma":0.00018252846,"threshold_uncertainty_score":0.995864},"labels":[],"label_agreement":null},{"id":"W4412708027","doi":"10.1016/j.esmoop.2025.105506","title":"Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb; Samsung; Genentech; Natera; Seagen; Puma Biotechnology; Pfizer; Incyte; BeiGene; Mersana Therapeutics; Menarini Silicon Biosystems; Astex Pharmaceuticals; Eisai; Jazz Pharmaceuticals; McGill University; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Oncology; Internal medicine; Cancer research; Cancer; Breast cancer; Medicine; Biology; Estrogen receptor","score_opus":0.017361168536061036,"score_gpt":0.3840519532464865,"score_spread":0.3666907847104255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412708027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854577,0.00012041562,0.00056664896,0.008226336,0.00015119168,0.004530719,0.0004194619,0.000016197746,0.0005113301],"genre_scores_gemma":[0.99376607,0.0000028793631,0.0018365834,0.0012898128,0.00015212456,0.0026424578,0.000085832595,0.000021590375,0.00020266556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887365,0.00011811986,0.0002558282,0.00032824138,0.000213402,0.00021074327],"domain_scores_gemma":[0.9991726,0.00039137877,0.00013084835,0.00015315671,0.00010573139,0.000046279623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000349191,0.0001790284,0.0003161787,0.00009629208,0.0001763064,0.00006891066,0.0001208581,0.000033556422,0.00008163608],"category_scores_gemma":[0.00011218768,0.00011992655,0.000050637635,0.00024994276,0.00008971299,0.00019562167,0.0000885811,0.00017765113,8.4880804e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54921937,0.0055990093,0.012077272,0.0007260484,0.0011183843,0.0006298953,0.026676198,0.00031064806,0.0005956245,0.00477649,0.0008132534,0.3974578],"study_design_scores_gemma":[0.6247355,0.008687858,0.29345512,0.00965855,0.00092520006,0.0005825554,0.012899761,0.028028546,0.0034205744,0.014873724,0.0016032167,0.0011294086],"about_ca_topic_score_codex":0.00021964789,"about_ca_topic_score_gemma":0.00046244744,"teacher_disagreement_score":0.3963284,"about_ca_system_score_codex":0.00017690909,"about_ca_system_score_gemma":0.00028560506,"threshold_uncertainty_score":0.4890463},"labels":[],"label_agreement":null},{"id":"W4413054238","doi":"10.1016/j.esmoop.2025.105539","title":"Impact of clonal hematopoiesis on cardiovascular outcomes in cancer patients of the UK Biobank","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Montreal Heart Institute","funders":"Fonds de Recherche du Québec - Santé; Canada Research Chairs","keywords":"Hazard ratio; Medicine; Internal medicine; Odds ratio; Oncology; Genotyping; Cancer; Proportional hazards model; Exome; Confidence interval; Mutation; Genetics; Biology; Exome sequencing; Genotype; Gene","score_opus":0.020626628533596744,"score_gpt":0.3460208503551015,"score_spread":0.32539422182150474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413054238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944241,0.0000740522,0.0000034572342,0.00028315274,0.00010742363,0.0006656594,0.000030062152,0.0000029519922,0.0044091456],"genre_scores_gemma":[0.99940324,0.00002884639,0.00002114289,0.00022619194,0.000010457901,0.000028215862,0.000006980025,0.000006067717,0.00026884416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993012,0.000047337748,0.0002033682,0.0001261787,0.00023067929,0.000091252696],"domain_scores_gemma":[0.99944615,0.000037104553,0.00006534794,0.00036025245,0.00007129639,0.000019856647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001864653,0.00008380952,0.00044126256,0.00006956317,0.000020939413,0.0000055910987,0.00017349109,0.00006337565,0.00008416342],"category_scores_gemma":[0.000076445045,0.0000521751,0.0004246205,0.0002595388,0.000042196873,0.000033120803,0.00007351138,0.00009148778,9.93716e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013176055,0.00021482295,0.9922967,0.000052579686,0.00088370714,7.128416e-7,0.00022916883,0.00009166018,0.002373797,0.00013149003,0.0004802219,0.00311338],"study_design_scores_gemma":[0.0017917801,0.00007164632,0.82467717,0.00026667822,0.00007088239,3.155209e-7,0.000023199613,0.0000029070009,0.17283356,0.000083827945,0.00014087591,0.00003713957],"about_ca_topic_score_codex":0.007998427,"about_ca_topic_score_gemma":0.00023640016,"teacher_disagreement_score":0.17045976,"about_ca_system_score_codex":0.00015095783,"about_ca_system_score_gemma":0.00018739066,"threshold_uncertainty_score":0.9986074},"labels":[],"label_agreement":null},{"id":"W4413111668","doi":"10.1016/j.esmoop.2025.105544","title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Eisai; Daiichi-Sankyo; Arena Pharmaceuticals; G1 Therapeutics; Incyte; Sanofi; Exelixis; Merck KGaA; Gilead Sciences; Ipsen; Mirati Therapeutics; Clovis Oncology; EUSA Pharma; Seagen; Roche; Pfizer; Eli Lilly and Company; AstraZeneca; National Cancer Institute; Accuray","keywords":"Medicine; Pembrolizumab; Internal medicine; Carboplatin; Gemcitabine; Oncology; Metastatic Urothelial Carcinoma; Clinical endpoint; Chemotherapy; Phases of clinical research; Population; Cisplatin; Cancer; Gastroenterology; Bladder cancer; Randomized controlled trial; Urothelial carcinoma; Immunotherapy","score_opus":0.06668643470950594,"score_gpt":0.42626148429913696,"score_spread":0.35957504958963105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413111668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990616,0.00013273525,0.00017530247,0.00021852035,0.00009203909,0.0071938587,0.000034083605,0.00002692955,0.0015104929],"genre_scores_gemma":[0.99806124,0.00002438111,0.00040425023,0.00026156503,0.000009715417,0.00081029464,0.00005400724,0.000029172406,0.0003453656],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977903,0.00026374916,0.00064139307,0.0005301793,0.0004303183,0.00034407945],"domain_scores_gemma":[0.9989562,0.000077321594,0.00015987095,0.00047993692,0.00020155207,0.0001251225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040059947,0.00032605365,0.0009334638,0.00030353034,0.000046858935,0.00004026121,0.00032523373,0.000043429136,0.00019767028],"category_scores_gemma":[0.00008749377,0.00024217898,0.000061027065,0.0015007819,0.000056070654,0.00024850568,0.000082650986,0.00012938016,0.0000073775113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6861902,0.025281202,0.20622477,0.0003240409,0.0024555898,0.0011376619,0.012224059,0.0009218,0.0009498282,0.00016494632,0.00019862615,0.06392731],"study_design_scores_gemma":[0.63953775,0.03746598,0.2988008,0.0010338349,0.0015393974,0.000014278612,0.006724923,0.0009014869,0.013260018,0.00011419814,0.00010823503,0.0004990889],"about_ca_topic_score_codex":0.0122400755,"about_ca_topic_score_gemma":0.024215588,"teacher_disagreement_score":0.09257601,"about_ca_system_score_codex":0.0007203572,"about_ca_system_score_gemma":0.0017166891,"threshold_uncertainty_score":0.9943375},"labels":[],"label_agreement":null},{"id":"W4413137691","doi":"10.1016/j.esmoop.2025.105513","title":"Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"European Society for Medical Oncology; Associazione Italiana per la Ricerca sul Cancro; Korea Health Industry Development Institute; Breast Cancer Research Foundation","keywords":"Medicine; Pregnancy; Breast cancer; Interquartile range; Obstetrics; Cumulative incidence; Retrospective cohort study; Incidence (geometry); Gynecology; Cancer; Cohort; Internal medicine","score_opus":0.013120325659892,"score_gpt":0.3045750932487701,"score_spread":0.29145476758887806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413137691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903824,0.004553696,0.0000063029347,0.00053864636,0.00026154664,0.0014027671,0.00016588824,0.00001183164,0.0026769477],"genre_scores_gemma":[0.99529034,0.0027417473,0.00006767617,0.00002817975,0.00001929143,0.00062335876,0.0000066586044,0.000020940884,0.0012017846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986886,0.000035153564,0.0005064532,0.0003164864,0.00019093762,0.0002623755],"domain_scores_gemma":[0.99925303,0.000030446825,0.00015614423,0.0003924043,0.00009017544,0.00007780744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082206956,0.00016266952,0.0005304195,0.00016135066,0.00003967784,0.000016681874,0.0002397805,0.00008713802,0.00064762414],"category_scores_gemma":[0.000034522363,0.00014586381,0.00010981398,0.0003870807,0.00007772233,0.00017868154,0.00025329512,0.00016943147,8.8743803e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006377151,0.00013349623,0.98170006,0.00073758024,0.00011289866,0.000048276837,0.0018675313,0.000018047169,0.00027399155,0.000037515543,0.000036045516,0.014396828],"study_design_scores_gemma":[0.0024839907,0.000039003527,0.96462965,0.024551252,0.00011693867,0.000007783609,0.00022614135,0.000011434601,0.0076702153,0.000013393416,0.00012759719,0.00012257238],"about_ca_topic_score_codex":0.054503012,"about_ca_topic_score_gemma":0.027339095,"teacher_disagreement_score":0.027163915,"about_ca_system_score_codex":0.00037180047,"about_ca_system_score_gemma":0.0003750115,"threshold_uncertainty_score":0.99040943},"labels":[],"label_agreement":null},{"id":"W4414042050","doi":"10.1016/j.esmoop.2025.105576","title":"Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Aminex Therapeutics","keywords":"Metabolism; Phase (matter); Immune system; Enzyme; Polyamine","score_opus":0.016307949896201733,"score_gpt":0.32409459663163254,"score_spread":0.3077866467354308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414042050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667104,0.0026948072,0.015104745,0.0004481984,0.00053560804,0.0024392968,0.00027210906,0.000026202011,0.011768633],"genre_scores_gemma":[0.9883178,0.00025723485,0.004755025,0.00017548737,0.00033932322,0.00052095874,0.0016160597,0.000028171049,0.003989962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982096,0.00019559858,0.00059475156,0.00052111316,0.00018612879,0.00029278937],"domain_scores_gemma":[0.9987318,0.00003562274,0.00032967044,0.0006866625,0.00012885056,0.00008739649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552542,0.00024965245,0.00046217872,0.000108114706,0.00017738533,0.000085903,0.0006671791,0.00017543847,0.000047121568],"category_scores_gemma":[0.00027208464,0.00022203056,0.00015368046,0.00038434222,0.00012582517,0.000022344895,0.00074409536,0.00015845145,0.000008510636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007806198,0.0020910422,0.000032546763,0.00005049535,0.00043213845,0.000002079685,0.00026860196,0.00012167584,0.9625004,0.002363033,0.007174812,0.017157007],"study_design_scores_gemma":[0.079694934,0.00040980912,0.0029282367,0.000030382884,0.00035761998,0.000004220393,0.0002684247,0.00069248927,0.7794964,0.00042288663,0.13520274,0.00049190986],"about_ca_topic_score_codex":0.0003574921,"about_ca_topic_score_gemma":0.0000069424614,"teacher_disagreement_score":0.18300402,"about_ca_system_score_codex":0.000014503301,"about_ca_system_score_gemma":0.00020250531,"threshold_uncertainty_score":0.90541434},"labels":[],"label_agreement":null},{"id":"W4414163820","doi":"10.1016/j.esmoop.2025.105555","title":"Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Institute of Cancer Research; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Roche; Bayer","keywords":"Mesenchymal stem cell; RNA; Genome; Sarcoma; DNA sequencing","score_opus":0.04593409775580879,"score_gpt":0.36091724509136597,"score_spread":0.31498314733555716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414163820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9020964,0.0006264645,0.00014678907,0.006354901,0.0002274774,0.0009414302,0.000005135153,0.000046391815,0.08955505],"genre_scores_gemma":[0.99218446,0.000024020894,0.0030319737,0.0012595133,0.000047094527,0.00015585513,0.000051329167,0.000018866354,0.003226857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864954,0.00007149098,0.00034189963,0.00037469334,0.00019399227,0.00036839524],"domain_scores_gemma":[0.9992442,0.00013011489,0.00006708823,0.00039105455,0.000051756942,0.000115748386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003847061,0.00017984211,0.00045764146,0.00021764354,0.00018111627,0.000207275,0.0002431751,0.000077509256,0.00059768604],"category_scores_gemma":[0.000117537515,0.00014894782,0.00008070594,0.00055229093,0.00003858666,0.00041361002,0.0003271941,0.00023169979,0.00012154053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007680315,0.0010770593,0.9431425,0.00009124128,0.00021231943,0.0023248747,0.00060698664,0.00012294124,0.008472715,0.0022031493,0.005772453,0.035896987],"study_design_scores_gemma":[0.00316971,0.000077898636,0.9649757,0.001204046,0.00014121804,0.00005920255,0.0009721475,0.0011274524,0.013703823,0.0013174813,0.013023944,0.00022734559],"about_ca_topic_score_codex":0.0067213485,"about_ca_topic_score_gemma":0.00070991676,"teacher_disagreement_score":0.09008813,"about_ca_system_score_codex":0.0004269999,"about_ca_system_score_gemma":0.0004628253,"threshold_uncertainty_score":0.999893},"labels":[],"label_agreement":null},{"id":"W4414710065","doi":"10.1016/j.esmoop.2025.105690","title":"113P Evaluating molecular diagnostic tools for detecting ALK and ROS1 mutations in non-small cell lung cancer: A real-world analysis","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"ROS1; Lung; Mutation; Cell; Lung cancer","score_opus":0.027228960125445022,"score_gpt":0.4147688840025716,"score_spread":0.3875399238771266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492844,0.00048865343,0.005183099,0.0010678503,0.00008168428,0.003287595,0.00005832486,0.00002163673,0.014882721],"genre_scores_gemma":[0.98697096,0.00008760544,0.008167382,0.0003469407,0.000020991589,0.002188023,0.0001422394,0.00001661793,0.0020592157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990488,0.000040982377,0.0002786879,0.00033020548,0.00009378661,0.00020752627],"domain_scores_gemma":[0.9985158,0.0010063427,0.00009205476,0.00021143556,0.00010976322,0.000064601576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027575434,0.00012553122,0.00033105598,0.00031642025,0.00016924454,0.00014770743,0.00010212313,0.000038038837,0.000045821966],"category_scores_gemma":[0.0005411646,0.00011817368,0.0000795889,0.0009669505,0.000017665703,0.00013255495,0.0000853898,0.00009042601,7.7173763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013581217,0.0002932732,0.87423635,0.0005060905,0.002690085,0.00008122334,0.0037022466,0.01714008,0.0015980607,0.00043910384,0.0003149233,0.09886278],"study_design_scores_gemma":[0.008792895,0.000232941,0.88315284,0.00096232595,0.0145973675,0.0000018088456,0.0014248508,0.08125741,0.008141186,0.00049838505,0.0006049393,0.00033302995],"about_ca_topic_score_codex":0.022617271,"about_ca_topic_score_gemma":0.03246793,"teacher_disagreement_score":0.098529756,"about_ca_system_score_codex":0.0002824848,"about_ca_system_score_gemma":0.0003778602,"threshold_uncertainty_score":0.985187},"labels":[],"label_agreement":null},{"id":"W4414710091","doi":"10.1016/j.esmoop.2025.105598","title":"20MO Hallmarks of gut health influence toxicity and survival outcomes after immune-checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Toxicity; Disease; Immune system; Population; Clinical trial","score_opus":0.014115074469789716,"score_gpt":0.3278406466024053,"score_spread":0.3137255721326156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98275566,0.0013497339,0.000018245597,0.009253577,0.0002782352,0.0006951787,0.000013728894,0.000016523201,0.0056190914],"genre_scores_gemma":[0.99416184,0.00033526172,0.0002977297,0.0026709884,0.00001633392,0.000036761066,0.000007283818,0.00000996056,0.0024638074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988117,0.000073699455,0.00052214536,0.00023545485,0.00015954553,0.00019744913],"domain_scores_gemma":[0.9993033,0.0000688637,0.00014209721,0.00035684276,0.00005999777,0.00006892865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699479,0.00014150405,0.0005273586,0.00009039519,0.00006334346,0.000035852772,0.00018366288,0.000075549986,0.0001743428],"category_scores_gemma":[0.00007962203,0.00011153697,0.00010481031,0.00019404068,0.00015052459,0.00013168245,0.0002638638,0.00014313594,0.0000032476428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004017963,0.00032854604,0.9593943,0.0004288356,0.00042672243,0.0000147033725,0.0009663315,0.0000011379203,0.0074488884,0.00021433548,0.0018302602,0.02492798],"study_design_scores_gemma":[0.0028221023,0.00017925417,0.97982144,0.00047459264,0.000023813473,0.00000389561,0.00018665123,0.0000040145446,0.007723419,0.00008667477,0.008573982,0.000100140685],"about_ca_topic_score_codex":0.0138024045,"about_ca_topic_score_gemma":0.0014835183,"teacher_disagreement_score":0.02482784,"about_ca_system_score_codex":0.000093380884,"about_ca_system_score_gemma":0.00029928618,"threshold_uncertainty_score":0.9927648},"labels":[],"label_agreement":null},{"id":"W4414710138","doi":"10.1016/j.esmoop.2025.105611","title":"35P Detection of methylated circulating tumor DNA by digital PCR in patients with metastatic non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Circulating tumor cell; Circulating tumor DNA; Digital polymerase chain reaction; Lung cancer; Real-time polymerase chain reaction; DNA; Polymerase chain reaction","score_opus":0.004734892264835404,"score_gpt":0.23517142972784583,"score_spread":0.23043653746301043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964246,0.00022906002,0.0012011027,0.000013588917,0.00007689799,0.0004939591,0.00010938633,0.0000020970388,0.0014493071],"genre_scores_gemma":[0.99928916,0.000019268015,0.00019743286,0.00009487162,0.000009533854,0.000053352276,0.00014902919,0.000014445255,0.0001729086],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99935263,0.000016937021,0.00019759704,0.00023468117,0.000057250058,0.00014087508],"domain_scores_gemma":[0.99959195,0.000019796711,0.00010939507,0.00017514681,0.00007327945,0.00003043883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072149865,0.00010663435,0.00016135626,0.000039785864,0.000031207965,0.00005247602,0.0001800999,0.000036852656,0.000008381645],"category_scores_gemma":[0.000039832234,0.00010076043,0.00002837668,0.00014731487,0.00002105928,0.0000079357,0.00016661054,0.000056384404,5.368443e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007195856,0.0005952004,0.6491634,0.000265918,0.00036724246,0.0000070563874,0.00022639665,0.0032574772,0.32950237,0.000015683878,0.0011054338,0.014774191],"study_design_scores_gemma":[0.0044452143,0.00036960703,0.13503993,0.00013900815,0.0001067077,4.6899277e-7,0.00009436879,0.00094041706,0.8564202,0.000047008198,0.0020630201,0.0003340358],"about_ca_topic_score_codex":0.001612043,"about_ca_topic_score_gemma":0.00093578745,"teacher_disagreement_score":0.5269178,"about_ca_system_score_codex":0.00004196826,"about_ca_system_score_gemma":0.00014285918,"threshold_uncertainty_score":0.4108891},"labels":[],"label_agreement":null},{"id":"W4414710139","doi":"10.1016/j.esmoop.2025.105597","title":"19MO Desaminotyrosine is a key driver of the success of immunotherapy with fecal microbial transplantation in cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre","funders":"","keywords":"Immunotherapy; Cancer; Fecal bacteriotherapy; Transplantation; Key (lock); Cancer immunotherapy","score_opus":0.013192074235955316,"score_gpt":0.3068517226223231,"score_spread":0.29365964838636777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950184,0.0005117477,0.00007334929,0.002263821,0.00011461058,0.000735803,0.00004572355,0.0000036047602,0.00123292],"genre_scores_gemma":[0.99666756,0.0007453194,0.00020804386,0.0010884675,0.000011011974,0.000034984198,0.00000947203,0.0000090373505,0.0012261028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993595,0.000039999435,0.0002435732,0.00013738441,0.00011617764,0.00010339509],"domain_scores_gemma":[0.99959445,0.0000257543,0.000098990466,0.00021244596,0.00005748404,0.000010867263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013409992,0.00009103977,0.00024930187,0.00006983917,0.000031040498,0.0000115376715,0.0002540951,0.00005556393,0.0003327977],"category_scores_gemma":[0.0000021525518,0.000056787645,0.000061340375,0.00040021894,0.00014715514,0.00007399257,0.00002392096,0.00008717894,3.706599e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02740349,0.00044103427,0.54946584,0.00039245875,0.00052326324,0.000008362146,0.0059937844,0.000021387252,0.38750988,0.00014241027,0.0016934456,0.026404671],"study_design_scores_gemma":[0.0063734427,0.000118164906,0.6289694,0.0010051847,0.000053716933,0.0000044624853,0.0000500451,0.000009755485,0.36093923,0.000011025903,0.0024108568,0.00005470535],"about_ca_topic_score_codex":0.029407807,"about_ca_topic_score_gemma":0.008272588,"teacher_disagreement_score":0.07950358,"about_ca_system_score_codex":0.00006974082,"about_ca_system_score_gemma":0.00029538714,"threshold_uncertainty_score":0.97705543},"labels":[],"label_agreement":null},{"id":"W4414710160","doi":"10.1016/j.esmoop.2025.105542","title":"Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"National Cancer Institute; Astellas Pharma; Society for Anthropological Sciences; Merck Sharp and Dohme; Merck; MSD","keywords":"Pembrolizumab; Trastuzumab; Chemotherapy; Clinical trial; Randomized controlled trial; Cancer","score_opus":0.027309563687702917,"score_gpt":0.3591426641774245,"score_spread":0.3318331004897216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92871463,0.0022486683,0.010806234,0.04345875,0.00028240067,0.012535333,0.00016380132,0.000047686524,0.0017424655],"genre_scores_gemma":[0.98940516,0.0010333664,0.0017089193,0.0039575174,0.00007491242,0.00083206955,0.00020077857,0.000023858354,0.0027634467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788535,0.0003262309,0.0008262895,0.00043089146,0.00025948425,0.00027177093],"domain_scores_gemma":[0.99752766,0.001325344,0.0005423775,0.0003868349,0.000118199445,0.000099573386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011205379,0.00023399436,0.0019667125,0.00018957279,0.000171994,0.00006545088,0.00029435748,0.000064633714,0.00019879847],"category_scores_gemma":[0.00023968545,0.00014337122,0.00032492678,0.0011007099,0.00016074808,0.00009874933,0.00008717102,0.00015901306,5.7721127e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9392354,0.00017753296,0.019353023,0.00007734733,0.008707829,0.0000013206401,0.001063503,0.00011514304,0.0000037939824,0.0007603398,0.0020487807,0.028456023],"study_design_scores_gemma":[0.79984605,0.00069481233,0.19358379,0.00016655737,0.00266962,4.0376142e-7,0.0006286787,0.00045484025,0.000036578673,0.00030466996,0.0014670434,0.00014697427],"about_ca_topic_score_codex":0.03515515,"about_ca_topic_score_gemma":0.0036830131,"teacher_disagreement_score":0.17423077,"about_ca_system_score_codex":0.0001584327,"about_ca_system_score_gemma":0.00051263464,"threshold_uncertainty_score":0.97126985},"labels":[],"label_agreement":null},{"id":"W4414710167","doi":"10.1016/j.esmoop.2025.105651","title":"76eP Clinical-grade comprehensive genomic profiling (CGP) of urothelial carcinoma (UC)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Urothelial carcinoma; Profiling (computer programming); Urothelial cancer; Gene expression profiling; Bladder cancer; Genomic sequencing","score_opus":0.08534673143963108,"score_gpt":0.4059433389521601,"score_spread":0.32059660751252905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430814,0.00051103655,0.00008898156,0.0012275908,0.00066743983,0.0021263731,0.000062699386,0.000034922006,0.0521996],"genre_scores_gemma":[0.9902976,0.000086054766,0.0022737936,0.0017488564,0.00018358813,0.00007803953,0.00004170636,0.000026572601,0.005263776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985796,0.00009916494,0.0005283239,0.00038180585,0.00015289731,0.00025819152],"domain_scores_gemma":[0.9990192,0.000110851506,0.00012327533,0.00051347085,0.00012454284,0.00010867498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018974426,0.00017719432,0.0006244767,0.00008606645,0.00008418381,0.000027242892,0.0003507149,0.00011415477,0.0002576486],"category_scores_gemma":[0.00004440194,0.00014924433,0.00017046508,0.00018221236,0.00012627961,0.00006775834,0.00031822795,0.0002129411,0.000077937395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002379951,0.0010327267,0.9563696,0.00032634856,0.0010264207,0.00014864249,0.00040961133,0.000008375403,0.008388233,0.0026652466,0.006811397,0.02043345],"study_design_scores_gemma":[0.010672722,0.0008246759,0.9074126,0.00022623084,0.000515431,0.000023455475,0.00026483028,0.000084920095,0.04080376,0.00078492425,0.038183242,0.00020320246],"about_ca_topic_score_codex":0.0025257661,"about_ca_topic_score_gemma":0.00006487325,"teacher_disagreement_score":0.04895699,"about_ca_system_score_codex":0.0000766426,"about_ca_system_score_gemma":0.0005947317,"threshold_uncertainty_score":0.6086007},"labels":[],"label_agreement":null},{"id":"W4414710173","doi":"10.1016/j.esmoop.2025.105580","title":"2MO Personalised therapy in CUP: A feasibility study of Bayesian AI digital twins using ctDNA","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Scientific Computing and Data Management","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Bayesian probability; Precision medicine; MEDLINE; Bayesian inference","score_opus":0.27481728071319256,"score_gpt":0.4883514190893929,"score_spread":0.21353413837620033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837867,0.000011558227,0.0023490298,0.0004913299,0.00042111086,0.0010883114,0.000022232593,0.000014182441,0.011815558],"genre_scores_gemma":[0.99737173,3.9545324e-7,0.00028964132,0.00023277265,0.000011828242,0.0000073649408,0.0000049190166,0.0000040143045,0.002077324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972376,0.0002653821,0.0006276882,0.00082901906,0.00083407527,0.00020621846],"domain_scores_gemma":[0.9978793,0.00039856284,0.00014688027,0.0013780429,0.00014594628,0.00005125807],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.005085474,0.00011800353,0.00032467843,0.0003671251,0.00014881432,0.0015455905,0.0023366762,0.000027372651,0.0002729844],"category_scores_gemma":[0.0010621832,0.000088231696,0.000066601846,0.0018908598,0.00007597419,0.0007342965,0.0015056356,0.00010021556,0.000019836261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018794922,0.001985734,0.8962726,0.000004182401,0.000039268525,0.000014163749,0.004855511,0.00059572206,0.000017714241,0.00041040863,0.009337665,0.08627911],"study_design_scores_gemma":[0.0032602611,0.00022562219,0.933283,0.000059487036,0.000009700491,7.770831e-7,0.017625734,0.026508274,0.000051336145,0.008976285,0.009793403,0.00020612928],"about_ca_topic_score_codex":0.003557746,"about_ca_topic_score_gemma":0.0014461774,"teacher_disagreement_score":0.08607298,"about_ca_system_score_codex":0.0000669459,"about_ca_system_score_gemma":0.00014398445,"threshold_uncertainty_score":0.9994909},"labels":[],"label_agreement":null},{"id":"W4414904246","doi":"10.1016/j.esmoop.2025.105846","title":"Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute","keywords":"Workflow; Reliability (semiconductor); Cancer; Selection (genetic algorithm); Clinical Practice; Patient care","score_opus":0.026522509209520297,"score_gpt":0.34086700075067344,"score_spread":0.3143444915411531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414904246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159033,0.0017949201,0.000048418024,0.003373333,0.0002243523,0.0006605395,0.0000025291104,0.00001846022,0.0122871185],"genre_scores_gemma":[0.9961422,0.00057251495,0.0006058345,0.0017967619,0.000040411658,0.000086517,0.000011943316,0.000010323044,0.0007335127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986127,0.0001492674,0.0003649913,0.00046238053,0.00016250298,0.00024816653],"domain_scores_gemma":[0.9993783,0.0001938204,0.000039603456,0.00023386245,0.000037309648,0.00011708039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041054765,0.00017896076,0.00040240277,0.0004152241,0.00008287516,0.00008180168,0.0001255251,0.00013853714,0.00010506021],"category_scores_gemma":[0.00016963847,0.0001473041,0.000035429573,0.00067691854,0.00016519282,0.00014600699,0.00014494828,0.00038038593,0.0000031958198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043129222,0.0007262321,0.95967853,0.000106283405,0.000032249303,0.0011794819,0.0003385967,0.0000039769952,0.00025889894,0.004495197,0.0023699515,0.026497703],"study_design_scores_gemma":[0.0045071105,0.00063284254,0.9922869,0.0002055713,0.000029382883,0.000050278453,0.00016529343,0.00014549213,0.0000455957,0.00039715422,0.0014265132,0.00010784344],"about_ca_topic_score_codex":0.0015595641,"about_ca_topic_score_gemma":0.0003629037,"teacher_disagreement_score":0.032608416,"about_ca_system_score_codex":0.00031343408,"about_ca_system_score_gemma":0.00034086514,"threshold_uncertainty_score":0.6006887},"labels":[],"label_agreement":null},{"id":"W4415943874","doi":"10.1016/j.esmoop.2025.105833","title":"Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure","year":2025,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Clinical trial; Nivolumab; Immunotherapy; Immune checkpoint; Cancer; PD-L1; Immune system; Antibody therapy","score_opus":0.04539532483745746,"score_gpt":0.37766122912169303,"score_spread":0.3322659042842356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415943874","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005995678,0.9930403,0.000005943344,0.00062026014,0.00023088703,0.0033877038,0.00015279361,0.000040063325,0.001922479],"genre_scores_gemma":[0.0014907323,0.99332273,0.0003360594,0.00014633547,0.00020382725,0.0012671406,0.00034899972,0.000064334694,0.0028198694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981038,0.00014032592,0.00059999904,0.0005987043,0.00022825958,0.00032893906],"domain_scores_gemma":[0.99887854,0.00007450919,0.00032220667,0.00055756804,0.00008053451,0.00008663587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039758577,0.00052172254,0.0015523492,0.00010805542,0.00014271164,0.0001871973,0.00022481872,0.00038344442,0.00034132655],"category_scores_gemma":[0.000015825513,0.00033726246,0.00028264898,0.00032908702,0.00019278169,0.00018160288,0.0002035958,0.0004049673,0.000008382388],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029342861,0.000078124474,0.00009620208,0.00794343,0.001875644,0.000117067604,0.001006941,3.7900733e-8,0.000003425007,0.000009936078,0.0003275031,0.9856074],"study_design_scores_gemma":[0.0033251552,0.0006504612,0.0009288673,0.045072224,0.00089200615,0.00012230792,0.0003410981,2.4180852e-7,0.000078721736,0.000013108336,0.94816315,0.0004126842],"about_ca_topic_score_codex":0.0017417991,"about_ca_topic_score_gemma":0.0028155851,"teacher_disagreement_score":0.98519474,"about_ca_system_score_codex":0.00081218674,"about_ca_system_score_gemma":0.0010377963,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W4416815225","doi":"10.1016/j.esmoop.2025.105909","title":"Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union—a comparative overview","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Clinical Laboratory Practices and Quality Control","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"","keywords":"Variety (cybernetics); Diagnostic test; Health care; Process (computing); Medical care; Quality (philosophy); Best practice; Medical device","score_opus":0.07849617145854261,"score_gpt":0.41868611730293537,"score_spread":0.34018994584439277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416815225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645338,0.0009818785,0.0000069386833,0.032714225,0.00002215622,0.00093570334,0.00000955928,0.000006499488,0.00078921067],"genre_scores_gemma":[0.992497,0.0012055254,0.000054461285,0.0061560934,0.000012489899,0.000024491474,0.000024499917,0.000006350827,0.000019080007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950688,0.0039515984,0.0005223138,0.0001731726,0.00018189866,0.0001022493],"domain_scores_gemma":[0.98907,0.010422829,0.00015436743,0.00020681287,0.00010368818,0.000042307325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0081266025,0.00009231031,0.00039322875,0.00009896063,0.000039092338,0.00005625421,0.0002086363,0.000047280264,0.000019166238],"category_scores_gemma":[0.00545002,0.000051213337,0.00001095842,0.0009299504,0.00021118076,0.0001512049,0.0001665645,0.00030535905,0.0000020761838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003997674,0.001088925,0.94355005,0.0004938515,0.0001705911,0.0001726482,0.016879281,0.00007288168,0.00015821394,0.016184486,0.001337436,0.015893977],"study_design_scores_gemma":[0.006440966,0.000040978113,0.9754751,0.0005991147,0.000040692634,0.0000011846931,0.0016220994,0.0011012481,0.000033989912,0.00042078953,0.014167051,0.00005683282],"about_ca_topic_score_codex":0.00343607,"about_ca_topic_score_gemma":0.018243065,"teacher_disagreement_score":0.03192502,"about_ca_system_score_codex":0.000018410296,"about_ca_system_score_gemma":0.00018350667,"threshold_uncertainty_score":0.99967146},"labels":[],"label_agreement":null}]}